{"title": "PDF", "author": "PDF", "url": "helvia.uco.es/bitstream/handle/10396/20173/2020000002051.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": "TESIS DOCTORAL\n\u201cBIOMONITORIZACI\u00d3N DE  MARCADORES DE  ESTR\u00c9S OXIDATIVO,\nINFLAMACI\u00d3N, MICROBIOTA INTESTINAL Y DE LA EXPOSICI\u00d3N A\nMETALES PESADOS EN EL TRASTORNO DEL ESPECTRO AUTISTA EN LA\nINFANCIA\u201d\nAutor: Antonio Rafael G\u00f3mez Fern\u00e1ndez.\nDirectores: \nProf. Dr. Juan Lu\u00eds P\u00e9rez Navero.\nProf. Dra. Mercedes Gil Campos.\nDEPARTAMENTO: ESPECIALIDADES M\u00c9DICO-QUIR\u00daRGICAS. \u00c1REA DE PEDIATR\u00cdA.\nFACULTAD DE MEDICINA Y ENFERMER\u00cdA.\nUNIVERSIDAD DE C\u00d3RDOBA\nTITULO:BIOMONITORIZACI\u00d3N DE MARCADORES DE ESTR\u00c9S OXIDATIVO,\nINFLAMACI\u00d3N, MICROBIOTA INTESTINAL Y  DE LA EXPOSICI\u00d3N A\nMETALES PESADOS EN EL TRASTORNO DEL ESPECTRO\nAUTISTA EN LA INFANCIA.\nAUTOR:Antonio Rafael G\u00f3mez Fern\u00e1ndez\n\u00a9 Edita: UCOPress. 2020 \nCampus de Rabanales\nCtra. Nacional IV, Km. 396 A\n14071 C\u00f3rdoba\nhttps://www.uco.es/ucopress/index.php/es/\nucopress@uco.es \n \n \n \n \n \n \n \n \nT\u00cdTULO DE LA TESIS: BIOMONITORIZACI\u00d3N DE MARCADORES DE ESTR\u00c9S \nOXIDATIVO, INFLAMACI\u00d3N, MICROBIOTA INTESTINAL Y DE LA EXPOSICI\u00d3N A \nMETALES PESADOS EN EL TRASTORNO DEL ESPECTRO AUTISTA EN LA \nINFANCIA  \n \n \nDOCTORANDO/A: ANTONIO RAFAEL G\u00d3MEZ FERN\u00c1NDEZ  \n \n \nINFORME RAZONADO DEL/DE LOS DIRECTOR/ES DE LA TESIS  \n \n \nD. JUAN LUIS P\u00c9REZ NAVERO, con DNI 30.060.508 Z. Prof. Titular de Pediatr\u00eda, del \nDepartamento de Especialidades M\u00e9dico -Quir\u00fargicas de la Facultad de Medicina y \nEnfermer\u00eda de la Universidad de C\u00f3rdoba y Jefe de Servicio de Pediatr\u00eda, Cr\u00edticos y \nUrgencias del Hospital Universitario Reina Sof\u00eda de C\u00f3rdoba, informa que:  \n \nEl Doctorando rese\u00f1ado anteriormente, ha realizado un trabajo de investigaci\u00f3n \nexhaustivo, en relaci\u00f3n con la revisi\u00f3n bibliogr\u00e1fica, el ma terial y los m\u00e9todos, la \nselecci\u00f3n de los pacientes y los controles, as\u00ed como, en el aprendizaje de las pruebas \nde campo, cl\u00ednicas y de laboratorio, abordando las diferentes tecnolog\u00edas que se han \naplicado en este trabajo de investigaci\u00f3n. Igualmente, ha a prendido la metodolog\u00eda del \nan\u00e1lisis estad\u00edstico y de la investigaci\u00f3n aplicada a valorar los resultados.  \nEl excelente trabajo de investigaci\u00f3n llevado a cabo por el Doctorando se pone de \nmanifiesto a trav\u00e9s de los art\u00edculos publicados derivados de esta Te sis, as\u00ed como en \nlas comunicaciones presentadas en Congresos Nacionales e Internacionales y en los \npremios obtenidos. Por todo lo anterior, solicito que D. Antonio Rafael G\u00f3mez \nFern\u00e1ndez, pueda optar al grado de Doctor por la Universidad de C\u00f3rdoba, \nautori zando la presentaci\u00f3n y defensa de su Tesis Doctoral.  \n \n \n \n \n \n \nLo que firmo en C\u00f3rdoba, a 23 de Septiembre  de  2019  \n \n \n \n \n \n \n \n \n \nFdo.:Juan Luis P\u00e9rez Navero  \n \n \n \n \n \n \n \n \n \nT\u00cdTULO DE LA TESIS: BIOMONITORIZACI\u00d3N DE MARCADORES  DE ESTR\u00c9S \nOXIDATIVO, INFLAMACI\u00d3N, MICROBIOTA INTESTINAL Y DE LA EXPOSICI\u00d3N A \nMETALES PESADOS EN EL TRASTORNO DEL ESPECTRO AUTIST A EN LA \nINFANCIA  \n \n \n \nDOCTORANDO/A: ANTONIO RAFAEL G\u00d3MEZ FERN\u00c1NDEZ  \n \n \n \nINFORME RAZONADO DEL/DE LOS DIRECTOR/ES DE LA TESIS  \n(se har\u00e1 menci\u00f3n a la evoluci\u00f3n y desarrollo de la tesis, as\u00ed como a trabajos y publicaciones derivado s de la misma).  \n \n \n \nD\u00f1a. MARIA MERCEDES GIL CAMPOS, con DNI 44286271R, como directora de esta \ntesis doctoral, Prof. Titular de Pediatr\u00eda, del Dpt o de Especialidades M\u00e9dico-\nQuir\u00fargicas de la Facultad de Medicina, informa que : \n \nSe ha realizado un trabajo de tesis doctoral exhaus tivo y de gran calidad. El \ndoctorando ha aprendido metodolog\u00eda de la investiga ci\u00f3n, y ha trabajado \nprofundamente tanto en el trabajo de selecci\u00f3n, cl\u00ed nico y de muestreo, as\u00ed como en el \naprendizaje de pruebas de campo y t\u00e9cnico en difere ntes laboratorios abordando \ndistintas tecnolog\u00edas aplicables a su \u00e1mbito profes ional y de conocimiento, y en la \npreparaci\u00f3n y redacci\u00f3n de las publicaciones que se  exponen en esta tesis doctoral.  \nLos art\u00edculos publicados a partir de esta Tesis, as \u00ed como comunicaciones en \ncongresos nacionales e internacionales, y varios pr emios recibidos, indican el \nexcelente trabajo de investigaci\u00f3n realizado. Por e llo, solicito que el doctorando \nAntonio Rafael G\u00f3mez Fern\u00e1ndez pueda optar al grado  de Doctor por la Universidad \nde C\u00f3rdoba. \n \n \nPor todo ello, se autoriza la presentaci\u00f3n de la te sis doctoral. \n \nC\u00f3rdoba,  23 Septiembre  2019 \n \nFirma de la directora \n \n \n \nFdo.: Mercedes Gil Campos                                   \nAGRADECIMIENTOS\nEste largo y duro camino que supone realizar la tesis, en un mundo tan\ncompetitivo como el de la medicina, no hubiera podido en modo alguno haberlo\nrecorrido sin la ayuda de muchas personas. Es por tanto el trabajo no de un\ndoctorando, sino de un verdadero equipo, el que ha hecho posible los logros\nque a continuaci\u00f3n expongo.\nQuiero citar en primer lugar, mi mujer, mi gran apoyo. Sin ella ninguno de\nmis peque\u00f1os logros hubieran sido posibles. Nunca nadie, habr\u00e1 tenido tanto\napoyo como el que me ha brindado mi querida esposa, mi compa\u00f1era, mi\nconsuelo, mi fuente de energ\u00eda. A ella le debo y c\u00f3mo no, le dedico, todo el\ntrabajo que a continuaci\u00f3n expongo, que durante a\u00f1os, ha supuesto robarme\nun tiempo precioso que pasar con ella, y por supuesto, con nuestros dos\nmaravillosos  hijos.  Muchas  gracias  a  los  tres,  y  siento  de  coraz\u00f3n  esos\nmomentos dif\u00edciles que he pasado, y que en ocasiones se han visto reflejados\nen mi car\u00e1cter, pagando las consecuencias las personas que m\u00e1s quiero, y a\nlas que todo les debo. \nPara  mis  tutores  de  Tesis,  Profesores  Juan  Luis  P\u00e9rez  Navero  y\nMercedes Gil Campos solo tengo palabras de agradecimiento; jam\u00e1s pens\u00e9\nque pudiera recibir tanto apoyo por su parte, y no solo en las numerosas horas\nde trabajo que hemos compartido, sino especialmente por el apoyo emocional\nque he recibido de su parte, especialmente cuando en mis peores momentos,\nhe  sentido  la  tentaci\u00f3n  de  abandonar,  por  el  inmenso  trabajo  que  me  ha\nsupuesto y lentas recompensas alcanzadas. Os agradezco de todo coraz\u00f3n,\ncada uno de los consejos que me hab\u00e9is brindado, fruto de vuestra dilatada\nexperiencia.  Os  reservo  un  lugar  privilegiado,  en  lo  m\u00e1s  profundo  de  mi\ncoraz\u00f3n. Solo espero, que mi trabajo haya sido de vuestro agrado, y haber\nestado a la altura de vuestras expectativas, y espero de coraz\u00f3n que me\nrecord\u00e9is  como  un  buen  doctorando,  el  cual  no  ha  desperdiciado  las\nnumerosas horas que os ha supuesto mi tesis.\nA  las Dras  Maria Jos\u00e9 de la Torre Aguilar  y Katherine Flores-Rojas  de\nlas que adem\u00e1s de su amistad, he recibido un gran apoyo por su parte, adem\u00e1s\nde un sinf\u00edn de horas de trabajo juntos. Gracias de coraz\u00f3n. A Pilar Mart\u00edn, de\nla que adem\u00e1s de su amistad y gran ayuda, he aprendido gran parte de losconocimientos sobre la patolog\u00eda de la que trata el presente trabajo. Y por\n\u00faltimo, al servicio de Anestesia, y especialmente a Pilar P\u00e9rez Navero, sin los\nque no hubiera podido recolectar las muestras de los ni\u00f1os controles.\nA todos vosotros por tanto, os dedico este enorme esfuerzo y trabajo,\nfruto de nuestra colaboraci\u00f3n, de nuestra amistad, de la labor de un magn\u00edfico\nequipo de trabajo. Gracias por todo. \nFinalmente, quiero hacer una menci\u00f3n especial a todas las familias de\npacientes TEA, y a la de los controles, que han aceptado su inclusi\u00f3n en el\nproyecto, a pesar de que como bien es sabido, los conocimientos adquiridos en\neste tipo de estudios, suelen originar nuevas l\u00edneas de investigaci\u00f3n, m\u00e1s que\npoder dar una respuesta o alguna medida que pueda mejorar el pron\u00f3stico de\nsus  hijos.  A pesar  de  ello,  todas  las  familias,  tanto  las  de  los  controles,\nsabedoras de que el objetivo principal era ayudar a ni\u00f1os con TEA, como las\nfamilias de los pacientes TEA, se ofrecieron generosamente a todo aquello que\nle hab\u00edamos propuesto.RESUMEN\nEsta  memoria  de  tesis  doctoral  por  compendio  de  art\u00edculos  publicados  en\nrevistas con  factor de impacto en los cuartiles 1 y 2, implica a los art\u00edculos que\nse  han publicado como resultado de la investigaci\u00f3n sobre marcadores de\nestr\u00e9s  oxidativo,  inflamaci\u00f3n,  microbiota  intestinal,  exposici\u00f3n  a  metales\npesados en el Trastorno de Espectro Autista (TEA) en la infancia as\u00ed como los\nresultados  del  ensayo  cl\u00ednico  para  valorar  la  eficacia  del  \u00e1cido\ndocosahexaenoico.  Adem\u00e1s,  es  el  resultado  del  inicio  de  una  l\u00ednea  de\ninvestigaci\u00f3n  in\u00e9dita  en  la  Unidad  de  Investigaci\u00f3n  Pedi\u00e1trica  del  Hospital\nUniversitario  Reina  Sof\u00eda,  que  seguir\u00e1  aportando  resultados  en  un  futuro\npr\u00f3ximo. Son por tanto, muchos los subproyectos que se han derivado los\ncuales, en parte se incluyen en el presente documento, dado que son fruto del\nmismo esfuerzo y trabajo en equipo que el de los art\u00edculos publicados para\nelaborar la presente tesis doctoral. Es de esperar por tanto, que en los meses o\na\u00f1os venideros aparezcan futuras publicaciones similares a las que aqu\u00ed se\nexponen.  Por  tanto  no  solo  se  rese\u00f1an  los  resultados  de  estos  a\u00f1os  de\ninvestigaci\u00f3n, sino tambi\u00e9n los  trabajos que actualmente se est\u00e1n llevando a\ncabo, que se publicar\u00e1n en un futuro pr\u00f3ximo.\nContenido de la investigaci\u00f3n\nSe  han  descrito  varias  teor\u00edas  etiopatog\u00e9nicas  sobre  la  alteraci\u00f3n  en  el\nneurodesarrollo  y  la  sintomatolog\u00eda  del  TEA,  en  las  que  se  eval\u00faan  los\nmecanismos inflamatorios, estr\u00e9s oxidativo y alteraciones metab\u00f3licas, en la\nmicrobiota intestinal o incluso tras la exposici\u00f3n a metales pesados. Por ello, se\nrealiz\u00f3 un estudio de casos y controles, de pacientes TEA en edad preescolar y\ncontroles sanos de la misma edad y desarrollo neurol\u00f3gico t\u00edpico. El grupo de\npacientes  TEA se  clasificaron  en  funci\u00f3n  de  la  presencia  o  ausencia  de\nregresi\u00f3n del neurodesarrollo, mediante una escala dise\u00f1ada para tal fin, y\nbasada en la descripci\u00f3n de la regresi\u00f3n de la Autism Diagnostic Interview-\nRevised (ADI-R). Se determinaron en muestras de sangre perif\u00e9rica en los\ngrupos de estudio  los principales indicadores de inflamaci\u00f3n y estr\u00e9s oxidativo\nas\u00ed como los principales metabolitos y el perfil metabol\u00f3mico. Adem\u00e1s, se llev\u00f3\na  cabo  en  muestras  fecales,  la  determinaci\u00f3n  de  la  microbiota  intestinal,\nmediante un estudio metagen\u00f3mico para comparar los tres grupos.Resultados \nEn relaci\u00f3n con los marcadores inflamatorios, se observaron niveles m\u00e1s altos\ndel Factor de Crecimiento Nervioso (NGF) en el grupo TEA en comparaci\u00f3n\ncon el grupo control. En el an\u00e1lisis de los subgrupos de TEA, se encontraron\nniveles m\u00e1s bajos en plasma de la mol\u00e9cula NCAM y niveles m\u00e1s elevados de\nNGF en el grupo de ni\u00f1os TEA sin regresi\u00f3n en el neurodesarrollo. Por otro\nlado, detectamos niveles m\u00e1s elevados de Actinobacteria, Proteobacteria y\nBacilli, adem\u00e1s de Erysipelotrichi y Gammaproteobacteria en heces de ni\u00f1os\nTEA en comparaci\u00f3n con el grupo control. Los pacientes con regresi\u00f3n en el\nneurodesarrollo presentaron niveles m\u00e1s altos de proteobacterias. De igual\nmodo,  hallamos  diferencias  significativas  en  los  perfiles  metabol\u00f3micos\nimplicados en el metabolismo de los amino\u00e1cidos, l\u00edpidos y nicotinamida entre\nel  grupo  TEA  y  control  y  entre  ambos  subgrupos  de  TEA  con  y  sin\nneuroregresi\u00f3n.\nConclusiones\nNuestros  resultados  indican  que  en  el  desarrollo  del  TEA  podr\u00edan  estar\ninvolucrados diferentes mecanismos etiopatog\u00e9nicos, y que incluso dentro del\namplio espectro de pacientes que representa el TEA, podr\u00edan existir diferentes\nsubgrupos de TEA  con distinta fisiopatolog\u00eda. Se necesitar\u00edan realizar estudios\nmultic\u00e9ntricos  amplios  que  trataran  de  profundizar  m\u00e1s  en  los  diferentes\nmecanismos fisiopatol\u00f3gicos implicados en el desarrollo del TEA, as\u00ed como en\nlos  diferentes subgrupos  de  ni\u00f1os con  TEA,  para poder  desarrollar dianas\nterap\u00e9uticas espec\u00edficas.ABSTRACT\nBackground\nThis doctoral thesis report by compendium of articles published in journals with\nimpact factor in quartiles 1 and 2, implies a result of research on markers of\noxidative stress, inflammation, intestinal microbiota, or metal exposure in Autism\nSpectrum Disorder (ASD) in childhood as well as the results of the clinical trial\nto assess the efficacy of docosahexaenoic acid suplemmentation. In addition, it\nis the result of the beginning of a new research line in the Pediatric Research\nUnit of the Reina Sof\u00eda University Hospital, which will continue to provide results\nin  the  near  future.  Therefore,  there  are  many  subprojects  that  have  been\ndeveloped which, in part, are included in this document, since they are the\nresult of the same effort and team work. So, not only the results of these years\nof research are reviewed, but also the works that are currently being carried out,\nwhich will be published in the near future.\nResearch Content\nSeveral etiopathogenic theories about neurodevelopmental alteration and ASD\nsymptomatology  have  been  described,  in  which  inflammatory  mechanisms,\noxidative  stress  and  metabolic  alterations  are  evaluated  in  the  intestinal\nmicrobiota or even after exposure to heavy metals. So, a case-control study of\nASD patients in preschool age and healthy controls of the same age and typical\nneurological  development  was  performed.  The  group  of  ASD  patients  was\nclassified  according  to  the  presence  or  absence  of  neurodevelopmental\nregression,  using  a  scale  designed  for  this  purpose,  and  based  on  the\ndescription of the regression of the Autism Diagnostic Interview-Revised (ADI-\nR). The main indicators of inflammation and oxidative stress as well as the main\nmetabolites  and  metabolomic  profile  were  determined  in  peripheral  blood\nsamples in the study groups. In addition, the determination of the intestinal\nmicrobiota was carried out in faecal samples by means of a metagenomic study,\ncomparing both groups.\nResults\nIn relation to inflammatory markers, higher levels of the Nerve Growth Factor(NGF) were observed in the ASD group compared to the control group. In the\nanalysis of the subgroups of ASD, lower plasma levels of the NCAM molecule\nand higher levels of NGF were found in the group of ASD children without\nregression in neurodevelopment. On the other hand, we detected higher levels\nof Actinobacteria, Proteobacteria and Bacilli, in addition to Erysipelotrichi and\nGammaproteobacteria in feces of ASD children compared to the control group.\nPatients  with  neurodevelopmental  regression  showed  higher  levels  of\nProteobacteria.  Similarly,  significant  differences  in  the  metabolomic  profiles\ninvolved in the metabolism of amino acids, lipids and nicotinamide between the\nASD and control group and between both ASD subgroups with and without\nneuroregression, were found.\nConclusions\nOur results indicate that different etiopathogenic mechanisms may be involved\nin the development of ASD, and that even within the broad spectrum of patients\nrepresented by ASD, there may be different subgroups of ASD with different\npathophysiology.  Extensive  multicentric  studies  would  be  needed  to  try  to\ninvestigate more in the different pathophysiological mechanisms involved in the\ndevelopment of ASD, as well as in the different subgroups of ASD, in order to\ndevelop specific therapeutic targetsABREVIATURAS \nA\nAA: acontecimiento adverso\nAAG: acontecimiento adeverso grave\nABC: the aberrant behavior checklist \nABTS: 3-ethylbenzothiazoline-6-sulphonic acid\nAc: anticuerpos\nADDM: autism and developmental disabilities monitoring\nADIR-R: the autism diagnostic interview-revised\nADOS-2: the autism diagnostic observation schedule-2\nALA: \u00e1cido \u03b1-linol\u00e9nico\nALT: alanina aminotransferasa\nAMR: autism mental regression\nANMR: autism no mental regression\nAPA: american psychiatric association\nAST: aspartato aminotransferasa\nATP: adenos\u00edn trifosfato\nB\nBASC-2: the behavior assessment system for children-2\nBDNF: brain-derived neurotrophic factor\nBEDCA: base de datos espa\u00f1ola de composici\u00f3n de alimentos\nBHE: barrera hematoencef\u00e1lica\nBLAST: basic local alignment search tool\nC\nCARS: the childhood autism rating scale\nCD: cluster of differentiation\nCd: cadmio\nCDC: centers for disease control and prevention\nCGI-I: the clinical global impressions-improvement\nCMH: complejo mayor de histocompatibilidad\nCIE-10: clasificaci\u00f3n internacional de enfermedades, d\u00e9cima versi\u00f3n\nCSF: colony-stimulating factor\nD\nDHA: \u00e1cido docosaexahenoico\nDPA: \u00e1cido docosapentaenoico\nDMSA: \u00e1cido dimercaptosucc\u00ednico\nDNA: \u00e1cido desoxirribonucleico \nDSM-4: diagnostic and statistical manual of mental disorders, cuarta versi\u00f3n\nDSM-4-TR: diagnostic and statistical manual of mental disorders, cuarta versi\u00f3n, \nversi\u00f3n revisada\nDSM-5: diagnostic and statistical manual of mental disorders, quinta versi\u00f3n\nE\nEDTA: \u00e1cido etilendiaminotetraac\u00e9tico\nEFSA: autoridad europea para la seguridad de los alimentos\nEN ISO: europea+internacional\nEPA: \u00e1cido eicosapentaenoico4-EPS: 4-ethylphenylsulfate\nERO: especie reactiva de ox\u00edgeno\nF\nFA: fatty acids\nG\nG-CSF: granulocyte colony-stimulating factor\nGFAP: glial fibrillary acidic protein\nGGT: gamma-glutamil transferasa\nGI: gastrointestinal\nGM-CSF: granulocyte macrophage colony-stimulating factor\nGPRD: general practice research database\nGR: glutati\u00f3n reductasa\nGSH: glutati\u00f3n\nGSH-PX: glutati\u00f3n peroxidasa\nGSSG: glutati\u00f3n disulfuro\nGSSGR: glutati\u00f3n reductasa\nH\nH2O2: per\u00f3xido de hidr\u00f3geno\nHDL: high density lipoprotein\nHg: mercurio\nHLA: human leukocyte antigen\nHPLC: cromatograf\u00eda l\u00edquida de alta resoluci\u00f3n\nHURS: hospital universitario reina sof\u00eda\nI\nIFN: interfer\u00f3n\nIg: inmunoglobulina\nIl: interleukina\nIMC: \u00edndice de masa corporal\nIMIBIC: instituto maim\u00f3nides de investigaci\u00f3n biom\u00e9dica de c\u00f3rdoba\nL\nLAK: limphokine-activated killer\nLC-PUFA: acidos grasos poliinsaturados de cadena larga\nLCR: l\u00edquido cefalorraqu\u00eddeo\nLDL: low density lipoproteins\nLTC: linfocito t citot\u00f3xico\nM\nMAC: membrane attack complex\nMCP-1: monocyte chemoattractant protein 1\nMDA: malondialdeh\u00eddo\nMIA: activaci\u00f3n inmune maternal\nMn: manganesio\nMPO: mieloperoxidasaN\nNAD: nicotin adenin dinucle\u00f3tido\nNADPH: nicotinamida adenina dinucle\u00f3tido fosfato\nNCAM: neural cell adhesion molecule\nNFG: factor de crecimiento nervioso\nNF-KB: nuclear factor kappa-light-chain-enhancer of activated b cells\nNK: natural killer\nO\nOMS: organizaci\u00f3n mundial de la salud\nOTU: unidad taxon\u00f3mica operativa\nP\nPAI-1: factor inhibidor del plasmin\u00f3geno 1\nPb: plomo\nPb: pares de bases\nPBMC: peripheral blood mononuclear cell\nPCR: reacci\u00f3n en cadena de la polimerasa\nPDDBI: the pervasive developmental disorders behavioral inventory\nR\nRANTES: regulated on activation, normal t cell expressed and secreted\nRDP: ribosomal data project\nRNA: \u00e1cido ribonucleico\nS\nSA: s\u00edndrome de angelman\nSDQ: the strengths and difficulties questionnaire\nSICAM: soluble intercellular adhesion molecule-1 \nSNC: sistema nervioso central\nSOD: supe\u00f3xido dismutasa\nSPSS: statistical package for the social sciences\nSPW: s\u00edndrome de prader-willi\nSVCAM-1: soluble vascular cell adhesion molecule-1\nSXF: s\u00edndrome del x fr\u00e1gil\nT\nTBARS: thiobarbituric acid reactive substances\nTDAH: trastorno por d\u00e9ficit de atenci\u00f3n e hiperactividad\nTEA: trastorno del espectro autista\nTGF-\u03b21: transforming growth factor beta 1\nTh: linfocito t helper\nTNF: tumor necrosis factor\nU\nUNESCO: organizaci\u00f3n de las naciones unidas para la educaci\u00f3n, la ciencia y la cultura\nUSMIJ: unidad de salud mental infantil y juvenil\u00cdNDICE\n1 INTRODUCCI\u00d3N \n1.1 Historia y definici\u00f3n\n1.2 Epidemiolog\u00eda\n1.3 Clasificaci\u00f3n del Trastorno del Espectro Autista\n1.4 Etiopatogenia en el Trastorno del Espectro Autista primario\n1.4.1 Inflamaci\u00f3n\n1.4.2 Estr\u00e9s oxidativo\n1.4.3 Perfil metabol\u00f3mico\n1.4.4 Metales Pesados \n1.4.5 Microbiota intestinal \n1.4.6 \u00c1cidos grasos poliinsaturados\n2 HIPOTESIS Y OBJETIVOS\n3 MATERIAL Y M\u00c9TODOS\n3.1 Dise\u00f1o de los esudios\n3.2 Sujetos de estudio\n3.3 Historia cl\u00ednica , exploraci\u00f3n f\u00edsica, antropometr\u00eda y encuesta nutricional \n3.4 Extracci\u00f3n sangu\u00ednea y an\u00e1lisis bioqu\u00edmicos en plasma y eritrocitos\n3.5 An\u00e1lisis de la microbiota intestinal\n3.6 Estudio de metales pesados en cabello y orina\n3.7 An\u00e1lisis estad\u00edstico\n3.8 Aspectos \u00e9ticos\n4 RESULTADOS\n5 BIBLIOGRAF\u00cdA\n6 ANEXOS\n7 OTRA PRODUCCI\u00d3N CIENT\u00cdFICA Y RECONOCIMIENTOS 1. INTRODUCCI\u00d3N\n1.1 Historia y definici\u00f3n \nEl concepto de \u201cautismo\u201d (del griego eaftismos: encerrado en uno mismo), fue\nintroducido en el campo de la psicopatolog\u00eda por primera vez en 1911, cuando\nun psiquiatra alem\u00e1n, Eugen Bleuer,describi\u00f3 un s\u00edntoma observado en los\ncasos m\u00e1s severos de esquizofrenia, concepto que tambi\u00e9n hab\u00eda definido. El\nautismo se caracteriza seg\u00fan \u00e9l por el repliegue de la vida mental sobre s\u00ed\nmisma, constituyendo as\u00ed un mundo cerrado, separado de la realidad exterior y\npor la dificultad extrema o la imposibilidad de comunicarse con los dem\u00e1s. Pero\nBleuer, no solo hace referencia al autismo como s\u00edntoma, si no que habla del\n\"pensamiento  autista\",  que  seg\u00fan  \u00e9l  tiene  su  origen  en  una  mente\nesquizofr\u00e9nica,  y  por  tanto  fragmentada,  y  caracterizado  por  los  deseos\ninfantiles de evitar realidades insatisfactorias y reemplazarlas con fantas\u00edas y\nalucinaciones (Evans, 2013).\nHace m\u00e1s de 70 a\u00f1os que un m\u00e9dico austr\u00edaco, L\u00e9o Kanner, estudiando a\nun grupo de ni\u00f1os diagnosticados de esquizofrenia infantil, describi\u00f3 en su\ntrabajo \u201cAutistic Disturbance of Affective Contact\u201d (1943), a un grupo de 11\nni\u00f1os  peque\u00f1os,  la  mayor\u00eda  varones,  que  presentaban  una  serie  de\nalteraciones  comunes  que  consist\u00edan  en  un  retraso  o  ausencia  en  la\nadquisici\u00f3n del lenguaje, incapacidad para relacionarse con las personas e\ninsistencia obsesiva por mantener el ambiente sin cambios, y con tendencia a\nrealizar  ritualizaciones.  Lo  denomin\u00f3  \u201cautismo  infantil  precoz\u201d  por  la  edad\ntemprana  de  su  aparici\u00f3n,  y  realiz\u00f3  una  detallada  descripci\u00f3n  de  las\ncaracter\u00edsticas comunes, algunas de las cuales contin\u00faan siendo referencia hoy\nen d\u00eda para definir al autismo.\nCasi  de  forma  simult\u00e1nea,  en  1944  un  pediatra  austr\u00edaco,  Hans\nAspergerdescribi\u00f3  un  grupo  de  ni\u00f1os  con  caracter\u00edsticas  similares  a  las\ndescritas  por  Kanner.  En  su  trabajo  \u201cDie  Autistiche  Psychopathen  in\nKindersalter\u201d, que transcender\u00eda a\u00f1os despu\u00e9s debido a la ocupaci\u00f3n nazi de\nAustria, determin\u00f3 como caracter\u00edsticas centrales de la \u201cpsicopatolog\u00eda autista\u201d\nla limitaci\u00f3n en las relaciones sociales, extra\u00f1as pautas comunicativas y un\nimportante car\u00e1cter obsesivo en sus acciones y pensamientos. Pese a utilizar\nel t\u00e9rmino \u201cautista\u201d, se diferenciaba del \u201cautismo infantil precoz\u201d de Kanner enla  conservaci\u00f3n  del  lenguaje,  del  desarrollo  cognitivo  y  mayor  edad  de\npresentaci\u00f3n. A\u00f1os m\u00e1s tarde, cuando preguntaron a los dos autores si la\npatolog\u00eda que hab\u00edan descrito casi de forma simult\u00e1nea se correspond\u00eda en\nrealidad de la misma entidad nosol\u00f3gica, ambos estuvieron de acuerdo en que\nse trataba de dos patolog\u00edas completamente diferentes pese a la referencia\ncom\u00fan de la psicopatolog\u00eda autista. De hecho, durante muchos a\u00f1os, ambos\ns\u00edndromes se encontraron en la misma categor\u00eda (Trastornos Generalizados del\nDesarrollo) tanto en la CIE-10 (Clasificaci\u00f3n Internacional de Enfermedades de\nla OMS, d\u00e9cima versi\u00f3n) como en el DSM-4 (DSM: Diagn\u00f3stic and Statiscal\nManual of Mental Disorder) de la Asociaci\u00f3n Americana de Psiquiatr\u00eda (APA)\n(Tabla 1) (OMS, 1992; APA 1994) e incluso en la versi\u00f3n revisada del DSM-4\n(APA, 2000).\nTabla 1. Trastornos generalizados del desarrollo\nCIE-10\n- F84.0 Autismo infantil\n- F84.1 Autismo at\u00edpico\n- F84.2 S\u00edndrome de Rett\n- F84.3 Otro trastorno desintegrativo de la infancia\n- F84 Hiperactividad asociada a un retraso mental y a movimientos estereotipados\n- F84.5 S\u00edndrome de Asperger\n- F84.8 Otros trastornos invasores del desarrollo\n- F84.9 Otros trastornos invasores del desarrollo no precisados\nDSM-4\n- 299 Trastorno Autista\n- 299.10 Trastorno desintegrativo de la infancia\n- 299.80 S\u00edndrome de Rett\n- 299.80 S\u00edndrome de Asperger\n- 299.80 Otros trastornos invasores del desarrollo no especificados en otro lugar\nTomado de CIE-10 y DSM-4\nDurante d\u00e9cadas, se ha mantenido vigente la descripci\u00f3n que ofreciera\nKanner para definir a los s\u00edntomas nucleares del autismo, el fracaso en las\nrelaciones personales, intereses restringidos y estereotipados y alteraciones en\nla comunicaci\u00f3n, los cuales quedan reflejados en los criterios diagn\u00f3sticos del\nDSM-4-TR para Trastorno Autista y S\u00edndrome Asperger (Tablas 2 y 3). Tabla 2. DSM-4-TR Criterios diagn\u00f3sticos de Trastorno Autista\nA. Existe un total de 6 (o m\u00e1s) \u00edtems de 1, 2 y 3, con por lo menos dos de 1, y uno de 2 y de 3:\n1. Alteraci\u00f3n cualitativa de la interacci\u00f3n social, manifestada al menos por dos de las siguientes caracter\u00edsticas:\n(a) Importante alteraci\u00f3n del uso de m\u00faltiples comportamientos no verbales, como son contacto ocular, expresi\u00f3n facial,\nposturas corporales y gestos reguladores de la interacci\u00f3n social\n(b) Incapacidad para desarrollar relaciones con compa\u00f1eros adecuadas al nivel de desarrollo\n(c) Ausencia de la tendencia espont\u00e1nea para compartir con otras personas disfrutes, intereses y objetivos (p. ej., no\nmostrar, traer o se\u00f1alar objetos de inter\u00e9s)\n(d) Falta de reciprocidad social o emocional\n2. Alteraci\u00f3n cualitativa de la comunicaci\u00f3n manifestada al menos por dos de las siguientes caracter\u00edsticas:\n(a) Retraso o ausencia total del desarrollo del lenguaje oral (no acompa\u00f1ado de intentos para compensarlo mediante\nmodos alternativos de comunicaci\u00f3n, tales como gestos o m\u00edmica)\n(b) En sujetos con un habla adecuada, alteraci\u00f3n importante de la capacidad para iniciar o mantener una conversaci\u00f3n\ncon otros\n(c) Utilizaci\u00f3n estereotipada y repetitiva del lenguaje o lenguaje idiosincr\u00e1sico\n(d) Ausencia de juego realista espont\u00e1neo, variado, o de juego imitativo social propio del nivel de desarrollo\n3. Patrones de comportamiento, intereses y actividades restringidos, repetitivos y estereotipados, manifestados\npor lo menos mediante una de las siguientes caracter\u00edsticas:\n(a) Preocupaci\u00f3n absorbente por uno o m\u00e1s patrones estereotipados y restrictivos de inter\u00e9s que resulta anormal, sea\nen su intensidad, sea en su objetivo\n(b) Adhesi\u00f3n aparentemente inflexible a rutinas o rituales espec\u00edficos, no funcionales\n(c)  Manierismos  motores  estereotipados y repetitivos  (p.  ej., sacudir  o girar  las manos  o dedos, o movimientos\ncomplejos de todo el cuerpo)\n(d) Preocupaci\u00f3n persistente por partes de objetos\nB. Retraso o funcionamiento anormal en por lo menos una de las siguientes \u00e1reas, que aparece antes de los 3\na\u00f1os de edad: 1 interacci\u00f3n social, 2 lenguaje utilizado en la comunicaci\u00f3n social o 3 juego simb\u00f3lico o\nimaginativo\nC. El trastorno no se explica mejor por la presencia de un trastorno de Rett o de un trastorno desintegrativo\ninfatilTabla 3. DSM-4-TR: Criterios diagn\u00f3sticos de S\u00edndrome de Asperger \nA.  Alteraci\u00f3n  cualitativa  de  la  interacci\u00f3n  social,  manifestada  al  menos  por  dos  de  las  siguientes\ncaracter\u00edsticas:\n1. Importante alteraci\u00f3n del uso de m\u00faltiples comportamientos no verbales como contacto ocular, expresi\u00f3n facial,\nposturas corporales y gestos reguladores de la interacci\u00f3n social\n2. Incapacidad para desarrollar relaciones con compa\u00f1eros apropiadas al nivel de desarrollo del sujeto\n3. Ausencia de la tendencia espont\u00e1nea a compartir disfrutes, intereses y objetivos con otras personas (p.ej., no\nmostrar, traer o ense\u00f1ar a otras personas objetos de inter\u00e9s)\n4. Ausencia de reciprocidad social o emocional\nB. Patrones de comportamiento, intereses y actividades restrictivos, repetitivos y estereotipados, manifestados\nal menos por una de las siguientes caracter\u00edsticas:\n1. Preocupaci\u00f3n absorbente por uno o m\u00e1s patrones de inter\u00e9s estereotipados y restrictivos que son anormales, sea por\nsu intensidad, sea por su objetivo\n2. Adhesi\u00f3n aparentemente inflexible a rutinas o rituales espec\u00edficos, no funcionales\n3. Manierismos motores estereotipados y repetitivos (p. ej., sacudir o girar manos o dedos, o movimientos complejos de\ntodo el cuerpo)\n4. Preocupaci\u00f3n persistente por partes de objetos\nC. El  trastorno  causa un  deterioro  cl\u00ednicamente  significativo  de la  actividad  social, laboral y otras  \u00e1reas\nimportantes de la actividad del individuo\nD. No hay retraso general del lenguaje cl\u00ednicamente significativo (p. ej., a los 2 a\u00f1os de edad utiliza palabras\nsencillas, a los 3 a\u00f1os de edad utiliza frases comunicativas)\nE. No hay retraso cl\u00ednicamente significativo del desarrollo cognoscitivo ni del desarrollo de habilidades de\nautoayuda propias de la edad, comportamiento adaptativo (distinto de la interacci\u00f3n social) y curiosidad acerca\ndel ambiente durante la infancia\nF. No cumple los criterios de otro trastorno generalizado del desarrollo ni de esquizofrenia\nSin  embargo,  el  \u00faltimo  manual  de  diagn\u00f3stico  DSM-5  (APA,  2013)\npresenta  notables  diferencias  en  cuanto  a  la  definici\u00f3n  y  clasificaci\u00f3n  de\nautismo,  pasando  a  denominarse  \"Trastorno  del  Espectro  Autista\",\nelimin\u00e1ndose todas las categor\u00edas diagn\u00f3sticas englobadas en el DSM-4-TR\ndentro  de  los  \"Trastornos  Generalizados  del  Desarrollo\"  (S\u00edndrome  de\nAsperger, S\u00edndrome de Rett, Trastorno Autista, Trastorno Desintegrativo de la\nInfancia  y  Trastorno  Generalizado  del  Desarrollo  no  especificado).  Estos\ncambios pretenden reflejar la amplia heterogeneidad cl\u00ednica presente en el\nautismo, hablando de un espectro, un continuo de dos dimensiones (A y B),\nproponiendo  establecer  un  baremo  de  gravedad  de  los  s\u00edntomas  y  de\nafectaci\u00f3n  para  cada  una  de  las  dimensiones,  englobando  bajo  una  sola\nentidad  nosol\u00f3gica  a  un  grupo  de  pacientes  con  caracter\u00edsticas  similares\n(Tablas 4 y 5).Tabla 4. DSM-5: Criterios Diagn\u00f3sticos del Trastorno del Espectro Autista\nDebe cumplir los criterios A, B, C y D:\nA.  D\u00e9ficits persistentes en la comunicaci\u00f3n y en la interacci\u00f3n social en diversos contextos, no atribuibles a un\nretraso general del desarrollo, manifestando simult\u00e1neamente los tres d\u00e9ficits siguientes: \n1.D\u00e9ficits en la reciprocidad social y emocional; que pueden abarcar desde un acercamiento social anormal y una\nincapacidad para mantener la alternancia en una conversaci\u00f3n, pasando por la reducci\u00f3n de intereses, emociones y\nafectos compartidos, hasta la ausencia total de iniciativa en la interacci\u00f3n social\n2. D\u00e9ficits en las conductas de comunicaci\u00f3n no verbal que se usan en la comunicaci\u00f3n social; que pueden abarcar\ndesde una comunicaci\u00f3n poco integrada, tanto verbal como no verbal, pasando por anormalidades en el contacto visual\ny en el lenguaje corporal, o d\u00e9ficits en la comprensi\u00f3n y uso de la comunicaci\u00f3n no verbal, hasta la falta total de\nexpresiones o gestos faciales\n3- D\u00e9ficits en el desarrollo y mantenimiento de relaciones adecuadas al nivel de desarrollo (m\u00e1s all\u00e1 de las establecidas\ncon  los  cuidadores);  que  pueden  abarcar  desde  dificultades  para  mantener  un  comportamiento  apropiado  a  los\ndiferentes contextos sociales, pasando por  las dificultades para compartir  juegos imaginativos, hasta la aparente\nausencia de inter\u00e9s en las otras personas\nB. Patrones de comportamiento, intereses o actividades restringidas y repetitivas que se manifiestan al menos\nen dos de los siguientes puntos: \n4. Habla, movimientos o manipulaci\u00f3n de objetos estereotipada o repetitiva (estereotipias motoras simples, ecolalia,\nmanipulaci\u00f3n repetitiva de objetos o frases idiosincr\u00e1ticas)\n5. Excesiva fijaci\u00f3n con las rutinas, los patrones ritualizados de conducta verbal y no verbal, o excesiva resistencia al\ncambio (como rituales motores, insistencia en seguir la misma ruta o tomar la misma comida, preguntas repetitivas o\nextrema incomodidad motivada por peque\u00f1os cambios)\n6. Intereses altamente restrictivos y fijos de intensidad desmesurada (como una fuerte vinculaci\u00f3n o preocupaci\u00f3n por\nobjetos inusuales y por intereses excesivamente circunscritos y perseverantes)\n7. Hiper o hipo reactividad a los est\u00edmulos sensoriales o inusual inter\u00e9s en aspectos sensoriales del entorno (como\naparente indiferencia al dolor/calor/fr\u00edo, respuesta adversa a sonidos o texturas espec\u00edficas, sentido del olfato o del tacto\nexacerbado, fascinaci\u00f3n por las luces o los objetos que ruedan)\nC. Los s\u00edntomas han de estar presentes en las primeras fases del per\u00edodo de desarrollo (pero pueden no\nmanifestarse  totalmente  hasta  que  la  demanda  social  supera  las  capacidades  limitadas,  o  pueden  estar\nenmascarados por estrategias aprendidas en fases posteriores de la vida)\nD  Las alteraciones no se explican mejor por una discapacidad intelectual o por un retraso global del desarrollo\nE. Estas alteraciones no se explican mejor por la discapacidad intelectual (trastorno del desarrollo intelectual) o\npor el retraso global del desarrollo. La discapacidad intelectual y el trastorno del espectro del autismo con\nfrecuencia coinciden; para hacer diagn\u00f3sticos de comorbilidades de un trastorno del espectro del autismo y\ndiscapacidad intelectual, la comunicaci\u00f3n social ha de estar por debajo de lo previsto para el nivel general de\ndesarrolloTabla 5. DSM-5: Niveles de gravedad para el Trastorno del Espectro Autista\nComunicaci\u00f3n social Intereses  restringidos  y  conductas\nrepetitivas\nNivel  3:  \u201crequiere\nsoporte  muy\nsubstancial\u201dSeveros  d\u00e9ficits  en  habilidades  de\ncomunicaci\u00f3n social verbal y no verbal causan\nseveras  discapacidades  de  funcionamiento;\nmuy  limitada  iniciaci\u00f3n  de  interacciones\nsociales  y  m\u00ednima  respuesta  a  las\naproximaciones sociales de otrosPreocupaciones,  rituales  fijos  y/o  conductas\nrepetitivas  interfieren  marcadamente  con  el\nfuncionamiento en todas las esferas. Marcado\nmalestar  cuando  los  rituales  o  rutinas  son\ninterrumpidos; resulta muy dif\u00edcil apartarlo de un\ninter\u00e9s fijo o retorna a \u00e9l r\u00e1pidamente\nNivel  2:  \u201crequiere\nsoporte substancial\u201dMarcados  d\u00e9ficits  en  habilidades  de\ncomunicaci\u00f3n  social  verbal  y  no  verbal;\naparentes  discapacidades  sociales  incluso\nrecibiendo  apoyo;  limitada  iniciaci\u00f3n  de\ninteracciones sociales y reducida o anormal\nrespuesta a las aproximaciones sociales de\notros Rituales  y  conductas  repetitivas  y/o\npreocupaciones o intereses fijos aparecen con\nsuficiente frecuencia como para ser obvios al\nobservador  casual  e  interfieren  con  el\nfuncionamiento  en  variados  contextos.  Se\nevidencia  malestar  o  frustraci\u00f3n  cuando  se\ninterrumpen  rituales  y  conductas  repetitivas;\ndificultad a apartarlo de un inter\u00e9s fijo\nNivel  1:  \u201crequiere\nsoporte\u201dSin  recibir  apoyo,  d\u00e9ficits  en  comunicaci\u00f3n\nsocial  causan  discapacidades  observables.\nTiene  dificultad  al  iniciar  interacciones\nsociales  y  demuestra  claros  ejemplos  de\nrespuestas  at\u00edpicas  o  no  exitosas  a  las\naproximaciones  sociales  de  otros.  Puede\naparentar  una  disminuci\u00f3n  en  el  inter\u00e9s  a\ninteraccionar socialmenteRituales  y  conductas  repetitivas  causan\ninterferencia significativa con el funcionamiento\nen uno o m\u00e1s contextos. Resiste intentos de\notros  para  interrumpir  rituales  y  conductas\nrepetitivas o ser apartado de un inter\u00e9s fijo\n1.2 Epidemiolog\u00eda\nDesde principios de los 90 se ha incrementado notablemente la preocupaci\u00f3n\np\u00fablica por los aumentos registrados en los estudios de prevalencia del TEA, lo\nque  ha  puesto  de  manifiesto  la  necesidad  de  establecer  una  vigilancia\nsistem\u00e1tica por parte de los diferentes sistemas sanitarios (Sun et al, 2013).\nDebido a la falta de marcadores biol\u00f3gicos que permitan un diagn\u00f3stico precoz\ny  fiable  del  TEA,  los  estudios  epidemiol\u00f3gicos  han  cobrado  una  notable\nimportancia en el estudio de este trastorno, tratando de contribuir a esclarecer\nlos diferentes factores etiol\u00f3gicos que puedan influir en el desarrollo de la\nsintomatolog\u00eda autista.\nLos primeros trabajos de prevalencia de autismo refer\u00edan cifras en torno a\n4-5/10.000 (Posada-De la Paz et al, 2005) . En estudios posteriores las cifras se\nhan incrementado notablemente. Bertrand et al (2001), estimaron por su parteen Estados Unidos una prevalencia de 30-60/10.000. En Espa\u00f1a, un estudio\nrealizado en Canarias ( ForTEA et al, 2013),  estim\u00f3 una prevalencia de 1/164,\ncoincidiendo la mayor\u00eda de estudios en que  existe una mayor prevalencia de\nni\u00f1os que de ni\u00f1as, (4-5/1) y que no existe diferencia en cuanto a grupos\nsociales o razas (Sun et al 2013; Bertrand et al, 2001). En Estados Unidos, el\nCentro  de  Control  de  Enfermedades  ha  realizado  un  importante  estudio\nepidemiol\u00f3gico en el TEA a partir de los datos recogidos en el sistema de\nvigilancia \"Autism and Developmental Disabilities Monitoring\" (ADDM) en 1 4\nestados (CDC 2012). Los autores estimaron una prevalencia media de 1/88\nentre los 14 estados que participaron en el estudio. Separado por sexos, se\ndetermin\u00f3 una prevalencia de 1/54 ni\u00f1os y de 1/252 ni\u00f1as, con un radio a favor\nde los hombres que vari\u00f3 entre el 2.7 y 7.2 en los 14 estados. En cuanto a las\ndiferencias \u00e9tnicas,  la prevalencia entre ni\u00f1os blancos no hispanos fue de\n12/1000, significativamente mayor que la de los ni\u00f1os negros y los hispanos\n(10.2 y 7.9/1000 respectivamente). La alarma ocasionada tras la difusi\u00f3n de\neste estudio anim\u00f3 a Taylor et al, a realizar un estudio epidemiol\u00f3gico entre\n2004 y 2008 en ni\u00f1os de 8 a\u00f1os a partir de los datos registrados por m\u00e9dicos\ndel Reino Unido y registrados en la base de datos \"General Practice Research\nDatabase\"  (GPRD).  Los  autores  determinaron  una  prevalencia  en  torno  a\n4/1000 ni\u00f1os en 2008, cifra que pese a suponer un notable aumento respecto a\nestudios anteriores, es significativamente inferior a los 11/1000 registrados en\nEstados Unidos. Sin embargo, la diferencia puede deberse en parte a que el\nestudio estadounidense se basa en un sistema de estimaci\u00f3n de prevalencia a\npartir  de  la  presencia  de  sintomatolog\u00eda  autista  recogida  por  diferentes\nprofesionales en el ADDM, mientras que el estudio brit\u00e1nico contabiliza solo\ncasos confirmados. De cualquier modo, parece existir un importante aumento\nde la prevalencia del TEA, la cual puede deberse a un verdadero aumento de la\nincidencia o a otros factores como la mejora de los sistemas de diagn\u00f3stico y\nde detecci\u00f3n precoz, o modificaciones de los criterios diagn\u00f3sticos. 1.3 Clasificaci\u00f3n del Trastorno del Espectro Autista\nTrastorno del Espectro Autista Primario\nPor  lo  general,  cuando  hablamos  de  autismo,  nos  referimos  al  autismo\nprimario,  aquel  que  no  se  asocia  a  otro  s\u00edndrome  o  enfermedad  con\nmanifestaciones  propias  y  distintas  al  TEA.  Como  hemos  comentado\nanteriormente,  en  este  grupo  se  encuentran  la  mayor\u00eda  de  pacientes\ndiagnosticados de TEA, y al igual que en los casos sindr\u00f3micos, parecen influir\nnumerosos factores etiol\u00f3gicos en el desarrollo de la sintomatolog\u00eda autista.\nRecordemos que en su origen, el autismo era considerado como un desorden\npsicol\u00f3gico  pr\u00f3ximo  a  la  esquizofrenia  infantil,  originado  por  una  crianza\nan\u00f3mala por parte de unos padres distantes, incapaces de dar al ni\u00f1o los\ncuidados y cari\u00f1o que necesita. La visi\u00f3n actual del TEA primario es la de un\ndesorden  neurobiol\u00f3gico  que  parece  responder  a  un  modelo  de\nmulticausalidad.  Sin  embargo,  gran  parte  de  los  hallazgos  no  han  sido\nconstantes  en  los  diferentes  estudios  realizados,  por  lo  que  a  menudo\nhablamos  de  \"hip\u00f3tesis\"  o  \"teor\u00edas\"  etiopatog\u00e9nicas,  de  las  cuales\ndesarrollaremos las que incumben a este trabajo, en el apartado 1.4.\nTrastorno del Espectro Autista Secundario\nTradicionalmente el TEA se ha clasificado en primario o idiop\u00e1tico y secundario\no sindr\u00f3mico. Este \u00faltimo es aquel que se asocia a otro s\u00edndrome o alteraci\u00f3n\nque puede ocasionar sintomatolog\u00eda autista, pero que no est\u00e1 definido por la\nmisma.  De  hecho  en  muchos  casos,  se  cataloga  a  los  pacientes  con  el\ndiagn\u00f3stico del s\u00edndrome asociado, obviando el de TEA. Pese a que la mayor\u00eda\nde estudios cifran la proporci\u00f3n de casos secundarios en torno al 10%, es\nobligado  descartar  en  el  proceso  diagn\u00f3stico  las  asociaciones  m\u00e1s\nfrecuentemente asociadas al TEA (Artigas-Pallar\u00e9s et al, 2005), de las cuales\nrevisaremos  algunas  de  las  m\u00e1s  frecuentes.  Hasta  el  momento  se  han\nidentificado numerosos s\u00edndromes asociados al TEA, en los cuales el autismo\nes considerado como secundario, pudiendo presentarse cl\u00ednicamente como el\nautismo primario o como formas incompletas (Tabla 6). Pese a que el presentetrabajo se basa principalmente en el TEA primario, revisaremos tan solo las\nprincipales asociaciones de s\u00edndromes de base gen\u00e9tica asociados a autismo.\nTabla 6. TEA sindr\u00f3mico de base gen\u00e9tica\n- Delecciones y duplicaciones 15q11-13\nS\u00edndrome de Prader-Willi\nS\u00edndrome de Angelman\nInversi\u00f3n-duplicaci\u00f3n 15q11-13   \n- S\u00edndrome del X-fr\u00e1gil\n- S\u00edndrome de Williams\n- S\u00edndrome de Ret\n- Deleci\u00f3n 2q37.3\n- S\u00edndrome XYY\n- S\u00edndrome de Smith-Lemli-Opitz\n-S\u00edndrome de Apert\n- Mutaciones del Gen ARX\n- S\u00edndrome de Lange\n- S\u00edndrome de Smith-Magenis\n- S\u00edndrome de Noonan\n- S\u00edndrome de Down\n- S\u00edndrome Velocardiofacial\n- Distrofia Miot\u00f3nica de Steinert\n- Complejo esclerosis tuberosa- Enfermedad de Duchenne\n- S\u00edndrome de Timothy\n- Delecci\u00f3n terminal 10p\n- S\u00edndrome de Cowden\n- Mosaicismos 45,X/46,XY\n- S\u00edndrome de Myhre\n- S\u00edndrome de Sotos\n- S\u00edndrome de Cohen\n- S\u00edndrome de Goldenhar\n- S\u00edndrome de Joubert\n- S\u00edndrome deLujan-Fryns\n- S\u00edndrome de Moebius\n- Hipomelanosis de Ito\n- Neurofibromatosis I\n- S\u00edndrome CHARGE\n- S\u00edndrome HEADD\nTomado de Artigas-Pallar\u00e9s J et al (2006)\nEl s\u00edndrome del X fr\u00e1gil (SXF) es posiblemente la causa hereditaria m\u00e1s\ncom\u00fan de retraso mental, presentando una prevalencia aproximada de 1/5160\nvarones (Zafeiriou et al, 2013; Coffee et al, 2009). Presenta una herencia ligada\nal X, afectando fundamentalmente a varones. Se debe a una mutaci\u00f3n en el\ngen FMR1 y el consiguiente d\u00e9ficit de su producto, la prote\u00edna FMRP, causado\npor una expansi\u00f3n del triplete de nucle\u00f3tidos CGG, la cual se encuentra en la\nregi\u00f3n no traducida 5\u00b4 del gen. El SXF se produce a partir de 200 repeticiones\ndel triplete, mientras que la presencia de 55 a 199 se considera estado de\nportador o premutaci\u00f3n, pudiendo originar cuadros incompletos o m\u00e1s leves del\nSXF.  Los  sujetos  afectos  del  SXF  presentan  discapacidad  intelectual  y  un\nfenotipo conductual que asocia hiperactividad, impulsividad, disminuci\u00f3n del\ncontacto  ocular,  timidez  y  estereotipias.  F\u00edsicamente  presentan  un  fenotipo\ncaracter\u00edstico no siempre evidente, que consiste en cara alargada, frente y\norejas prominentes, macroorquidismo postpuberal y estatura alta (Berry-Kravis\net al, 2010). Al nacimiento pueden presentar peso elevado y fontanela anterior\nde gran tama\u00f1o (Terracciano et al, 2005).  Los \u00faltimos estudios epidemiol\u00f3gicos\nestiman  una  prevalencia  de  TEA  en  sujetos  con  SXF  entre  el  25-50%dependiendo de los criterios y m\u00e9todos utilizados (Clifford et al, 2007; Garc\u00eda-\nNonell et al, 2008; Hall et al, 2008). A la inversa, el SXF se diagnostica en el 0-\n3% de los pacientes con TEA (Kosinavsky et al, 2005; Reddy 2005; McInnes et\nal, 2005). En lo que refiere a la sintomatolog\u00eda autista, los pacientes con SXF\npresentan  diferencias  cualitativas  en  diversos  aspectos  respecto  al  TEA\nidiop\u00e1tico.  Suelen  presentar  gran  ansiedad  social,  timidez  extrema,\nhiperexcitaci\u00f3n, mientras que las habilidades de la interacci\u00f3n social rec\u00edproca\ny de comunicaci\u00f3n est\u00e1n menos limitadas que en el TEA idiop\u00e1tico (Hall et al,\n2010), mostrando una aparente sensibilidad emocional conservada y voluntad\nde interactuar (Roberts et al, 2007), presentando por lo general un fenotipo de\nTEA menos severo que los casos idiop\u00e1ticos.\nLa regi\u00f3n 15q11-q13 est\u00e1 cobrando gran inter\u00e9s en los estudio gen\u00e9ticos\ndel TEA. Existe una estrecha relaci\u00f3n entre esta regi\u00f3n y el desarrollo de TEA\ntanto  secundario  como  primario.  La  presencia  de  un  cromosoma  15\nisodic\u00e9ntrico da lugar a un s\u00edndrome que se caracteriza por diversos grados de\ndeficiencia intelectual, discurso pobre, hipoton\u00eda, rasgos dism\u00f3rficos, epilepsia\ny autismo (Battaglia et al, 2010) hasta un 92-95% de los casos (Hogart et al,\n2010).  Sin  embargo,  pese  a  presentar  rasgos  claros  de  TEA,  algunas\nconductas  como  la  evoluci\u00f3n  de  la  interacci\u00f3n  social  o  la  adquisici\u00f3n  de\nhabilidades comunicativas a lo largo del tiempo llevaron a Battaglia et al a\nsugerir que los individuos con cromosoma 15 isodic\u00e9ntrico no son \"verdaderos\nautistas\" pese a la presencia de numerosas conductas autistas.\nEl S\u00edndrome de Prader-Willi (SPW) se origina como consecuencia de la\nfalta  de  expresi\u00f3n  de  la  regi\u00f3n  15q11-q13  de  origen  paterno  por  disom\u00eda\nuniparental, mutaci\u00f3n del gen materno o impronta  gen\u00e9tica, aunque no se\npuede  excluir  la  implicaci\u00f3n  de  otros  genes  (Buiting,  2010).  El  SPW  se\ncaracteriza  por  retraso  mental,  hipogonadismo,  obesidad  y  alteraciones\nconductuales  caracter\u00edsticas  como  rasgos  obsesivo-compulsivos,  conducta\ncentrada en la obtenci\u00f3n de comida, conducta manipuladora y reiterativa. El\nTEA alcanza una tasa de prevalencia del 19-36.5% (Descheemaeker et al,\n2006). El S\u00edndrome de Angelman (SA) tiene una gran similitud gen\u00e9tica con el\nSPW pero manifestaciones completamente diferentes. Se origina por la falta de\nexpresi\u00f3n del gen UBE3A de origen materno en la regi\u00f3n 15q11-q13, por losmismos mecanismos citados anteriormente o bien por la mutaci\u00f3n puntual del\nUBE3A, aunque para el desarrollo de TEA en este caso pueden contribuir la\nparticipaci\u00f3n  de  otros  genes  (Bonati  et  al,  2007).  El  gen  UBE3A materno\ncodifica la E AP-3A ubiquitin protein lipasa, importante en la degradaci\u00f3n de\nsustratos proteicos en las neuronas, que se ha asociado adem\u00e1s de con el SA,\ncon casos de autismo familiar. Los pacientes afectos del SA presentan un\nevidente retraso en el desarrollo de forma precoz (Buiting, 2010), retraso en la\nadquisici\u00f3n del lenguaje, risas inmotivadas y convulsiones. Suele acompa\u00f1arse\nde hipoton\u00eda de tronco con hipertrofia de extremidades, falta de equilibrio y\ntendencia  a  aumentar  la  base  de  sustentaci\u00f3n.  Suelen  ser  hiperactivos,\nexcitables y es frecuente el aleteo de manos y problemas en las relaciones\nsociales. Sin embargo a menudo es dif\u00edcil identificar el TEA en estos pacientes\npor su profunda discapacidad, aunque est\u00e1 presente entre el 50-61% de los\ncasos de SA (Bonati et al, 2007; Sahoo et al, 2006).\nSe han hallado duplicaciones proximales 15q en personas con TEA y\ndiversos grados de retraso mental. En un estudio en el que una madre era\nportadora de una duplicaci\u00f3n 15q11-13, dos hijos autistas hab\u00edan heredado la\nduplicaci\u00f3n mientras un tercer hijo no afecto, no hab\u00eda heredado la duplicaci\u00f3n\nmaterna. La duplicaci\u00f3n de la madre proced\u00eda \"de novo\" del cromosoma 15\npaterno. Este ejemplo pone en evidencia la importancia del origen materno o\npaterno de la duplicaci\u00f3n, y una posible explicaci\u00f3n pudiera ser el fen\u00f3meno de\nla impronta gen\u00e9tica (Artigas-Pallar\u00e9s et al, 2005). Adem\u00e1s de la relaci\u00f3n del\nTEA y s\u00edndromes 15q11-q13 existe una relaci\u00f3n a la inversa. La presencia de\nalteraciones en esta regi\u00f3n se encuentran en aproximadamente el 1% de los\ncasos de TEA catalogados como primarios. Depienne et al (2009), sugieren\nque los pacientes con TEA deben ser examinados de forma sistem\u00e1tica las\nregiones descritas, especialmente cuando se asocia a retraso mental.\nEl S\u00edndrome  de  Rett  es un  cuadro  severo  del  desarrollo  del  sistema\nnervioso que afecta solo a mujeres, y que se engloba dentro de los Trastornos\nGeneralizado del Desarrollo del DSM-4. Se produce por una mutaci\u00f3n en el\ngen MeCP2 del cromosoma X. Se caracteriza por un desarrollo aparentemente\nnormal los primeros 6 a 18 meses, seguida de una regresi\u00f3n r\u00e1pida de distintas\nhabilidades  motoras,  ling\u00fc\u00edsticas,  apareciendo  alteraciones  motoras,estereotipias, falta de interacci\u00f3n social, y desarrollo de microcefalia (Artigas-\nPallar\u00e9s et al, 2005) (Tabla 7).\nTabla 7. DSM 5 Criterios Diagn\u00f3sticos del S\u00edndrome de Rett\nA. Todas las caracter\u00edsticas siguientes:\n1. Desarrollo prenatal y perinatal aparentemente normal\n2. Desarrollo psicomotor aparentemente normal durante los primeros 5 meses despu\u00e9s del nacimiento\n3. Circunferencia craneal normal en el nacimiento\nB. Aparici\u00f3n de todas las caracter\u00edsticas siguientes despu\u00e9s del per\u00edodo de desarrollo normal:\n1. Desaceleraci\u00f3n del crecimiento craneal entre los 5 y 48 meses de edad\n2. P\u00e9rdida de habilidades manuales intencionales previamente adquiridas entre los 5 y 30 meses de edad, con el\nsubsiguiente desarrollo de movimientos manuales estereotipados (p. ej., escribir o lavarse las manos)\n3. P\u00e9rdida de implicaci\u00f3n social en el inicio del trastorno (aunque con frecuencia la interacci\u00f3n social se desarrolla\nposteriormente)\n4. Mala coordinaci\u00f3n de la marcha o de los movimientos del tronco\n5. Desarrollo del lenguaje expresivo y receptivo gravemente afectado, con retraso psicomotor grave\n1.4 Etiopatogenia en el Trastorno del Espectro Autista primario\n1.4.1 Inflamaci\u00f3n\nLa  inflamaci\u00f3n  es  la  respuesta  originada  por  el  sistema  inmune  ante  una\nagresi\u00f3n ocasionada por un microorganismo o sus productos, o por  cualquier\notro agente biol\u00f3gico, mec\u00e1nico, f\u00edsico o qu\u00edmico capaz de generar una lesi\u00f3n\ntisular.Es por tanto, un mecanismo de defensa innato e inespec\u00edfico, que se\norigina  como  respuesta  reparadora  ante  una  injuria,  pese  a  que  pueda\nocasionar por si misma una lesi\u00f3n tisular como veremos a continuaci\u00f3n. En la\ninflamaci\u00f3n  intervienen  diversos  tipos  celulares  y  un  amplio  grupo  de\nmediadores e inductores proinflamatorios ( Tabla 8 ). Tabla 8. Principales citoquinas implicadas en el autismo primario\nCITOQUINASORIGEN FUNCI\u00d3N\nIL-1\u03b1\nIL-1\u03b2Monocitos-Macr\u00f3fagos Fiebre (pir\u00f3geno end\u00f3geno), sue\u00f1o, anorexia, inflamaci\u00f3n,\nexpresi\u00f3n de CD 54 en las c\u00e9lulas endoteliales y liberaci\u00f3n\ndel\nfactor tisular, activaci\u00f3n linfocitaria, producci\u00f3n de IL-6 Y CSF\nIL-2 C\u00e9lulas T Induce  la  proliferaci\u00f3n  de  la  c\u00e9lula  T,  coestimula  la\nproliferaci\u00f3n y\ndiferenciaci\u00f3n de la c\u00e9lula B\nIL-3 C\u00e9lulas T, mastocitos Potencia a las c\u00e9lulas NK y LAK \nIL-4 C\u00e9lulas T, mastocitos Induce la proliferaci\u00f3n del mastocito, proliferaci\u00f3n de la c\u00e9lula\nhematopoy\u00e9tica pluripotencial\nIL-5C\u00e9lulas T, mastocitos Induce la proliferaci\u00f3n de la c\u00e9lula T y la generaci\u00f3n de \nLTC, coestimula la proliferaci\u00f3n de la c\u00e9lula B, sinergiza con\nla IL-\n3 en la proliferaci\u00f3n del mastocito, estimula la producci\u00f3n de\nIg E\ne Ig G 4, induce la expresi\u00f3n y liberaci\u00f3n de CD 23,  la clase ll\ndel\nCMH en la c\u00e9lulas B, cambia de TH a TH2.\nIL-6Monocitos, fibroblastos Induce la diferenciaci\u00f3n de eosin\u00f3filos y la producci\u00f3n de Ig A\nIL-7C\u00e9lulas de la m\u00e9dula\n\u00f3sea y del estroma t\u00edmicoPirog\u00e9nica, induce la proliferaci\u00f3n de plasmocitomas e\nhibridomas, aumenta la producci\u00f3n de Ig, la clase l en los\nfibroblastos, acci\u00f3n con la IL-2 en la producci\u00f3n de Proteinas\nde\nFase Aguda por lo hepatocitos, acci\u00f3n sin\u00e9rgica con la IL-3\nen la\nproducci\u00f3n  de  la  c\u00e9lula  hematopoy\u00e9tica,  induce  la\ndiferenciaci\u00f3n\ndel LTC. Induce la proliferaci\u00f3n de las c\u00e9lulas pro y pre B de\nlos\nlinfocitos inmaduros\nIL-8 (quimiocina)Monocitos, c\u00e9lulas\nendoteliales, macr\u00f3fagos\nalveolares, fibroblastos.Induce la quimiotaxis y activaci\u00f3n de neutr\u00f3filos y c\u00e9lulas T\nIL-10C\u00e9lulas T Induce la proliferaci\u00f3n de algunas c\u00e9lulas T, potencia la\nproliferaci\u00f3n del mastocito inducida por la IL-3\nIL-11C\u00e9lulas T, c\u00e9lulas B activadas y\nmonocitos.Inhibe la activaci\u00f3n del MAC, estimula la producci\u00f3n de c\u00e9lula\nB y\nla producci\u00f3n de Ac, estimula los mastocitos y cambia de TH\na\nTH2\nIL-12C\u00e9lulas del\nmicroambiente\nhematopoy\u00e9ticoEstimula la producci\u00f3n de Ac, acci\u00f3n sin\u00e9rgica con la IL-3 en\nla\nproducci\u00f3n de megacariocitos, estimula los progenitores del\nmacr\u00f3fago\nIL-13Monocitos, macr\u00f3fagos,\nalgunas c\u00e9lulas B y\nmastocitos.Activa a las NK para secretar IFN-\u03b3, cambia TH a TH1,\ninhibe la producci\u00f3n de Ig E inducida por la IL-4IL-14C\u00e9lulas T Induce la proliferaci\u00f3n y diferenciaci\u00f3n de c\u00e9lulas B e inhibe\nla\nproducci\u00f3n de IL-1\nIL-15C\u00e9lulas B y macr\u00f3fagos Induce la secreci\u00f3n de Ig E\nIL-16C\u00e9lulas T Induce la proliferaci\u00f3n de la c\u00e9lula B\nIL-17C\u00e9lulas no linfoides,\nmuscularesInduce la proliferaci\u00f3n y citotoxicidad de las c\u00e9lulas NK\nIL-18C\u00e9lulas endoteliales y\nmonocitosInmunomoduladora\n(Pe\u00f1a, http://Inmunolig\u00edaenlinea.es)\nTabla 9. Interferones relacionados con el autismo  \nINTERFERONORIGEN FUNCI\u00d3N\nIFN-\u03b1 Linfocitos Coestimula la producci\u00f3n de la c\u00e9lula T, induce la secreci\u00f3n de\nla\nIL-6,  IL-8  y  G-CSF  a  partitr  de  las  c\u00e9lulas  endoteliales,\nepiteliales\ny fibrobl\u00e1stica\nIFN-\u03b2Fibroblastos y c\u00e9lulas\namni\u00f3ticasIncrementa la expresi\u00f3n de ant\u00edgenos de clase I y II HLA. Y la\nactividad de c\u00e9lulas NK. Induce el factor Inductor del IFN-\u03b3\nsimilar a la IL-1\nIFN-\u03b3Linfocitos CD 4+ y CD\n8+, c\u00e9lulas NK y Th 1Posee  efectos  antivirales  e  inmunomodulatorios.  Es\nquimiot\u00e1ctico\npara monocitos y aumenta en ellos la expresi\u00f3n de HLA clase I\n(Pe\u00f1a, http://Inmunolig\u00edaenlinea.es)\nTabla 10. Factores de Necrosis Tumoral relacionadoscon el autismo primario \nTNFORIGEN FUNCI\u00d3N\nTNF-\u03b1Fibroblastos, c\u00e9lulas NK,\nneutr\u00f3filos, astrositos,\nc\u00e9lulas endoteliales y\nc\u00e9lulas del m\u00fasculo lisoProinflamatorio, antitumoral. Agente neovascularizante y\nestimulante de la resorci\u00f3n \u00f3sea\nTNF-\u03b2Linfocitos Similar al anterior\n(Pe\u00f1a, http://Inmunolig\u00edaenlinea.es)Inflamaci\u00f3n y enfermedades neurol\u00f3gicas\nEn los \u00faltimos a\u00f1os la inflamaci\u00f3n est\u00e1 cobrando gran inter\u00e9s en los estudios\netiopatog\u00e9nicos  de  las  enfermedades  mentales,  como  en  el  caso  de  la\ndepresi\u00f3n  mayor.  En  comparaci\u00f3n  con  individuos  sanos,  los  sujetos  con\ndepresi\u00f3n  mayor  presentan  todas  las  caracter\u00edsticas  cardinales  de  la\ninflamaci\u00f3n  (Miller  et  al,  2009),  incluyendo  elevaciones  de  citoquinas\ninflamatorias y sus receptores solubles en sangre y l\u00edquido cefalorraqu\u00eddeo\n(LCR), as\u00ed como elevaciones en sangre de los niveles de prote\u00ednas de fase\naguda,  mol\u00e9culas  de  adhesi\u00f3n  y  mediadores  inflamatorios  como  las\nprostaglandinas  (Raison  et  al,  2006).  La  asociaci\u00f3n  entre  los  marcadores\ninflamatorios  y  algunos  de  los  s\u00edntomas  depresivos  (Meyers  et  al,  2005;\nMotivala et al, 2005) como la fatiga, disfunci\u00f3n cognitiva y alteraciones del\nsue\u00f1o se han relacionado con los niveles elevados de IL-6 y con el aumento de\nactividad del factor nuclear kappa B (NF-KB) (Irwin et al, 2008; Reichenberg et\nal, 2001). Por otro lado, existen varias l\u00edneas de evidencia que indican que la\nadministraci\u00f3n de citoquinas o inductores de citoquinas como liposac\u00e1ridos o la\nvacunac\u00f3n  en  sujetos  sanos  pueden  causar  s\u00edntomas  relacionados  con  la\ndepresi\u00f3n  como  fatiga,  confusi\u00f3n,  angustia  o  tristeza  (Brydon  et  al,  2008;\nMendlewicz et al, 2006). Por \u00faltimo, algunos estudios han mostrado mejor\u00eda de\nla  respuesta  al  tratamiento  con  antidepresivos  al  a\u00f1adir  un  ihibidor  de  la\nciclooxigenasa como la aspirina (Mendlewicz et al, 2006) o el celecoxib (Muller\net al, 2006).\nLa inflamaci\u00f3n y la disfunci\u00f3n inmunol\u00f3gica pueden tener un papel en la\netiolog\u00eda de los trastornos psic\u00f3ticos (Suvisaaril et al, 2013).Hay evidencias de\nun aumento de la actividad inflamatoria del sistema inmune tanto innato como\nadaptativo  en  la  esquizofrenia  y  en  el  trastorno  bipolar  (Drexhage  et  al,\n2010).Se  han  detectado  elevaciones  en  suero  y  LCR  de  citoquinas\ninflamatorias  y  otros  mediadores  inflamatorios,  as\u00ed  como  el  aumento  de\nexpresi\u00f3n de genes relacionados con la actividad inflamatoria de los monocitos\n(Drexhage et al, 2010; Padmos et al 2008; Drexhage et al, 2011; Suvisaari et al,\n2013). Existe evidencia de que la actividad inflamatoria o inmunol\u00f3gica en la\netapa prenatal aumenta el riesgo de desarrollar esquizofrenia y otros trastornos\npsic\u00f3ticos (Miller et al, 2013).\nLas  citoquinas  participan  activamente  en  el  desarrollo  y  funci\u00f3n  delsistema  nervioso  central  (SNC),  lo  que  puede  explicar  la  relaci\u00f3n  de  las\nenfermedades mentales y la actividad inflamatoria. Se ha demostrado que las\ncitoquinas  son especialmente  importantes  para  el desarrollo  neuronal  y  su\nfunci\u00f3n (Deverman et al, 2009; Carpentier et al, 2009). Durante el desarrollo\nfetal contribuyen a la regulaci\u00f3n de la neurog\u00e9nesis, gliog\u00e9nesis, a la migraci\u00f3n\nde  progenitores,  a  la  proliferaci\u00f3n  axonal  y  al  desarrollo  de  la  microg\u00eda\n(Deverman et al, 2009; Boulanger, 2009). Participan en la regulaci\u00f3n de la\nsupervivencia neuronal, la modulaci\u00f3n de sinapsis, la renovaci\u00f3n de c\u00e9lulas\nmadre neuronales, la diferenciaci\u00f3n celular y la reparaci\u00f3n cerebral (Deverman\net al, 2009; Bauer et al, 2009; de Araujo et al, 2009). Un papel importante de las\ncitoquinas  es  su  participaci\u00f3n  en  la  plasticidad  neuronal,  que  incluye  el\ndesarrollo  y  estabilizaci\u00f3n  de  sinapsis,  fen\u00f3meno  importante  en  funciones\nmentales superiores como la memoria, o en mantener en equilibrio circuitos de\nexcitaci\u00f3n e inhibici\u00f3n (Boulanger, 2009). La neurog\u00e9nesis en el hipocampo, en\nla  cual  participan  las  citoquinas,  es  de  gran  inter\u00e9s  en  los  trastornos\npsiqui\u00e1tricos debido a que las nuevas neuronas ejercen funciones cr\u00edticas en el\nhipocampo como la participaci\u00f3n en procesos de aprendizaje y la memoria\n(Kempermann, 2011).\nInflamaci\u00f3n y Trastorno del Espectro Autista \nEn los \u00faltimos a\u00f1os se han desarrollado diferentes trabajos que apoyan la\nteor\u00eda  de  que  en  un  grupo  de  pacientes  autistas  existe  un  componente\ninflamatorio,  y  que  esta  situaci\u00f3n  proinflamatoria  podr\u00eda  contribuir  en  la\nfisiopatolog\u00eda del TEA (Rodriguez et al, 2011). Pardo  et al (2005), Vargas et al\n(2005),y  Morgan  et  al  (2010),  encontraron  un  aumento  de  citoquinas\nproinflamatorias  en  el  cerebro  y  LCR  de  ni\u00f1os  con  TEA.  Los  autores\nencontraron  un  patr\u00f3n  inflamatorio  activo  en  la  corteza  cerebral,  sustancia\nblanca y particularmente en cerebelo. Los autores se\u00f1alaron que la activaci\u00f3n\nmicroglial hallada puede jugar un papel fundamental en la patog\u00e9nesis del\ncerebro autista. Encontraron significativamente m\u00e1s microgl\u00eda en la corteza\nfronto insular y visual que los controles.\nAhlsen et al (1993), determinaron los niveles de la Prote\u00edna \u00c1cida Glial\nCerebral (GFAP) en LCR de ni\u00f1os autistas, encontrando un nivel promedio tres\nveces  superior  al  del  grupo  control.  Los  autores  determinaron  que  estasituaci\u00f3n podr\u00eda indicar gliosis y da\u00f1o cerebral. Por su parte, Laurence et al\n(2005), cuantificaron los niveles de GFAP en muestras de tejido cerebral post\nmorten  de  pacientes  con  autismo,  encontrando  niveles  superiores  a  las\nmuestras de control en la corteza frontal, parietal y en cerebelo, concluyendo\nque  la  elevaci\u00f3n  de  la  GFAP  podr\u00eda  confirmar  la  activaci\u00f3n  microglial  y\nastroglial en el autismo, e indicar\u00eda gliosis, lesi\u00f3n reactiva y perturbaci\u00f3n de los\nprocesos de migraci\u00f3n neuronal. Fatemi et al (2008), hallaron un incremento\nsignificativo en pacientes autistas de los marcadores de astrocitos acuoporina 4\ny conexina 43 en \u00e1reas como el cerebelo, el \u00e1rea 40 de Brodmann y la corteza\nfrontal superior, lo que indicar\u00eda activaci\u00f3n de  astrocitos.\nParecen existir evidencias de un incremento de citoquinas inflamatorias\nen el cerebro y LCR de ni\u00f1os autistas. Li et al (2009), afirm\u00f3 que los niveles de\nTNF-\u03b1, IL-6, IL-8, GM-CSF e IFN- \u03b3 eran significativamente superiores en los\ncerebros de pacientes con TEA que en controles. Vargas et al (2005), hallaron\nniveles  significativamente  superior  del  TGF- \u03b21  de  origen  neuroglial  en  la\ncircunvoluci\u00f3n frontal media respecto a controles. Tambi\u00e9n encontraron niveles\nsuperiores de la Prote\u00edna Quimiot\u00e1ctica de Macr\u00f3fagos (MCP-1), IL-6, IL-8, e\nIFN-\u03b1 en la circunvoluci\u00f3n cingular anterior, y de MPC-1, IL-6, IL-8 e IFN- \u03b1 en\nLCR. Chez et al (2007), tambi\u00e9n demostraron un aumento significativo de los\nniveles de TNF-\u03b1 en LCR de pacientes autistas respecto a controles. \nMolloy et al (2006), realizaron un estudio de casos y controles en el que\nhallaron que las c\u00e9lulas mononucleares de sangre perif\u00e9rica (PBMC) de la\nmuestra de ni\u00f1os autistas producen niveles significativamente m\u00e1s altos de las\ncitoquinas Th2 IL-2, IL4, IL-5 e IL-13. Tambi\u00e9n existi\u00f3 una tendencia hacia\nniveles superiores de IL-2 y la interleuquina Th1 IFN- \u03b3. Esta diferencia entre\ncasos y controles no persisti\u00f3 despu\u00e9s de la estimulaci\u00f3n mit\u00f3gena de las\nPBMC.  Los  autores  sugieren  que  este  aumento  de  las  citoquinas  sin\nestimulaci\u00f3n puede indicar una respuesta inmune alterada, con una repuesta\npredominante, aunque no exclusiva de c\u00e9lulas Th2. El aumento de cualquiera\nde las citoquinas Th1 o Th2 debe producir un aumento compensatorio de la IL-\n10 con efecto inmunomodulador (Moore et al, 2001), sin embargo los autores\nrefieren una ausencia de aumento compensatorio de la IL-10 en los pacientes\nautistas. Adem\u00e1s hallaron un mayor n\u00famero de eosin\u00f3filos en sangre perif\u00e9rica\nen los casos respecto a los controles. Finalmente, los autores valoraron comolimitaci\u00f3n del estudio la no exclusi\u00f3n de ni\u00f1os con tratamiento farmacol\u00f3gico.\nSin embargo, tras una revisi\u00f3n de la literatura (Bastererzi et al, 2005; Zhang et\nal,  2004)  concluyeron  que  es  poco  probable  que  los  f\u00e1rmacos  fueran\nresponsables de las diferencias encontradas.\nAngelidou  et  al  (2012),  realizaron  una  interesante  revisi\u00f3n  sobre\ninflamaci\u00f3n cerebral y estr\u00e9s perinatal asociado al TEA. Los autores planTEAn\nla posibilidad de la existencia de un endofenotipo de autismo con disrregulaci\u00f3n\nautoinmune, tal y como han referido diversos autores (Mostafa et al, 2009;\nEnstrom et al, 2009; Wills et al, 2007), y que \u00e9sta podr\u00eda participar en la\npatogenia de los s\u00edntomas autistas en estos pacientes. En una cohorte de ni\u00f1os\nautistas egipcios, el 54.5% presentaron anticuerpo antineurona (Mostafa et al,\n2010), lo que puede indicar una p\u00e9rdida de la auto tolerancia a los ant\u00edgenos\nneuronales  durante  las  primeras  fases  del  neurodesarrollo,  aunque  por  el\nmomento se desconoce su papel exacto en la patogenia de la sintomatolog\u00eda\nautista. Por otro lado, los autores valoraron la importancia del papel del TGF- \u03b21\nen el TEA. Hay autores que han detectado niveles bajos del TGF- \u03b21 en ni\u00f1os\nTEA (Ashwood et al, 2008), aunque la importancia de este hallazgo no est\u00e1\nclaro bas\u00e1ndonos en estudios animales, ya que una sobreexpresi\u00f3n de TGF- \u03b21\ndespu\u00e9s del nacimiento, podr\u00eda relacionarse con disminuci\u00f3n de la interacci\u00f3n\nsocial en ratones, mientras una sobreexpresi\u00f3n cr\u00f3nica de TGF- \u03b21 en ratones\nadultos  condiciona  un  comportamiento  opuesto,  lo  que  podr\u00eda  estar  en\nconsonancia con la sobreexpresi\u00f3n de TGF-beta1 hallada en pacientes autistas\n(Depino et al, 2011).\nLa  expresi\u00f3n  de  NF-KB  podr\u00eda  participar  en  la  neuroinflamaci\u00f3n  de\nalgunos  pacientes  con  TEA.  Young  et  al  (2011),  afirmaron  que  NF-KB  se\nexpresa de forma aberrante en la corteza orbitofrontal en pacientes con TEA, lo\ncual podr\u00eda formar parte de una cascada molecular inflamatoria que tendr\u00eda\nlugar  fundamentalmente  en  regiones  del  cerebro  implicadas  en  la\nsintomatolog\u00eda autista. Naik et al (2011), examinaron las muestras de sangre\nperif\u00e9rica de 67 ni\u00f1os autistas y 29 ni\u00f1os controles, y determinaron que el\ngrupo  de  autistas  present\u00f3  un  aumento  de  la  actividad  de  NF-KB\nestad\u00edsticamente significativa respecto al grupo de control. 1.4.2 Estr\u00e9s oxidativo\nEl estr\u00e9s oxidativo es aquella situaci\u00f3n caracterizada por un desequilibrio entre\nla generaci\u00f3n de especies reactivas de ox\u00edgeno (ERO) y la disponibilidad o\nacci\u00f3n de los mecanismos antioxidantes compensatorios. El estr\u00e9s oxidativo\npuede causar muerte celular o desencadenar la apoptosis, o incluso cuando es\nmuy  intenso  puede  originar  necrosis.  Como  norma  general,  las  c\u00e9lulas\nmantienen en su interior un estado reducido gracias a la acci\u00f3n de enzimas\nreductoras. Cuando se produce un disbalance en este estado redox, predomina\nla  producci\u00f3n  de  per\u00f3xidos  y  radicales  libres  que  da\u00f1an  los  componentes\ncelulares como las prote\u00ednas, l\u00edpidos y el DNA. Un aspecto particularmente\ndestructivo del estr\u00e9s oxidativo es la producci\u00f3n de ERO, que incluyen los\nradicales libres y los per\u00f3xidos. La mayor\u00eda de estas especies derivadas del\nox\u00edgeno se producen en un nivel bajo en condiciones normales de metabolismo\naer\u00f3bico y el da\u00f1o que causan a las c\u00e9lulas es reparado constantemente. Sin\nembargo, bajo los graves niveles de estr\u00e9s oxidativo que causa la necrosis, el\nda\u00f1o produce agotamiento de adenos\u00edn trifosfato (ATP) impidiendo la muerte\ncelular por apoptosis controlada. La fuente m\u00e1s importante de ox\u00edgeno reactivo\nen  condiciones  normales  en  organismos  aer\u00f3bicos  es  probablemente  la\np\u00e9rdida de ox\u00edgeno activado de las mitocondrias durante el funcionamiento\nnormal de la respiraci\u00f3n oxidativa.\nAnte el peligro que representa el da\u00f1o oxidativo, las c\u00e9lulas se encuentran\nhabilitadas  con  mecanismos  de  protecci\u00f3n:  preventivos,  secuestradores  y\nreparadores de este deterioro. Los antioxidantes celulares mejor estudiados\nson las enzimas super\u00f3xido dismutasa (SOD), catalasa y glutati\u00f3n peroxidasa\n(GSH-Px). Antioxidantes enzim\u00e1ticos menos estudiados (pero probablemente\nmuy importantes) son la peroxirredoxina y la sulfirredoxina. Otras enzimas que\ntienen propiedades antioxidantes (aunque \u00e9sta no es su funci\u00f3n primordial)\nincluyen  la  paraoxonasa,  la  glutati\u00f3n  S-transferasa,  y  la  aldeh\u00eddo\ndeshidrogenasa. La medici\u00f3n del estr\u00e9s oxidativo puede realizarse a trav\u00e9s de\nlos siguientes par\u00e1metros:\n- Concentraci\u00f3n de GSH-Px: se realiza bas\u00e1ndose en el consumo de NADPH\n(nicotinamida adenina dinucle\u00f3tido fosfato) a 340nm, coenzima involucrada en\nla reacci\u00f3n catalizada por la glutati\u00f3n reductasa (GSSGR).\n- Concentraci\u00f3n de glutati\u00f3n (GSH): el glutati\u00f3n es un trip\u00e9ptido que contieneun enlace pept\u00eddico inusual entre el grupo amino de la ciste\u00edna y el grupo\ncarboxilo de la cadena lateral del glutamato. El glutati\u00f3n es un antioxidante que\nayuda a proteger las c\u00e9lulas de especies reactivas de ox\u00edgeno.  El glutati\u00f3n\nreduce  cualquier  enlace  disulfuro  (-S-S-)  formado  dentro  de  prote\u00ednas\ncitoplasm\u00e1ticas de ciste\u00ednas, al actuar como un donante de electrones. En el\nproceso, el glutati\u00f3n se convierte en su forma oxidada disulfuro de glutati\u00f3n\n(GSSG). El glutati\u00f3n se encuentra casi exclusivamente en su forma reducida,\nya que la enzima que cataliza la reducci\u00f3n, la glutati\u00f3n reductasa (GR), es\nconstitutivamente  activa  e  inducible  por  estr\u00e9s  oxidativo.  De  hecho,  la\nproporci\u00f3n de glutati\u00f3n reducido a glutati\u00f3n oxidado dentro de las c\u00e9lulas a\nmenudo se utiliza cient\u00edficamente como una medida de la toxicidad celular.\n- Lipoperoxidaci\u00f3n en tejidos animales: los radicales libres atacan a los \u00e1cidos\ngrasos  poliinsaturados  de  las  membranas  celulares  y  lipoprote\u00ednas\ntransform\u00e1ndolos  en  \u00e1cidos  grasos  peroxidados,  los  cuales  sufren  un\nacortamiento de su cadena lateral liberando malondialdeh\u00eddo (MDA), de tal\nmanera que la concentraci\u00f3n s\u00e9rica de MDA, es proporcional a los \u00e1cidos\ngrasos  poliinsaturados  oxidados  y  por  lo  tanto  un  buen  indicador  de\nperoxidaci\u00f3n lip\u00eddica.\nEstr\u00e9s oxidativo y enfermedades neurol\u00f3gicas\nEl cerebro consume gran cantidad de ox\u00edgeno para desarrollar sus funciones\nfisiol\u00f3gicas, lo que origina gran cantidad de radicales libres. Algunos factores\nhacen que el SNC sea susceptible al ataque de las ERO, como el d\u00e9ficit de\nmecanismos  antioxidantes,  la  alta  composici\u00f3n  en  \u00e1cidos  grasos\npoliinsaturados y la selectividad de la barrera hematoencef\u00e1lica (BHE), que\nreduce la difusi\u00f3n de algunos antioxidantes como la vitamina E (Diaz-Hung et\nal,  2013).El  estr\u00e9s  oxidativo  ha  sido  estudiado  fundamentalmente  en  las\nenfermedades neurodegenerativas como la enfermedad de Alzheimer (Lovell et\nal, 2007), la enfermedad de Parkinson (Nikam et al, 2009; Zhou et al, 2008) y la\nesclerosis lateral amiotr\u00f3fica (Chi et al, 2007). En estas enfermedades se ha\nencontrado da\u00f1o oxidativo incluso en etapas tempranas de la enfermedad, lo\nque podr\u00eda indicar que los radicales libres est\u00e1n relacionados con la etiolog\u00eda\nde estos procesos. En la enfermedad de Alzheimer se afectan espec\u00edficamente\nlas neuronas piramidales del hipocampo y la corteza parietal, y la sustancianegra  compacta,  las  neuronas  del  estriado  y  las  motoneuronas  en  la\nenfermedad  de  Parkinson,  Huntington  y  la  esclerosis  lateral  amiotr\u00f3fica,\nrespectivamente.  Desafortunadamente,  los  mecanismos  que  determinan  la\nvulnerabilidad neuronal selectiva actualmente son desconocidos (Mattson et al,\n2006).\nEstr\u00e9s oxidativo y Trastorno del Espectro Autista \nRecientemente se est\u00e1 consolidando la teor\u00eda de que el estr\u00e9s oxidativo podr\u00eda\nintervenir en la patogenia del TEA (Kern et al, 2013; Essa et al, 2012). Varios\nestudios (L\u00f3pez-Hurtado et al, 2008; Evans et al, 2008; Sjadel-Sulkowska et al,\n2008, 2009 y 2011; Chauhan et al, 2011 y 2012) de tejido cerebral postmorten\nrevelaron que en personas diagnosticadas de TEA se detect\u00f3 un estado de\nestr\u00e9s oxidativo. Un ejemplo de ello lo encontramos en el estudio de L\u00f3pez-\nHurtado et al (2008),  en el que los autores informaron que la densidad de la\nlipofuscina, un material de dep\u00f3sito que se forma como consecuencia de la\noxidaci\u00f3n  en  los  tejidos,  era  mayor  en  las  \u00e1reas  cerebrales  corticales  en\nrelaci\u00f3n con la comunicaci\u00f3n en pacientes con TEA que en los controles, lo\ncual puede estar en relaci\u00f3n al d\u00e9ficit de la capacidad comunicativa y del\nlenguaje relacionada con el autismo. Sajdel-Sulkowska et al (2011), informaron\nque existe unos niveles m\u00e1s altos en pacientes autistas de los marcadores de\nestr\u00e9s oxidativo 3-nitrotirosina en la corteza orbitofrontal, el \u00e1rea de Wernicke,\nvermis cerebeloso, hemisferios cerebelosos y puente del enc\u00e9falo, \u00e1reas del\ncerebro asociadas con el lenguaje, el procesamiento sensorial, la coordinaci\u00f3n\nmotora,  la emoci\u00f3n,  la  interacci\u00f3n  social y la  memoria.  En otros  estudios,\nSajdel-Sulkowska et al (2008 y 2009), encontraron niveles m\u00e1s elevados de los\nmarcadores de estr\u00e9s oxidativo 3-nitrotirosina y neurotrofina-3 en el cerebelo\nde pacientes diagnosticados de TEA que en el grupo de control. Evans et al\n(2008), encontraron elevados los niveles de carboxietil pirrol e iso 4 levugland\u00edn\nprote\u00edn  adducts,  metabolitos  que  indican  estr\u00e9s  oxidativo  en  tejido  cortical\ncerebral de personas con TEA en comparaci\u00f3n con los controles. Chauhan et al\n(2012) estudiaron tejidos cerebrales postmorten del cerebelo, y de los l\u00f3bulos\nfrontales, temporales y parietales, as\u00ed como de la corteza occipital de pacientes\ndiagnosticados de TEA y de controles de la misma edad con un desarrollo\nneurol\u00f3gico normal. Determinaron que la oxidaci\u00f3n del DNA se increment\u00f3significativamente en el grupo de pacientes TEA. Por otra parte, los niveles de\nglutati\u00f3n  reducido  fueron  significativamente  menores  en  la  corteza  frontal,\ntemporal  y  cerebelo,  mientras  que  los  niveles  de  glutation  oxidado  fueron\nsignificativamente superiores en la corteza temporal y cerebelo del grupo de\nindividuos con TEA. Chauhan et al (2011), hallaron niveles de per\u00f3xidos de\nl\u00edpidos  significativamente  mayores  en  la  corteza  temporal  y  cerebelo  de\nindividuos diagnosticados de TEA en comparaci\u00f3n con los controles.\nEn  una  cohorte  saud\u00ed  de  ni\u00f1os  autistas  (Al  Gadani  et  al,  2009),  los\ninvestigadores  concluyeron  que  los  niveles  plasm\u00e1ticos  de  MDA  eran\nsignificativamente mayores en el plasma de ni\u00f1os autistas que en el grupo de\ncontrol, el cual podr\u00eda deberse al aumento de la producci\u00f3n de ERO. Como\nhemos comentado anteriormente, el MDA procede de la peroxidaci\u00f3n de \u00e1cidos\ngrasos  poliinsaturados,  los  cuales  est\u00e1n  presentes  en  las  membranas\ncelulares, por lo que podr\u00edan ser indicativos de lesi\u00f3n celular. En este sentido\nZoroglu  et  al  (2004),informaron  de  un  aumento  de  los  niveles  de  TBARS\n(productos reactivos del \u00e1cido tiobarbit\u00farico) en el suero de pacientes autistas\nrespecto  al  grupo  control,  lo  que  indicar\u00eda  un  aumento  de  la  peroxidaci\u00f3n\nlip\u00eddica. Por otra parte Ming et al (2005),refirieron un aumento de la excrecci\u00f3n\nurinaria  de  8-isoprostano-alfa  en  ni\u00f1os  autistas  respecto  a  controles,  que\nindicar\u00eda un estado de estr\u00e9s oxidativo. El aumento reportado de peroxidaci\u00f3n\nlip\u00eddica  en  ni\u00f1os  autistas,  podr\u00eda  ser  correlacionado  con  la  disfunci\u00f3n\nmitocondrial  como  indican  otros  autores  (Napoli  et  al,  2013).  Sen  et  al\n(2007),demostraron  que  la  p\u00e9rdida  del  potencial  de  membrana  a  nivel\nmitocondrial  y  el  deterioro  en  la  actividad  en  la  cadena  de  transporte  de\nelectrones pueden ser secundarios a la peroxidaci\u00f3n de l\u00edpidos de membrana.\nEn base a esta informaci\u00f3n, los autores planTEAn la posibilidad de que el\nestr\u00e9s oxidativo registrado podr\u00eda ser correlacionado con el insulto neuronal en\nel autismo. Kern et al (2006), planTEAn la hip\u00f3tesis de que la p\u00e9rdida de\nc\u00e9lulas de Purkinje y el aumento del volumen cerebral en el autismo est\u00e1n\nrelacionados con la toxicidad y aumento de la peroxidaci\u00f3n lip\u00eddicos. Adem\u00e1s,\nel elevado nivel de peroxidaci\u00f3n lip\u00eddica se correlaciona directamente con la\nreactividad plaquetaria anormal y el flujo sangu\u00edneo alterado en ni\u00f1os TEA (Yao\net al, 2001).  \nDiversos estudios (Al Gadani et al, 2009; Geier et al, 2008; Vojdani et al,2008) han mostrado un descenso de los niveles de GSH y de la relaci\u00f3n\nGSH/GSSG en pacientes con TEA, lo que podr\u00eda indicar un estado de estr\u00e9s\noxidativo.  La  GSH-Px,  es  una  enzima  inducible  por  estr\u00e9s  oxidativo  que\nproporciona un mecanismo eficaz de defensa celular, ya que elimina per\u00f3xido\nde hidr\u00f3geno (H2O2) y per\u00f3xidos de l\u00edpidos (Al Gadani et al, 2009).Sogout et al\n(2003), observaron un aumento de la GSH-Px en eritrocitos de pacientes con\nTEA en  comparaci\u00f3n  con  controles,  lo  cual  est\u00e1  en  consonancia  con  los\nresultados hallados en la cohorte de ni\u00f1os TEA saud\u00eds, aunque Yorbik et al\n(2002), informaron de la presencia de niveles significativamente m\u00e1s bajos de\nesta enzima en ni\u00f1os TEA. Por otro lado, tambi\u00e9n se ha reportado un aumento\nde la actividad de la catalasa en ni\u00f1os TEA (Al Gadani et al, 2009), enzima que\nprotege a las c\u00e9lulas de la acumulaci\u00f3n de H2O2, de la cual, las  mitocondrias\nson la principal fuente de producci\u00f3n. Concluyen los autores, que el aumento\nde  la  actividad  de  la  GSH-Px  junto  con  el  aumento  de  la  actividad  de  la\ncatalasa  podr\u00edan  apoyar  la  teor\u00eda  de  disfunci\u00f3n  mitocondrial  observada\npreviamente en ni\u00f1os TEA.\nLa vitamina E es el antioxidante liposoluble m\u00e1s importante. Protege las\nmembranas celulares de la oxidaci\u00f3n por acci\u00f3n de radicales libres y se ha\nsugerido que la funci\u00f3n m\u00e1s importante de la vitamina E es la protecci\u00f3n del\nda\u00f1o neuronal (Zingg et al, 2004). Hay estudios que han reportado niveles\nsignificativamente menores de vitamina E en pacientes TEA (Al Gadani et al,\n2009)  y  dado  que  el  cerebro  tiene  un  alto  contenido  de  material  lip\u00eddico,\nsusceptible de ser protegido de la oxidaci\u00f3n por la vitamina E, se ha propuesto\nsu  utilizaci\u00f3n  en  el  tratamiento  del  autismo  y  de  otras  enfermedades\nneurodegenerativas (Kontush et al, 2004). El \u00e1cido asc\u00f3rbico o vitamina C es\nun antioxidante hidrosoluble que protege al organismo de la acci\u00f3n de radicales\nlibres (Padayatty et al, 2003). Algunos autores (Gupta et al, 1998; Adamas et al,\n2004), han reportado que los ni\u00f1os autistas ten\u00edan niveles de vitamina C muy\npor debajo de los controles de ni\u00f1os sanos. Sin embargo estos hallazgos no\nhan sido constantes en otros estudios (Al Gadani et al, 2009).\n1.4.3 Perfil metabol\u00f3mico\nUnos de los principales problemas asociados a la investigaci\u00f3n en el TEA es la\ngran variedad de fenotipos englobados bajo un mismo t\u00e9rmino, que a pesar deque comparten las mismas dificultades, no puede descartarse que se traten de\npatolog\u00edas  diferentes  con  distintos  mecanismos  fisiopatol\u00f3gicos.  En  este\nsentido,  nuevas  t\u00e9cnicas  como  el  estudio  del  perfil  metabol\u00f3mico  pueden\ncontribuir a esclarecer el origen de los diferentes fenotipos del TEA a trav\u00e9s de\nsu  potencial  para  realizar  el  an\u00e1lisis  global  de  metabolitos  de  bajo  peso\nmolecular, lo que podr\u00eda correlacionarse con alteraciones sit\u00e9micas.\nYap  et  al  (2010),  informaron  una  alteraci\u00f3n  en  la  v\u00eda  metab\u00f3lica  del\ntript\u00f3fano-\u00e1cido  nicot\u00edmico  utilizando  una  plataforma  basada  en  resonancia\nmagn\u00e9tica  nuclear  en  orina  de  ni\u00f1os  autistas.  Otros  autores  hallaron\nalteraciones del metabolismo de los amino\u00e1cidos, carbohidratos y de las v\u00edas\ndel  estr\u00e9s  oxidativo  en  muestras  de  orina  mediante  cromatograf\u00eda  l\u00edquida-\nespectrometr\u00eda de masas (LC \u2013 MS) (Bitar et al, 2018; Mavel et al, 2013; Ming\net al, 2012) y resonancia magn\u00e9tica nuclear (Noto et al, 2014) en pacientes\nTEA. En general, el TEA se ha asociado a alteraciones en los metabolomas de\nmuestras  de  plasma  y  orina  relacionadas  con  las  v\u00edas  metab\u00f3licas  del\ntript\u00f3fano,  \u00e1cido  nicot\u00ednico,  purinas,  vitamina  B6  y  el  aumento  del  estr\u00e9s\noxidativo, as\u00ed como alteraciones de la microbiota intestinal (Gevi et al, 2016;\nLussu et al, 2017; Mavel et al, 2013; Mussap et al. 2016; Nadal-Desbarats et al,\n2014). \nRecientemente, West et al (2014) han descrito alteraciones en las rutas\nmetab\u00f3licas del aspartato, citrato, creatinina, DHEA-S, isoleucina, glutamato y\nglutarato en plasma, que no hab\u00edan sido descritas anteriormente en orina. Por\ntanto, el an\u00e1lisis metab\u00f3lico en plasma parece ser una herramienta adecuada\npara una profundizar en la investigaci\u00f3n de los mecanismos fisiopatol\u00f3gicos de\neste trastorno y con potencial para identificar perfiles metab\u00f3licos dentro del\nespectro.\n1.4.4 Metales Pesados\nUna de las teor\u00edas etiopatog\u00e9nicas m\u00e1s estudiada es la posibilidad de que una\nintoxicaci\u00f3n con metales pesados podr\u00eda contribuir a producir los s\u00edntomas del\nTEA, especialmente por el mercurio (Hg). El Hg un es metal que no cumple\nninguna funci\u00f3n biol\u00f3gica en el organismo, y su presencia en el cuerpo por\ntanto es ex\u00f3gena, procedente fundamentalmente de la ingesta de alimentos\ncontaminados, especialmente pescados de gran tama\u00f1o y de la industria. Elexceso de Hg en el organismo solo puede deberse a dos factores, un aumento\nen su aporte o un d\u00e9ficit en su eliminaci\u00f3n, la cual parece ser la que tendr\u00eda\nuna  mayor  relaci\u00f3n  con  el  TEA.  El  mercurio  es  oxidado  en  los  eritrocitos\ngracias a la acci\u00f3n del GSH, y es eliminado fundamentalmente por las heces a\ntrav\u00e9s de la bilis, por orina y mediante la incorporaci\u00f3n al cabello. El mercurio\nno oxidado es muy liposoluble, y puede atravesar la BHE y producir toxicidad\nneuronal (Flora, 2009).\nLa utilizaci\u00f3n del timerosal, compuesto organomerc\u00farico empleado como\nconservante  en  las  vacunas  ha  creado  una  enorme  controversia  sobre  la\nposibilidad de que exista relaci\u00f3n entre la vacunaci\u00f3n y el TEA. Bernard et al\n(2001), planTEAron por primera vez la hip\u00f3tesis de que el TEA se relaciona con\nla toxicidad por Hg, basada en la similitud de los s\u00edntomas de la intoxicaci\u00f3n\ncr\u00f3nica del Hg y los del TEA. Este estudio ha sido citado a menudo en los\ntrabajos que apoyan los tratamientos de quelaci\u00f3n de metales pesados y la\ntoxicidad  por  timerosal,  aunque  Nelson  et  al  (2003),  examinaron  ambas\nentidades y concluyeron que en el autismo no se aprecian manifestaciones\npropias  de  la  intoxicaci\u00f3n  por  mercurio  como  la  ataxia,  las  alteraciones\nvisuales,  neuropat\u00eda  perif\u00e9ricas,  hipertensi\u00f3n,  erupci\u00f3n  cut\u00e1nea  o  la\ntrombocitopenia. Sin embargo en una reciente revisi\u00f3n, Geier et al (2018),\ninform\u00f3 sobre la plausibilidad biol\u00f3gica de la intoxicaci\u00f3n por Hg para inducir el\nTrastorno Generalizado del Desarrollo, rechazando la hip\u00f3tesis de Nelson, a\npesar de que la citada entidad no es equivalente al TEA, si no que supone un\ngrupo de trastornos m\u00e1s heterog\u00e9neos (APA, 2000).  Por su parte, Wecker et al\n(1985), no detectaron diferencias significativas de la cantidad de Hg en el pelo\nde  ni\u00f1os  TEA  en  relaci\u00f3n  con  controles,  aunque  Holmes  et  al  (2003),\ndeterminaron que los ni\u00f1os con TEA ten\u00edan niveles inferiores de Hg en cabello\ny que este posible d\u00e9ficit de la eliminaci\u00f3n de Hg podr\u00eda relacionarse con los\nefectos t\u00f3xicos del metal y la sintomatolog\u00eda del TEA, aunque en un meta-\nan\u00e1lisis  Kwok  et  al  (2007),  no  encontraron  suficientes  evidencias  para\ndemostrar que los niveles de mercurio en el cabello de pacientes con TEA es\ninferior al de los controles. El mismo an\u00e1lisis determin\u00f3 que la exposici\u00f3n al\ntimerosal no aumentaba significativamente el riesgo de desarrollar TEA. Sin\nembargo  Kern  et  al  (2016),   en  una  revisi\u00f3n  de  la  literatura  encontr\u00f3  91\nestudios que examinan la posible relaci\u00f3n entre el Hg y el TEA desde 1999hasta febrero de 2016. De estos estudios, la gran mayor\u00eda (74%) sugiere que el\nHg es un factor de riesgo para el TEA.\nPese a que de momento no existe evidencia de la participaci\u00f3n del Hg\ncomo  factor  determinante  en  el  desarrollo  del  TEA,  se  han  desarrollado\ndiversos estudios que valoran las terapias de quelaci\u00f3n en pacientes con TEA.\nAs\u00ed, Lonsdale et al (2002), afirmaron que la terapia de quelaci\u00f3n puede tener\nefectos beneficioso en algunos ni\u00f1os con TEA, y Bradstrreet y col (2003),\nestudiando la carga corporal de metales pesados en ni\u00f1os con TEA informaron\nque la eliminaci\u00f3n urinaria de Hg aument\u00f3 3,1 veces tras administrar \u00e1cido 2-3\ndimercapto succ\u00ednico (DMSA). \nOtros metales pesados se han relacionado con el TEA. Blaylock y col\n(2009), determin\u00f3 que la exposici\u00f3n al aluminio podr\u00eda empeorar los s\u00edntomas\nde los pacientes con TEA, posiblemente por un aumento del estr\u00e9s oxidativo a\nnivel cerebral, y Al-Ayadhi (2005), hall\u00f3 niveles significativamente mayores de\nars\u00e9nico, antimonio, cadmio, plomo y Hg en ni\u00f1os con TEA en comparaci\u00f3n\ncon ni\u00f1os sanos. Por su parte Blaucok et al (2012), administraron DMSA a una\ncohorte de ni\u00f1os con TEA e informaron de un aumento significativo de la\neliminaci\u00f3n urinaria de Hg, cadmio y plomo tras la terapia de quelaci\u00f3n, y que\nexisti\u00f3 una mejor\u00eda de la severidad de los s\u00edntomas autistas medidas por The\nChildhood Autism Rating Scale (CARS), resultados en consonancia con los de\nAdams et al (2009),  que afirmaron que la severidad del TEA podr\u00eda estar\nrelacionada  significativamente  con  la  presencia  de  metales  pesados  en  el\norganismo. \n1.4.5 Microbiota intestinal \nNumerosos  estudios  han  evaluado  la  presencia  de  alteraciones\ngastrointestinales (GI) en el TEA y su posible implicaci\u00f3n en el desarrollo de\ndicho trastorno. En este sentido Coury et al (2012), en una revisi\u00f3n al respecto\ninformaron  que  la  prevalencia  de  alteraciones  gastrointestinales  entre  los\npacientes con TEA oscila entre el 9 y el 91%, presentando dolor o malestar\nabdominal entre el 2 y el 41%, diarrea entre el 3 y el 77%, diarrea cr\u00f3nica del 8\nal 19% y estre\u00f1imiento del 6 al 45%. Por el momento se desconoce la relaci\u00f3n\nentre  las  alteraciones  GI  y  la  etiolog\u00eda  o  los  s\u00edntomas  del  TEA,  siendo\nnecesarios m\u00e1s estudios que traten de aclarar esta situaci\u00f3n. Dentro de las alteraciones GI en el TEA, la alteraci\u00f3n de la microbiota\nintestinal  es  una  de  las  l\u00edneas  de  investigaci\u00f3n  m\u00e1s  reciente.  Existe  una\nhip\u00f3tesis  de  que  una  alteraci\u00f3n  en  la  permeabilidad  intestinal  junto  con\nalteraciones en la flora al mismo nivel pueden participar en la sintomatolog\u00eda\nautista. Son varios los estudios que han informado sobre una alteraci\u00f3n en la\nfunci\u00f3n de la barrera intestinal (de Magistris et al, 2010), y recientemente Altieri\net  al  (2011),  informaron  de  un  aumento  significativo  en  pacientes  TEA de\nproductos bacterianos en la orina como el p-cresol. Por su parte Finegold et al\n(2008 y 2010), informaron de un recuento superior de especies de Clostridium,\nBacteroides y Firmicutes en ni\u00f1os con TEA respecto a controles. Adem\u00e1s,\nrecientemente est\u00e1 creciendo la evidencia de que la alteraci\u00f3n en la microbiota\nintestinal  puede  estar  relacionada  con  alteraciones  del  comportamiento\nfrecuentes en el TEA como la ansiedad, la reactividad emocional (Heijtz et al\n2011; Forsythe et al, 2010; Cryan et al, 2011; Collins et al, 2009) e interferir en\nel metabolismo de la serotonina (Desbonnet et al, 2008),  la cual se planTEA\ncomo posible marcador biol\u00f3gico en el TEA. \nRecientemente Hsaio et al (2013), reprodujeron sintomatolog\u00eda autista en\ncr\u00edas de rat\u00f3n tras  activaci\u00f3n  inmune  materna (MIA).  Informaron  como  los\ncambios  en  la  microbiota  intestinal  origin\u00f3  la  presencia  de  metabolitos  en\nplasma que originan sintomatolog\u00eda similar a la autista, y posteriormente, la\nadministraci\u00f3n de Bacteroides fragilis revirti\u00f3 las alteraciones neurol\u00f3gicas e\ninmunol\u00f3gicas.  Los  autores informaron de un aumento  de 46 veces de  4-\nethylphenylsulfate (4EPS) en el plasma de las cr\u00edas de ratones MIA que revirti\u00f3\na niveles normales tras la administraci\u00f3n de las cepas de Bacteroides. Adem\u00e1s,\nlos ratones normales presentan niveles indetectables de 4EPS en plasma, y la\nadministraci\u00f3n  de  4EPS  en  ratones  sin  alteraciones  GI  origin\u00f3  s\u00edntomas\nsimilares a la ansiedad. Parece ser que el 4EPS se relaciona con el metabolito\np-cresol, que como hemos comentado anteriormente est\u00e1 presente en la orina\nde algunos pacientes con TEA. De hecho Persico et al (2013), sugieren que el\np-cresol podr\u00eda utilizarse como marcador biol\u00f3gico en el TEA en humanos. En\nel  mismo modelo de rat\u00f3n,  se  observ\u00f3  un  aumento de otro metabolito,  el\nindolpiruvato, generado por la flora GI a partir del catabolismo del tript\u00f3fano.\nEsta  elevaci\u00f3n  del  indolpiruvato  refieren  los  autores  que  podr\u00eda  estar  en\nrelaci\u00f3n  tanto  con  el  indolil-3-acryloylglycine  como  con  los  niveles  s\u00e9ricosaumentados  de  serotonina,  ambos  posibles  biomarcadores  del  TEA  en\nhumanos (Gilbert et al, 2013).\n1.4.6 Acidos grasos poliinsaturados\nA pesar  de  que  existen  f\u00e1rmacos  aprobados  para  el  tratamiento  de  las\ncomorbilidades del TEA, no contamos con ninguno para paliar los s\u00edntomas\ncardinales,  por  lo  que  de  momento  no  existe  un  tratamiento  curativo\n(Stepanova et al, 2017). Son por tanto, los programas de atenci\u00f3n temprana los\n\u00fanicos  que  verdaderamente  han  sido  capaces  de  mejorar  las  alteraciones\nconductuales,  favorecer  el  neurodesarrollo  y  disminuir  la  gravedad  de  los\ns\u00edntomas del TEA (Tachibana et al, 2017). Es por esto, que gran parte de las\ninvestigaciones que se han desarrollado sobre el TEA en los \u00faltimos a\u00f1os se\nhan centrado en la b\u00fasqueda de tratamientos coadyuvantes a la intervenci\u00f3n\npsicol\u00f3gica,  siendo  los  suplementos  alimenticios  posiblemente  los  m\u00e1s\nestudiados. A pesar de que existe cierta evidencia de que suplementos como\nantioxidantes, vitaminas o \u00e1cidos grasos (FA) omega-3 pueden favorecer el\ndesarrollo cognitivo, el papel que pueden jugar en la salud mental a\u00fan no est\u00e1\nbien delimitado (Parletta et al, 2013).\nLos \u00e1cidos grasos poliinsaturados de cadena larga (LC-PUFA) de la serie\nomega-3,  que  incluyen  el  \u00e1cido  docosahexaenoico  (DHA)  y  \u00e1cido\neicosapentaenoico (EPA), son componentes estructurales de las membranas\ncelulares, especialmente en el SNC y cada vez existe m\u00e1s evidencia de que\nadem\u00e1s de la funci\u00f3n estructural, juegan un papel fundamental en el desarrollo\ndel  SNC,  interviniendo  en  importantes  funciones  como  el  crecimiento  y\ndiferenciaci\u00f3n neuronal, la sinapsis, la agudeza visual o incluso la regulaci\u00f3n de\nla expresi\u00f3n g\u00e9nica (Lauritzen et al 2016; Schuchardt et al 2010), adem\u00e1s de\ncontar  con  propiedades  antiinflamatorias  y  regulador  del  estr\u00e9s  oxidativo\n(Agostoni  et  al,2017).  En  los  \u00faltimos  a\u00f1os,  est\u00e1  creciendo  el  inter\u00e9s  en\npsiquiatr\u00eda  sobre  la  suplementaci\u00f3n  con  omega-3  en  algunos  trastornos\nneuropsiqui\u00e1tricos como la esquizofrenia, trastornos del humor unipolares y\nbipolares, trastornos de ansiedad, trastorno obsesivo-compulsivo, trastorno por\nd\u00e9ficit  de  atenci\u00f3n  con  hiperactividad  (TDAH),  agresi\u00f3n,  hostilidad  e\nimpulsividad, trastorno l\u00edmite de la personalidad, abuso de sustancias, anorexia\nnerviosa y por supuesto TEA (Bozzatello et al, 2016), y aunque ya hay estudiosque muestran el beneficio de la suplementaci\u00f3n con omega-3 en el TDAH\n(Cooper  et  al,  2016),  por  el  momento  son  escasos  los  trabajos  que  han\nvalorado la eficacia y seguridad de los omega-3 en el TEA y con resultados\ncontradictorios.\nAminger et al (2007), en un peque\u00f1o ensayo cl\u00ednico de 13 pacientes TEA\nde 5 a 17 a\u00f1os, en el que se administr\u00f3 durante 6 semanas 1.5 grs diarios de\nomega-3 o placebo, inform\u00f3 de la superioridad del omega-3 al placebo en las\nsubescalas  de  hiperactividad  y  la  estereotipia  de  la   Aberrant  Behavior\nChecklist  (ABC).  Sin  embargo  Mankad  et  al  (2015),  en  un  ensayo  cl\u00ednico\ntambi\u00e9n con 1.5 grs de omega-3 FA durante 6 meses en un grupo de 38\npacientes de 2 a 5 a\u00f1os, no alcanz\u00f3 diferencias significativas entre ambos\ngrupos,  medidas  por  las  escalas  Pervasive  Developmental  Disorders\nBehavioral Inventory (PDDBI) y la puntuaci\u00f3n de problemas de externalizaci\u00f3n\ndel  Behavior  Assessment  System  for  Children-2  (BASC-2).  Adem\u00e1s,  los\ncambios  en  las  citoquinas  durante  el  tratamiento  no  se  correlacionaron\nsignificativamente  con  la  respuesta  al  tratamiento.  Bent  et  al,  realizaron  2\nensayos cl\u00ednicos en 2011 y 2014, pero con pacientes diferentes. En el primero\nde ellos, en una muestra de 27 ni\u00f1os con TEA de 3 a 8 a\u00f1os, a los que se le\nadministr\u00f3 1.3 g diarios de omega-3 o placebo durante 12 semanas, mostr\u00f3\nuna correlaci\u00f3n negativa entre la interleucina-2 y la hiperactividad, y una fuerte\ncorrelaci\u00f3n entre cinco \u00e1cidos grasos e hiperactividad. En el segundo ensayo\ncl\u00ednico, describieron una mejor\u00eda en la hiperactividad en el grupo tratado con\nomega-3 sin alcanzar de nuevo la significaci\u00f3n estad\u00edstica, y mejor\u00edas en las\nsubescalas  de estereotipia y letargo estad\u00edsticamente significativas.  Por su\nparte Voigt et al (2014), report\u00f3 que la suplementaci\u00f3n diet\u00e9tica con 200 mg de\nDHA/d\u00eda durante 6 meses no mejora los s\u00edntomas centrales del TEA medidos\npor la escala Clinical Global Impressions-Improvement (CGI-I), y que de los 48\npacientes reclutados, solo 3 ni\u00f1os (6%) ten\u00edan niveles bajos de DHA y 1 (2%)\nten\u00eda un nivel bajo de EPA, pero ninguno ten\u00eda un nivel bajo de \u00e1cido \u03b1-\nlinol\u00e9nico (ALA; 18:3n-3 ), \u00e1cido docosapentaenoico (DPA; 22:5n-3) o niveles\ntotales de omega-3, e incluso 10 ni\u00f1os (21%) ten\u00edan niveles altos de DHA, 11\n(23%) niveles altos de ALA, 4 (8%) niveles altos de EPA y 7 (15%) niveles altos\nde omega-3 totales. En cambio Yui et al (2012), en un peque\u00f1o ensayo de 13\npacientes, inform\u00f3 de mejoras significativas en la retracci\u00f3n social de la ABC  yen  la  comunicaci\u00f3n  de  la  Social  Responsiveness  Scale,  y  que  existieron\ndiferencias significativas en el cambio en los niveles de transferrina en plasma\ny una tendencia hacia una diferencia significativa en el cambio en los niveles de\nSOD en plasma entre los 2 grupos. \nTres  son  hasta  el  momento  los  metaan\u00e1lisis  que  han  analizado  la\nsuplementaci\u00f3n con FA en el TEA.  El primer metan\u00e1lisis (James et al, 2011),\nque incluy\u00f3 solo dos ensayos cl\u00ednicos, no pudo mostrar ning\u00fan beneficio en la\nadministraci\u00f3n de omega-3 en el TEA. Posteriormente Horvath et al (2017),\ntampoco demostr\u00f3 un impacto positivo significativo de la suplementaci\u00f3n de\nomega-3 en la mayor\u00eda de las subescalas de la ABC. Finalmente Cheng et al\n(2017), concluy\u00f3 que la suplementaci\u00f3n con FA omega-3 puede mejorar la\nhiperactividad, la letargia y estereotipias en pacientes con TEA, aunque no\nparece  mejorar  el  funcionamiento  global.  En  los  estudios  analizados  los\nsuplementos variaron con respecto a la dosis y la fuente de omega-3 DHA y\nEPA. Las dosis variaron desde 0.2 g DHA/d\u00eda hasta 1.5 g EPA + DHA/d\u00eda. Las\nfuentes de suplementos de omega-3 incluyeron aceite de pescado y aceite de\nalgas. Las intervenciones duraron desde las 6 semanas hasta los 6 meses\n(Cheng et al, 2017).2-HIPOTESIS Y OBJETIVOS\nHip\u00f3tesis\nEn  la  etiopatogenia  y  evoluci\u00f3n  del  TEA se  han  descrito  varias  hip\u00f3tesis\nposibles como alteraciones en par\u00e1metros bioqu\u00edmicos, inflamatorios, estr\u00e9s\noxidativo,  o  incluso  alteraciones  metab\u00f3licas  tras  la  exposici\u00f3n  a  metales\npesados y diferencias en la microbiota intestinal que podr\u00edan influir de forma\nnegativa  en  el  correcto  establecimiento  de  sinapsis  neuronales  y  su\nfuncionamiento,  en  una  situaci\u00f3n  de  mayor   plasticidad  sin\u00e1ptica,\nespecialmente durante la infancia.\nObjetivo principal\nEvaluar  los  niveles  de  citoquinas  proinflamatorias  y  los  biomarcadores  de\nestr\u00e9s  oxidativo,  as\u00ed  como  el  perfil  de  \u00e1cidos  grasos,  la  concentraci\u00f3n  de\nmetales pesados o diferencias en la microbiota intestinal en una muestra de\npacientes con TEA infantil y compararlos con un grupo de ni\u00f1os sanos de la\nmisma edad.\nObjetivos secundarios\n1- Evaluar los par\u00e1metros de inflamaci\u00f3n , el perfil de \u00e1cidos grasos y estr\u00e9s\noxidativo en ambos grupos de ni\u00f1os.\n2- Estudiar la composici\u00f3n de la microbiota intestinal de ni\u00f1os con TEA y\nestudiar la relaci\u00f3n con s\u00edntomas de la enfermedad y otros gastro-intestinales,\nas\u00ed como comparaci\u00f3n con el grupo de ni\u00f1os sanos.\n3- Realizar una biomonitorizaci\u00f3n de metales pesados en muestras de pelo y\norina  de  ni\u00f1os  con  TEA  y  estudiar  la  relaci\u00f3n  con  los  s\u00edntomas  de  la\nenfermedad y comparaci\u00f3n con el grupo de ni\u00f1os sanos.3 MATERIAL Y M\u00c9TODOS\n3.1 Dise\u00f1o de los estudios\nSe ha realizado  un estudio prospectivo observacional, y adem\u00e1s un ensayo\ncl\u00ednico doble ciego aleatorizado controlado por placebo en grupos paralelos en\npacientes menores de  siete a\u00f1os diagnosticados de TEA por la Unidad de\nSalud Mental Infantil y Juvenil (USMIJ) del Hospital Universitario Reina Sof\u00eda de\nC\u00f3rdoba (HURS), en base a los criterios DSM-5 y la Escala de Observaci\u00f3n\npara  el  Diagn\u00f3stico  de  Autismo-2  (ADOS-2).  En  las  Unidades  de\nNeuropediatr\u00eda e Investigaci\u00f3n Pedi\u00e1trica y USMIJ del HURS se han realizado\nla historia cl\u00ednica, las exploraciones complementarias y toma de muestras o\nprocesamiento  de  las  muestras.  En  colaboraci\u00f3n  con  el  Departamento  de\nBioqu\u00edmica y Biolog\u00eda Molecular II y el Instituto de Nutrici\u00f3n y Tecnolog\u00eda de los\nAlimentos \"Jos\u00e9 Mataix\" de la Universidad de Granada se han medido los\ndiferentes  par\u00e1metros  bioqu\u00edmicos,  estudio  metabol\u00f3mico  y  estudio  de  la\nmicrobiota de las muestras estudiadas en sangre, orina, y heces. El estudio de\nmetales pesados se ha realizado en cabello y orina en el Departamento de\nToxicolog\u00eda de la Universidad de Granada. Los resultados  se compararon con\nlos de ni\u00f1os sanos de la misma edad . \nEste estudio ha constado de 2 fases: una primera fase que incluye el\nreclutamiento de los ni\u00f1os con TEA y un grupo control que ha permitido realizar\nun estudio descriptivo observacional de la muestra pedi\u00e1trica en estudio con\nrespecto a su estado nutricional, caracter\u00edsticas demogr\u00e1ficas y estudio basal\nde par\u00e1metros oxidativos, inflamaci\u00f3n y mol\u00e9culas de adhesi\u00f3n celular, metales\npesados y microbiota intestinal compar\u00e1ndolos con un grupo control de ni\u00f1os\nsanos de la misma edad \nUna segunda fase con un ensayo cl\u00ednico en fase III, de no inferioridad,\nunic\u00e9ntrico  nacional  con  car\u00e1cter  independiente  sin  inter\u00e9s  comercial  para\nvalorar la eficacia y  seguridad del  DHA en el grupo  de ni\u00f1os  autistas.Los\npacientes con TEA fueron incluidos en el ensayo de forma consecutiva, y se\ndividieron en dos grupos paralelos de acuerdo a la aleatorizaci\u00f3n generada por\nel programa inform\u00e1tico SIGESMU\u00ae con asignaci\u00f3n aleatoria 1:1: la mitad de\nsujetos con TEA recibieron 800mg de DHA y 350 mg de EPA al d\u00eda y la otra\nmitad,  un  placebo  de  caracter\u00edsticas  lip\u00eddicas  similares  salvo  que  no  ten\u00edacontenido en DHA y EPA, y durante un periodo de 6 meses, doble ciego.\nTranscurrido los 6 meses, se volvi\u00f3 a realizar una evaluaci\u00f3n cl\u00ednica y el mismo\nestudio anal\u00edtico basal.\nIntervenci\u00f3n\nEl suplemento nutricional empleado es un producto comercializado de acuerdo\na  la  regulaci\u00f3n  de  la  Uni\u00f3n  Europea.  Este  suplemento  (EUPOLY-3\u00ae  DHA\nInfant) fue provisto por Biosearch SA (Granada, Espa\u00f1a), as\u00ed como el placebo,\nen id\u00e9nticos contenedores etiquetados con un c\u00f3digo num\u00e9rico (C\u00f3digo de\nproducto: EUP007). La composici\u00f3n de ambos difiere \u00fanicamente en que la\nf\u00f3rmula con DHA es de aceite de pescado refinado y estabilizado mediante la\nadici\u00f3n  de  lecitina  de  soja,  tocoferoles  de  origen  natural  y  palmitato  de\nasc\u00f3rbico. Adem\u00e1s, est\u00e1 controlado su nivel de t\u00f3xicos en la materia prima.\nEste producto, y el placebo, mantienen el resto de perfil de \u00e1cidos grasos\nsimilar (ej. contenido en \u00e1cidos grasos linoleico y linol\u00e9nico). Se prepar\u00f3 en una\nformulaci\u00f3n  adecuada  a  ni\u00f1os  con  TEA,  en  forma  l\u00edquida  y  en  una  dosis\nconcentrada  para  ingerir  v\u00eda  oral  en  la  menor  cantidad  posible\n(aproximadamente 2 cc en cada toma). El plan de adherencia a la intervenci\u00f3n\nincluy\u00f3 llamadas telef\u00f3nicas de los pediatras investigadores a los tutores cada\n2 meses con  las  que se  valor\u00f3 la  evoluci\u00f3n,  incidencias,  administraci\u00f3n y\ntolerancia del producto.\nIncidencia de acontecimientos adversos\nUn acontecimiento adverso (AA) se define como cualquier episodio m\u00e9dico no\ndeseado  que  se  produzca  en  un  voluntario  durante  su  participaci\u00f3n  en  el\nestudio,  se  considere  o  no  relacionado  con  el  mismo.  Tras  evaluar  la\nbibliograf\u00eda respecto al uso del DHA en la dosis que se precisa en este ensayo\ny teniendo en cuenta el documento de la Autoridad Europea para la Seguridad\nde los Alimentos (EFSA, 2012), es improbable que se produzcan reacciones\nadversas. Aun as\u00ed, los acontecimientos adversos se han evaluado siguiendo el\ncriterio  establecido  por  la  norma  europea  EN  ISO  (Europea+internacional)\n14155-1, relativa a la protecci\u00f3n de los participantes en estudios cl\u00ednicos, seg\u00fan\nla cual un acontecimiento adverso se considera grave (AAG) en el caso de que:\na) Amenace la vida del voluntario.b) Provoca un deterioro de la salud, es decir, causa una enfermedad o lesi\u00f3n\npotencialmente mortal o una insuficiencia permanente o un ingreso hospitalario\no una intervenci\u00f3n m\u00e9dica o quir\u00fargica para prevenir una insuficiencia. \nTodos aquellos AA que no cumplan los criterios de \u201cgrave\u201d se consideran no\ngraves. Si existen sospechas razonables que indiquen que la medicaci\u00f3n del\nestudio tiene una relaci\u00f3n causal con el AA, es decir, hay hechos (indicios) o\nargumentos  que  sugieren  dicha  relaci\u00f3n,  se  considerar\u00e1  el  algoritmo  de\ncausalidad  usado  por  el  Sistema  Espa\u00f1ol  de  F\u00e1rmaco-Vigilancia  (Karch  y\nLasagna modificado).\nEl investigador principal recogi\u00f3 en el cuaderno de datos, todos los AA\nque  se  manifestaron  desde  el  momento  en  que  el  paciente  firma  el\nconsentimiento informado hasta la \u00faltima visita de seguimiento. Estos datos\nquedaron reflejados en los cuadernos de recogida de datos. Aquellos pacientes\nque sus padres o tutores notificaron un posible efecto adverso \"no grave\"\nfueron  controlados  m\u00e1s  estrechamente  y  en  caso  de  persistencia  ser\u00edan\nnotificados oficialmente a la direcci\u00f3n del hospital. El grupo adquiri\u00f3 una p\u00f3liza\nde responsabilidad civil para ejecutar este ensayo cl\u00ednico.\nControl de sesgos\nLas medidas para tratar de eliminar los factores de sesgo son en primer lugar la\nasignaci\u00f3n aleatoria de los pacientes a los diferentes tratamientos del estudio,\nproporci\u00f3n de asignaci\u00f3n 1:1 mediante el programa inform\u00e1tico SIGESMU\u00ae. El\ndise\u00f1o es doble ciego, el paciente y el investigador desconoce los tratamientos\nrecibidos.  Para  asegurar  que  los  pacientes  e  investigadores  permanezcan\nciego, la preparaci\u00f3n del placebo se llev\u00f3 a cabo en la empresa que prepar\u00f3 el\nproducto, de forma que estuvo lo suficientemente enmascarado, con un envase\ny etiquetado igual, y ambos productos presentaban propiedades organol\u00e9pticas\nsimilares. Para evitar posibles sesgos debido a la retirada de pacientes tras la\naleatorizaci\u00f3n, se ha llevado a cabo un an\u00e1lisis por intenci\u00f3n de tratar. Otras\nacciones para evitar sesgos han sido: homogeneizar criterios y diagnosticar\ncon  gran  rigor  a  los  pacientes  con  TEA para  evitar  asociaci\u00f3n  con  otras\nalteraciones  cognitivas  que  alteren  los  resultados  o  que  afecten  al\nincumplimiento del tratamiento, y no variar las condiciones del ensayo.3.2 Sujetos de estudio\nSe seleccion\u00f3 una muestra de 54 ni\u00f1os con TEA  (45 ni\u00f1os y 9 ni\u00f1as) de 2 a 6\na\u00f1os  de  edad.  El  diagn\u00f3stico  de  TEA  se  bas\u00f3  en  el  juicio  cl\u00ednico  de\nprofesionales especializados en la identificaci\u00f3n de los perfiles de desarrollo\ncaracter\u00edsticos de los sujetos con TEA. La informaci\u00f3n se obtuvo de entrevistas\nde  desarrollo  cl\u00ednico  semiestructuradas  y  pruebas  psicol\u00f3gicas  y  de\ncomportamiento reconocidas internacionalmente como fiables y v\u00e1lidas para\neste prop\u00f3sito. En este estudio, dos psic\u00f3logos cl\u00ednicos, un psiquiatra y un\nterapeuta ocupacional con amplia experiencia cl\u00ednica y capacitaci\u00f3n en pruebas\nde diagn\u00f3stico para la investigaci\u00f3n en TEA realizaron el diagn\u00f3stico utilizando\nlos criterios establecidos por el DSM-5. Dos pediatras especializados revisaron\nla historia cl\u00ednica y realizaron una valoraci\u00f3n antropom\u00e9trica, exploraci\u00f3n f\u00edsica\ny anal\u00edtica general, con el fin de descartar cualquier patolog\u00eda asociada al TEA.\nLa velocidad de reclutamiento del grupo de ni\u00f1os con TEA dependi\u00f3 del\nn\u00famero de pacientes activos en la USMIJ con reciente diagn\u00f3stico, y de la\nincidencia de ni\u00f1os con TEA. Se requirieron 18 meses para alcanzar la cifra de\n54 pacientes que finalmente incluimos en el estudio. \nCriterios de inclusi\u00f3n\n- Pacientes con TEA de 2 a 6 a\u00f1os diagnosticados seg\u00fan los criterios DSM-5 y\nvalidados por el ADOS-2 score.\nCriterios de exclusi\u00f3n\n- Cualquier otra patolog\u00eda asociada al TEA.\n- Estar recibiendo medicaci\u00f3n por comorbilidades del TEA o por otra patolog\u00eda.\n- Estar recibiendo o haber recibido cualquier tipo de suplemento alimenticio.\n- Estar llevando a cabo dietas espec\u00edficas con fines terap\u00e9uticos.\n- Tener planificado modificar en los pr\u00f3ximos meses el tipo o el n\u00famero de\nhoras de intervenci\u00f3n de atenci\u00f3n temprana.\nEn  el  caso  del  ensayo  cl\u00ednico,  se  establecieron  adem\u00e1s  unos  criterios  de\nretirada:\nCriterios de retirada \n-Ni\u00f1os  que  no  mantengan  una  adherencia  o  cumplimiento  adecuado  al\ntratamiento seg\u00fan valoraci\u00f3n por el investigador. \n-Ni\u00f1os en los que no se pueda completar el estudio por dificultades en la\nobtenci\u00f3n de las muestras. -Aparici\u00f3n  de  patolog\u00eda  neurol\u00f3gica  asociada  que  no  permita  tener  un\ndiagn\u00f3stico \u00fanico de TEA. \nDe los 56 pacientes inicialmente preseleccionados, 2 fueron excluidos,\nuno por presentar enfermedad celiaca y otro por estar en tratamiento con DHA. \nAsimismo se seleccion\u00f3 un n\u00famero similar de ni\u00f1os controles sanos de la\nmisma edad con un neurodesarrollo t\u00edpico. Debido a la dificultad de seleccionar\ncontroles  sanos  de  corta  edad  para  realizarles  una  venopunci\u00f3n  para  la\nextracci\u00f3n sangu\u00ednea, \u00e9stos fueron seleccionados de un grupo de pacientes en\nlista de espera para ser intervenidos de patolog\u00eda no inflamatoria, siendo en la\nmayor\u00eda de los casos fimosis o hernias abdominales no complicadas, y en los\nque se confirmara ausencia cl\u00ednica y anal\u00edtica de enfermedad. Esta selecci\u00f3n la\nrealizaron facultativos especialistas en Pediatr\u00eda de la Unidad de investigaci\u00f3n\nPedi\u00e1trica del HURS que habitualmente atienden a pacientes con patolog\u00edas\nmetab\u00f3licas y neurol\u00f3gicas.\nPara establecer de forma adecuada el diagn\u00f3stico, y para establecer la\ngravedad  de  los  pacientes  con  TEA se  realizaron  los  siguientes  tests  o\ncuestionarios:\na)  Escala  de  Observaci\u00f3n  para  el  Diagn\u00f3stico  de  Autismo  ( Autism\nDiagnostic Observation Schedule-2  (ADOS-2)) (Lord et al, 2001). Esta es\nuna  escala  de  evaluaci\u00f3n  estandarizada  y  semiestructurada  que  valora  la\ncomunicaci\u00f3n, la interacci\u00f3n social, el juego y el uso imaginativo de objetos.\nTodos los ni\u00f1os con TEA en el estudio superaron los puntos de corte para el\ndiagn\u00f3stico de TEA.\nb)  Inventario General de Comportamiento de Trastornos del Desarrollo\n(Developmental  Disorders  Behavior  Inventory   Parent  Ratings  (PDDBI))\n(Cohen, 2003). Esta prueba, administrada a todos los padres de ni\u00f1os con\nTEA, ten\u00eda como objetivo evaluar el d\u00e9ficit conductual caracter\u00edstico del TEA\n(d\u00e9ficits en la interacci\u00f3n social, lenguaje y comunicaci\u00f3n pragm\u00e1tica y estereo -\ntipada), dificultades de comportamiento adicionales (miedos, comportamientos\nagresivos) y conductas adaptativas (escalas de las habilidades sociales, lin -\ng\u00fc\u00edsticas y de aprendizaje de los ni\u00f1os). Se utiliz\u00f3 para medir la gravedad de lasintomatolog\u00eda autista y para llegar a un consenso sobre el diagn\u00f3stico. Todos\nlos ni\u00f1os con TEA en el estudio obtuvieron una puntuaci\u00f3n \u2265 a 30.\nc) Escala de Valoraci\u00f3n de Autismo Infantil ( Childhood Autism Rating Scale\n(CARS-2)) (Sholper et al, 2010). Esta escala se utiliz\u00f3 para la cuantificaci\u00f3n de\nla gravedad de la patolog\u00eda del autismo: leve, moderada o grave.\nd)  Cuestionario  de  Fortalezas  y  Dificultades  ( Strengths  and  Difficulties\nQuestionnaire (SDQ))(Goodman, 1997): Se utiliz\u00f3 para evaluar la presencia de\ndificultades de comportamiento, as\u00ed como las conductas adaptativas.\n3.3  Historia  cl\u00ednica,  exploraci\u00f3n  f\u00edsica,  antropometr\u00eda  y  encuesta\nnutricional \nEn los pacientes seleccionados diagnosticados de TEA, un neuropediatra del\ngrupo de investigaci\u00f3n y la psic\u00f3loga cl\u00ednica realizaron de manera coordinada\nlas siguientes actuaciones: exploraci\u00f3n f\u00edsica general y una evaluaci\u00f3n del nivel\nde afectaci\u00f3n de las diferentes \u00e1reas del desarrollo por medio de: Inventario\nBattelle, ADI-R, ADOS-2, CARS-2, SDQ, y PDDBI. Al grupo control se le realiz\u00f3\nuna historia cl\u00ednica detallada, valorando el motivo de consulta, junto con la\nexploraci\u00f3n f\u00edsica. \nEn  ambos  grupos se midieron el peso,  la talla, y el  \u00edndice  de  masa\ncorporal (IMC) de acuerdo con las tablas recomendadas de antropometr\u00eda de la\npoblaci\u00f3n infantil espa\u00f1ola (Hern\u00e1ndez et al, 1998). Se realiz\u00f3 una encuesta\ndiet\u00e9tica  normalizada  de  frecuencia  de  consumo  para  obtener  informaci\u00f3n\nsobre los h\u00e1bitos alimentarios. La ingesta energ\u00e9tica diaria y la composici\u00f3n de\nla  dieta  por macronutrientes  se calcul\u00f3  mediante un programa inform\u00e1tico,\nrealizando una aproximaci\u00f3n entre los datos de la encuesta normalizada de\nfrecuencia de consumo y las tablas de composici\u00f3n de los alimentos espa\u00f1oles\nde la base de datos BEDCA (Bedca.net, 2014).3.4 Extracci\u00f3n sangu\u00ednea y an\u00e1lisis bioqu\u00edmicos en plasma y eritrocitos\nLas extracciones de las muestras sangu\u00edneas se realizaron en los d\u00edas 0 y al\nfinalizar la intervenci\u00f3n en los dos grupos de pacientes con TEA, y una sola\nmuestra basal en el grupo control. Tras 12 h de ayuno, se extrajeron 6 ml de\nsangre, que se dividieron en tres tubos, dos con EDTA y otro con gelosa, para\nobtenci\u00f3n de plasma, suero, leucocitos y eritrocitos. Las muestras se guardaron\na  -80\u00baC  en  diferentes  al\u00edcuotas  codificadas  hasta  la  realizaci\u00f3n  de  las\ndeterminaciones que se detallan, para evitar variaciones interensayo. \n-  Al\u00edcuota  1:  hemograma  y  bioqu\u00edmica  general:  prote\u00ednas,  glucosa,  urea,\ncreatinina,  iones,  transaminasas  (AST,  ALT y  GGT),  triglic\u00e9ridos,  colesterol\ntotal, LDLcolesterol, LDLcolesterol, apoprote\u00ednas B y A-I, \u00e1cido \u00farico y prote\u00edna\nC-reactiva ultrasensible. Se han determinado mediante an\u00e1lisis colorim\u00e9tricos y\nenzim\u00e1ticos  espec\u00edficos,  utilizando  un  autoanalizador  con  m\u00e9todos\nestandarizados  y  controlados  interlaboratorios  mediante  test  de  control  de\ncalidad.\n- Al\u00edcuota 2 (plasma y eritrocitos): \u00e1cidos grasos totales, perfil de \u00e1cidos grasos.\nPrimero  se  hizo  la  extracci\u00f3n  de  l\u00edpidos  plasm\u00e1ticos  y  a  continuaci\u00f3n  se\ndetermin\u00f3 la composici\u00f3n en \u00e1cidos grasos del plasma en un cromat\u00f3grafo de\ngas-l\u00edquido. \n-  Al\u00edcuota  3:  sE-Selectina,  mol\u00e9culas  de  adhesi\u00f3n  celular  vasculares  e\nintercelulares (sVCAM-1, sICAM) y factor inhibidor del plasmin\u00f3geno 1 (PAI-1)e\ninterleuquinas 1-\u03b2, IL-6, IL-8, IL-10, INF-\u03b3, MCP-1, TNF-\u03b1. \nEl  an\u00e1lisis  de los biomarcadores de inflamaci\u00f3n  se  llev\u00f3  a cabo  mediante\ndetecci\u00f3n simult\u00e1nea de multi-analitos utilizando kits de ensayo LINCOplex y la\nTecnolog\u00eda de detecci\u00f3n LuminexMAP \n- Al\u00edcuota 4: an\u00e1lisis de metabol\u00f3mica en plasma. Las muestras de plasma se\nanalizaron con una metodolog\u00eda de plataforma \u00fanica de metabol\u00f3mica basada\nen  cromatograf\u00eda  l\u00edquida-espectrometr\u00eda  de  masas.  Se  realiz\u00f3  un  an\u00e1lisis\nunivariado  y  multivariado,  incluyendo  discriminante  de  m\u00ednimos  cuadrados\nparciales  ortogonales.  Se  realizaron  modelos  de  an\u00e1lisis  y  gr\u00e1ficos  de\nestructuras \u00fanicas y compartidas utilizando MetaboAnalyst 4.0 y SIMCA-P 15.\n-  Al\u00edcuota  5  (plasma):  capacidad  antioxidante  total  del  plasma  (ABTS)  y\npar\u00e1metros  de  estr\u00e9s  oxidativo  como  GSH  y  GSSG.  Determinaci\u00f3n  por\ncromatograf\u00eda l\u00edquida de alta resoluci\u00f3n (HPLC) con un detector electroqu\u00edmico.-  Al\u00edcuota  6:  eritrocitos  para  determinaci\u00f3n  de  actividades  de  enzimas\nrelacionadas con el sistema de defensa antioxidante celular: SOD, catalasa,\nGR,   GSH-Px.  Se  realiza  mediante  kits  comerciales  y  m\u00e9todos\nespectrofotom\u00e9tricos. \n- Al\u00edcuota 7 (plasma y eritrocitos): vitamina E (\u03b1-tocoferol), retinol, \u03b1-caroteno,\nvitamina C, coenzima Q10. El an\u00e1lisis se lleva a cabo mediante HPLC con\ndetecci\u00f3n electroqu\u00edmica. \n3.5 An\u00e1lisis de la microbiota intestinal\na) Muestras de heces, extracci\u00f3n de DNA y secuenciaci\u00f3n masiva:  las\nmuestras de heces se recolectaron en botes de pl\u00e1sticos est\u00e9riles conservados\na -80\u00baC. La extracci\u00f3n de DNA se realiz\u00f3 con el mini kit QIAamp DNA stool\n(QIAGEN, Barcelona, Espa\u00f1a). Posteriormente, la cuantificaci\u00f3n se efectu\u00f3 en\nun  espectrofot\u00f3metro  NanoDrop  ND-1000  (Nano-Drop  Technologies).  Las\nmuestras de DNA recibidas, se amplificaron en la regi\u00f3n variable V3-V1 del gen\n16S del RNA ribosomal con un tama\u00f1o de 600 pares de bases (pb), utilizando\ncebadores marcados con c\u00f3digos de barras. La secuenciaci\u00f3n masiva de la\namplificaci\u00f3n de la reacci\u00f3n en cadena de la polimerasa (PCR) se realiz\u00f3 en el\nequipo Roche/454 GS Titanium (Branford, CT, USA). \nb) An\u00e1lisis taxon\u00f3mico: las secuencias han sido seleccionadas para estimar\nla  diversidad  total  de  bacterias  de  las  muestras  de  DNA de  una  manera\ncomparable. Las secuencias seleccionadas se sometieron a un an\u00e1lisis con la\nplataforma RDP (Ribosomal data project) para definir las unidades taxon\u00f3micas\noperacionales, de su sigla OTU en ingl\u00e9s. La secuencia m\u00e1s abundante de\ncada OTU se seleccionaron como representante de la secuencia y se clasific\u00f3\ntaxon\u00f3micamente mediante una b\u00fasqueda BLAST.\n3.6 Estudio de metales pesados  en cabello y orina\nSe recogi\u00f3 un m\u00ednimo de 100 mg de cabello de la parte occipital del cuero\ncabelludo de los ni\u00f1os participantes. Las muestras de cabello se transportaron\ny almacenaron en bolsas de papel hasta su an\u00e1lisis. Se recogieron muestras\nde  orina  de  una  micci\u00f3n  espont\u00e1nea.  Las  muestras  se  transportaron\nrefrigeradas a -4 \u00baC hasta el laboratorio donde se almacenaron a -20 \u00b0C. Todoslos metales pesados objeto de estudio (Cd, Hg, Mn y Pb) se analizaron por\nmedio de un espectofot\u00f3metro de absorci\u00f3n at\u00f3mica equipado con c\u00e1mara de\ngrafito en el Departamento de Toxicolog\u00eda de la Universidad de Granada. \nTodas estas variables secundarias se  han medido  al inicio del estudio y\ntras la intervenci\u00f3n de 6 meses de tratamiento con 800mg de DHA y 350 mg de\nEPA/d\u00eda  en  comparaci\u00f3n  con  otro  grupo  homog\u00e9neo  que  recibi\u00f3  placebo.\nAdem\u00e1s, se compararon con el grupo de referencia de ni\u00f1os sanos a nivel\nbasal. \n3.7 An\u00e1lisis estad\u00edstico\nPara el c\u00e1lculo del tama\u00f1o muestral se utiliz\u00f3 el software GRANMO (2012) y se\ntuvo en consideraci\u00f3n la necesidad de incluir ni\u00f1os sanos y TEA, y estos\n\u00faltimos sometidos a una intervenci\u00f3n (con DHA o sin DHA). Adem\u00e1s, en la\nbibliograf\u00eda consultada (Parletta et al, 2016), se conoce que los niveles medios\nde  DHA eritrocitario  pueden  oscilar  alrededor  de  4.97  (+/-1.02).  Por  tanto,\naceptando un riesgo alfa de 0.05 y un riesgo beta de 0.2 en un contraste\nbilateral y para detectar una diferencia igual o superior a 2.5 unidades con una\nestimaci\u00f3n de una tasa de p\u00e9rdidas de seguimiento del 5%: \n- En el caso de grupos independientes (sanos-TEA) se precisan 46 sujetos en\ncada grupo. Se asume que la desviaci\u00f3n est\u00e1ndar com\u00fan es de 0.5.\n- En el caso de grupos relacionados (TEA con/sin DHA, para evaluaci\u00f3n antes-\ndespu\u00e9s), se precisan 28 sujetos en cada grupo para detectar una diferencia\nigual o superior a 1.2 unidades.\nSe asume que la desviaci\u00f3n est\u00e1ndar com\u00fan es de 0.7 y un coeficiente de\ncorrelaci\u00f3n entre la medida inicial y final de 0.5.\nEn definitiva, se precisar\u00edan 112 ni\u00f1os en total, 56 ni\u00f1os sanos (se ampl\u00eda al\nmayor tama\u00f1o de muestra) y 56 ni\u00f1os con TEA para detectar estas diferencias. \nTodos  los  an\u00e1lisis  de  datos  se  han  llevado  a  cabo  con  el  paquete\nestad\u00edstico Statistical Package for the Social Sciences (SPSS) versi\u00f3n 21.0. El\nan\u00e1lisis  estad\u00edstico  consisti\u00f3  en  un  estudio  descriptivo  de  las  variables\ncontinuas  mediante  la  media  \u00b1  desviaci\u00f3n  est\u00e1ndar  o  mediana  y  rango\nintercuart\u00edlico. Las variables cualitativas se expresan en frecuencias absolutas\no relativas. La distribuci\u00f3n de las variables se determinaron mediante la pruebade Shapiro-Wilk test y la homogeneidad de las varianzas se realiz\u00f3 mediante el\ntest de Levene. Las diferencias entre los valores medios de cada grupo se\nrealiz\u00f3 mediante la prueba t de Student, o U de Mann-Whitney dependiendo de\nla idoneidad. Las comparaciones de variables continuas entre sujetos de los\nmismos  grupos  (basal  vs.  tiempo  de  intervenci\u00f3n  final),  entre  sujetos  de\ndiferentes grupos y la interacci\u00f3n tiempo x tratamiento se llev\u00f3 a cabo mediante\nmodelos  lineales  de  varianza.  La  asociaci\u00f3n  entre  variables  diferentes\nmultidependientes se hizo mediante test de regresi\u00f3n m\u00faltiple. \n3.8 Aspectos \u00c9ticos\nEl  estudio  ha  sido  elaborado  respetando  los  principios  fundamentales\nestablecidos en la Declaraci\u00f3n de Helsinki (1964), en el Convenio del Consejo\nde Europa relativo a los derechos humanos y la biomedicina (1997), en la\nDeclaraci\u00f3n Universal de la UNESCO sobre el genoma humano y los derechos\nhumanos  (1997),  as\u00ed  como  cumpliendo  los  requisitos  establecidos  en  la\nlegislaci\u00f3n espa\u00f1ola en el \u00e1mbito de la investigaci\u00f3n biom\u00e9dica, la protecci\u00f3n\nde datos de car\u00e1cter personal y la bio\u00e9tica. El estudio ha sido aprobado por los\nComit\u00e9s de \u00c9tica correspondientes, y ha seguido las normas de la Ley 14/2007\nde  Investigaci\u00f3n  Biom\u00e9dica  y  la  Ley  Org\u00e1nica  15/1999,  RD  1720/2007  de\nprotecci\u00f3n de datos de car\u00e1cter personal as\u00ed como las internacionales para las\ninvestigaciones  que  utilizan  muestras  procedentes  de  seres  humanos.  Los\npadres o tutores firmaron el consentimiento informado para poder participar en\nel estudio tras ser informados por los investigadores. Adem\u00e1s, se les dio a los\nni\u00f1os, la informaci\u00f3n verbal de forma comprensible, y se tendr\u00e1 en cuenta su\ndecisi\u00f3n  siempre  y  cuando  sea  posible,  teniendo  en  cuenta  su  nivel  de\ndiscapacidad. 4 RESULTADOS \nDe este  proyecto se han derivado hasta ahora las siguientes 3 publicaciones\nque cumplen con los criterios de calidad para defender esta tesis doctoral, en\nrevistas con factor de impacto en JCR y clasificadas en Q1 y Q2. De ellas, se\nexponen los res\u00famenes en castellano a continuaci\u00f3n, as\u00ed como los art\u00edculos\ncompletos anexos.\n4.1 Antonio Gomez-Fernandez, Maria J. de la Torre-Aguilar, Mercedes Gil-\nCampos*,  Katherine  Flores-Rojas,  Maria  D.  Cruz-Rico,  Pilar  Martin-\nBorreguero,  Juan  Luis  Perez-Navero.  Children  With  Autism  Spectrum\nDisorder With Regression Exhibit a Different Profile in Plasma Cytokines\nand Adhesion Molecules Compared to Children Without Such Regression.\nFront Pediatr. 2018; 6: 264. doi: 10.3389/fped.2018.00264. ISSN 2296-2360;\nFactor impacto: 2.349 Pediatrics 33/124, Tercil 2. Q2.\nResumen\nEn la etiopatogenia del TEA, se ha sugerido que una afecci\u00f3n proinflamatoria,\nas\u00ed como una alteraci\u00f3n en las mol\u00e9culas de adhesi\u00f3n en las primeras etapas\ndel desarrollo neurol\u00f3gico, pueden desempe\u00f1ar un papel en la fisiopatolog\u00eda\ndel trastorno. Este estudio propone evaluar los niveles plasm\u00e1ticos de ciertas\ncitoquinas inflamatorias, mol\u00e9culas de adhesi\u00f3n y factores de crecimiento en\nuna muestra de pacientes pedi\u00e1tricos con TEA y compararlos con los niveles\nen un grupo control de ni\u00f1os sanos.\nM\u00e9todos.  54 ni\u00f1os (45 ni\u00f1os y 9 ni\u00f1as) de 2 a 6 a\u00f1os de edad, que fueron\ndiagnosticados de TEA, y un grupo de control de 54 ni\u00f1os con un desarrollo\nt\u00edpico de edades similares fueron seleccionados. El diagn\u00f3stico de TEA se\nrealiz\u00f3 de acuerdo con los criterios del DSM-5 y los datos obtenidos de una\nentrevista cl\u00ednica semiestructurada de desarrollo y la prueba de evaluaci\u00f3n\nADOS-2.  Se  realizaron  pruebas  adicionales  para  identificar  el  nivel  de\ndesarrollo  de  los  ni\u00f1os  y  la  gravedad  de  la  sintomatolog\u00eda  de  TEA.  Los\npacientes con TEA se dividieron en dos subgrupos seg\u00fan los par\u00e1metros de\ndesarrollo:  ni\u00f1os con TEA con regresi\u00f3n en el neurodesarrollo (AMR) y  ni\u00f1os\ncon TEA sin regresi\u00f3n en el neurodesarrollo (ANMR). Se realizaron an\u00e1lisis de\nmol\u00e9culas plasm\u00e1ticas, tales como catepsina, IL1\u03b2, IL6, IL8, MPO, RANTES,MCP, BDNF, NCAM PAI, SICAM, SVCAM Y NGF.\nResultados.  Se observaron niveles m\u00e1s altos de NGF en el grupo TEA en\ncomparaci\u00f3n con los niveles en el grupo de control (p<0.05). Sin embargo, en\nel an\u00e1lisis de los subgrupos de TEA, se encontraron niveles m\u00e1s bajos en\nplasma de NCAM y niveles m\u00e1s elevados de NGF en el grupo de ni\u00f1os con\nTEA ANMR en comparaci\u00f3n con los niveles en el grupo de ni\u00f1os con desarrollo\nt\u00edpico.\nConclusiones.  Estos  resultados  sugieren  diferencias  que  podr\u00edan  estar\nrelacionadas con diferentes mecanismos fisiopatol\u00f3gicos en el TEA. No existe\nun perfil espec\u00edfico relevante  para la expresi\u00f3n de citoquinas plasm\u00e1ticas,\nmol\u00e9culas  de  adhesi\u00f3n  o  factores  de  crecimiento  en  ni\u00f1os  con  TEA en\ncomparaci\u00f3n  con  el  de  ni\u00f1os  con  desarrollo  t\u00edpico.  Sin  embargo,  en  los\nsubgrupos de TEA  ANMR y AMR, algunas de las mol\u00e9culas de adhesi\u00f3n y los\nfactores  de  crecimiento  neuronal  muestran  diferencias  que  pueden  estar\nrelacionadas con la sinaptog\u00e9nesis.\n4.2 Julio Plaza-D\u00edaz*, Antonio G\u00f3mez-Fern\u00e1ndez*, Natalia Chueca, Mar\u00eda\nJos\u00e9 de la Torre-Aguilar, \u00c1ngel Gil, Juan Luis Perez-Navero, Katherine\nFlores-Rojas,  Pilar  Mart\u00edn-Borreguero,  Patricio  Solis-Urra,  Francisco\nJavier  Ruiz-Ojeda,  Federico  Garcia,  Mercedes  Gil-Campos.  Autism\nSpectrum  Disorder  (ASD)  with  and  without  Mental  Regression  is\nAssociated with  Changes in  the Fecal Microbiota.  Nutrients.  2019 Feb\n5;11(2).  pii:  E337.  ISSN  2072-6643,  DOI:  10.3390/nu11020337.  FI  2018:\n4,171. Categor\u00eda Nutrition and Dietetics: 16/86, Tercil 1. Q1\n* ambos autores  han contribuido  igual\nResumen\nLas  nuevas  tecnolog\u00edas  de  secuenciaci\u00f3n  de  microbiomas  proporcionan\ninformaci\u00f3n  novedosa  sobre  las  posibles  interacciones  entre  los\nmicroorganismos intestinales y el hu\u00e9sped en algunas neuropatolog\u00edas como el\nTEA.  El  eje  microbiota  /intestino/cerebro  es  un  aspecto  emergente  en  la\ngeneraci\u00f3n de comportamientos autistas; la evidencia en modelos animales\nsugiere que los cambios microbianos intestinales pueden producir cambios que\nse ajustan al cuadro cl\u00ednico del autismo. El objetivo del presente estudio fue\nevaluar los perfiles metagen\u00f3micos fecales en ni\u00f1os con TEA y compararloscon  controles  sanos.  Esta  comparaci\u00f3n  nos  permite  determinar  c\u00f3mo  la\nregresi\u00f3n mental (una variable importante en el TEA) podr\u00eda influir en el perfil\nde la microbiota intestinal. Por este motivo, se realiz\u00f3 una subclasificaci\u00f3n en\nni\u00f1os  con  TEA  en  AMR  y  ANMR.  El  presente  trabajo   fue  un  estudio\nobservacional descriptivo. Cuarenta y ocho ni\u00f1os de 2 a 6 a\u00f1os con TEA se\nincluyeron: 30 ANMR y 18 AMR. Adem\u00e1s, se seleccion\u00f3 un grupo de control de\n57 ni\u00f1os con un neurodesarrollo t\u00edpico y se compar\u00f3 con el grupo de TEA por\nsexo y edad.\nLas muestras fecales se analizaron con un enfoque metagen\u00f3mico utilizando\nuna plataforma de secuenciaci\u00f3n de pr\u00f3xima generaci\u00f3n. Se detectaron varias\ndiferencias entre los ni\u00f1os con TEA, en comparaci\u00f3n con el grupo sano. Es\ndecir,  Actinobacteria  y  Proteobacteria  a  nivel  de  Phylum,  as\u00ed  como\nActinobacteria, Bacilli, Erysipelotrichi y Gammaproteobacteria a nivel de clase\nse encontraron en proporciones m\u00e1s elevadas  en  los ni\u00f1os con TEA. Adem\u00e1s,\nlos niveles de Proteobacterias mostraron un aumento exclusivo en ni\u00f1os con\nAMR.  Los  resultados  preliminares,  utilizando  un  an\u00e1lisis  de  componentes\nprincipales, mostraron patrones diferenciales en ni\u00f1os con TEA, ANMR y AMR,\nen comparaci\u00f3n con el grupo sano, tanto para la microbiota intestinal como\npara  los  patrones  de  alimentos.  En  este  estudio,  detectamos  niveles  m\u00e1s\nelevados de Actinobacteria, Proteobacteria y Bacilli, adem\u00e1s de Erysipelotrichi\ny Gammaproteobacteria en los  ni\u00f1os con TEA en comparaci\u00f3n con el grupo\nsano.  Adem\u00e1s,  los  ni\u00f1os  con  AMR  presentaron  niveles  m\u00e1s  altos  de\nProteobacterias.  Se  necesitan  m\u00e1s  an\u00e1lisis  utilizando  estos  resultados\npreliminares  y  mezclando  tecnolog\u00edas  metagen\u00f3micas  y  otras  tecnolog\u00edas\n\"\u00f3micas\" en cohortes m\u00e1s grandes de ni\u00f1os con TEA para confirmar estos\ncambios de microbiota intestinal.\n4.3 O. D. Rangel Huerta*, A. Gomez Fern\u00e1ndez*, M. J. de la Torre Aguilar,\nA. Gil, J. L. Perez Navero, K. Flores Rojas, P. Mart\u00edn Borreguero, M. Gil\nCampos.  Metabolic profiling in children with autism spectrum disorder\nwith  and  without  mental  regression:  preliminary  results  from  a  cross\nsectional  case\u2013control  study.  Metabolomics  2019;  15:99.\ndoi.org/10.1007/s11306-019-1562-x.  FI:  3,167.  Categor\u00eda:  Endocrinology\nand Metabolism 71/145. Tercil 2. Q2.* Ambos autores  han contribuido  igual\nResumen \nIntroducci\u00f3n.  Es  un  desaf\u00edo  establecer  los  mecanismos  involucrados  en  la\nvariedad de fenotipos cl\u00ednicos bien definidos en el TEA y las v\u00edas involucradas\nen sus patogenias.\nObjetivos . El objetivo de este estudio fue evaluar los perfiles metabol\u00f3micos de\nlos  ni\u00f1os  con  TEA  subclasificados  por  el  fenotipo  de  regresi\u00f3n  del\nneurodesarrollo AMR y ANMR.\nM\u00e9todos. El presente trabajo fue un estudio transversal de casos y controles.\nSe incluyeron 30 ni\u00f1os de 2 a 6 a\u00f1os con TEA: 15 AMR y 15 ANMR. Adem\u00e1s,\nse seleccion\u00f3 un grupo de control de 30 ni\u00f1os con neurodesarrollo t\u00edpico y se\najustaron el grupo TEA por edad y sexo. Las muestras de plasma se analizaron\ncon  una  metodolog\u00eda  metabol\u00f3mica  de  plataforma  \u00fanica  basada  en\ncromatograf\u00eda  l\u00edquida-espectrometr\u00eda  de  masas.  Se  realizaron  an\u00e1lisis\nunivariante y multivariante, incluidos los modelos de an\u00e1lisis ortogonales de\nm\u00ednimos  cuadrados-discriminantes  parciales  y  de  estructuras  \u00fanicas  y\ncompartidas, utilizando metabo analyst 4.0 y Simca-p 15. El punto final principal\nfue la caracterizaci\u00f3n metab\u00f3lica entre ni\u00f1os sanos y ni\u00f1os autistas y sus\nsubgrupos.\nResultados.  Se compararon los perfiles metab\u00f3licos de 30 ni\u00f1os sanos, 15\nAMR y 15 ANMR. Se detectaron varias diferencias entre ni\u00f1os sanos y ni\u00f1os\ncon TEA, que involucran principalmente el metabolismo de amino\u00e1cidos, l\u00edpidos\ny nicotinamida. Adem\u00e1s, reportamos diferencias entre los grupos AMR y ANMR.\nConclusiones.  En  este  estudio,  se  informa  por  primera  vez,  los  perfiles\nmetabol\u00f3micos  plasm\u00e1ticos  de  ni\u00f1os  con  TEA,  que  incluyen  dos  fenotipos\ndiferentes de perfiles dependiendo del estado de regresi\u00f3n del neurodesarrollo.\nEl uso de una plataforma de cromatograf\u00eda l\u00edquida-espectrometr\u00eda de masas\npara la metabol\u00f3mica en ni\u00f1os con TEA utilizando plasma parece ser muy\neficiente y agrega m\u00e1s apoyo a los hallazgos previos en la orina. Adem\u00e1s, el\npresente estudio documenta varios cambios relacionados con los amino\u00e1cidos,\nNAD+ y el metabolismo de los l\u00edpidos que, tales como alteraciones en las  rutas\nde la arginina y del glutamato, que parecen estar asociadas con el fenotipo\nAMR. Se necesitan an\u00e1lisis espec\u00edficos adicionales en una cohorte m\u00e1s grande\npara validar los resultados presentados en este trabajo.Existen en proceso de redacci\u00f3n, revisi\u00f3n o publicaci\u00f3n, otros trabajos deriva -\ndos de este  proyecto y tesis doctoral, que se resumen a continuaci\u00f3n:\n4.4.1 Gomez-Fern\u00e1ndez AR, Martin-Borreguero P, de la Torre-Aguilar MJ,\nGil-Campos  M,  Flores-Rojas  K,  P\u00e9rez-Navero  JL.  Neuropsychological\nprofile  in  children  with  autism  spectrum  disorder  with  a  history  of\nneurodevelopmental regression . \nResumen\nLa regresi\u00f3n del desarrollo neurol\u00f3gico no se incluye entre los criterios de\ndiagn\u00f3stico para el TEA .\nObjetivos.  Determinar,  en  un  grupo  de  ni\u00f1os  con  TEA,  la  presencia  de\nregresi\u00f3n del neurodesarrollo en relaci\u00f3n con la presencia de manifestaciones\nCl\u00ednicas y la severidad  del autismo.\nM\u00e9todos.  Los  pacientes  con  TEA se  clasificaron  en  dos  grupos,  regresivo\n(AMR)  y  no  regresivo  (ANMR)  mediante  una  escala  basada  en  el  autism\ndiagnostic  interview-revised  (adi-r).  La  gravedad  del  TEA  y  el  desarrollo\nneurol\u00f3gico  se  evaluaron  con  pruebas  espec\u00edficas  al  inicio  del  estudio  y\ndespu\u00e9s de 24 meses de seguimiento.\nResultados  .  Se incluyeron 52 pacientes de 2 a 6 a\u00f1os con TEA; 19 fueron\nclasificados como AMR y 33 fueron clasificados como ANMR. El grupo  AMR\npresent\u00f3 una mayor gravedad de los s\u00edntomas autistas y puntuaciones m\u00e1s\naltas de autismo. Adem\u00e1s, mostraron un  neurodesarrollo general m\u00e1s bajo,\nseg\u00fan se cuantific\u00f3 en el inventario de Battelle.  A los 24 meses, las diferencias\nsignificativas  en  la  gravedad  y  la  evaluaci\u00f3n  de  los  s\u00edntomas  autistas  se\nmantuvieron para   ambos grupos,  as\u00ed como en el inventario de Battelle.\nConclusiones. Los grupos AMR y ANMR presentan diferentes manifestaciones\ncl\u00ednicas y pron\u00f3sticos en cuanto  a la gravedad de los s\u00edntomas autistas y el\nDesarrollo neurol\u00f3gico. Las investigaciones futuras deber\u00edan centrarse en estos\nfenotipos para determinar si requieren estrategias  terap\u00e9uticas diferentes.\n4.4.2  Fernando  Gil-Hern\u00e1ndez*,  Antonio  G\u00f3mez-Fern\u00e1ndez*,Juan  Luis\nP\u00e9rez-Navero, Mar\u00eda Jos\u00e9 de la Torre-Aguilar, Katherine Flores-Rojas, Pilar\nMart\u00edn-Borreguero, Mercedes Gil- Campos.  Neurotoxicity by mercury is\nnot associated with autism spectrum disorders in spanish children.  * ambos autores  han contribuido  igual\nResumen \nLa etiolog\u00eda  fisiopatol\u00f3gica que precipita los s\u00edntomas de TEA siguen siendo\ncontrovertidos.  Diferentes  autores  han  estudiado  neurotox\u00ednas  como  el\nmercurio y su relaci\u00f3n con el TEA. El objetivo de este estudio es evaluar los\nniveles de hg en el cabello en un grupo de ni\u00f1os con TEA (exposici\u00f3n cr\u00f3nica)\ny en la excreci\u00f3n urinaria (exposici\u00f3n actual) en comparaci\u00f3n con un grupo de\ncontrol.\nM\u00e9todos. Se realiz\u00f3 un estudio de casos y controles. Comparamos un grupo de\n54  ni\u00f1os  con  TEA (de  2  a  6  a\u00f1os  de  edad),  sin   ninguna  otra  patolog\u00eda\nasociada, con un grupo de control con  neurodesarrollo t\u00edpico (54 sujetos).\nResultados. No hubo diferencias en los valores de hg en  la orina (p: 0,631) y el\ncabello (p: 1) en los porcentajes de las muestras por debajo de los l\u00edmites de\ndetecci\u00f3n entre los grupos control y TEA, y tampoco entre los pacientes con\nTEA, en el  subgrupo  con neuroregresi\u00f3n  (AMR) (p: 0,08) y el subgrupo sin\nneuroregresi\u00f3n (ANMR) (p: 0,705). Cuando el an\u00e1lisis se ajust\u00f3 por edad y\nsexo, las diferencias entre los niveles de hg no fueron significativas. No hubo\ncorrelaciones entre las concentraciones de hg en el grupo TEA en su conjunto\n(p: 0.739), o cuando se subdividieron en TEA-AMR (p: 0.739) y TEA-ANMR (p:\n0.363).\nConclusiones. El presente estudio no muestra pruebas, en  nuestro medio, que\nrespalden  una  asociaci\u00f3n  entre  la  neurotoxicidad  por  mercurio  y  la\netiopatogenia del TEA.\n4.4.3 Gomez-Fern\u00e1ndez AR, de la Torre-Aguilar MJ , Gil-Campos M, Martin-\nBorreguero  P,  Flores-Rojas  K,  P\u00e9rez-Navero  JL.  Evaluaci\u00f3n  de  la\nrepercusi\u00f3n del tratamiento coadyuvante  con  \u00e1cido  docosahexaenoico\nen el perfil plasm\u00e1tico de citoquinas proinflamatorias  y mol\u00e9culas de\nadhesi\u00f3n  en ni\u00f1os  con trastorno del espectro autista\nResumen\nEn la etiopatogenia del TEA se han descrito varias  hip\u00f3tesis, entre ellas se\nincluyen las alteraciones en los mecanismos proinflamatorios, que  podr\u00edan\ninfluir  de  forma  negativa  en  el  correcto  establecimiento  de  las  sinapsisneuronales y  su  funcionamiento.  Terapias coadyuvantes  con  \u00e1cidos grasos\npoliinsaturados omega-3 podr\u00edan modificar estas alteraciones.\nObjetivo. Evaluar los cambios cl\u00ednicos y en el perfil de citoquinas y mol\u00e9culas\nde  adhesi\u00f3n  celular  plasm\u00e1tica  en  pacientes  pediatricos  con  TEA tras  la\nsuplementaci\u00f3n con DHA. \nMaterial y m\u00e9todos .  Se ha realizado un estudio de intervenci\u00f3n nutricional\nunic\u00e9ntrico e independiente, aleatorizado de grupos paralelos, doble ciego,\nplacebo-control. Se seleccionaron  un grupo de 44 ni\u00f1os menores de 7 a\u00f1os\ndiagnosticados de TEA sin ninguna otra patolog\u00eda asociada, subdivididos en\ndos  subgrupos:  TEA-i:19, que  recibieron 800 mg de DHA y 350 mg de\nEPA/d\u00eda durante 6 meses; TEA-noi: 25, subgrupo placebo. Se incluy\u00f3 un grupo\ncontrol con  56 ni\u00f1os sanos. El an\u00e1lisis de mieloperoxidasa, PAI-1, RANTES,\nMCP-1, catepsina, BDNF, NCAM, SICAM-1, SVCAM-1 Y NGF se realizaron  en\ntodos los sujetos.\nResultados.  Se  observaron  niveles  m\u00e1s  elevados  de   catepsina  (p:0002),\nNCAM (p:0.009), SICAM-1 (p:0.047) en el grupo de TEA sin tratamiento  en\ncomparaci\u00f3n con el grupo de postratamiento con DHA. En relaci\u00f3n con  las\npruebas de evaluaci\u00f3n psicolog\u00eda del TEA  se obtuvo  significaci\u00f3n en el grupo\npre-tratamiento con el post-tratamiento con dha en el CARS-2 (p <0001), SDQ\nal conducta (p: 0.02), SDQ corresponde (p: 0.014), SDQ (p : 0.001).\nConclusiones.  La suplementaci\u00f3n con dha en pacientes con TEA  podr\u00edan\nmodificar  el perfil de la actividad proteol\u00edtica  (captesina ) y  las mol\u00e9culas de\nadhesi\u00f3n celular (NCAM y SICAM-1) e igualmente la intervenci\u00f3n con DHA\npodr\u00eda modificar s\u00edntomas asociados al TEA incluyendo \u00e1reas de comunicaci\u00f3n\ne interacci\u00f3n social y alteraciones conductuales.\n4.4.4  Gomez-Fern\u00e1ndez  AR,  de  la  Torre-Aguilar  MJ  ,  P\u00e9rez-Navero  JL,\nMartin-Borreguero P, Flores-Rojas K, Gil-Campos M. A randomized double\nblind  controlled  trial  with  omega-3 fatty acids  in  children with  autism\nspectrum disorder. Study protocol\nResumen\nExiste un creciente inter\u00e9s por la suplementaci\u00f3n con DHA en el TEA debido a\nposibles alteraciones en los procesos de absorci\u00f3n, metabolismo o incluso laingesta de \u00e1cidos grasos omega-3 en ni\u00f1os con TEA. El objetivo principal fue\nevaluar los niveles basales de FA en ni\u00f1os con TEA y evaluar la seguridad y\neficacia del DHA y EPA tras seis meses de tratamiento.\nMaterial y m\u00e9todos. Se ha realizado un estudio de intervenci\u00f3n nutricional\nunic\u00e9ntrico e independiente, aleatorizado de grupos paralelos, doble ciego,\nplacebo-control, y un estudio de casos y controles. Se seleccion\u00f3 un grupo de\n44 ni\u00f1os menores de 7 a\u00f1os diagnosticados de TEA sin ninguna otra patolog\u00eda\nasociada, subdivididos en dos subgrupos: TEA-i:19, que  recibi\u00f3 800 mg de\nDHA y 350 mg de EPA/d\u00eda durante 6 meses; TEA-noi: 25, subgrupo placebo\nque recibi\u00f3 aceite de girasol alto oleico. Adem\u00e1s se seleccion\u00f3 un grupo control\nde  56  ni\u00f1os  de  similar  edad  y  con  desarrollo  t\u00edpico.  Ambos  preparados\n(tratamiento  y  placebo)  fueron  aromatizados  con  lim\u00f3n  para  ocultar  sus\npropiedades  organol\u00e9pticas.  Se  realizaron  los  cuestionarios  CARS,  SDQ  y\nPDDBI basal y tras los 6 meses de intervenci\u00f3n en ambos grupos de pacientes\nTEA. Se realiz\u00f3 una determinaci\u00f3n basal de los principales FA en los 3 grupos,\ny tras los 6 meses de intervenci\u00f3n en ambos grupos de pacientes TEA.\nConclusiones. El an\u00e1lisis de los datos obtenidos en este estudio nos permitir\u00e1\nvalorar  la  seguirdad  y  eficacia  de  los  FA  omega-3  como  tratamiento\ncoadyuvante  del  TEA.  Por  otro  lado,  podremos  objetivar  si  existe  alguna\nalteraci\u00f3n en los procesos de absorci\u00f3n o metabolismo de los FA en el TEA.5 BIBLIOGRAFIA\nAdams JB, Baral M, Geis E, Mitchell J, Ingram J, Hensley A, et al. Safety and\nefficacy of oral DMSA therapy for children with autism spectrum disorders: Part\nA-medical results. BMC Clin Pharmacol. 2009; 9:16.\nAdamas  JB,  Hollowey  C,  Jeny  A.  Pilot  study  of  a  moderate  dose\nmultivitamin/mineral supplement for children with autistic spectrum disorder. J\nAltern Complem Med 2004; 10:1033-1039.\nAgostoni C, Nobile M, Ciappolino V, Delvecchio G, Tesei A, Turolo S, et al. The\nRole of Omega-3 Fatty Acids in Developmental Psychopathology: A Systematic\nReview on Early Psychosis, Autism, and ADHD. Int J Mol Sci. 2017; 18(12).\nAhlsen G, Rosengren L, Belfrage M, Palm A, Haqlid K, Hamberger A, et al. Glial\nfibrillary acidic protein in the cerebrospinal fluid of children with autism and other\nneuropsychiatric disorders. Biol Psychiatry. 1993; 33(10):734-743. \nAL-Ayadhi L. Y.  Heavy metals and trace elements in hair samples of autistic\nand normal children in central Saudi Arabia. Neurosciences 2005; 10:213-218.\nAl-Gadani Y, El-Ansary A, Attas O, Al-Ayadhi L. Metabolic biomarkers related to\noxidative stress and antioxidant status in Saudi autistic children. Clin Biochem.\n2009; 42(10-11):1032-1040.\nAltieri L, Neri C, Sacco R, Curatolo P, Benvenuto A, Muratori F, et al. Urinary p-\ncresol  is  elevated  in  small  children  with  severe  autism  spectrum  disorder.\nBiomarkers. 2011; 16(3):252-260.\nAmminger  GP,  Berger  GE,  Sch\u00e4fer  MR,  Klier  C,  Friedrich  MH,  Feucht  M.\nOmega-3 fatty acids supplementation in children with autism: a double-blind\nrandomized, placebo-controlled pilot study. Biol Psychiatry. 2007; 61(4):551-\n553.\nAngelidou  A,  Asadi  S,  Alysandratos  KD,  Karagkouni  A,  Kourembanas  S,Theoharides TC. Perinatal stress, brain inflammation and risk of autism-review\nand proposal. BMC Pediatr. 2012; 12:89.\nAmerican Psychiatric Association. Diagnostic and Statistical Manual of Mental\nDisorders. (4th edR) APA, Washington, DC. 1994.\nAmerican Psychiatric Association. Diagnostic and Statistical Manual of Mental\nDisorders  DSM-IVTR.  4.  American  Psychiatric  Association  Publishing  Inc;\nWashington DC, USA: 2000.\nAmerican Psychiatric Association. Diagnostic and Statistical Manual of Mental\nDisorders. 5th ed. Arlington, VA: American Psychiatric Association; 2013. \nArtigas-Pallar\u00e9s J, Gabau-Vila E, Guitart-Feliubadal\u00f3 M. El autismo sindr\u00f3mico:\nI. Aspectos generales. Neurol 2005; 40 Supl 1:143-149.\nArtigas-Pallar\u00e9s J, Gabau-Vila E, Guitart-Feliubadal\u00f3 M.  El autismo sindr\u00f3mico:\nII. S\u00edndromes de base gen\u00e9tica asociados a autismo. Rev Neurolog\u00eda. 2005; 40\nSupl 1:151-162.\nAshwood P, Enstrom A, Krakowiak P, Hertz-Picciotto I, Hansen RL, Croen LA, et\nal.  Decreased  transforming  growth  factor  beta1  in  autism:  A potential  link\nbetween immune dysregulation and impairment in clinical behavioral outcomes.\nJ Neuroimmunol 2008; 204:149-153.\nAsperger.  Die  Autistiche  psychopathen  in  kindersalter.  Archiv  Psychiatrie\nNervenkrankeiten 1944; 117:76-136.\nAutism and Developmental Disabilities Monitoring Network Surveillance Year\n2008  Principal  Investigators;  Centers  for  Disease  Control  and  Prevention.\nPrevalence  of  autism  spectrum  disorders--Autism  and  Developmental\nDisabilities Monitoring Network, 14 sites, United States, 2008. MMWR Surveill\nSumm. 2012; 61(3):1-19.Bauer S. Cytokine control of adult neural stem cells. Ann N Y Acad Sci. 2009;\n1153:48-56.\nBasterzi A. D, Aydemir C, Kisa C, Aksaray S, Tuzer V, Yazici K, et al. IL-6 levels\ndecrease  with  SSRI  treatment  in  patients  with  major  depression.  Hum.\nPsychopharmacol. 2005; 20:473-476.\nBattaglia A, Parrini B, Tancredi R. The behavioral phenotype of the idic(15)\nsyndrome. Am J Med Genet Part C. 2010; 154:448-455.\nBEDCA .  Base  de  Datos Espa\u00f1ola de  Composici\u00f3n de  Alimentos.  Espa\u00f1a\n[Internet]. Consultado en 2014. Disponible en http://www.bedca.net/bdpub/.\nBent S, Bertoglio K, Ashwood P, Bostrom A, Hendren RL. A pilot randomized\ncontrolled trial of omega-3 fatty acids for autism spectrum disorder. J Autism\nDev Disord. 2011; 41(5):545-554.\nBent S, Hendren RL, Zandi T, Law K, Choi JE, Widjaja F, et al. Internet-based,\nrandomized, controlled trial of omega-3 fatty acids for hyperactivity in autism. J\nAm Acad Child Adolesc Psychiatry. 2014; 53(6):658-666. \nBerry-Kravis E, Raspa M, Loggin-Hester L, Bishop E, Holiday D, Bailey DB.\nSeizures in fragile X syndrome: Characteristics and comorbid diagnoses. Am J\nIntellect Dev Disabil. 2010; 115:461-472.\nBernard S, Enayati A, Redwood L, Roger H, Binstock T. Autism: a novel form of\nmercury poisoning. Med. Hypotheses 2001; 56:462-471. \nBertrand J,  Mars A, Bove F, Yeargin-Allsopp M,  Decoufle P. Prevalence of\nautism  in  a  United  States:  the  Brick  Township,  New  Jersey,  investigation.\nPediatrics. 2001; 108:1155-1161.\nBitar T, Mavel S, Emond P, Nadal-Desbarats L, Lef\u00e8vre A, Mattar H, et al.\nIdentification  of  metabolic  pathway  disturbances  using  multimodalmetabolomics in autistic disorders in a Middle\nEastern population. J Pharm Biomed Anal. 2018; 152:57-65.\nBlaucok-Busch E, Amin OR, Dessoki HH, Rabah T. Efficacy of DMSA Therapy\nin  a  Sample  of  Arab  Children  with  Autistic  Spectrum  Disorder.  Maedica\n(Buchar). 2012; 7(3):214-221.\nBlaylock  RL,  Strunecka  A.  Immune  glutametric  dysfunction  as  a  central\nmechanism of the Autism Spectrum Disorders. Curr Med Chem. 2009; 16:157-\n170.\nBleuler  E.  Dementia  Praecox  or  the  Group  of  Schizophrenias.  New  York:\nInternational Universities. (1950[1911]).\nBonati MT, Russo S, Finelli P, Valsecchi MR, Cogliati F, Cavalleri F, et al.\nEvaluation of autism traits in Angelman syndrome: A resource to unfold autism\ngenes. Neurogenetics. 2007; 8:169-178.\nBoulanger LM. Immune proteins in brain development and synaptic plasticity.\nNeuron. 2009; 64: 93-109.\nBozzatello P, Brignolo E, De Grandi E, Bellino S. Supplementation with Omega-\n3 Fatty Acids in Psychiatric Disorders: A Review of Literature Data. J Clin Med.\n2016; 5(8).\nBradstreet J, Geier D. A, Kartzinel J. J, Adams J. B, Geier M. R.  A Case-Control\nstudy of mercury burden in children with Autistic Spectrum Disorders. J Am\nPhys Surg. 2003; 8:76-79.\nBrydon  L,  Harrison  NA,  Walker  C,  Steptoe  A,  Critchley  HD.  Peripheral\ninflammation  is  associated  with  altered  substantia  nigra  activity  and\npsychomotor slowing in humans. Biol Psychiatry. 2008; 63:1022-1029.\nBuiting K. Prader\u2013Willi syndrome and Angelman syndrome. Am J Med GenetPart C. 2010; 154C:365-376.\nCarpentier  PA,  Palmer  TD.  Immune  influence  on  adult  neural  stem  cell\nregulation and function. Neuron. 2009; 64(1):79-92.\nChauhan  A,  Audhya  T,  Chauhan  V.  Brain  region-specific  glutathione  redox\nimbalance in autism. Neurochem Res. 2012; 37:1681-1689.\nChauhan A, Gu F, Essa MM, Wegiel J, Kaur K, Brown WT, et al. Brain region-\nspecific deficit in mitochondrial electron transport chain complexes in children\nwith autism. J Neurochem.  2011; 117:209-220.\nCheng  YS,  Tseng  PT,  Chen  YW,  Stubbs  B,  Yang  WC,  Chen  TY,  et  al.\nSupplementation of omega 3 fatty acids may improve hyperactivity, lethargy,\nand stereotypy in children with autism spectrum disorders: a meta-analysis of\nrandomized controlled trials. Neuropsychiatr Dis Treat. 2017; 13:2531-2543.\nChez MG, Dowling T, Patel PB, Khanna P, Kominsky M. Elevation of tumor\nnecrosis factor-alpha in cerebrospinal fluid of autistic children. Pediatr Neurol.\n2007; 36(6):361-365.\nChi L, Ke Y, Luo C, Gozal D, Liu R. Depletion of reduced glutat-hione enhances\nmotor neuron degeneration in vitro and in vivo. Neuroscience. 2007; 144:991-\n1003. \nClifford S, Dissanayake C, Bui QM, Huggins R, Taylor AK, Loesch DZ. Autism\nspectrum  phenotype  in  males  and  females  with  fragileXfull  mutation  and\npremutation. J Autism Dev Disord. 2007; 37:738-747.\nCoffee B, Keith K, Albizua I, Malone T, Mowrey J, Sherman SL, et al. Incidence\nof fragile X syndrome by newborn screening for methylated FMR1 DNA. Am J\nHum Genet. 2009; 85:503-514.\nCollins SM, Bercik P. The relationship between intestinal microbiota and thecentral  nervous  system  in  normal  gastrointestinal  function  and  disease.\nGastroenterology. 2009; 136(6):2003-2014.\nCohen IL. Criterion-related validity of the PDD Behavior Inventory. J Autism Dev\nDisord. 2003; 33:47-53. \nCooper RE, Tye C, Kuntsi J, Vassos E, Asherson P. The effect of omega-3\npolyunsaturated  fatty  acid  supplementation  on  emotional  dysregulation,\noppositional behaviour and conduct problems in ADHD: a systematic review\nand meta-analysis. J Affect Disord. 2016; 190:474-482.\nCoury  DL,  Ashwood  P,  Fasano  A,  Fuchs  G,  Geraghty  M,  Kaul  A,  et  al.\nGastrointestinal  conditions  in  children  with  autism  spectrum  disorder:\ndeveloping a research agenda. Pediatrics. 2012;130 Suppl 2:160-168.\nCryan  JF,  O\u2019Mahony  SM.  The  microbiome-gut-brain  axis:  from  bowel  to\nbehavior. Neurogastroenterol Motil. 2011; 23(3):187-192. \nde Araujo EG, da Silva GM, Dos Santos AA. Neuronal cell survival: the role of\ninterleukins. Ann N Y Acad Sci. 2009; 1153:57-64.\nde Magistris L, Familiari V, Pascotto A, Sapone A, Frolli A, Iardino P, et al.\nAlterations  of  the  intestinal  barrier  in  patientstheir  first-degree  relatives.  J\nPediatr Gastroenterol Nutr. 2010; 51(4):418-424. \nDepienne C, Moreno-De-Luca D, Heron D, Bouteiller D, Gennetier A, Delorme\nR, et al. Screening for genomic rearrangements and methylation abnormalities\nof the 15q11-q13 region in autism spectrum disorders. Biol Psychiatry. 2009;\n66:349-359.\nDepino AM, Lucchina L, Pitossi F.  Early and adult hippocampal TGF-beta1\noverexpression have opposite effects on behavior. Brain Behav Immun. 2011;\n25:1582-1591.Desbonnet L, Garrett L, Clarke G, Bienenstock J, Dinan TG. The probiotic\nBifidobacteria infantis: An assessment of potential antidepressant properties in\nthe rat. J Psychiatr Res. 2008; 43(2):164-174.\nDescheemaeker  MJ,  Govers  V,  Vermeulen  P,  Fryns  JP.  Pervasive\ndevelopmental disorders in Prader-Willi syndrome: the Leuven experience in 59\nsubjects and controls. Am J Med Genet A. 2006; 140(11):1136-1142.\nDeverman BE, Patterson PH. Cytokines and CNS development. Neuron. 2009;\n64(1):61-78.\nD\u00edaz-Hung  ML,  Gonz\u00e1lez  Fraguela  ME.  El  estr\u00e9s  oxidativo  en  las\nenfermedades neurol\u00f3gicas: \u00bfcausa o consecuencia? Neurolog\u00eda: Publicaci\u00f3n\noficial de la Sociedad Espa\u00f1ola de Neurolog\u00eda. 2013; 29(8):451-452.\nDrexhage  RC,  Hoogenboezem  TA,  Cohen  D,  Versnel  MA,  Nolen  WA,  van\nBeveren NJ, et al. An activated set point of T-cell and monocyte inflammatory\nnetworks in recent-onset schizophrenia patients involves both pro- and anti-\ninflammatory forces. Int J Neuropsychopharmacol. 2011; 14(6):746-755.\nDrexhage RC, Knijff EM, Padmos RC, Heul-Nieuwenhuijzen Lv, Beumer W,\nVersnel  MA  et  al.  The  mononuclear  phagocyte  system  and  its  cytokine\ninflammatory  networks  in  schizophrenia  and  bipolar  disorder.  Expert  Rev\nNeurother. 2010; 10(1):59-76.\nDrexhage RC, van der Heul-Nieuwenhuijsen L, Padmos RC, van Beveren N,\nCohen D, Versnel MA, et al. Inflammatory gene expression in monocytes of\npatients with schizophrenia: overlap and difference with bipolar disorder. A study\nin  naturalistically  treated  patients.  Int  J  Neuropsychopharmacol.  2010;\n13(10):1369-1381.\nEnstrom AM, Van de Water JA, Ashwood P. Autoimmunity in autism. Curr Opin\nInvestig Drugs 2009; 10:463-473.Essa MM, Guillemin GJ, Waly MI, Al-Sharbati MM, Al-Farsi YM, Hakkim FL, et\nal. Increased markers of oxidative stress in autistic children of the Sultanate of\nOman. Biol Trace Elem Res. 2012; 147(1-3):25-27.\nEvans B. How autism became autism: The radical transformation of a central\nconcept of child development in Britain. Hist Human Sci. 2013; 26(3):3-31.\nEvans TA, Siedlak SL, Lu L, Fu X, Wang Z, McGinnis WR, et al. The autistic\nphenotype  exhibits  a  remarkably  localized  modification  of  brain  protein  by\nproducts of free radical-induced lipid oxidation. Am J Biochem Biotechnol. 2008;\n4:61-72.\nFatemi SH, Folsom TD, Reutiman TJ, Lee S. Expression of astrocytic markers\naquaporin  4  and  connexin  43  is  altered  in  brains  of  subjects  with  autism.\nSynapse. 2008; 62(7):501-507.\nFinegold SM. Therapy and epidemiology of autism-clostridial spores as key\nelements. Med Hypotheses. 2008; 70(3):508-511.\nFinegold SM, Dowd SE, Gontcharova V, Liu C, Henley KE, Wolcott RD, et al.\nPyrosequencing  study  of  fecal  microflora  of  autistic  and  control  children.\nAnaerobe. 2010;16(4):444-453.\nFlora SJ. Metal poisoning: threat and management. Al Ameen J Med Sci. 2009;\nvol. 2:4-26. \nForsythe P, Sudo N, Dinan T, Taylor VH, Bienenstock J. Mood and gut feelings.\nBrain Behav Immun. 2010; 24(1):9-16.\nForTEA MS, Escandell MO, Castro JJ. Estimaci\u00f3n de la prevalencia de los\ntrastornos  del  espectro  autista  en  Canarias.  An  Pediatr\u00eda  (Barc).  2013;\nvol.79(6):352-359.Garc\u00eda-Nonell C, Ratera ER, Harris S, Hessl D, Ono MY, Tartaglia N, et al.\nSecondary medical diagnosis in fragile X syndrome with and without autism\nspectrum disorder. Am J Med Genet Part A. 2008; 146A:1911-1916.\nGeier DA, Ken JK, Graver CR, Adams JB. Biomarkers of environmental toxicity\nand susceptibility in autism. Neural Sci. 2008; 6:431 -561.\nGeier DA, Kern JK, Sykes LK, Geier MR. Mercury-associated diagnoses among\nchildren diagnosed with pervasive development disorders. Metab Brain Dis.\n2018; 33(3):949-960.\nGevi F, Zolla L, Gabriele S, Persico AM. Urinary metabolomics of young Italian\nautistic  children  supports  abnormal  tryptophan  and  purine  metabolism.  Mol\nAutism. 2016; 7:47.\nGilbert JA, Krajmalnik-Brown R, Porazinska DL, Weiss SJ, Knight R. Toward\neffective probiotics for autism and other neurodevelopmental disorders. Cell.\n2013; 155(7):1446-1448.\nGoodman R. The Strengths and Difficulties Questionnaire: a research note. J\nChild Psychol Psychiatry. 1997; 38(5):581-586.\nGupta P, Kar S. Role of ascorbic acid in cadmium-induced thyroid dysfunction\nwith lipid peroxidation in children with autism. J Appl Toxicol 1998; 12:317-319.\nHall  SS,  Lightbody  AA,  Hirt  M,  Rezvani  A,  Reiss  AL.  Autism  in  fragile  X\nsyndrome: A category mistake? J Am Acad Child Adolesc Psychiatry. 2010;\n49:921-933.\nHall  SS,  Lightbody  AA,  Reiss  AL.  Compulsive,  self-injurious,  and  autistic\nbehavior  in  children  and  adolescents  with  fragile  X  syndrome.  Am  J  Ment\nRetard. 2008; 113:44-53.\nHeijtz RD, Wang S, Farhana AF, Qian Y, Bj\u00f6rkholm B, Samuelsson A, et al.Normal gut microbiota modulates brain development and behavior. Proc Natl\nAcad Sci USA. 2011;108(7):3047-3052. \nHern\u00e1ndez CJ, Narvaiza JL, Rinc\u00f3n JM, Ruiz I, S\u00e1nchez E, Sobradillo B, et al.\nCurvas y Tablas de Crecimiento. Instituto de investigaci\u00f3n sobre crecimiento y\ndesarrollo. Madrid: Fundaci\u00f3n F. Orbegozo. Ediciones Garsi; 1988.\nHogart A,WuD, LaSalle JM, SchanenNC.  The comorbidity of autism with the\ngenomic disorders of chromosome 15q11.2\u2013q13. Neurobiol Dis. 2010; 38:181-\n191.\nHolmes AS,  Blaxill MF, Haley BE. Reduced levels of mercury in first  baby\nhaircuts of autistic children. Int J Toxicol. 2003; 22: 277-85.\nHorvath A, Lukasik J, Szajewska H. Omega-3 fatty acid supplementation does\nnot affect autism spectrum disorder in children: a systematic review and meta-\nanalysis. J Nutr. 2017; 147(3):367-376. \nHsiao  EY,  McBride  SW,  Hsien  S,  Sharon  G,  Hyde  ER,  McCue  T,  et  al.\nMicrobiota modulate behavioral and physiological abnormalities associated with\nneurodevelopmental disorders. Cell. 2013; 155(7):1451-1463. \nIrwin MR, Wang M, Ribeiro D, Cho HJ, OlmsTEAd R, Breen EC, et al. Sleep\nloss activates cellular inflammatory signaling. Biol Psychiatry. 2008; 64:538-540.\nJames S, Montgomery P, Williams K. Omega-3 fatty acids supplementation for\nautism  spectrum  disorders  (ASD)  (Review).  Cochrane  Database  Syst  Rev.\n2011; 9:CD007992.\nKanner L. Autistic disturbances of affective contact. Nervous Child. 1943; 217-\n250.\nKempermann G. Seven principles in the regulation of adult neurogenesis. Eur J\nNeurosci.  2011; 33(6):1018-1024. Kern JK, Geier DA, Sykes LK, Geier MR. Evidence of neurodegeneration in\nautism spectrum disorder. Transl Neurodegener. 2013; 2(1):17.\nKern JK, Geier DA, Sykes LK, Haley BE, Geier MR. The relationship between\nmercury and autism: A comprehensive review and discussion. J Trace Elem\nMed Biol. 2016; 37:8-24.\nKern JK, Geier DA, Sykes LK, Geier MR. Relevance of Neuroinflammation and\nEncephalitis in Autism. Front Cell Neurosci. 2016; 9:519.\nKern JK, Jones AM. Evidence of toxicity, oxidative stress and neuronal insult in\nautism. Toxicol Environ Health. 2006; 9:485 -499.\nKwok DK, Chan CH, Soo MT, Lee RS. Low-level chronic mercury exposure in\nchildren and adolescents: meta-analysis. Pediatr Int. 2007; 49(1):80-87.\nKontush  KO,  Schekatolina  A.  Vitamin  E  in  neurodegenerative  disorder:\nAlzheimers disease. Ann NY Acad. 2004; 1031:249 -262.\nKosinovsky B, Hermon S, Yoran-Hegesh R, Golomb A, Senecky Y, Goez H, et\nal.  The yield of laboratory investigations in children with infantile autism. J\nNeural Transm. 2005; 112:587-596.\nLaurence JA, Fatemi SH. Glial fibrillary acidic protein is elevated in superior\nfrontal, parietal and cerebellar cortices of autistic subjects. Cerebellum. 2005;\n4:206-210. \nLauritzen L, Brambilla P, Mazzocchi A, Harsl\u00f8f LB, Ciappolino V, Agostoni C.\nDHA Effects in Brain Development and Function. Nutrients. 2016; 8(1).\nLi X, Chauhan A, Sheikh AM, Patil S, Chauhan V, Li XM, et al. Elevated immune\nresponse in the brain of autistic patients. J Neuroimmunol. 2009; 207(1-2):111-116.\nLopez-Hurtado E, Prieto JJ. A microscopic study of language-related cortex in\nautism. Am J Biochem Biotechnol. 2008; 4:130-145.\nLonsdale D, Shamberger RJ, Audhya T. Treatment of Autism Spectrum children\nwith thiamine tetrahydrofurfuryl disulfide: a pilot study. Neuroendocrinol. 2002;\n23:303-308. \nLord C, Rutter M, DiLavore PC, Risi S, Gotham K, Bishop SL. Autism diagnostic\nobservation schedule (ADOS): Manual. WPS; 2001.\nLovell M, Markesbery W. Oxidative DNA damage in mild cognitiveimpairment\nand late-stage Alzheimer\u2019s disease. Nucleic AcidsRes. 2007; 35:7497-7504.\nLussu M, Noto A, Masili A, Rinaldi AC, Dess\u00ec A, De Angelis M, et al. The urinary\n(1) H-NMR metabolomics profile of an italian autistic children population and\ntheir unaffected siblings. Autism Res. 2017; 10(6):1058-1066.\nMankad D, Dupuis A, Smile S, Roberts W, Brian J, Lui T, et al. A randomized,\nplacebo controlled trial of omega-3 fatty acids in the treatment of young children\nwith autism. Mol Autism. 2015; 6:18. \nMattson M, Magnus T. Ageing and neuronal vulnerability. Nat RevNeurosci.\n2006; 7:278-294.\nMavel  S,  Nadal-Desbarats  L,  Blasco  H,  Bonnet-Brilhault  F,  Barth\u00e9l\u00e9my  C,\nMontigny F, et al.   1H-13C NMR-based urine metabolic profiling in autism\nspectrum disorders. Talanta. 2013; 114:95-102.\nMcInnes LA, Gonzalez PJ, Manghi ER, Esquivel M, Monge S, Delgado MF, et\nal.  A genetic study of autism in Costa Rica: Multiple variables affecting IQ\nscores observed in a preliminary sample of autistic cases. BMC Psychiatry.\n2005; 5:15.Mendlewicz J, Kriwin P, Oswald P, Souery D, Alboni S, Brunello N. Shortened\nonset of action of antidepressants in major depression using acetylsalicylic acid\naugmentation:  A  pilot  open-label  study.  Int  Clin  Psychopharmacol.  2006;\n21:227-231.\nMeyers CA, Albitar M, Estey E. Cognitive impairment, fatigue, and cytokine\nlevels  in  patients  with  acute  myelogenous  leukemia  or  myelodysplastic\nsyndrome. Cancer. 2005; 104:788-793.\nMiller A,  Maletic V, Raison C. Inflammation and Its Discontents: The Role of\nCytokines in the Pathophysiology of Major Depression. Biol Psychiatry. 2 009;\n65:732-741.\nMiller BJ, Culpepper N, Rapaport MH, Buckley P. Prenatal inflammation and\nneurodevelopment  in  schizophrenia:  a  review  of  human  studies.  Prog\nNeuropsychopharmacol Biol Psychiatry. 2013; 42:92-100. \nMing X, Stein TP, Barnes V, Rhodes N, Guo L. Metabolic perturbance in autism\nspectrum disorders: a metabolomics study. J Proteome Res. 2012; 11(12):5856-\n5862.\nMing X, Stein TP, Brimacombe M, Johnson WG, Lamber GH, Wagner GC.\nIncreased excretion of a lipid peroxidation biomarker in autism. Prostaglandins\nLeukot Essent Fatty Acids. 2005; 73:379 -84.\nMolloy  CA,  Morrow  AL,  Meinzen-Derr  J,  Schleifer  K,  Dienger  K,  Manning-\nCourtney P, et al. Elevated cytokine levels in children with autism spectrum\ndisorder. J Neuroimmunol. 2006; 172(1-2):198-205. \nMoore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the\ninterleukin-10 receptor. Annu Rev Immunol. 2001; 19:683-765.\nMorgan JT, Chana G, Pardo CA, Achim C, Semendeferi K, Buckwalter J, et al.Microglial  activation  and  increased  microglial  density  observed  in  the\ndorsolateral prefrontal cortex in autism. Biol Psychiatry. 2010; 68(4):368-376.\nMostafa GA, El-Hadidi ES, Hewedi DH, Abdou MM. Oxidative stress in Egyptian\nchildren with autism: relation to autoimmunity. J Neuroimmunol. 2010; 219(1-\n2):114-118.\nMostafa  GA,  Kitchener  N.  Serum  anti-nuclear  antibodies  as  a  marker  of\nautoimmunity in Egyptian autistic children. Pediatr Neurol. 2009; 40:107-112.\nMotivala SJ, Sarfatti A, Olmos L, Irwin MR.  Inflammatory markers and sleep\ndisturbance in major depression. Psychosom Med. 2005; 67:187-194.\nMuller N, Schwarz MJ, Dehning S, Douhe A, Cerovecki A, Goldstein-Muller B, et\nal. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major\ndepression: Results of a double-blind, randomized, placebo controlled, add-on\npilot study to reboxetine. Mol Psychiatry. 2006; 11:680-684.\nMussap M, Noto A, Fanos V. Metabolomics of autism spectrum disorders: early\ninsights regarding mammalian-microbial cometabolites. Expert Rev Mol Diagn.\n2016; 16(8):869-881.\nNadal-Desbarats L, A\u00efdoud N, Emond P, Blasco H, Filipiak I, Sarda P, et al.\nCombined 1H-NMR and 1H-13C HSQC-NMR to improve urinary screening in\nautism spectrum disorders. Analyst. 2014; 139(13):3460-3468.\nNaik US, Gangadharan C, Abbagani K, Nagalla B, Dasari N, Manna SK. A study\nof nuclear transcription factor-kappa B in childhood autism. PLoS One. 2011;\n9:6(5).\nNapoli E, Wong S, Giulivi C. Evidence of reactive oxygen species-mediated\ndamage to mitochondrial DNA in children with typical autism. Mol Autism. 2013;\n4(1):2.Nelson KB, Bauman ML. Thimerosal and autism? Pediatrics. 2003; 111:674-\n679.  \nNikam  S,  Nikam  P,  Ahaley  S,  Sontakke  A.  Oxidative  stress  inParkinson\u2019s\ndisease. Indian J Clin Biochem. 2009; 24:98-101.\nNoto A, Fanos V, Barberini L, Grapov D, Fattuoni C, Zaffanello M, et al. The\nurinary metabolomics profile of an Italian autistic children population and their\nunaffected siblings. J Matern Fetal Neonatal Med. 2014; 27 Suppl 2:46-52.\nOMS. CIE-10. The ICD Classification of Mental and Behavioural Disorders:\nDiagnostic criteria for research. 10\u00aa Rev. Madrid: Meditor; 1992.\nPadayatty S, Katz A,Wang Y, Eck P, Kwon O, Lee JH, et al. Vitamin C as an\nantioxidant: evaluation of its role in disease prevention. J Am Coll Nutr. 2003;\n22:18-35.\nPadmos RC, Hillegers MH, Knijff EM, Vonk R, Bouvy A, Staal FJ, et al. A\ndiscriminating  messenger  RNA signature  for  bipolar  disorder  formed  by  an\naberrant expression of inflammatory genes in monocytes. Arch Gen Psychiatry.\n2008; 65(4):395-407.\nPardo  CA,  Vargas  DL,  Zimmerman  AW.  Immunity,  neuroglia  and\nneuroinflammation in autism. Int Rev Psychiatry. 2005; 17(6):485-495. \nParletta N, Milte CM, Meyer BJ. Nutritional modulation of cognitive function and\nmental health. J Nutr Biochem. 2013; 24(5):725-743. \nParletta N, Niyonsenga T, Duff J. Omega-3 and Omega-6 Polyunsaturated Fatty\nAcid Levels and Correlations with Symptoms in Children with Attention Deficit\nHyperactivity  Disorder,  Autistic  Spectrum  Disorder  and  Typically  Developing\nControls. PLoS One. 2016; 11(5).\nPersico  AM,  Napolioni  V.  Urinary  p-cresol  in  autism  spectrum  disorder.Neurotoxicol Teratol. 2013; 36:82-90.\nPosada-De la Paz M, Ferrari-Arroyo MJ. Touri\u00f1o E, Boada L. Investigaci\u00f3n\nepidemiol\u00f3gica en el autismo: una visi\u00f3n integradora. Rev Neurolog\u00eda. 2005; 40\n(Supl):191-198.\nRaison CL, Capuron L, Miller AH. Cytokines sing the blues: Inflammation and\nthe pathogenesis of major depression. Trend Immunol. 2006; 27:24-31.\nReddy  KS.  Cytogenetic  abnormalities  and  fragile-X  syndrome  in  Autism\nspectrum disorder. BMC Med Genet. 2005; 6:3.\nReichenberg  A,  Yirmiya  R,  Schuld  A,  Kraus  T,  Haack  M,  Morag  A,  et  al.\nCytokine-associated emotional and cognitive disturbances in humans. Arch Gen\nPsychiatry. 2001; 58:445-452.\nRoberts  JE,  Weisenfeld  LA,  Hatton  DD,  Heath  M,  Kaufmann  WE.  Social\napproach and autistic behavior in children with fragile X syndrome. J Autism\nDev Disord. 2007; 37:1748-1760.\nRodriguez JI, Kem JK.  Evidence of microglial activation in autism and possible\nrole in brain underconnectivity. Neuron Glia Biology. 2011; 7:205-213.\nSahoo T, Peters SU,  Madduri NS, Glaze DG,  German JR, Bird LM, et al.\nMicroarray based comparative genomic hybridization testing in deletion bearing\npatients with Angelman syndrome: Genotype-phenotype correlations. J Med\nGenet. 2006; 43:512-516. \nSajdel-Sulkowska EM, Lipinsk B, Windom H, Audhya T, McGinnis W. Oxidative\nstress  in  autism:  elevated  cerebellar  3-nitrotyrosine  levels.  Am  J  Biochem\nBiotechnol. 2008; 4:73-84.\nSajdel-Sulkowska EM, Xu M, Koibuchi N. Increase in cerebellar neurotrophin-3\nand oxidative stress markers in autism. Cerebellum. 2009; 8:366-372.Sajdel-Sulkowska EM, Xu M, McGinnis W, Koibuchi N.  Brain region-specific\nchanges  in  oxidative  stress  and  neurotrophin  levels  in  autism  spectrum\ndisorders (ASD). Cerebellum. 2011; 10:43-48.\nScholper E, Van Bourgondien ME, Wellman GJ, Love SR. Childhood Autism\nRating  Scale-(CARS2).  Los  Angeles,  CA:  Western  Psychological  Services;\n2010.\nSchuchardt JP, Huss M, Stauss-Grabo M, Hahn A. Significance of long-chain\npolyunsaturated  fatty  acids  (PUFAs)  for  the  development  and  behaviour  of\nchildren. Eur J Pediatr. 2010; 169(2):149-164.\nSen CK, Khanna N, Rin CC, Roy S. Tocotrienols: the emerging face of natural\nvitamin E. Vitam Horm. 2007; 76:203 \u2013261.\nSogut S, Zoroglu SS, Ozyurt H, Ramazan YH, Ozugurlu F, Sivash E, et al.\nChanges in nitric oxide levels and antioxidant enzyme activities may have a role\nin the pathophysiological mechanisms involved in autism. Clin Chim Acta. 2003;\n331:111-117.\nStepanova E, Dowling S, Phelps M, Findling RL. Pharmacotherapy of emotional\nand behavioral symptoms associated with autism spectrum disorder in children\nand adolescents. Dialogues Clin Neurosci. 2017; 19(4):395-402.\nSun X, Allison C, Matthews FE, Sharp SJ, Auyeung B, Baron-Cohen S, et al.\nPrevalence of autism in mainland China, Hong Kong and Taiwan: a systematic\nreview and meta-analysis. Mol Autism. 2013; 4(1):7.\nSuvisaari J, Mantere O. Inflammation theories in psychotic disorders: a critical\nreview. Infect Disord Drug Targets. 2013; 13(1):59-70.\nTachibana Y, Miyazaki C, Ota E, Mori R, Hwang Y, Kobayashi E, et al.  A\nsystematic review and meta-analysis of comprehensive interventions for pre-school children with autism spectrum disorder (ASD). PLoS One. 2017;12(12). \nTaylor B, Jick H, Maclaughlin D. Prevalence and incidence rates of autism in the\nUK: time trend from 2004-2010 in children aged 8 years. BMJ Open. 2013;\n3(10). \nTerracciano A, Chiurazzi P, Neri G. Fragile X syndrome. Am J Med Genet Part\nC. 2005;  137C:32-37.\nUniversidad de C\u00f3rdoba. C\u00f3rdoba [Internet]. Consultado en 2012.  Pe\u00f1a. No\ndisponible.  http://Inmunolig\u00edaenlinea.es\nVargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA. Neuroglial\nactivation  and  neuroinflammation  in  the  brain  of  patients  with  autism.  Ann\nNeurol. 2005; 57(1):67-81.\nVoigt RG, Mellon MW, Katusic SK, Weaver AL, Matern D, Mellon B, et al.\nDietary  docosahexaenoic  acid  supplementation  in  children  with  autism.  J\nPediatr Gastroenterol Nutr. 2014; 58(6):715-22.\nVojdani A, Bock K, Hirani AK. Low natural killer cell cytotoxic activity in autism:\nthe role of glutathion, IL-2 and IL-15. J Neuroimmunal. 2008; 205:148 -154.\nWecker L, Miller SB, Cochran SR. Trace element concentrations in hair from\nautistic children. J Ment Defic Res. 1985; 29:15-22. \nWest  PR,  Amaral  DG,  Bais  P,  Smith  AM,  Egnash  LA,  Ross  ME,  et  al.\nMetabolomics as a tool for discovery of biomarkers of autism spectrum disorder\nin the blood plasma of children. PLoS One. 2014; 9(11).\nWills  S,  Cabanlit  M,  Bennett  J,  Ashwood  P,  Amaral  D,  Van  de  Water  J.\nAutoantibodies in autism spectrum disorders (ASD). Ann N Y Acad Sci. 2007;\n1107:79-91.Yap IK, Angley M, Veselkov KA, Holmes E, Lindon JC, Nicholson JK. Urinary\nmetabolic phenotyping differentiates children with autism from their unaffected\nsiblings and age-matched controls. J Proteome Res. 2010; 9(6):2996-3004.\nYao UK, Reddy RD, Van DP. Oxidative damage and schizophrenia: an overview\nof the evidence and its therapeutic implications. CNS Drugs. 2001; 15:237 -310.\nYorbik O, Sayal A, Akay C, Akbiyik DI, Sohmen T. Investigation of antioxidant\nenzymes in children with autistic disorder. Prostaglandins Leukot Essent Fatty\nAcids. 2002; 67(5):341-343.\nYoung AM, Campbell E, Lynch S, Suckling J, Powis SJ. Aberrant NF-kappaB\nexpression in autism spectrum condition: a mechanism for neuroinflammation.\nFront Psychiatry. 2011; 2:27.\nYui  K,  Koshiba  M,  Nakamura  S,  Kobayashi  Y.  Effects  of  large  doses  of\narachidonic  acid  added  to  docosahexaenoic  acid  on  social  impairment  in\nindividuals with autism spectrum disorders: a double-blind, placebo-controlled,\nrandomized trial. J Clin Psychopharmacol. 2012; 32(2):200-206.\nZafeiriou DI, Ververi A, Dafoulis V, Kalyva E, Vargiami E.  Autism Spectrum\nDisorders: The Quest for Genetic Syndromes. Am J Med Genet Part B. 2013;\n162B:327-366.\nZhang, X. Y, Zhou D. F, Cao L. Y, Zhang P. Y, Shen Y. C. Changes in serum\ninterleukin-2, -6, and -8 levels before and during treatment with risperidone and\nhaloperidol: relationship to outcome in schizophrenia. J. Clin. Psychiatry. 2004;\n65:940-947.\nZhou C, Huang Y, Przedborski S. Oxidative stress in Parkinson\u2019sdisease. A\nmechanism of pathogenic and therapeutic signifi-cance. Ann N Y Acad Sci.\n2008; 1147:104.\nZingg JM, Azzi A. Non-antioxidant activities of vitamin E. Curr Chem Med. 2004;11:1113-1133.\nZoroglu SS, Armutcu F, Ozen S, Gurel A, Sivasli E, Yetkin O, et al. Increased\noxidative stress and altered activities of erythrocyte free radical scavenging\nenzymes in autism. Eur Arch Psychiatry Clin Neurosci. 2004; 254:143 -147.6 ANEXOS\nAnexo 1: Art\u00edculo : Gomez-Fern\u00e1ndez A , de la Torre-Aguilar MJ, Gil-Campos \nM, Flores-Rojas K, Cruz-Rico MD, Martin-Borreguero P, Perez-Navero JL. Chil-\ndren With Autism Spectrum Disorder With Regression Exhibit a Different Profile \nin Plasma Cytokines and Adhesion Molecules Compared to Children Without \nSuch Regression.  Front Pediatr. 2018 Sep 26;6:264 . doi: \n10.3389/fped.2018.00264. eCollection 2018. PMID: 30320048\nAnexo 2: Art\u00edculo : Plaza-D\u00edaz J 1\u2020, G\u00f3mez-Fern\u00e1ndez A   1\u2020 Chueca N, Torre-\nAguilar MJ, Gil \u00c1, Perez-Navero JL, Flores-Rojas K, Mart\u00edn-Borreguero P, Solis-\nUrra P, Ruiz-Ojeda FJ, Garcia F, Gil-Campos M. Autism Spectrum Disorder \n(ASD) with and without Mental Regression is Associated with Changes in the \nFecal Microbiota. Nutrients. 2019 Feb 5;11(2).  pii: E337. doi: \n10.3390/nu11020337. PMID: 30764497\nAnexo  3: Art\u00edculo  :Rangel-Huerta OD  1\u2020, Gomez-Fern\u00e1ndez A  1\u2020, de la Torre-\nAguilar MJ, Gil A, Perez-Navero JL, Flores-Rojas K, Mart\u00edn-Borreguero P, Gil-\nCampos M. Metabolic profiling in children with autism spectrum disorder with \nand without mental regression: preliminary results from a cross-sectional case-\ncontrol study.  Metabolomics. 2019 Jun 27;15(7):99. doi: 10.1007/s11306-019-\n1562-x. PMID: 31250215\nAnexo 4: Ficha t\u00e9cnica de Eupoly-3\u00ae DHA Infant, administrado a los ni\u00f1os\ncon TEA  seleccionados en este estudio .  Es un  aceite de at\u00fan purificado,\nrefinado, desodorizado y estabilizado, rico en\u00e1cido docosahexaenoico (DHA).\nEste producto se utiliza en la elaboraci\u00f3n de f\u00f3rmulas infantiles. Cumple con los\nniveles m\u00e1s estrictos de todos los contaminantes posibles, y  su administraci\u00f3n\nes microencapsulada.ORIGINAL RESEARCH\npublished: 26 September 2018\ndoi: 10.3389/fped.2018.00264\nFrontiers in Pediatrics | www.frontiersin.org 1 September 2018 | Volume 6 | Article 264Editedby:\nPaoloCuratolo,\nUniversit\u00e0degliStudidiRomaTor\nVergata,Italy\nReviewedby:\nLeonardoEmbertiGialloreti,\nUniversit\u00e0degliStudidiRomaTor\nVergata,Italy\nRominaMoavero,\nBambinoGes\u00f9OspedalePediatrico\n(IRCCS),Italy\n*Correspondence:\nMercedesGil-Campos\nmercedes_gil_campos@yahoo.es\nSpecialtysection:\nThisarticlewassubmittedto\nPediatricNeurology,\nasectionofthejournal\nFrontiersinPediatrics\nReceived: 03July2018\nAccepted: 05September2018\nPublished: 26September2018\nCitation:\nGomez-FernandezA,\ndelaTorre-AguilarMJ,Gil-CamposM,\nFlores-RojasK,Cruz-RicoMD,\nMartin-BorregueroPand\nPerez-NaveroJL(2018)ChildrenWith\nAutismSpectrumDisorderWith\nRegressionExhibitaDifferentPro\ufb01lein\nPlasmaCytokinesandAdhesion\nMoleculesComparedtoChildren\nWithoutSuchRegression.\nFront.Pediatr.6:264.\ndoi:10.3389/fped.2018.00264Children With Autism Spectrum\nDisorder With Regression Exhibit a\nDifferent Pro\ufb01le in Plasma Cytokines\nand Adhesion Molecules Compared\nto Children Without Such Regression\nAntonioGomez-Fernandez1,MariaJ.delaTorre-Aguilar1,MercedesGil-Campos2*,\nKatherineFlores-Rojas2,MariaD.Cruz-Rico3,PilarMartin-Borreguero4and\nJuanLuisPerez-Navero1\n1DepartmentofPediatrics,ReinaSo\ufb01aUniversityHospital,U niversityofC\u00f3rdoba,Maim\u00f3nidesInstituteforBiomedical\nResearchofC\u00f3rdoba(IMIBIC),Cordoba,Spain,2PediatricMetabolismUnit,ReinaSo\ufb01aUniversityHospital, Maim\u00f3nides\nInstituteforBiomedicalResearchofC\u00f3rdoba(IMIBIC),Univers ityofC\u00f3rdoba,CentrodeInvestigaci\u00f3nBiom\u00e9dicaen\nRed-Fisiopatolog\u00edadelaObesidadyNutrici\u00f3n(CIBEROBN),C ordoba,Spain,3DepartmentofBiochemistryandMolecular\nBiologyII,InstituteofNutritionandFoodTechnology,Center ofBiomedicalResearch,UniversityofGranada,Granada,Sp ain,\n4DepartmentofChildandAdolescentClinicalPsychiatryand Psychology,ReinaSo\ufb01aUniversityHospital,Maim\u00f3nides\nInstituteforBiomedicalResearchofC\u00f3rdoba(IMIBIC),Cordoba ,Spain\nBackground: In the etiopathogenesis of autism spectrum disorder (ASD), it has\nbeen suggested that a proin\ufb02ammatory condition, as well as a n alteration in\nadhesion molecules in the early stages of neurodevelopment , may play a role in the\npathophysiologyofthedisorder.Thisstudysetouttoevalu atetheplasmalevelsofcertain\nin\ufb02ammatorycytokines,adhesionmolecules,andgrowthfac torsinasampleofpediatric\npatients with ASD and compare them to the levels in a control g roup of healthy children.\nMethods: Fifty-fourchildren(45malesandninefemales)aged2-6,wh owerediagnosed\nwith ASD, and a control group of 54 typically-developing chi ldren of similar ages were\nselected. The diagnosis of ASD was carried out in accordance with the DSM-5 criteria\nand the data obtained from a developmental semi-structured clinical interview and\nthe ADOS evaluation test. Additional testing was carried ou t to identify the children\u2019s\ndevelopmentallevelandseverityofASDsymptomatology.Pa tientswithASDwerefurther\ndivided into two subgroups based on developmental paramete rs: ASD children with\nneurodevelopmental regression (AMR) and ASD children with out neurodevelopmental\nregression (ANMR). Analyses of plasma molecules, such as ca thepsin, IL1 \u03b2, IL6, IL8,\nMPO, RANTES, MCP, BDNF, PAI NCAM, sICAM, sVCAM and NGF, were p erformed.\nResults: Higher levels of NGF were observed in the ASD group compared w ith the\nlevels in the control group ( p<0.05). However, in the analysis of the ASD subgroups,\nlower plasma levels of NCAM and higher levels of NGF were foun d in the group of\nASD children without developmental regression compared to the levels in the group of\ntypically-developing children.Gomez-Fernandez et al. Cytokines in Autism Children\nConclusions: These results suggest differences that could be related to d ifferent\npathophysiological mechanisms in ASD. There is not a speci\ufb01 c pro\ufb01le for the expression\nof relevant plasma cytokines, adhesion molecules or growth factors in children with\nASD compared with that in typically-developing children. H owever, in the ANMR and\nAMR subgroups, some of the adhesion molecules and neuronal g rowth factors show\ndifferences that may be related to synaptogenesis.\nKeywords: autism spectrum disorder, cell adhesion molecule s, children, cytokines, neurodevelopmental\nregression\nINTRODUCTION\nAutism spectrum disorder (ASD) is a neurodevelopmental\ndisorder that is characterized by persistent de\ufb01cits in soci al\ncommunication and social interaction across multiple conte xts\nand by the presence of repetitive and restricted patterns of\nbehaviors,activities,andinterests.Thesede\ufb01citsarepre sentfrom\nearly childhood, although some di\ufb03culties may not manifest\nthemselves until the demands of the environment exceed the\ncapacity of the child ( 1). ASD mainly a\ufb00ects males, by a ratio of\n4:1(2),andisgenerallydetectedinthesecondyearoflife.\nIt is well established that children with ASD do not\nconstitute a homogeneous clinical group, and many di\ufb00erent\npathologiesshowasimilarconstellationofbehavioralsympt oms\nthat converge within ASD. The existence of developmental\nregression in some children with ASD has been corroborated\nby multiple studies ( 3). Children with ASD who lose skills\nbelong to a subgroup designated with the term \u201cregressive\nautism.\u201d Regressive autism usually refers to a child whose\nparents report an early history of normal development for 12\u2013\n24 months, followed by a loss of previously acquired skills.\nLanguage regression is the most obvious form of regression,\nbut regressive autism can also be accompanied by more global\nregression involving loss of social attention, social skil ls and\nsocialinterest( 4).\nKnowledge about the etiology and neuropathology of ASD\nremains elusive however, and no biological markers have bee n\nfound. Most studies concur that there has been a signi\ufb01cant\nincrease in the prevalence of autism, a\ufb00ecting approximately\n0.75\u20131.55%ofthepediatricpopulation( 5,6).Ithasrecentlybeen\nreported that the prevalence of ASD reaches nearly 3% in some\ncommunities in the United States, representing an increase of\n150%since2000( 7).\nVarious studies published in recent years have supported the\nidea that a proin\ufb02ammatory situation may play a role in the\npathophysiology of ASD ( 8). An increase in proin\ufb02ammatory\nAbbreviations: ASD, Autism Spectrum Disorder; AMR, mental regression\ngroup; ANMR, non-mental regression group; BDNF, brain derived neurotro phic\nfactor; BMI, Body mass index; CARS, Childhood Autism Rating Sca le Test;\nC-CRP, C-reactive protein HGF, hepatocyte growth factor; ICAM, int ercellular\nadhesionmolecule;IL,interleukin;MCP-1,monocytechemotacticpro tein;MPO,\nmyeloperoxidase; NCAM, neuronal cell adhesion molecules; NGF, nerve growth\nfactor; PAI, plasminogen activator factor; PDDBI, PDD Behavior I nventory;\nRANTES, regulated on activation normal t cell expressed and secreted ; TNF \u03b1,\ntumornecrosisfactor \u03b1;VCAM,vascularcelladhesionmolecules.cytokines has been reported in samples of post-mortem brain\ntissue and cerebrospinal \ufb02uid, plasma, and mononuclear cell\ncultures ( 9,10). Levels of tumor necrosis factor alpha (TNF- \u03b1),\ninterleukins 6 and 8 (IL-6, IL-8), monocyte-macrophage colo ny\nstimulating factor (GM-CSF) and interferon gamma (IFN- \u03b3)\nhave also been reported as being higher in the brains of patient s\nwith ASD than in the brains of the healthy population ( 11).\nThe increase in cytokines may indicate an impaired immune\nresponse, with a predominant response of Th2 cells. Some\nauthors have suggested the existence of an endophenotype of\nASDlinkedtoanautoimmunedysregulation( 12).Others( 13,14)\nhave described altered levels of immune mediators linked to\ngreaterdeteriorationinbehavior.Ithasthusbeensuggest edthat\na dysregulation of the immune response may be related to the\nbehaviorandcognitiveimpairmentofchildrenwithASD.\nChemokines and their receptors have been implicated in the\ncirculation and movement of mononuclear cells in the CNS,\nmediating the recruitment of myeloid cells into areas of dama ge\nand in\ufb02ammation. Increased levels of various chemokines\n(macrophage in\ufb02ammatory proteins [MIP-1B], regulated on\nactivation, normal T cell expressed and secreted [RANTES],\nmonocyte Chemoattractant protein-1 [MCP-1]) have been\nreported in astrocytes in the cerebellum and brain tissue,\nas well as in peripheral blood in children with ASD. They\nhave been linked to a deterioration in communication skills ,\nstereotyped behaviors and hyperactivity, and an impairment of\ncognitivefunctionsandadaptiveskills( 15,16).Thecelladhesion\nmoleculeisanIgsuperfamilyadhesionmolecule(CAM)withan\nestablished role in axon growth and repulsion. Serum samples\nhave been reported to exhibit a decrease in the levels of vascu lar\nand intercellular cell adhesion molecules, notably sPECAM-\n1 (soluble platelet-endothelial cell adhesion molecule-1) a nd\nsVCAM-1(solublevascularcelladhesionmolecule-1),whichc an\nalsoplayaroleinthedevelopmentofASD( 17).\nMultiple hypotheses have been put forward to account for\ntheetiopathogenesisanddevelopmentaltrajectoriesofASD. The\nroles of cytokines, adhesion molecules and growth factors h ave\nnot been clari\ufb01ed precisely in this regard, but they may have an\nadverse bearing on the establishment of neuronal synapses an d\ntheirfunctioninginasituationofgreatersynapticplastici ty.The\ngoal of the present study was therefore to analyze the plasma\nlevels of some relevant molecules in children with ASD and to\ncompare these to the values exhibited by a group of typically-\ndeveloping children. The study also focused on the possible\nrelationships between the levels of such cytokines and the\nFrontiers in Pediatrics | www.frontiersin.org 2 September 2018 | Volume 6 | Article 264Gomez-Fernandez et al. Cytokines in Autism Children\nclinicalseverityofASDcoresymptomatologyandtheregress ion\nphenotypeinASD.\nMATERIALS AND METHODS\nThis observational case-control study was approved by the\nClinical Research and Bioethics Committee at the authors\u2019\nhospital and was conducted in full compliance with the\nfundamental principles established in the Declaration of\nHelsinki. The data relating to the ASD patients were collecte d at\nthetimetheywererecruitedintothestudy.Theselectedsub jects\nwereincorporatedintothestudyafterallthecriteriaforin clusion\nwere ful\ufb01lled, and informed written consent was obtained fr om\nthechildren\u2019slegalguardians.\nSubjects\nThe patients with ASD were recruited from the Department of\nChild and Adolescent Clinical Psychiatry and Psychology at the\nauthors\u2019hospital.Someofthepatients(aged2\u20133)wererecrui ted\nat the time of their ASD diagnosis, whereas the older patients\n(aged 3\u20136) were selected from among those who had already\nbeen diagnosed at the same unit. The control group comprised\nchildrendiagnosedwithphimosisandhernias,lackinganyot her\npathology, who attended preoperative anesthesia consultatio ns\nprior to surgical corrections. None of the controls belonged to\nthesamefamiliesastheASDcases.\nThe diagnosis of ASD was based on the clinical judgment\nof professionals specialized in the identi\ufb01cation of the uniq ue\ndevelopmental pro\ufb01le of subjects with ASD. The diagnostic\ndecision was based on the information obtained from semi-\nstructuredclinicaldevelopmentinterviewsandpsychologic aland\nbehavioral tests internationally recognized as reliable a nd valid\nfor this purpose. In this study, two clinical psychologists, a\npsychiatristandanoccupationaltherapistwithextensivecli nical\nexperience and training in diagnostic tests for research in A SD\nperformed the diagnosis using the criteriaestablishedby DS M-5\n(1). Two specializedpediatriciansreviewed the medical histor ies\nofthechildrenandperformedexaminationsofallthechildre n.\nInclusion criteria: the ASD children were 2\u20136 years old with\na clinical diagnosis con\ufb01rmed by validated scores. Additio nally,\na control group of typically-developing children was selecte d\nand matched to the ASD group by gender and age. A physical\nexamination, assessing neurological development and a bloo d\nanalysis were performed to con\ufb01rm that they were healthy\nchildren.\nAny children with ASD presenting other neurological,\nmetabolic or genetic diagnoses were excluded, as were child ren\nreceiving medical treatment for autism-related behaviora l\ncomorbidities. The group of ASD children was further divide d\ninto two subgroups based on the presence or absence of\nneurodevelopmental regression during the \ufb01rst two years of l ife,\nwhich was assessed using a \ufb01ve-item questionnaire following\nthe guidelines used by the Autism Diagnostic Interview-Revi sed\n(ADI-R) for the evaluation of this process ( 18). The ASD\nchildren who obtained a score equal to or >3 were included\nin the neurodevelopmental regression ASD group (AMR), andthose with a score of less than 3 were included in the non-\nneurodevelopmental regression ASD group (ANMR). The ASD\ngroupwasalsoclassi\ufb01edaccordingtowhetherchildrenprese nted\nneurodevelopmental delay (i.e., a score lower than 70 in the\ncognitivequotientoftheBattelledevelopmentaltest).\nStandardized Diagnostic Measurements\nand Assessments of ASD Severity\nAll the children with ASD underwent an initial developmental\nclinical interview, which identi\ufb01ed the core symptomatolog y\nof ASD according to DSM-5 clinical diagnostic criteria.\nAdditionally, the following tests were administered to all t he\nchildren:\na)Autism Diagnostic Observation Schedule-2 (ADOS-2) (19).\nThis is a standardized and semi-structured assessment scale\ndesigned to measure communication, social interaction, pla y,\nandtheimaginativeuseofmaterials.Thechildrenweregive n\nanADOSmoduleconsistentwiththeirlanguagedevelopment\nand age. This was administered by two clinical psychologists\nwith o\ufb03cial formal training in the administration and\nquantitative interpretation of the test for research purposes.\nAllchildrenwithASDinthestudyexceededthecut-o\ufb00point\nforthediagnosisofASD.\nb)Pervasive Developmental Disorders Behavior Inventory\nParent Ratings (PDDBI), standardized version for the\nSpanish-speaking European population. ( 20) This test was\nused to evaluate the symptomatic severity of pervasive\ndevelopmental disorders in ASD patients aged from 2 to 6\nyears.Thistest,whichwasadministeredtoalltheparents(n ot\nteachers)ofthechildrenwithASD,evaluatesthecharacter istic\nASD core behavioral de\ufb01cit (de\ufb01cits in social interaction,\nlanguage and pragmatic communication and stereotyped\nbehavior), additional behavioral di\ufb03culties (fears, aggr essive\nbehaviors), and adaptive behaviors (scales of the children\u2019 s\nsocial, linguistic, and learning skills). All the children with\nASDinthestudyobtainedascore \u226530.\nc)Childhood Autism Rating Scale Test (CARS-2 )(21). This\nscale was used for the quanti\ufb01cation of the severity of autis m\npathology:mild,moderateorsevere.\nd)Battelle Developmental Inventory, Second Edition (BDI-2)\n(22).Thistestassessesthechild\u2019scurrentlevelofdevelopmen t\nand functioning in \ufb01ve areas (i.e., personal/social, adaptiv e,\nmotor,communication,andcognitiveareas).\ne)Strengths and Di\ufb03culties Questionnaire (SDQ) (23): Two to\nfouryears.Thisquestionnairewasusedtoassessthepresence\nofbehavioraldi\ufb03culties,aswellasadaptivebehaviors.\nClinical Evaluation\nA thorough developmental clinical history, including major\nchildhood illnesses and immunisations, was taken. A physical\nexamination was also conducted with a special emphasis\non neurological and nutritional status. Anthropometric\nmeasurements (weight, height and body mass index) were\nobtained using standard techniques, and validated nutriti onal\nquestionnaireswerealsoadministered.\nFrontiers in Pediatrics | www.frontiersin.org 3 September 2018 | Volume 6 | Article 264Gomez-Fernandez et al. Cytokines in Autism Children\nBiochemical Analysis\nAfter overnight fasting, blood samples were collected from\nthe children with ASD and the healthy controls from the\nantecubital vein into 6-ml blood collection tubes containi ng\nEDTA. After centrifugation at 3,500g for 10min, plasma\nwas divided into aliquots and processed within 2h from\nsampling, and then frozen at \u221280\u25e6C until analysis. Blood\ncount and a general biochemical analysis were performed to\ncon\ufb01rm the absence of other diseases. C-reactive protein (C-\nCRP) (mg/l) was also measured as an in\ufb02ammatory marker.\nThese analyses were performed in the hospital laboratory\nusing colorimetric, enzymatic, kinetic, indirect potentio metry,\nor immunoturbidimetric methods previously standardized,\nusing an automatic autoanalyzer (Roche-Hitachi Modular PYD\nautoanalyzer,RochLaboratorySystems,Mannheim,Germany) .\nIn the light of observations made in the existing literature\n(24,25), molecules that have previously been linked to autism\nwereselectedforplasmaanalysis:IL-1beta,IL-6andIL-8,M CP-1,\nTNF-\u03b1, myeloperoxidase (MPO), RANTES, cathepsin D, brain-\nderived neurotrophic factor (BDNF), hepatocyte growth facto r\n(HGF),nervegrowthfactor(NGF),plasminogenactivatorfac tor\n(PAI)andcelladhesionmolecule(NCAM,sICAM,VCAM).\nThese biomarkers were analyzed through simultaneous\ndetection of multi-analytes using LINCOplex assay kits and\nLuminex xMAP Detection Technology. The sensitivity of this\nassay enabled the detection of chemokine concentrations to the\nfollowing concentrations: IL1- \u03b2, 0.4183 pg/ml; IL-6, 0.2 pg/ml;\nIL-8, 0.3 pg/ml; MCP-1, 2 pg/ml; TNF- \u03b1, 0.3 pg/ml; MPO, 20\nug/L; cathepsin D, 8.06 ug/L; RANTES: 12 ug/L; BDNF, 0.23\nug/L;HGF,4pg/ml;NGF,0.3pg/ml;plasminogenactivatorfacto r\n(PAI), 0.48 ug/L; NCAM, 4.81 ug/L; sICAM-1, 6.29 ug/L, and\nsVCAM,6.44ug/L).\nStatistical Analysis\nWith regard to the size of the ASD sample used in this study,\ngiven that the prevalence of ASD in Spain is calculated at 1%\n(5), 50 patients with ASD needed to be recruited for the study,\ntaking into account a 5% margin of errors and a 95% con\ufb01dence\ninterval. The sample size for this study was calculated based on\nthemostrelevantin\ufb02ammatoryparametersusingpublisheddat a\nresults (16), choosing the one that required a larger sample size\n(RANTES). Accepting alpha errors of 0.05 and beta errors of\n0.2 in a bilateral contrast, 54 subjects per group were requir ed\nto detect a di\ufb00erence equal to or >400 pg/ml. The standard\ndeviationwasassumedtobe720.\nThe values of the molecules that were not detected were\nconsidered to be lost values, and the statistical study was\nperformed on the remaining values. The data are expressed\nas mean \u00b1SD (95% con\ufb01dence intervals), median (IQR) or\nabsolute (relative frequencies). The Shapiro\u2013Wilk test was u sed\nfor typically distributed data. Homogeneity of variances wa s\nestimated using Levene\u2019s test. The mean values for typically -\ndistributed continuous variables among groups were compared\nusing the unpaired Student\u2019s t-test. The Mann\u2013Whitney U-\ntest was used for asymmetrically distributed data. Bonferr oni\ncorrection was used for multiple comparisons to avoid chance.Categoricalvariableswereassessedusingthe \u03c7\u00b2-testortheFisher\nexacttest.\nComparisonsbetweensubgroupsofASDandwiththecontrol\ngroup were performed using ANOVA, with the Sidak correction\nfor post hoc comparisons. Correlations between the biomarker\nlevels and the scores resulting from the various tests carri ed out\nwereperformedusingSpearman\u2019sp(rho).Allthetestsweretwo -\ntailed, and a P-value <0.05 was considered to be statistically\nsigni\ufb01cant. The data were analyzed using the Statistical Pack age\nfor the Social Sciences (SPSS for Windows, release 18.0.0 201 0,\nSPSSInc,Chicago,IL,USA).\nRESULTS\nInitially, 57 ASD children were selected for this study. Of t hese,\nthreechildrenwerelaterexcludedfornotmeetingthediagno stic\ncriteria for ASD during the subsequent follow-up interview s at\n30 months. The clinical and psychological characteristics o f the\nASDpatients,thesubgroupwithneurodevelopmentalregressi on\n(AMR) and subgroup without neurodevelopmental regression\n(ANMR) and the typically-developing controls are shown in\nTable1. Within the ASD group, there were 20 children included\nin the AMR subgroup and 32 in the ANMR subgroup; two\nchildren could not be classi\ufb01ed in these subgroups because th ey\nwere adoptees, allocated by a national adoption agency. Clini cal\ndi\ufb00erences between these two ASD subgroups were re\ufb02ected in\nthe di\ufb00erent behavioral tests scores obtained. All the child ren\nobtained scores above the ASD cut-o\ufb00 point in the ADOS-2\ntest.However,thepatientsintheAMRsubgroupobtainedlower\nscoresintheBattelledevelopmentaltestthanthoseintheAN MR\nsubgroup, as well as higher scores in the CARS-2 test and total\nautismseverityscoreinthePDBBtest( Table1).\nAll the proin\ufb02ammatory biomarkers were detected in the\nplasma samples of more than 50% of the children with ASD,\nexcept for IL1 \u03b2, which was detected in the plasma of only 16%\nof children with ASD and 6% of typically-developing children\n(\u03c7\u00b2: 2,7; p: 0.141), and NGF, which was detected in 37% of\nchildren with ASD and 27% of the control children ( \u03c7\u00b2: 1,77;\np: 0.183). No di\ufb00erences were found between the two groups\nin terms of the cytokine and adhesion molecule levels studie d,\nexcept for NGF, in which the group of ASD children was found\nto have twice the plasma levels compared to the control group\n(Table2).\nWithin the ASD group, the ANMR subgroup had lower\nNCAM plasma levels than both the AMR subgroup and\ntypically-developing children, and higher NGF levels than th e\ntypically-developing children in the control group ( Figure1).\nThere was no association between NCAM and NGF levels\nin any of the groups. There was no correlation between\nthe levels of NCAM and NGF in either ASD subgroup,\nwhether AMR or ANMR. No di\ufb00erences were identi\ufb01ed in\nthe levels of the molecules when comparing ASD subgroups\neither between high and low-functioning ASD children (in\naccordance with the cognitive scores from the Battelle test) ,\nor between female and male ASD children (results not\nshown).\nFrontiers in Pediatrics | www.frontiersin.org 4 September 2018 | Volume 6 | Article 264Gomez-Fernandez et al. Cytokines in Autism Children\nTABLE 1 | Demographic and anthropometric data in children with autis m spectrum disorders (ASD) compared to controls.\nASD CONTROL P\nTotal AMR ANMR\nAge (months) 43.76 \u00b111.2\n43.5 (33\u201352.5)43.74\u00b111.9\n44 (32\u201352.5)43.64\u00b110.7\n43 (35.5\u201352)48.81\u00b118.33\n51 (31\u201360)ns\nGender (male) 45 (83%) 17 (85%) 27(82%) 46 (84%) ns\nWeight (kg) 16.97 \u00b13.51 17.28 \u00b14.17 16.65 \u00b13.08 17.06 \u00b14.5 ns\nHeight (cm) 102.7 \u00b18.3 101.9 \u00b18.3 102.9 \u00b18.3 101.96 \u00b111.1 ns\nBMI (kg/m2) 15.94 \u00b11.71 16.4 \u00b11.67 15.67 \u00b11.73 16.16 \u00b11.74 ns\nBattelle test 55.69 \u00b113.8 47.05 \u00b110.33 60.96 \u00b113.29 0.002*\nCARS test 32.6 \u00b17.29 35.9 \u00b18.12 30.6 \u00b16.11 0.009*\nPDBBI test 48.86 \u00b110.82 53.93 \u00b110.39 46.13 \u00b110.47 0.023*\nASD, autism spectrum disorders; AMR, mental regression group; ANMR, non- mental regression group; BMI, body mass index; CARS, Childhood Autism Rating S cale Test; PDDBI,\nPDDBehaviorInventory.ns,nosigni\ufb01cantdifferencebetweenAS Dvs.controlandAMRandANMR.P *valuebetweenAMRvs.ANMR.Dataaregivenasthemean \u00b1standarddeviation\nand median (interquartile range). P-values were obtained from the Man n-Whitney U-test, Student\u2019s T test, or the Fisher exact test, as appropriate. P v alue ASD P <0.05 value was\nconsideredtobestatisticallysigni\ufb01cant.\nTABLE 2 | Plasma cytokine levels in patients with childhood autism (A SD)\ncompared to the levels in the healthy control group.\nBiochemical\nbiomarkersn ASD n Control p\nC-CRP (mg/L) 54 1.9 \u00b14.7 54 2.09 \u00b15.09 0.77\nCathepsin D (ug/L) 54 119.5 (81.07\u2013165.4) 54 107.2 (79.1\u2013165 .5) 0.874\nIL1\u03b2(pg/ml)a9 1.08 (0.6\u20133.07) 4 2.16 (1.2\u20134.24) 0.825\nIL6 (pg/ml) 44 1.38 (0.34\u20132.98) 54 0.7 (0.24\u20131.46) 0.148\nIL8 (pg/ml) 52 1.84 (0.84\u20133.82) 54 1.34 (0.67\u20132.77) 0.171\nTNF\u03b1(pg/ml) 54 3.16 (2.2\u20134.56) 54 2.66 (1.83\u20133.69) 0.07\nMPO (ug/L) 53 80.03 (54.96\u2013148.5) 54 88.2 (61.4\u2013141.5) 0.551\nMCP\u22121(pg/ml) 54 122.46 (100.8\u2013156.32) 54 117.13 (98.2\u2013141.51) 0 .228\nRANTES (ug/L) 54 70.97 (41.47\u2013135.8) 54 59.75 (28.95\u201394.92) 0.175\nPAI (ug/L) 54 70.07 (45.52\u201392.65) 54 62.91 (40.62\u2013111.53) 0. 766\nNCAM (ug/L) 54 392.20 \u00b173.567 54 410.13 \u00b172.68 0.196\nICAM (ug/L) 54 173.1 (148.85\u2013189.9) 54 159.9 (143.2\u2013188.6) 0. 166\nVCAM (ug/L) 54 1083.7 (903.8\u20131216.8) 54 1047.6 (840.2\u20131162. 48) 0.283\nHGF (pg/ml) 54 162.7 (136.1\u2013222.3) 54 163.17 (131.07\u2013194.36 ) 0.514\nBDNF (ug/L) 54 5.04 (2.95\u20137.62) 54 5.36 (3.48\u201310.19) 0.825\nNGF (pg/ml) 21 4.78 (2.93\u201313.18) 16 2.06 (1.25\u20137.36) 0.05\nBDNF, brain-derived neurotrophic factor; C-CRP, C-reactive protein ; HGF, hepatocyte\ngrowth factor; ICAM, intercellular adhesion molecule; IL, interle ukin; MCP-1, monocyte\nchemotactic protein; MPO, myeloperoxidase; NCAM, neuronal cell adhes ion molecule;\nNGF, nerve growth factor; PAI, plasminogen activator factor; RANTES, regulated on\nactivation normal t cell expressed and secreted; TNF \u03b1, tumor necrosis factor \u03b1; VCAM,\nvascularcelladhesionmolecule.\nData are given as the mean \u00b1SD or median values interquartile range. P-values\nwere obtained from the Mann-Whitney U-test or Student\u2019s T-test, as appropria te using\nBonrrefonicorrection.P <0.05wasconsideredtobestatisticallysigni\ufb01cant. P-values in\nboldarestatisticallysigni\ufb01cant.\nAssociations between plasma chemokine levels and clinical\nbehavioral and developmental outcomes were studied.\nOnly correlations with r>0.3 are shown in Table3. No\nassociations between the scores obtained in behavioral\nand developmental tests and the cytokines in the ASD\ngroup were observed. However, within the ASD group, theANMR subgroup exhibited a negative correlation between\nICAM and language and social communication scores.\nIn the AMR subgroup, some in\ufb02ammatory parameters\nshowed an association with repetitive behavior (MPO and\nRANTES), stereotypes (IL8), and social interaction scores\n(IL6).\nDISCUSSION\nThe study results show that there are no signi\ufb01cant di\ufb00erence s\nbetween the levels of cytokines, cell adhesion molecules\nor growth factors in ASD children compared to those in\ntypically-developing children. Nevertheless, in the ANMR\nsubgroup of autistic children, lower plasma levels of the\nNCAM adhesion molecule were detected compared to\nthe levels in the AMR subgroup and the control group.\nThis ANMR group also exhibited higher NGF levels than\nthe typically-developing children, which could indicate an\nalteration in neuronal development. These results seem to\ncon\ufb01rm the great heterogeneity of autism and the need to\ndi\ufb00erentiate the pathophysiological pathways to de\ufb01ne the\nphenotype spectrum and more speci\ufb01c and individualized\ntherapies.\nIn addition to the established criteria of DMS-5 and the\nuse of ADOS 2 for the diagnostic assessment of patients\nwith ASD, other complementary tests were performed to\nevaluate the developmental level and the severity of the auti stic\nsymptomatology. These included the Battelle Developmental\nInventory ,PDDBI-ParentRatingsandCARS-2.Thesetestswere\ninstrumental in the identi\ufb01cation of clinical characterist ics\nin the ASD neurodevelopmental regression subgroup\nand ASD-diagnosed children without neurodevelopmental\nregression.\nThe immunological role in the etiopathogenesis of ASD is a\nmatterofongoingdebateamongresearchers.Thereiseviden ceof\nanalterationintheimmunesystemofchildrenwithASD,whic h\nincludes increased cytokine levels in both the brain and plas ma\nFrontiers in Pediatrics | www.frontiersin.org 5 September 2018 | Volume 6 | Article 264Gomez-Fernandez et al. Cytokines in Autism Children\nFIGURE 1 | The neuronal cell adhesion molecule (NCAM) and nerve growth factor (NGF) plasma levels in children with autism subdivid ed as follows: AMR (mental\nregression group), ANMR (non-mental regression group) and a healthy control group.\nTABLE 3 | Signi\ufb01cant correlations between plasma biomarker levels an d\nbehavioral impairments and associated quantitative clini cal traits.\nAutism Spectrum Disorders ANMR AMR\nTests/Biomarkers ICAM MPO IL8 MCP-1\nPDDBI EXPRESS r:\u22120.406\np: 0.023\nSOCAPP r:\u22120.359\np: 0.048\nREPRITC r: 0.507\np: 0.038\nADOS Stereotypes r: 0.84\np: 0.01\nBattelle Personal r:\u22120.52\np: 0.024\nExpression r:\u22120.75\np: 0.001\nCommunication r:\u22120.71\np: 0.001\nAMR,mentalregressiongroup;ANMR,non-mentalregressiongroup;ICA M,intercellular\nadhesion molecule; MPO, myeloperoxidase; IL8, interleukin 8; MCP- 1, monocyte\nchemotacticprotein.ADOS,AutismDiagnosticObservationSchedule;C ARS,Childhood\nAutism Rating Scale Test; PDDBI, PDD Behavior Inventory; EXPRESS, Expr essive\nlanguage; EXSCA, expressive social communication abilities composi te; REPRITC,\nrepetitive, ritualistic and pragmatic problems composite. SOCAPP, Soci al Approach\nBehaviors.\n(14,26).Thistheoryofimmunologicalalterationisbasedonthe\nknowledge that the brain is able to recognize cytokines, suc h as\ntheproin\ufb02ammatorycytokinesIL-1a,IL-1 \u03b2,TNF- \u03b1,andIL-6,as\nmolecular signals of sickness ( 27). The immune system and the\nnervous system are in constant two-way communication, with\neachexertingadegreeofcontrolovertheother( 28).\nAlthough many studies have reported altered levels of\nimmune-related biomarkers or abnormal immune function in\nASD, it has been surprisingly di\ufb03cult to identify a consisten t\npattern of immunological alteration across the various stud ies,\nor develop a pathophysiological description of this alteratio n.\nFor example, Onore et al. ( 29), have reported increased levels ofproin\ufb02ammatorycytokines(IL-1 \u03b2,IL-6,IL-8,IL-12,p40),aswell\nas macrophage migration inhibitory factor and platelet-deri ved\ngrowth factor (PDGF) in patients with autism. El-Ansary et al .\n(30) reported that Saudi patients with autism have markedly\nhigher plasma HSP70, TGF- \u03b22, Caspase-7, and INF- \u03b3levels\ncompared to age and gender-matched controls. Other authors\nhave also reported that children with ASD showed altered\nlevels of immunological parameters, including CCL2, CCL5,\nand CXCL9 levels, compared to healthy children ( 31). Recently,\n\ufb01ndingsshowingincreasedlevelsofS100BandTNF \u03b1inpatients\nwith ASD have been published ( 26). Xie et al. ( 25) have also\nobserved increased blood TNF \u03b1concentrations associated with\nsymptom severity. Indeed, the levels of TNF \u03b1in the Xie autism\ngroup showed a tendency toward signi\ufb01cance ( p: 0.07). It is\npossible therefore that the statistical signi\ufb01cance would tend to\nincreaseiftheprotocolwerereplicatedinalargersample.\nOther authors ( 32) by contrast, as in the present study, have\nfound no di\ufb00erence between the cytokine levels of children wi th\nASD and those of typically-developing children. For example,\nNapolini et al. ( 33) observed no increase in cytokines in a\nbatch of up to 40 in\ufb02ammatory parameters in the peripheral\nblood of children with ASD aged 6\u20138, and evidence that the\nimmune pro\ufb01les of children with ASD did not di\ufb00er from\nthose of their typically-developing siblings. Ashwood et al. (14)\nin anin vitrostudy and Guloksuz et al. ( 26) in their plasma\nstudiesalsoreportednodi\ufb00erencesincytokinelevelscompari ng\ndi\ufb00erent subtypes of ASD. These results cannot support a direct\nrelation between an in\ufb02ammatory status and ASD. However,\nan etiopathogenic implication of an immunological activatio n\nduringtheprenatalperiodhasbeendescribed( 34),butperipheral\nblood cytokine measurements may not directly correlate wit h\nchangesinthecentralnervoussystem.\nCathepsin D, a protease abundantly expressed in the brain,\ncan trigger apoptosis and secretion of cytokines, including I L-\n4, IL-8, IL-10, and IL-13. Malik et al. ( 35) have reported an\nincrease in cathepsin D, and the corresponding increase in\nproin\ufb02ammatory cytokines (TNF \u03b1-and IL-6) and apoptosis in\nautistic lymphoblasts, suggesting that cathepsin D may play an\nimportant role in cytokine-induced apoptosis. However, this\nFrontiers in Pediatrics | www.frontiersin.org 6 September 2018 | Volume 6 | Article 264Gomez-Fernandez et al. Cytokines in Autism Children\nstudy was conducted using a small sample of six children with\nASD and was an in vitrostudy, which may account for the\ndi\ufb00erenceswiththepresent\ufb01ndings.\nImmune globulin-like cell adhesion molecules (CAMs)\nconstitute a broad family, including NCAM, sICAM-1 and\nvCAM-1, required for tissue formation, maintenance and\nfunction. NCAM is related to a dynamic connection between\ncells,anddecreasedplasmalevelsofchildrenwithASDcompar ed\ntothoseinage-matchedcontrolshavebeenreported.This\ufb01nd ing\nemphasizes the di\ufb00erence with other psychiatric pathologies,\nsuch as schizophrenia, in which these levels are elevated ( 36).\nHowever, other studies have found that NCAM mRNA levels\nwere not altered in either serum samples or postmortem brain\nsamples(37)takenfromchildrenwithASD.Jovanova-Nesicetal.\n(38)havealsoobservedadecreaseintheexpressionofNCAM-1\nin the CA1 and CA3 \ufb01elds of the hippocampus and, to a lesser\nextent, in the basal ganglia, limbic structures and cervica l spinal\ncord.\nA protective e\ufb00ect of glial cell line-derived neurotrophic\nfactor (GDNF) on injured DA cells has been shown through\nits in\ufb02uence on NCAM ( 39). In the present study, a decrease\nin NCAM levels was detected in the ANMR subgroup; this\nmay point to an incident having taken place at an earlier time,\npossibly during the early stages of embryonic development. Th e\n\ufb01rst years of development are known to be crucial for the\nformation of neural circuits, when there is a high predisposit ion\nto interruption. CAMs play a crucial role in many aspects of\nneuralcircuitformationandanalterationinthesemolecul escan\nleadtoanalterationinneuronalgrowthandsynaptogenesis.\nThe plasma levels of VCAM and ICAM have been studied in\nhigh-functioning adults with ASD, revealing a decrease in t he\nformer molecule and normal levels of the latter ( 40). Similar\nresults have been observed in other patients with ASD ( 17).\nHowever, the present study, focusing on the plasma levels of\nchildrenwithASDaged2-6,didnotdetectanysuchanomalies.\nThere are multiple lines of evidence indicating that immune\nresponses and CAM levels correlate to the severity of behavio ral\nimpairments and associated symptoms and quantitative clinic al\ntraits (13,14). Thus, dysregulation of IL-1 is implicated\nin impairments in memory and learning, and increases\nin MIP-1 \u03b1, MIP-1 \u03b2, and IP-10 are signi\ufb01cantly associated\nwith social behavior ( 16). Furthermore, disrupting NCAM\nhas been shown to lead to several memory and learning\nde\ufb01cits. In the present study, the levels of the biological\nparameters studied di\ufb00ered between the children with ASD\nwho exhibited neurodevelopmental regression and those\nwho did not show regression, suggesting an association\nbetween the parameters and behavioral/developmental\noutcomes. This \ufb01nding supports the theory of di\ufb00erent\npathophysiological pathways with an earlier incident in\nthe ANMR subgroup, as opposed to a possible subsequent\naggression during the early stages of life in the AMR subgroup,\nsomething that requires clari\ufb01cation in future research.\nHowever, the signi\ufb01cant association of cytokine levels wit h\nquantitative traits and the clinical subgroups analyzed sugg ests\nthat altered immune responses may a\ufb00ect the core ASD\ncharacteristics.An increasing body of evidence indicates that growth factor s\nmodulate motor, emotional and cognitive functions, which may\nexplain several clinical manifestations of these disorders ( 41).\nThe results regarding plasma levels of BDNF in patients with\nASD (24,42,43) are inconsistent. BDNF, which is the most\nabundant neurotrophin in the CNS, can cross the blood-brain\nbarrier, and levels in plasma and brain are highly correlated .\nOthergrowthfactorshavenotbeeninvestigatedaswidely.N GFis\nalso a member of the neurotrophin family and is involved in the\ngrowth, di\ufb00erentiation, survival and regeneration of nerve cells\nbystimulatingTrkA(atransmembranetyrosinekinase)andp75\nreceptors. NGF is primarily present in highly functional brain\nregions (41). In line with the present authors, other researchers\nhave observed increased levels of NGF in children with ASD\n(44) and hyperactivity ( 45). In the present study, NGF was\ndetected in fewer than 50% of the children with ASD and\ntypically-developing children, which may be related to the ea rly\nstage of life, or the sensitivity of the analysis. Second, in creased\nNGF levels were observed in the ANMR subgroup, which also\nexhibited decreased levels of NCAM. Thus, although we did not\nobserve an inverse association between these two molecules in\ntheANMRsubgroup,theenhancementinNGFlevelsafterbrain\ndisruption may be a part of a neuronal recovery process. This\nmechanism is possibly similar to the one related to NCAM and\nGDNF (39). HGF seems to be particularly active in the nervous\nsystem, and it plays a signi\ufb01cant role in the neurodevelopment al\nprocess, including synapse formation ( 46). Signi\ufb01cantly low\nlevels of HGF have been described in high-functioning child ren\nwith ASD ( 47). An associationhas been described between HGF\nserum levels and the presence of gastrointestinal disease, wh ich\nissometimeslinkedtoASDinsubgroupsofchildren( 48).Inour\nstudy,nodi\ufb00erenceswereidenti\ufb01edinthegroupofchildrenw ith\nASD.\nThe present observational case-control study has certain\nlimitations. Given that the prevalence of ASD is 1%, 50 patients\nwith ASD needed to be recruited to the study; an advantage is\nthat clinical variability is avoided when the study is perfor med\nin a single hospital with a strict protocol and very restrictive\ninclusionandexclusioncriteria.Itisimpossibletoknowwh ether\nthe variations detected in the ASD group are a cause or a\nconsequence of the disorder. Such highly varying results ma y\nbe accounted for not only by the di\ufb00erences in the way this\nstudy was approached but also by the natural heterogeneity\nof ASD, which is still not well understood. However, this\nstudy bene\ufb01ts from a careful selection of children of simila r\nages, as well as the complete diagnosis of ASD with multiple\ntests, clinical follow-up and associated complementary test s.\nIn addition, none of the ASD children were undergoing any\nconcomitant treatment shown to modify the plasma levels\nof the molecules being measured. Discrepancies within the\nauthors\u2019 results may be partly explained by the di\ufb00erent\ntechniques used for analysis, as the ELISA and RIAC assays\nare more sensitive than the Luminex assay; however, the latt er\nallows the measurement of more analytes with a minimal\nvolume.\nIn conclusion, the results of this study show that there is no t\na typical pro\ufb01le for the expression of relevant plasma cytokines ,\nFrontiers in Pediatrics | www.frontiersin.org 7 September 2018 | Volume 6 | Article 264Gomez-Fernandez et al. Cytokines in Autism Children\nadhesion molecules or growth factors in children with ASD\ncompared with that in typically-developing children. However ,\nin the ANMR and AMR subgroups, some of the adhesion\nmolecules and neuronal growth factors that could be involve d\ninanearlyalterationinneurodevelopmentexhibiteddi\ufb00eren ces.\nASD is a heterogeneous pathology that converges in di\ufb00erent\nASD phenotypes; the key biomarkers in the etiology of ASD,\nwhich remains unknown, must therefore be subjected to furth er\ninvestigation.\nETHICS STATEMENT\nThis protocol was approved by the Clinical Research and\nBioethics Committee at the Hospital Reina So\ufb01a of C\u00f3rdoba,\nrespecting the fundamental principles established in the\nDeclaration of Helsinki and informed consent was obtained\nfrom the parent or guardian of each participant before\ntesting.AUTHOR CONTRIBUTIONS\nAG-F, MG-C, and JP-N contributed to the study conception\nand study design. AG-F, KF-R, and PM-B collected all the\ndata, acquired the behavioral data, and assisted with regula tory\nresponsibilities. MC-R carried out the analysis. MJT-A and\nMG-Cwereresponsiblefortheinterpretationofthedata,aswell\nas drafting the manuscript. All authors read and approved the\n\ufb01nalmanuscript.\nFUNDING\nThis study was supported by the FUNDACI\u00d3 AGRUPACI\u00d3\n\u00c0mbit de la Inf\u00e0ncia, 404 Research Grant INVEST from the\nSpanish Society of Pediatrics and Red de Salud Materno Infanti l\n(RED SAMID). The funding bodies did not have any role in the\ndesign,collection,analyses,orinterpretationofdataorin writing\nthemanuscript.\nREFERENCES\n1. APA.DSM-V(2013).Availableonlineat:www.dsm5.org/Pages/Default.aspx.\n2. Menezo YJR, Elder K, Dale B. Link between increased prevalence\nof autism spectrumdisorder syndromes and oxidative stress, DNA\nMethylation, and Imprinting. JAMA Pediatr . (2015) 169:1066\u20137.\ndoi:10.1001/jamapediatrics.2015.2125\n3. Kern JK, Geier DA, Geier MR. Evaluation of regression 413 in aut ism\nspectrumdisorderbasedonparentalreports. NAm JMedSci .(2014)6:41\u20137.\ndoi:10.4103/1947-2714.125867\n4. Hansen RL, Ozono\ufb00 S, Krakowiak P, Angkustsiri K, Jones C, Depre y LJ, et\nal. Regression in autism: prevalence and associated factors in the CHARGE\nstudy.AmbulPediatr .(2008)8:25\u201331.doi:10.1016/j.ambp.2007.08.006\n5. Morales-Hidalgo P, Roig\u00e9-Castellv\u00ed J, Hern\u00e1ndez-Mart\u00ednez C, Volta s N,\nCanals J. Prevalence and characteristics of autism spectrum disorde r among\nspanish school-age children. J Autism Dev Disord. (2018) 48:3176\u201390.\ndoi:10.1007/s10803-018-3581-2\n6. Baxter AJ, Brugha TS, Erskine HE, Scheurer RW, Vos T, Scott JG. The\nepidemiology and global burden of autism spectrum disorders . Psychol Med.\n(2015)45:601\u201313.doi:10.1017/S003329171400172X\n7. Baio J, Wiggins L, Christensen DL, Maenner MJ, Daniels J, Warre n Z, et al.\nPrevalenceofautismspectrumdisorderamongchildrenaged8years\u2013a utism\nand developmental disabilities monitoring network, 11 sites, Unite d States,\n2014.MMWRSurveillSumm. (2018)67:1\u201323.doi:10.15585/mmwr.ss6706a1\n8. Kern JK, Geier DA, Sykes LK, GeierMR. Relevance of neuroin\ufb02ammat ion\nand encephalitis in Autism. Front Cell Neurosci . (2016) 9:519.\ndoi:10.3389/fncel.2015.00519\n9. Molloy CA, Morrow AL, Meinzen-Derr J, Schleifer K, Dienger K,\nManning-Courtney P, et al. Elevated cytokine levels in children wit h\nautism spectrum disorder. J Neuroimmunol . (2006) 424:198\u2013205.\ndoi:10.1016/j.jneuroim.2005.11.007\n10. EnstromAM,OnoreCE,VandeWaterJA,AshwoodP.Di\ufb00erential monocyte\nresponses to TLR ligands in children with autism spectrum disorders. Brain\nBehavImmun .(2010)24:64\u201371.doi:10.1016/j.bbi.2009.08.001\n11. Theoharides TC, Tsilioni I, Patel AB, Doyle R. Atopic disease s and\nin\ufb02ammation of the brain in the pathogenesis of autism spectrum dis orders.\nTranslPsychiatry (2016)6:e844.doi:10.1038/tp.2016.77\n12. Angelidou A, Asadi S, Alysandratos KD,Karagkouni A, Kouremban as\nS, Theoharides TCl. TC. Perinatal stress, brain in\ufb02ammation and\nrisk of autism-review and proposal. BMC Pediatrics (2012) 12:89.\ndoi:10.1186/1471-2431-12-89\n13. Onore C, Enstrom A, Krakowiak P, Hertz-Picciotto I, Hansen R, V an de\nWater J, Ashwood P. Decreased cellular IL-23 but not IL-17 producti on inchildren with autism spectrum disorders. J Neuroimmunol . (2009) 216:126\u20139.\ndoi:10.1016/j.jneuroim.2009.09.005\n14. Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah IN, Van\nde Water J. Associations of impaired behaviors with elevated plasma\nchemokines in autism spectrum disorders. J Neuroimmunol . (2011)232:196\u2013\n9.doi:10.1016/j.jneuroim.2010.10.025\n15. Suzuki K, Sugihara G, Ouchi Y, Nakamura K, Futatsubashi M, Ta kebayashi\nK,etal.Microglialactivationinyoungadultswithautismspectru mdisorder.\nJAMAPsychiatry .(2013)70:49\u201358.doi:10.1001/jamapsychiatry.2013.272\n16. Shen Y, Ou J, Liu M, Shi L, Li Y, Xiao L, et al. Altered plasma levels of\nchemokines in autism and their association with social behav iors.Psychiatry\nRes.(2016)224:300\u20135.doi:10.1016/j.psychres.2016.07.057\n17. Kameno Y, Iwata K, Matsuzaki H,Miyachi T, Tsuchiya KJ, Mats umoto K,\net al. Serum levels of soluble platelet endothelial cell adhesion molecule- 1\nand vascular cell adhesion molecule-1 are decreased in subjects wit h autism\nspectrumdisorder .MolAutism (2013)4:19.doi:10.1186/2040-2392-4-19\n18. Kim SH, Lord C. New autism diagnostic interview-revised algo rithms for\ntoddlers and young preschoolers from 12 to 47 months of age. J Autism Dev\nDisord.(2012)42:82\u201393.doi:10.1007/s10803-011-1213-1\n19. Lord C, Rutter M, DiLavore PC, Risi S, Gotham K, Bishop SL. Autism\nDiagnostic Observation Schedule (ADOS): Manual . Los Angeles, CA: WPS\n(2001)\n20. Cohen IL; Sudhalter V. PDD Behavior Inventory (PDDBI) . Lutz, FL:\nPsychologicalAssessmentResources(2005).\n21. Scholper E, Van Bourgondien ME, Wellman GJ, Love SR. Childhood Autism\nRatingScale-454(CARS-2). LosAngeles,CA:WesternPsychologicalServices.\n(2010).\n22. Newborg S, Wnek G, Svinicki. Battelle Developmental Inventory Screening\nTest.Chicago,IL:RiversidePublishingCompany(2016).\n23. GoodmanA,GoodmanR.Strengthsanddi\ufb03cultiesquestionnaire scoresand\nmental health in looked after children . Br J Psychiatry (2012) 200:426\u20137.\ndoi:10.1192/bjp.bp.111.104380\n24. Zheng Z, Zhang L, Zhu T, Huang J, Qu Y, Mu D. Peripheral brain-deri ved\nneurotrophic factor in autism spectrum disorder: a systematic revie w and\nmeta-analysis. SciRep.(2016)6:31241.doi:10.1038/srep31241\n25. Xie J, Huang L, Li X, Li H, Zhou Y, Zhu H, et al. Immunological cytokine\npro\ufb01lingidenti\ufb01esTNF- \u03b1asakeymoleculedysregulatedinautisticchildren.\nOncotarget (2017)8:82390\u20138.doi:10.18632/oncotarget.19326\n26. Guloksuz SA, Abali O, Aktas Cetin E, BilgicGazioglu S, Deniz G ,\nYildirim A, Leckman, J.F. Elevated plasma concentrations of S100\ncalcium-binding protein B and tumor necrosis factor alpha in children\nwith autism spectrum disorders. RevBrasPsiquiatr . (2017) 39:195\u2013200.\ndoi:10.1590/1516-4446-2015-1843\nFrontiers in Pediatrics | www.frontiersin.org 8 September 2018 | Volume 6 | Article 264Gomez-Fernandez et al. Cytokines in Autism Children\n27. MasiA, Glozier N, Dale R,Guastella AJ. The immune system, cytoki nes, and\nbiomarkers in autism spectrum disorder. Neurosci Bull. (2017) 33:194\u2013204.\ndoi:10.1007/s12264-017-0103-8\n28. MeadJ,AshwoodP.Evidencesupportinganalteredimmuneresponsei nASD.\nImmunolLett. (2015)163:49\u201355.doi:10.1016/j.imlet.2014.11.006\n29. Onore C, Careaga M, Ashwood P. The role of immune dysfunction in\nthe pathophysiology of autism. Brain Behav Immun . (2012) 26:383\u201392.\ndoi:10.1016/j.bbi.2011.08.007\n30. El-AnsaryA,Al-AyadhiL.Neuroin\ufb02ammationinautismspectrumdi sorders.\nJNeuroin\ufb02amm .(2012)9:265.doi:10.1186/1742-2094-9-265\n31. Han YM, Cheung WK, Wong CK, Sze SL, Cheng TW, Yeung MK, et al.\nDistinctcytokineandchemokinePro\ufb01lesinautismspectrumDisord ers.Front\nImmunol. (2017)8:11.doi:10.3389/\ufb01mmu.2017.00011\n32. BrynV,AassHC,SkjeldalOH,IsaksenJ,SaugstadOD,OrmstadH.C ytokine\npro\ufb01le in autism spectrum disorders in children. J Mol Neurosci . (2017)\n61:1\u20137.doi:10.1007/s12031-016-0847-z\n33. Napolioni V, Ober-Reynolds B, Szelinger S, Corneveaux JJ, Paw lowski\nT, Ober-Reynolds S, et al. Plasma cytokine pro\ufb01ling in sibling pairs\ndiscordant for autism spectrum.Disorder. J Neuroin\ufb02am. (2013) 10:38.\ndoi:10.1186/1742-2094-10-38\n34. Abdallah MW, Larsen N, Mortensen EL, Atlad\u00f3ttir H\u00d3, N\u00f8rgaard-P edersen\nB, Bonefeld-J\u00f8rgensen EC, et al. l Neonatal levels of cytokines a nd\nrisk of autism spectrum disorders: anexploratory register-based his torical\nbirth cohort study utilizing the Danish Newborn Screening Bioban k.J\nNeuroimmunol .(2012)252:75\u201382.doi:10.1016/j.jneuroim.2012.07.013\n35. Malik M, Sheikh A M, Wen G, Spivack W, Brown WT, Li X.\nExpression of in\ufb02ammatory cytokines, Bcl2 and cathepsin D are altered\nin lymphoblasts of autistic subjects. Immunobiology (2011) 216:80\u20135.\ndoi:10.1016/j.imbio.2010.03.001\n36. Plioplys AV, Hemmens SE, Regan CM. Expression of a neural cell adhesi on\nmolecule serum fragment is depressed in autism. J Neuropsychiatry Clin\nNeurosci.(1990)2:413\u20137.doi:10.1176/jnp.2.4.413\n37. Purcell AE, Rocco M, Lenhart JA, Hyder K, Zimmerman AW, Pevsner, J .\nAssessment of neural cell adhesion molecule (NCAM) in autistic seru m and\npostmortembrain. JAutismDevdisord. (2001)31:183\u201394.\n38. Jovanova-Nesic K, Shoenfeld Y. MMP-2, VCAM-1 and NCAM-1 e xpression\nin the brain of rats with experimental autoimmune encephalomyelitis as a\ntrigger mechanism for synaptic plasticity and pathology. J Neuroimmunol.\n(2006)181:112\u201321.doi:10.1016/j.jneuroim.2006.08.013\n39. LiL,ChenH,WangM,ChenF,GaoJ,SunS,etal.NCAM-140Translo cation\ninto Lipid Rafts Mediates the Neuroprotective E\ufb00ects of GDNF. Mol\nNeurobiol .(2017)54:2739\u201351.doi:10.1007/s12035-016-9749-x\n40. Tsuchiya KJ, Hashimoto K, Iwata Y, Tsujii M, Sekine Y, Sugi hara G,\net al. Decreased serum levels of platelet-endothelial adhesion molecule\n(PECAM-1) in subjects with high-functioning autism: a negat ive correlationwith head circumference at birth. Biol Psychiatry (2007) 62:1056\u20138.\ndoi:10.1016/j.biopsych.2006.12.018\n41. Galvez-Contreras AY, Campos-Ordonez T, Gonzalez-Castaneda RE ,\nGonzalez-Perez O. Alterations of growth factors in autism and\nattention-de\ufb01cit/ hyperactivity disorder. Front Psychiatry . (2017) 8:126.\ndoi:10.3389/fpsyt.2017.00126\n42. Qin X-Y, Feng J-C, Cao C, Wu H-T, Loh YP, Cheng Y. Association of\nperipheral blood levels of brain-derived neurotrophic factor with autis m\nspectrum disorder in children: a systematic review and meta-analysis .JAMA\nPediatr.(2016)170:1079\u201386.doi:10.1001/jamapediatrics.2016.162 6\n43. Rodrigues DH, Rocha NP, Sousa LF da C, Barbosa IG, Kummer A, Tei xeira\nAL. Circulating levels of neurotrophic factors in autism spectrum di sorders.\nNeuroEndocrinolLett .(2014)35:380\u20134.\n44. Chaldarov GN, Tonchev AB, Aloe L. NGF and BDNF: from nerves to\nadipose tissue, fromneurokines to metabokines. Rivista di psichiatria . (2009)\n44:79\u201387.\n45. Guney E, Ceylan MF, Kara M, Tekin N, Goker Z, Senses Dinc G, et\nal. Serum nerve growth factor (NGF) levels in children with attentio n\nde\ufb01cit/hyperactivity disorder (ADHD). Neurosci Lett. (2014) 560:107\u201311.\ndoi:10.1016/j.neulet.2013.12.026\n46. Xie Z, Eagleson KL, Wu HH, Levitt P. Hepatocyte Growth Factor\nModulates MET receptortyrosine kinase and \u03b2-Catenin functional\ninteractions to enhance synapse formation. eNeuro (2016) 29:3.\ndoi:10.1523/ENEURO.0074-16.2016\n47. Sugihara G, Hashimoto K, Iwata Y, Nakamura K, Tsujii M, Tsuchi ya\nKJ, et al. Decreased serum levels of hepatocyte growth factor in male\nadults with high-functioning autism. Prog Neuropsychopharmacol\nBiol Psychiatry (2007) 31:412\u201315. doi: 10.1016/j.pnpbp.2006.\n10.010\n48. Russo AJ, Krigsman A, Jepson B, Wake\ufb01eld A. Decreased serum hepat ocyte\ngrowthfactor (HGF) in autistic children with severe gastrointest inal disease.\nBiomarkInsights (2009)27:181\u201390.\nCon\ufb02ict of Interest Statement: The authors declare that the research was\nconducted in the absence of any commercial or \ufb01nancial relations hips that could\nbeconstruedasapotentialcon\ufb02ictofinterest.\nCopyright\u00a92018Gomez-Fernandez,delaTorre-Aguilar,Gil-Campo s,Flores-Rojas,\nCruz-Rico, Martin-Borreguero and Perez-Navero. This is an op en-access article\ndistributed under the terms of the Creative Commons Attribu tion License (CC BY).\nThe use, distribution or reproduction in other forums is perm itted, provided the\noriginal author(s) and the copyright owner(s) are credited a nd that the original\npublication in this journal is cited, in accordance with acc epted academic practice.\nNo use, distribution or reproduction is permitted which doe s not comply with these\nterms.\nFrontiers in Pediatrics | www.frontiersin.org 9 September 2018 | Volume 6 | Article 264 \nNutrients\n \n2019\n,\n \n11\n, 337; doi:10.3390/nu11020337\n \nwww.mdpi.com/journal/nutrients\n \nArticle\n \nAutism \nSpectrum Disorder \n(ASD) with and without \nMental Regression \nis \nAssociated \nwith \nChanges \nin the \nFecal Microbiota\n \nJulio Plaza\n-\nD\u00edaz\n \n1,2,3,\u2020\n, Antonio G\u00f3mez\n-\nFern\u00e1ndez\n \n4,\u2020\n, Natalia Chueca\n \n3\n, \n \nMar\u00eda Jos\u00e9 de la Torre\n-\nAguilar\n \n4\n, \u00c1ngel Gil\n \n1,2,3,5\n, Juan \nLuis Perez\n-\nNavero\n \n4,\n*, \n \nKatherine Flores\n-\nRojas\n \n4,5\n, Pilar Mart\u00edn\n-\nBorreguero\n \n6\n, Patricio Solis\n-\nUrra\n \n7,8\n, \n \nFrancisco Javier Ruiz\n-\nOjeda\n \n9\n,\n \nFederico Garcia\n \n3\n \nand Mercedes Gil\n-\nCampos\n \n4,5\n \n1\n \nDepartment of Biochemistry and Molecular Biology II, School of Pharmacy, \nUniversity of Granada, \n \n18071\n \nGranada, Spain\n; \njrplaza@ugr.es (\nJ.P.\n-\nD.); agil@ugr.es (\u00c1.G.)\n \n2\n \nInstitute of Nutrition and Food Technology \n\u201c\nJos\u00e9 Mataix\n\u201d\n, Center of Biomedical Research, \n \nUniversity of Granada, 18016 Armilla, Granada, Spain\n \n \n3\n \nInstituto de Invest\nigaci\u00f3n Biosanitaria IBS.GRANADA, Complejo Hospitalario Universitario de Granada, \n18014 \nGranada, Spain\n; \nnaisses@yahoo.es (N.C.); fegarcia@ugr.es (F.G.)\n \n4\n \nPediatric Research and Metabolism Unit, Reina Sofia University Hospital, Maim\u00f3nides Institute for \nBiom\nedical Research of C\u00f3rdoba (IMIBIC), University of C\u00f3rdoba, 14010 C\u00f3rdoba, Spain\n; \nantoniogofedez@hotmail.com (A.G.\n-\nF.); delatorremj4@gmail.com (M.J.d.l.T.\n-\nA.)\n; \nkatherine1.flores@gmail.com (K.F.\n-\nR.)\n; mercedes_gil_campos@yahoo.es (M.G.\n-\nC.)\n \n5\n \nCIBEROBN (CIBER \nPhysiopathology of Obesity and Nutrition), Instituto de Salud Carlos III, \n \n28029 Madrid, Spain\n \n6\n \nDepartment of Child and Adolescent Clinical Psychiatry and Psychology, Reina Sofia University Hospital, \nMaim\u00f3nides Institute for Biomedical Research of C\u00f3rdoba\n \n(IMIBIC)\n,\n \n14010 Cordoba, Spain\n; \npmartin.psicologa@gmail.com \n \n7\n \nPROFITH \u201cPROmoting FITness and Health through physical activity\u201d research group, Department of \nPhysical Education and Sport, Faculty of Sport Sciences, University of Granada, \n18071\n \nGranada, Spa\nin\n; \npatricio.solis.u@gmail.com\n \n8\n \nIRyS Research Group\n,\n \nSchool of Physical Education\n,\n \nPontificia Universidad Cat\u00f3lica de Valpara\u00edso, \nValparaiso 2374631, Chile\n \n9\n \nRG Adipocytes and metabolism, Institute for Diabetes and Obesity, Helmholtz Diabetes Center at \nHe\nlmholtz Center Munich, 85748 Garching, Munich, Germany\n; \nfrancisco.ruiz@helmholtz\n-\nmuenchen.de\n \n\u2020\n \nBoth authors contributed equally\n.\n \n*\n \nCorrespondence: \njrplaza@correo.ugr.es; \nTel.: \n+\n34\n-\n957\n-\n736\n-\n467; Fax: 003\n-\n495\n-\n701\n-\n0019\n \nReceived: 31 December 2018; Accepted: 1 F\nebruary 2019; Published:\n \n5 February 2019\n \n5 February 2019\n \nAbstract: \nNew microbiome sequencing technologies provide novel information about the potential \ninteractions among intestinal microorganisms and the host in some neuropathologies as autism \nspectrum disorders (ASD\n). \nT\nhe m\nicrobiota\n\u2013\ngut\n\u2013\nbrain axis is an emerging aspect in the generation \nof autistic behaviors; evidence from animal models suggests that intestinal microbial shifts may \nproduce changes fitting the clinical picture of autism\n. \nThe aim of the present study was t\no evaluate \nthe \nfecal \nmetagenomic profiles in \nchildren with ASD\n \nand\n \ncompare\n \nthem\n \nwith healthy participants\n. \nThis comparison allow\ns\n \nus \nto ascertain how\n \nmental regression\n \n(an \nimportant\n \nvariable in ASD\n)\n \ncould influence the intestinal microbiota profile\n. For th\nis reason, a \nsubclassification\n \nin \nchildren with \nASD \nby mental reg\nression (AMR) and no\n \nmental\n \nregression \n(\nANMR\n) phenotype was performed. \nThe present \nreport \nwas a \ndescriptive observational \nstudy. Forty\n-\neight children aged 2\n\u2013\n6 years with \nASD were included: 30\n \nwith ANMR and 18 with AMR. In addition, a control group of 57 normally \ndeveloping children was selected and matched to the ASD group by sex and age. Fecal samples \nwere analyzed with a metagenomic approach\n \nusing\n \na\n \nnext\n-\ngeneration sequencing\n \nplatform\n. Sever\nal Nutrients\n \n2019\n,\n \n11\n, 337\n \n2\n \nof \n17\n \n \ndifferences between children with ASD\n,\n \ncompared \nwith the \nhealthy group\n,\n \nwere detected\n. \nNamely\n,\n \nActinobacteria\n \nand \nProteobacteria\n \nat phylum level, \nas well as, \nActinobacteria\n,\n \nBacilli\n, \nErysipelotrichi\n, and \nGammaproteobacteria\n \nat class level were\n \nfound at\n \nhigher\n \nproportions\n \nin children\n \nwith\n \nASD. \nAdditionally\n, \nProteobacteria \nlevels\n \nshowed to be\n \naugmented \nexclusively in\n \nAMR\n \nchildren\n. \nPreliminary results\n,\n \nusing a principal component analysis\n,\n \nshowed differential patterns\n \nin children \nwith ASD, ANMR and AMR, co\nmpared \nto \nhealthy group,\n \nboth\n \nfor intestinal microbiota and \nfood \npatterns\n. \nIn this study, we report, \nhigher \nlevels of \nActinobacteria\n, \nProteobacteria \nand \nBacilli\n,\n \naside \nfrom\n \nErysipelotrichi\n, and \nGammaproteobacteria\n \nin children \nwith \nASD compared \nto \nhealthy g\nroup. \nFurthermore, \nAMR\n \nchildren\n \nexhibited\n \nhigher levels of\n \nProteobacteria\n. \nFurther analysis using these \npreliminary results and mixing metagenomic and other \u201comic\u201d technologies are needed in larger \ncohorts of children with ASD to confirm these intestinal m\nicrobiota changes.\n \nKeywords:\n \na\nutism spectrum disorder;\n \nchildren\n; intestinal mi\ncrobiota\n; \nnutrients\n \n \n1. \nIntroduction\n \nThe advent of new sequencing technologies ha\ns\n \nstimulated \nthe beginning of new \nresearch \nto \nascertain the \nconnections between the microbial com\nmunities that reside in our gut and some \nphysiological \nand pathological \nconditions. The microbiota\n,\n \ndefined as the full collection of microbes \n(bacteria, fungi, virus\nes,\n \namong others) that naturally exist within a particular biological niche\n,\n \nis \nestimated \nto contain 500\n\u2013\n1,000 species \n[1\n\u2013\n3\n]\n, and has a\nn\n \nimportant \nimpact on human health. In \nparticular, the gut microbiota may play a key role in many essential processes in health and disease \nvia the activity of the gut\n-\nbrain axis, possibly contributing to autism\n \nspectrum disorders (ASD), \nAlzheimer\u2019s disease, Parkinson\u2019s disease, depression, and anxiety disorder\ns\n, among others \n[\n4\n]\n. \n \nASD is a severe neurodevelopmental disorder that impairs child\u2019s ability to communicate and \ninteract with others. Children with neuro\ndevelopmental disorders, including ASD, are regularly \naffected by gastrointestinal problems and dysbiosis of the gut microbiota \n[\n5\n]\n. Autism diagnoses have \nincreased rapidly over the last decade (currently 1 in 59 births, versus 1 in 150 reported in 2000 in\n \nthe\n \nUnited States \n[\n6\n]\n)\n.\n \nIn the case of Spain, the estimated prevalence is 1.55% in preschoolers and 1.00% \nin school\n-\nage children, and male\n-\nto\n-\nfemale ratio was around 4:1 \n[\n7\n]\n. \n \nThe pathophysiology of ASD still remains largely unknown. However, a disorder o\nf the \nmicrobiota\n\u2013\ngut\n\u2013\nbrain axis is emerging as a prominent factor in the generation of autistic behaviors \n[\n8\n]\n.\n \nEvidence so far suggests prognosis is not pre\n-\ndetermined and there is a dynamic component of \ndisease. Many studies highlight the possibility for \nenvironmental risk factors and associated medical \nco\n-\nmorbidities to contribute to core neurobehavioral symptoms of the disorder \n[9\n\u2013\n11\n]\n. \nCo\n-\nmorbid \ngastrointestinal symptoms in some subsets of ASD individuals include diarrhea/constipation, \nabdominal pain and\n \ngastric reflux. In relation with this phenotype, deficient integrity of the gut \nepithelium and increased intestinal permeability have been reported\n \n[\n12\n]\n.\n \nIn addition, evidence from \nanimal models suggest\ns\n \nthat certain microbial shifts in the gut may produc\ne changes consistent with \nthe clinical picture of autism, with proposed mechanisms including toxin production, aberrations in \nfermentation processes/products, and immunological and metabolic abnormalities \n[\n13\n]\n.\n \n \nCurrently, \nanimal model\n \nevidence\n \n[\n14\n,\n15\n]\n, as\n \nwell as more limited \nhuman \nstudies \nhave \ndemonstrated\n \nthat signaling along the gut\n-\nmicrobiome\n-\nbrain axis is a critical regulator of both \ncentral nervous system and immune function \n[\n16\n,\n17\n]\n. \nPrevious studies have shown microbial \nchanges in the intestinal mic\nrobiota of children with ASD compared \nwith \nhealthy \nsubjects \nin certain \nbacteria \ngenera belonging to the phyla \nBacteroidetes\n, such as \nBacteroides\n, \nBarnesiella\n, \nOdoribacter\n, \nParabacteroides\n, \nPrevotella\n \nand \nAlistipes\n, and\n \nbelonging to\n \nProteobacteria\n \n(e.g., \nPr\noteus\n, \nParasutterella\n). In \ncontrast, \nBifidobacterium\n \nspecies, belonging to the phylum \nActinobacteria\n, were decreased \n[\n18\n,\n19\n]\n. \nAkkermansia muciniphila\n \n(phylum \nVerrucomicrobia\n), was found \nin\n \nhigh level\ns\n \nin children \nsuffering\n \nASD \n[\n20\n,\n21\n]\n. \nHowever, \nthese studi\nes \nhave reported \na \nlow number of evaluated samples \n(\nfrom 11 to \n33 children\n), and none \nof the aforementioned \ndefined appropriately the diversity of phenotypes Nutrients\n \n2019\n,\n \n11\n, 337\n \n3\n \nof \n17\n \n \nwithin \nthe \nASD \nchildren population. It is well established that children with ASD do not constitut\ne a \nhomogeneous clinical group, and many different pathologies show a similar constellation of \nbehavioral symptoms that converge within ASD \n[\n22\n]\n \nf\nor example, t\nhe existence of developmental \nregression in some children with ASD has been corroborated by multi\nple studies \n[\n23\n]\n.\n \nMany studies \nreport dysbiosis of the gut microbiota in ASD individuals\n \n[\n24\n,\n25\n]\n.\n \nAlterations in the gut microbiota \nare observed in ASD individuals compared to neurotypical controls. Increased clostridia species in \nautism have been reported\n \nin several studies and microbiome alterations that might contribute to the \ndevelopment of autism include altered immune function and bacterial metabolites [\n26\n]\n. Other \nauthors have hypothesized that an increase in \nCandida\n \nspp. could be looked at as precoci\nous index of \nintestinal dysbiosis. However, none correlation was observed between detected counts of \nCandida \nspp. and gastrointestinal symptoms in ASD children \n[\n24\n]\n. \nASD severity was also linked to a \nreduction in short\n-\nchain fatty acids (SCFAs), including \nacetate, propionate and butyrate \n[\n27\n]\n, \nwhich \nare modulated by gut microbes. In the case of mental regression, the information is scarce.\n \nThe gastrointestinal tract is an organ that is co\n-\ndominated by the central nervous system (CNS), \nthe autonomic nervous \nsystem, and the enteric nervous system (ENS). Regulation of enteric nerves \nconsists of different levels of nervous regulation \n[\n28\n]. \nThis type of neuroendocrine network, which \nconnects the gastrointestinal tract with the CNS at different levels, is the stru\nctural basis for the \nfunction of the microbiota gut\n-\nbrain axis. Disorders of neurological control, such as ASD, at any level \nwill affect the function of the gut and brain. The gut has a direct neural connection with the brain \nthrough the vagus nerve, and b\nacteria can stimulate the afferent neurons of the ENS \n[\n29\n]. \nThe vagus \nsignal from the gut can trigger an anti\n-\ninflammatory response against the sepsis induced by \nmicroorganisms. Gut microorganisms can affect brain functions through the vagus nerve; after a\n \nvagotomy, the microorganisms will not be able to regulate behaviors\n \n[\n30\n,\n31\n]\n.\n \n \nGlial cells (in particular microglia and astrocytes) influence synapse formation and function\n \n[\n32\n,\n33\n]\n. \nMicroglia are immune cells in the CNS, and studies have found that the met\nabolism of gut \nmicroorganisms can regulate the maturation and function of microglia, thereby affecting CNS \nfunction \n[\n34\n]\n. \nBoth elevated microglial activation and altered microglia to neuron spatial distribution \npatterns have \nbeen \nobserved in the cerebral c\nortex and cerebellum of postmortem ASD brains\n \n[\n35\n,\n36\n]\n \nand surrogate markers of increased microglial activation have shown by positron\n-\nemission \ntomography imaging of living ASD individuals \n[\n37\n]\n. \n \nInterestingly, Erny and colleagues \nhave \ndemonstrate\nd\n \nthat the\n \nmicrobiome is required for \nproper development and function of adult brain microglia \n[\n34\n]\n. \nMicroglia from germ\n-\nfree mice \nexhibit altered morphology, with longer processes and increased branching, and altered \ntranscriptomes including down\n-\nregulation of cell\n \nactivation genes, reduction of genes for type 1 IFN \nreceptor signaling, and up\n-\nregulation of microglia transcription and survival factors compared to \nthose isolated from conventionally\n-\ncolonized controls. Re\n-\ncolonization of adult gnotobiotic mice \nwith a c\nonventional gut microbiota or supplementation with SCFAs corrects these deficiencies in \nmicroglial activation\n \n[\n34\n,\n38\n]\n. \nRecently, Lu et al. have reported that growth\n-\nassociated microbiota can \ninfluence early neuron and oligodendrocyte development and this e\nffect may be mediated by effects \non neuroinflammation and circulating IGF\n-\n1 \n[\n39\n]\n.\n \nIn \naddition\n, d\niet \nmight contribute to the development of phenotypic diversity in ASD children\n \ninfluencing their behavior \n[\n40\n]\n.\n \nRecently, changes in brain structure were found\n \nto be associated \nwith diet\n-\ndependent changes in gut microbiome populations using a machine learning classifier for \nquantitative assessment of the strength of microbiome\n-\nbrain region associations \n[\n41\n]\n. \n \nScarce information about children with ASD \nintestinal\n \nmicrobiota changes is available\n. \nFurthermore, there is a lack of knowledge about how mental regression would affect\n \neating behavior \nand\n \nintestinal microbiota in ASD children\n.\n \nThus,\n \nthe aim of the present study was to evaluate the \nfecal metagenomic profile\ns in children with ASD\n \nand\n \ncompare \nthem \nwith healthy participants, \nin \norder \nto ascertain how other important variable in ASD as mental regression could influence the \nintestinal microbiota profile. For this reason, a sub\n-\nclassification in children with ASD \nby mental \nregression (AMR) and no regression (A\nN\nMR) phenotype was performed\n \nto augment \nthe \nknowledge Nutrients\n \n2019\n,\n \n11\n, 337\n \n4\n \nof \n17\n \n \nof gut\n-\nbrain\n-\nmicrobiota axis, highlighting the potential impact of diet and metagenomic effects in \nneuropathologies.\n \n2. \nMaterial and \nMethods\n \n2.1. \nEthical \nS\ntatement\n \nThe present study was a cross\n-\nsectional case\n-\ncontrol study and was approved by the Clinical \nResearch and Bioethics Committee at Reina Sofia University Hospital respecting the fundamental \nprinciples established in the Declaration of Helsinki. The s\nelected subjects were incorporated into \nthe study after all inclusion criteria were fulfilled and informed written consent\ns\n \nfrom the children\u2019s \nlegal guardians \nwere \nobtained.\n \n2.2. \nParticipants\n \nFifty\n-\nseven children\n \nwith ASD\n \nwere initially selected for this \ndescriptive observational study \n(the recruitment started during 2015 in the Department of Psychology\n \nof the Pediatric Service\n). Of \nthose, three children were excluded for not meeting the diagnostic criteria for ASD during the \nsubsequent follow\n-\nup interview\ns at 18 months \n[\n22\n]\n. Such interview\ns\n \n(Autism Di\nag\nnostic \nInterview\n\u2014\nRevised ADI\n-\nR)\n \nwere \na follow\n-\nup to verify if the individuals continue\nd\n \nmeeting the \nDiagnostic and Statistical Manual of Mental Disorders (\nDSM\n-\n5\n)\n \ncriteria.\n \nAll \nselected \nchildren\n \nwith ASD\n \nwere\n \nbetween 2\n\u2013\n6 years old with an agreed clinical diagnosis \nusing the criteria of the International Classification Disease 10th Edition for ASD \n[\n42\n]\n \nand DSM\n-\n5 \n[\n43\n]\n. The diagnosis was confirmed by scores above the cut\n-\noff points of two tests, the Autism \nDiagno\nstic Observation Schedule test, with revised algorithms, and the Pervasive Developmental \nDisorders (Behavior Inventory \n[\nPDDBI\n])\n, the latter as a means of obtaining a measure of the severity \nof ASD. The ASD group was also classified according to whether the\n \nchildren presented \ndevelopmental delay (a score lower than 70 in the cognitive quotient of the Battelle developmental \ntest) or not. Within the ASD group, 20 children \nwere \nclassified as AMR and 32 as ANMR: two \nchildren could not be clearly classified into \neither subgroup. The subdivision (AN\nM\nR and AMR) \nwas based on the presence or absence of developmental regression during the first two years of life, \nwhich was assessed by a five\n-\nitem questionnaire following the guide used by the ADI\n-\nR clinical \ninterview fo\nr the evaluation of this process \n[\n44\n]\n. C\nhildren \nwith ASD \nwho obtained a \nscore equal\n \nt\no\n \nthree\n \nor greater\n,\n \nwere included in the mental regression group\n, whereas\n \nthose with a scor\ne of less \nthan \nthis value \nwere included in the non\n-\nmental regression group\n \n[\n22\n]\n.\n \nC\nhildren \nwith ASD \npresenting other known neurological, metabolic or genetic diagnoses were \nexcluded, as were children with medical treatment for autism\n-\nrelated behavioral comorbidities that \nmay interfere with the results, such as sedatives, muscle relaxan\nts or similar.\n \nAdditionally, a control group of 57 normally developing children was selected and matched to \nthe ASD group by sex and age. Children in \nthe\n \ncontrol group were chosen from those who came to \nthe hospital for pre\n-\nanesthesia for minor surgery (ma\ninly hernias). The clinical and analytical \nabsence of illness in this group of healthy children\n \nwas confirmed\n.\n \n \nFinally, the metagenomic \nfecal \nanalysis included 18 children classified as AMR, 30 classified as \nANMR and 57 as control group.\n \n2.3. \nAssessment o\nf \nDiet\n \nGuardians completed a \n24\n-\nh \ndietary record during \nthe \nintervention period. \nIn addition, \none of \nthe authors (KF) applied a validated semiquantitative food frequency questionnaire\n. \nEnergy \nconsumption and dietary intakes of macro\n-\n \nand micronutrients dat\na were \nestimated \nusing \nthe \nOdimet software (University of Santiago de Compostela, Spain; http://www.odimet.es/)\n.\n \nThe \nSpanish Community Nutrition Society (SENC) \nGuidelines for \nscholar age \nwere \nused to \ncompare the \nactual food intake of ASD and healthy childr\nen with the standard recommendations\n \n[\n45\n]\n.\n \n Nutrients\n \n2019\n,\n \n11\n, 337\n \n5\n \nof \n17\n \n \n \n2.4. \nMetagenomic \nAnalysis\n \n2.4.1. \nDNA \nExtraction\n \nFecal samples were collected \nin plastic sterile containers \nfrom each volunteer and then \ntransferred to \n-\n80\n \n\u00b0C until analysis. Fecal samples were homogenized in a S\ntomacher\n-\n400 blender. \nDNA was extracted using a QIAamp DNA Stool Mini Kit (QIAGEN, Barcelona, Spain) as directed \nby the manufacturer, with the exception that samples were mixed with the lysis buffer and \nincubated at a temperature of 95\n \n\u00b0C instead of 70\n \n\u00b0C \nto ensure lysis of both Gram\n-\npositive and \nGram\n-\nnegative bacteria. Quantification was conducted with a NanoDrop ND\n-\n1000 \nspectrophotometer (Thermo Fisher Scientific, DE, USA)\n. The\n, DNA yield was determined by \nmeasuring absorbance ratios spectrophotometricall\ny, and the measurement includes A260/280\n\u2009nm \nfor protein contamination and A260/230\n\u2009nm for salt and phenol contamination. \n \n2.4.2. \nSequencing \nAnalysis\n \nThe extracted DNA was PCR amplified using the primer pairs, 16S Amplicon PCR Forward \nPrimer: 5\n\u2019\nTCGTCGGCAGCG\nTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGCAG, and \n16S Amplicon PCR Reverse Primer: \n5\n\u2019\nGTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTACHVGGGTATCTAATCC \ntargeting the V3 and V4 hypervariable regions of the bacterial 16S rRNA gene \n[\n46\n]\n. All PCRs were \nperformed in 25\n \n\u03bcL \nreact\nion volumes containing 12.5\n \n\u03bcL \n2X KAPA HiFi Hotstart ready mix (KAPA \nBiosystems, Woburn, MA\n, USA\n), 5\n \n\u03bcL \nof each forward and reverse primers (1 \u03bcM) and 2.5\n \n\u03bcL \nof \nextracted DNA (10 ng) under the following cycling conditions: initial denaturation at 95 \u00b0C for\n \n3 \nmin, followed by cycles of denaturation at 95 \u00b0C for 30 s, annealing at 55 \u00b0C for 30 s, and elongation \nat 72 \u00b0C for 30 s, with a final extension at 72 \u00b0C for 5 min. PCR clean\n-\nup was performed using \nAMPure XP beads (Beckman Coulter, \nIndianapolis, IN\n, \nUSA\n) to purify the 16S V3 and V4 amplicon \naway from free primers and primer dimer species. Then, the next step was the index PCR, in this \nstep attaches dual indices and Illumina sequencing adapters using the Nextera XT Index Kit \n(Illumina,\n \nSan Diego\n, \nCA,\n \nUSA)\n, PCR conditions were\n:\n \n95\n \n\u00b0C for 3 \nmin\n; 8 cycles of 95\n \n\u00b0C for 30 \ns\n, 55\n \n\u00b0C for 30 \ns\n, 72\n \n\u00b0C for 30 \ns\n; 72\n \n\u00b0C for 5 \nmin\n, and hold at 4\n \n\u00b0C. The pooled PCR products were purified \nusing AMPure XP beads (Beckman Coulter,\n \nIndianapolis, IN,\n \nUSA) before quantificatio\nn. The \nresultant amplicons were sequenced at MiSeq (Illumina, USA), using paired\n-\nend (2x300nt) Illumina \nMiSeq sequencing system (Illumina,\n \nSan Diego\n, \nCA,\n \nUSA).\n \n2.4.3. \nTaxonomic \nAnalysis\n \nGalaxy \n[\n47\n]\n \nwith the Mothur tool was used for quality assessment of ra\nw reads, which were \nassembled and screened based on the minimum length of 250\n\u2009bp and a maximum length of 550\u2009bp. \nMG\n-\nRAST (metagenomics analysis server) \n[\n48\n]\n \nusing \nthe Ribosomal Database Project (RDP) for \nanalyses of all sequences. The input processing step\ns in MG\n-\nRAST included demultiplexing, quality \nfiltering, length filtering, dereplication, and removal of model organism sequences. The \npreprocessing options and details of data provided were: FASTQ sequences were filtered using a \ndynamic trimming. Fifteen \nwas the specific lowest Phred quality score that was counted as a \nhigh\n-\nquality base and the sequences containing five bases below the value score 15 were trimmed. \nThe raw microbiologic data were reported as relative abundances at the taxonomic levels of ph\nylum, \nfamily, and genus. Microbial community diversity, including \nalpha\n \ndiversity was analyzed. The \nobserved relative abundance of each taxon was estimated by counting the number of reads for each \ntaxon and then normalizing by the total number of reads per\n \nsample. \n \n2.5. \nStatistical \nAnalysis\n Nutrients\n \n2019\n,\n \n11\n, 337\n \n6\n \nof \n17\n \n \nData are given as the mean \u00b1 standard mean error \nor median and \nrange. P\n-\nvalues were obtained \nfrom the Mann\n\u2013\nWh\nitney U\n-\ntest or ANOVA test\n, as appropriate. \nP\n \nvalue <\n \n0.05 value was considered \nto be statistically significant\n. Labeled means\n \nor medians\n \nwithout a common letter differ, \nP\n \n<\n \n0.05.\n \nP\n-\nvalues were obtained from \nH Kruskal\n\u2013\nWallis test\ns\n \ncorrected by Bonferroni post\n-\nhoc test\n \nwhen \nAMR\n \nand \nANMR\n \ngroups\n \nwere compared with \nthe \ncontrol group. Principal component analysis \n(PCA) \nwas used to maximize the information gained for the predominant variables from diet. This \nmathematical model calculates new variables (principal components) that account for the variability \nin the \nmetagenomic \ndata and enables the study of covariances or co\nrrelations between variables \n(e.g.\n,\n \ntotal carbohydrates, total fat, among others). The combination of diet variables with the \ngreatest amount of variability is the first principal component. The subsequent components (second \nand third principal components)\n \ndescribe the maximum amount of remaining variability \n[\n49\n,\n50\n]\n. All \nof the analyses were performed using the statistical package SPSS (SPSS Inc, Chicago, IL\n, USA\n).\n \nBoxplots were generated using the R software utilizing the ggplot2 package\n.\n \n3. \nResults\n \nTable \n1 shows the general characteristics of ASD and healthy children participants.\n \nTable 1.\n \nDescriptive characteristic of\n \nautism spectrum disorder\n \nand healthy children participants.\n \nVariables\n \nASD\n \nControl (\nn\n \n=\n \n57)\n \nP \nvalue\n \nANMR (\nn\n \n=\n \n30)\n \nAMR (\nn\n \n=\n \n18)\n \nTotal (\nn\n \n=\n \n48)\n \nAge (months)\n \n44.51 \u00b1 2.06 \n \n43.69 \u00b1 2.7 \n \n44.19 \u00b1 1.6 \n \n51.00 \u00b1 2.59 \n \nn.s.\n \nWeight (kg)\n \n16.57 \u00b1 0.56 \n \n17.10 \u00b1 0.95 \n \n16.77 \u00b1 0.50 \n \n17.1 \u00b1 0.6\n \nn.s.\n \nHeight (cm)\n \n103.3 \u00b1 1.55 \n \n101.50 \u00b1 1.92\n \n102.5 \u00b1 1.20 \n \n102.0 \u00b1 1.5\n \nn.s.\n \nBMI (kg/cm\n2\n)\n \n15.52 \u00b1 0.33 \n \n16.37 \n\u00b1 0.39 \n \n15.86 \u00b1 0.26 \n \n16.2 \u00b1 0.2\n \nn.s.\n \nBattelle \ntest\n \n59.6 \u00b1 2.6\n \n47.5 \u00b1 2.6\n \n54.98 \u00b1 2.0\n \n-\n \n0.003\n \nCARS \ntest\n \n30.6 \u00b1 1.1 \n \n35.9 \u00b1 1.9\n \n32.7 \u00b1 1.1 \n \n-\n \n0.021\n \nPDDBI \ntest\n \n46.8 \u00b1 2.3\n \n53.6 \u00b1 1.6\n \n50.9 \u00b1 1.6\n \n-\n \n0.026\n \nData are given as the mean \u00b1 standard \nerror\n \nof the me\nan\n. \nP\n-\nvalues were obtained from the \nMann\n-\nWhitney U\n-\ntest, or \nANOVA test\n,\n \nas appropriate. \nP\n \n< 0.05 value was considered to be\n \nstatistically significant. Abbreviations: ASD, \nchildren with \nautism spectrum disorders; AMR, \nchildren with autism mental regression\n;\n \nANMR, \nchildren with autism \nnon\n-\nmental regression; BMI, \nbo\ndy mass index; CARS, Childhood \nAutism Rating Scale \nt\nest; n.s., non\n-\nsignificant; \nPDDBI, \nPervasive \nDevelopmental Disorder\n \nB\nehavior \nI\nnventory.\n \nTable 1 also shows the results of the Battelle, \nChildhood \nAutism Rating Scale (\nCARS\n)\n \nand \nPervasive Developmental Disorder\n \nBehavior Inventory (\nPDDBI\n)\n \npsychological tests for both\n,\n \nchildren with \nA\nM\nR and AN\nM\nR, which were significantly different\n \nbetween\n \neach of them\n.\n \nRegardless of that, only two ASD children out of 4\n8, reported frequent abdominal pain but no other \ngastrointestinal symptoms.\n \nASD \nChildren Show Fecal Metagenomic Differences Compared \nto \nHealthy Children\n \nTable 2 shows the relative abundances of predominant phyla and class\nes\n \nbetween healthy \nchildren \nand \nchi\nldren with \nASD\n. All data are\n \nclassified according to\n \nmental regression\n.\n \n \nTable 2.\n \nR\ne\nlative abundances \nof \nbacteria in fecal microbiota of \nchildren with \nASD and healthy \nchildren.\n \nVariables\n \nASD\n \n \nANMR \nGroup \n(\nn\n \n=\n \n30)\n \nAMR \nGroup \n(\nn\n \n=\n \n18)\n \nTotal\n \nASD\n \n(\nn\n \n= \n48)\n \nHeal\nthy \nControl Group \n(\nn\n \n=\n \n57)\n \nActinobacteria\n \n(phylum)\n \n2.6 \n(0.6\n\u2013\n14.9)\n \na\n \n3.2 (0.3\n\u2013\n16.8)\n \na\nb\n \n2\n.9\n \n(0.3\n\u2013\n16.8)\n \n*\n \n1.8 (0.1\n\u2013\n18.3)\n \nb\n \nBacteroidetes\n \n(phylum)\n \n43.4 (2.0\n\u2013\n58.1)\n \n39.5 (11.0\n\u2013\n51.7)\n \n43.0 (2.0\n\u2013\n58.1)\n \n42.9 (8.5\n\u2013\n67.9)\n Nutrients\n \n2019\n,\n \n11\n, 337\n \n7\n \nof \n17\n \n \nFirmicutes\n \n(phylum)\n \n45.4 (31.0\n\u2013\n82.9)\n \n44.0 (19\n.6\n\u2013\n61.6)\n \n \n44.7 (19.6\n\u2013\n82.9)\n \n42.2 (19.2\n\u2013\n81.1)\n \nProteobacteria\n \n(phylum)\n \n0.2 (0.0\n\u2013\n4.1)\n \na\n \n0.4 (0.1\n\u2013\n2.8)\n \nb\n \n0.4 (0.0\n\u2013\n4.1)\n \n*\n \n0.2 (0.0\n\u2013\n8.9)\n \na\n \nVerrucomicrobia\n \n(phylum)\n \n0.1 (0.0\n\u2013\n24.5)\n \n1\n.1\n \n(0.0\n\u2013\n30.9)\n \n0.3 (0.0\n\u2013\n30.9)\n \n0.7 (0.0\n\u2013\n23.2)\n \nActinobacteria\n \n(class)\n \n2.6 (0.6\n\u2013\n14.9\n)\n \na\n \n3.2 (0.3\n\u2013\n16.8)\n \na\nb\n \n2.9 (0.3\n\u2013\n16.8)\n \n*\n \n1.8 (0.0\n\u2013\n18.3)\n \nb\n \nBacilli\n \n(class)\n \n0.4 (0.1\n\u2013\n6.4)\n \n0.4 (0.0\n\u2013\n1.9)\n \n0.4 (0.0\n\u2013\n6.4)\n \n*\n \n0.3 (0.0\n\u2013\n2.4)\n \nBacteroidia\n \n(class)\n \n43.3 (1.9\n\u2013\n58.1)\n \n39.5 (7.7\n\u2013\n51.7)\n \n42.9 (1.9\n\u2013\n58.1)\n \n42.9 (8.5\n\u2013\n67.9)\n \nClostridia\n \n(class)\n \n36.0 (22.9\n\u2013\n51.3)\n \n35.\n6 (17.2\n\u2013\n57.1)\n \n35.6 (17.2\n\u2013\n57.1)\n \n37.5 (12.5\n\u2013\n65.8)\n \nDeltaproteobacteria\n \n(class)\n \n0.1 (0.0\n\u2013\n0.8)\n \n0.1 (0.0\n\u2013\n1.4)\n \n0.1 (0.0\n\u2013\n1.4)\n \n0.07 (0.0\n\u2013\n0.9)\n \nErysipelotrichi \n(class)\n \n0.6 (0.2\n\u2013\n10.1)\n \n0.9 (0.1\n\u2013\n4.8)\n \n0.8 (0.1\n\u2013\n10.1)\n \n*\n \n0.5 (0.2\n\u2013\n5.5)\n \nGammaproteobacteria\n \n(class)\n \n0.1 (0.0\n\u2013\n3.7)\n \n0.2 (0.0\n\u2013\n2.7)\n \n0.1 (0.0\n\u2013\n3.7)\n \n*\n \n0.04 (0.0\n\u2013\n8.8)\n \nNegativicutes\n \n(class)\n \n4.6 (0.2\n\u2013\n32.4)\n \n1.9 (0.4\n\u2013\n15.4)\n \n2.8 (0.2\n\u2013\n32.4)\n \n2.9 (0.5\n\u2013\n20.8)\n \nVerrucomicrobiae\n \n(class)\n \n0.1 (0.0\n\u2013\n24.5)\n \n1.1 (0.0\n\u2013\n30.9)\n \n0.3 (0.0\n\u2013\n30.9)\n \n0.7 (0.0\n\u2013\n23.2)\n \nU\nnclassified sequences \nderived from\n \nBacteria\n \n4.7 (1.4\n\u2013\n13.3)\n \na\n \n9.7 (2.2\n\u2013\n32.3)\n \nb\n \n5.9 (1.4\n\u2013\n32.3)\n \n8.0 (1.4\n\u2013\n31.8)\n \nb\n \nAlpha diversity\n \n33.5 (17.0\n\u2013\n86.0)\n \n28.5 (9.0\n\u2013\n55.0)\n \n30.5 (9.0\n\u2013\n86.0)\n \n32.0 (12.0\n\u2013\n62.0)\n \nData are given as median \nand \nrange. *\n \nP\n-\nvalues were obtained from the Mann\n-\nWhitney U\n-\ntest\n. \nLabel\ned medians with identical letters are not significant. Different letters means significant \ndifferences (\nP\n \n<\n \n0.05)\n \nand \nwere\n \ncalculated using a H Kruskal\n\u2013\nWallis test corrected by Bonferroni \npost\n-\nhoc test. \nASD, \nchildren with \nautism spectrum disorders; AMR, \nch\nildren with autism mental \nregression\n; ANMR, \nchildren with autism non\n-\nmental regression\n. Table \n2 \nshows only the \nphylum \nand \nclass abundances with a value \nhigher \nthan 0.1\n%\n.\n \nFollowing quality control, an average of 96,417 (range 25,633\n\u2013\n263,373), 229,679 (12,64\n4\n\u2013\n587,681) \nand 223,197 (range 15,611\n\u2013\n641,292) reads per sample were obtained for healthy children, children \nwith ANMR, and children with AMR, respectively. Reads were classified into more than 4,000 \ndifferent taxon\ns\n. All samples were rarefied to prevent bi\nas due to sampling depth.\n \nAt phylum level, \nActinobacteria \nand \nProteobacteria \nwere higher in \nchildren with \nASD compared \nto \nhealthy group. For \nthe mental regression, A\nNMR group\n \nshowed \naugmented \nlevels \nin \nActinobacteria\n \nphylum\n \nand class \ncompared \nwith the \nheal\nthy group\n, whereas \nchildren with \nAMR \nreported augmented \nProteobacteria \nrelative abundances compared \nwith the \ncontrol and ANMR groups. \nAt class level, we found the \nsame differences for \nActinobacteria\n \nclass\n \nand\n \nhigher levels\n \nfor \nBacilli\n, \nErysipelotrichi\n, and\n \nGammaproteobacteria\n \nin the comparison \nof\n \nchildren with\n \nASD and healthy \ngroup.\n \nAlpha diversity \nwas \nsimilar\n \nbetween groups.\n \nFigure 1 shows the bacterial families with higher representation in the intestinal microbiota. \nBacillaceae, Bifidobacteriaceae, Coryn\nebacteriaceae, Desulfohalobiaceae, Enterobacteriaceae, \nEnterococcaceae, Erysipelotrichaceae, Fusobacteriaceae, Microbacteriaceae, and \nThermoactinomycetaceae were significantly higher in children with ASD compared to the healthy \ngroup. Only Lachnospiraceae \nshowed to be lower in children with ASD in comparison to the healthy \ngroup. At family level, the differences between children with ASD and the healthy group were more \nnotorious in relative abundances with values less than 0.1%). Figure 2 shows the specific\n \ndifferences \namong children with ANMR, AMR and the healthy group. Children with ANMR and AMR had \nhigher levels of Bifidobacteriaceae, Microbacteriaceae, and Thermoanaerobacteraceae compared to \nthe healthy group. Corynebacteriaceae and Clostridiales Family \nXVII were exclusively higher in \nchildren with ANMR, whereas Thermoactinomycetaceae family was significantly increased in \nchildren with AMR. \n Nutrients\n \n2019\n,\n \n11\n, 337\n \n8\n \nof \n17\n \n \n \nFigure 1. \nRelative abundance of family bacterial taxon in feces of children with ASD and healthy \nchildren. \nBoxplo\nts were generated \nusing the \nR \nsoftware\n \nutilizing the ggplot2 package\n,\n \nand represent \nthe most \nimportant \nb\nacterial families \n\u00a5\n \nP\n \n<\n \n0.05 vs control group.\n \n \nFigure 2. \nRelative abundances of selected bacteria according to family taxon in feces of children with \nASD classified by mental regression and healthy children. \nBoxplots were generated \nusing the \nR \nso\nf\ntware \nutilizing the ggplot2 package and represent bacterial families \n*\n \nP\n \n<\n \n0.05 vs\n.\n \ncontrol group,\n \n\u2020\n \nP\n \n<\n \n0.05 vs\n.\n \ncontrol and AMR groups,\n \nand \n\u00a5\n \nP\n \n<\n \n0.05 vs\n.\n \nco\nntrol and A\nN\nMR groups using H \nKruskal\n-\nWallis test corrected by Bonferroni post\n-\nhoc test.\n Nutrients\n \n2019\n,\n \n11\n, 337\n \n9\n \nof \n17\n \n \nA\nt genus and species levels\n, \nBacillus\n, \nBifidobacterium\n, \nButyrivibrio\n, \nEnterococcus\n, \nHespellia\n, \nPrevotella\n,\n \nClostridium bolteae\n, and \nClostridium difficile\n \nwere signific\nantly \nhigher \nin \nchildren with ASD \ncompared to \nhealthy group. \nChildren with AMR and ANMR \nha\nd\n \nhigher levels of\n \nBifidobacterium\n \nand \nClostridium bolteae\n \ncompared \nto \nthe \nhealthy \ngroup\n, whereas\n \nonly\n \nEnterococcus \nwas significantly\n \nhigher \nin \nchildren with AMR\n \n(Tab\nle 3)\n.\n \nTable 3.\n \nRelative abundances of \nfecal bacteria (genus and species) in \nchildren with ASD\n \nclassified by \nmental regression\n \nand healthy children\n.\n \nVariables\n \nASD\n \nControl (\nn\n \n=\n \n57)\n \nANMR (\nn\n \n=\n \n30)\n \nAMR (\nn\n \n=\n \n18)\n \nTotal (\nn\n \n=\n \n48)\n \nAkkermansia\n \n0.06\n \n(0.0\n\u2013\n24.8)\n \n1.\n1 (0.0\n\u2013\n32.3)\n \n0.30 (0.0\n\u2013\n32.3)\n \n0.7 (0.0\n\u2013\n24.2)\n \nAlistipes\n \n3.9 (0.0\n\u2013\n13.8)\n \n3.8 (0.0\n\u2013\n20.0)\n \n3.9 (0.0\n\u2013\n20.0)\n \n5.7 (0.0\n\u2013\n26.1)\n \nBacillus\n \n0.03 (0.0\n\u2013\n0.1)\n \n0.03 (0.0\n\u2013\n0.1)\n \n0.03 (0.0\n\u2013\n0.1)\n \n*\n \n0.02 (0.0\n\u2013\n0.4)\n \nBacteroides\n \n30.3 (1.1\n\u2013\n60.8)\n \n23.2 (4.0\n\u2013\n48.4)\n \n28.6 (1.1\n\u2013\n60.8)\n \n29.4 (2.\n4\n\u2013\n51.3)\n \nBifidobacterium\n \n2.2 (0.2\n\u2013\n13.8)\n \na\n \n2.4 (0.3\n\u2013\n14.2)\n \na\n \n2.3 (0.2\n\u2013\n14.2)\n \n*\n \n0.9 (0.0\n\u2013\n14.0)\n \nb\n \nButyrivibrio\n \n1.0 (0.2\n\u2013\n5.3)\n \n1.0 (0.1\n\u2013\n4.7)\n \n1.0 (0.1\n\u2013\n5.3)\n \n*\n \n1.4 (0.2\n\u2013\n6.8)\n \nClostridium\n \n6.1 (3.0\n\u2013\n11.7)\n \n5.7 (3.0\n\u2013\n16.9)\n \n5.8 (3.0\n\u2013\n16.9)\n \n5.4 (1.8\n\u2013\n16.9)\n \nCollinsella\n \n0.4 (\n0.0\n\u2013\n4.4)\n \n0.2 (0.0\n\u2013\n8.2)\n \n0.4 (0.0\n\u2013\n8.2)\n \n0.5 (0.0\n\u2013\n5.0)\n \nDesulfovibrio\n \n0.001 (0.0\n\u2013\n0.5)\n \n0.002 (0.0\n\u2013\n1.3)\n \n0.002 (0.0\n\u2013\n1.3)\n \n0.0005 (0.0\n\u2013\n0.3)\n \nEnterococcus\n \n0.002 (0.0\n\u2013\n0.04)\n \na\n \n \n0.004 (0.0\n\u2013\n0.01)\n \nb\n \n \n0.004 (0.0\n\u2013\n0.04)\n \n*\n \n \n0.001 (0.0\n\u2013\n0.04)\n \na\n \nEubacterium\n \n4.0 (0.5\n\u2013\n10.9)\n \n2.6 \n(0.3\n\u2013\n8.4)\n \n3.6 (0.3\n\u2013\n10.9)\n \n2.6 (0.5\n\u2013\n13.5)\n \nFaecalibacterium\n \n11.7 (1.4\n\u2013\n22.8)\n \n9.6 (1.8\n\u2013\n37.0)\n \n10.7 (1.4\n\u2013\n37.0)\n \n11.4 (2.7\n\u2013\n37.1)\n \nHespellia\n \n0.2 (0.0\n\u2013\n1.9)\n \n0.2 (0.0\n\u2013\n0.7)\n \n0.2 (0.0\n\u2013\n1.9)\n \n*\n \n0.1 (0.0\n\u2013\n0.9)\n \nLactobacillus\n \n0.05 (0.0\n\u2013\n3.5)\n \n0.03 (0.0\n\u2013\n0.6)\n \n0.04 (0.0\n\u2013\n3.5)\n \n0.03 (\n0.0\n\u2013\n1.0)\n \nParabacteroides\n \n2.6\n \n(0.0\n\u2013\n8.3)\n \n2.1 (0.0\n\u2013\n5.5)\n \n2.4 (0.0\n\u2013\n8.3)\n \n1.9 (0.0\n\u2013\n10.0)\n \nPrevotella\n \n0.3 (0.0\n\u2013\n30.2)\n \n0.2 (0.0\n\u2013\n11.9)\n \n0.3 (0.0\n\u2013\n30.2)\n \n*\n \n0.1 (0.0\n\u2013\n43.7)\n \nRuminococcus\n \n3.1 (1.1\n\u2013\n10.3)\n \n3.3 (0.9\n\u2013\n15.8)\n \n3.1 (0.9\n\u2013\n15.8)\n \n3.2 (0.7\n\u2013\n26.5)\n \nVeillonella\n \n0.4 (0.1\n\u2013\n34.\n9)\n \n0.6 (0.0\n\u2013\n5.8)\n \n0.5 (0.0\n\u2013\n34.9)\n \n0.7 (0.0\n\u2013\n19.3)\n \nBacteroides fragilis\n \n0.33 (0.0\n\u2013\n9.1)\n \n0.39 (0.0\n\u2013\n7.9)\n \n0.35 (0.0\n\u2013\n9.1)\n \n0.34 (0.0\n\u2013\n32.1)\n \nBacteroides vulgatus\n \n2.9 (0.0\n\u2013\n28.1)\n \n1.2 (0.0\n\u2013\n36.7)\n \n1.4 (0.0\n\u2013\n36.7)\n \n8.5 (0.0\n\u2013\n36.3)\n \nClostridium bolteae\n \n0.1 (0.0\n\u2013\n1.7)\n \na\n \n0.1 (0.\n0\n\u2013\n1.2)\n \na\n \n0.1 (0.0\n\u2013\n1.7)\n \n*\n \n0.04 (0.0\n\u2013\n1.4)\n \nb\n \nClostridium difficile\n \n0.08 (0.0\n\u2013\n0.6)\n \n0.04 (0.0\n\u2013\n0.6)\n \n0.09 (0.0\n\u2013\n0.6)\n \n*\n \n0.06 (0.0\n\u2013\n0.8)\n \nFaecalibacterium prausnitzii\n \n11.3 (1.4\n\u2013\n21.9)\n \n9.1 (1.7\n\u2013\n36.0)\n \n10.3 (1.4\n\u2013\n36.0)\n \n11.3 (2.6\n\u2013\n35.7)\n \nRuminococcus gnavus\n \n0.3 (0.0\n\u2013\n4.5)\n \n0\n.2 (0.0\n\u2013\n1.7)\n \n0.3 (0.0\n\u2013\n4.5)\n \n0.3\n \n(0.0\n\u2013\n7.6)\n \nRuminococcus torques\n \n0.1 (0.0\n\u2013\n0.9)\n \n0\n.1\n \n(0.0\n\u2013\n3.2)\n \n0.1 (0.0\n\u2013\n3.2)\n \n0.08 (0.0\n\u2013\n5.0)\n \nData are given as the median \nand \nrange. *\n \nP\n-\nvalues were obtained from the Mann\n-\nWhitney U\n-\ntest. \nLabeled medians with identical letters a\nre not significant. Different letters means significant \ndifferences (\nP\n \n<\n \n0.05) \nand \nwere calculated using a H Kruskal Wallis test corrected by Bonferroni \npost\n-\nhoc test. ASD, children with autism spectrum disorders; AMR, children with autism mental \nregressio\nn; ANMR, children with autis\nm non\n-\nmental regression. Table three\n \nshows only the \nimportant genus \nand \nspecies abundances\n.\n \nChanges in intestinal microbiota \nmight \nbe \nrelated \nto food patterns and nutrient\n \nintake\ns\n. \nHence, \np\nrincipa\nl component analyse\ns (PCA) \nwere \nperformed with bacterial and \nfood consumption\n \nvariables. In healthy \nchildren\n,\n \ncomponent \none \nwas defined for fish\n,\n \nred meat and processed cold \nmeat variables\n, those\n \nthat were related inversely with cereal and milk consumption. Bacterial \nvariables in compone\nnt \none\n \nwere \nClostridium difficile\n \nand \nButyrivibrio\n, which\n \ncorrelated inversely \nwith \nPrevotella\n. Children with ASD \nshowe\nd \ndifferent nutritional variables related \nto \ncomponent \none\n, \ncakes and pastry with\n \nred\n \nand processed cold meat\n, as well as\n \nfish consumptio\nn \nwere associated \nnegatively with vegetables consumption. Finally, \nHespellia \nwas the only bacterial variable reported \nin component \none\n.\n \n Nutrients\n \n2019\n,\n \n11\n, 337\n \n10\n \nof \n17\n \n \nConcerning\n \nchildren with \nAMR,\n \nwe observed that\n \nvariables in component \none\n \nwere similar to \nchildren with ASD\n, where\nas\n \nch\nildren with ANMR \nhad \ndissimilar variables, such as cereal and eggs \nand white meat consumption, and \nEnterococcus\n, \nBacillus\n \nand \nButyrivibrio.\n \n \nComponent \ntwo\n \nin healthy children \nincluded\n \nbacterial variables related in a positive way; we \nfound here \nBifidobacte\nrium \nand \nEnterococcus\n. \nFood \nvariables were snacks\n,\n \ncakes and pastry \nconsumption, which\n \ncorrelated negatively with eggs and white meat. \nFinally, the component \nthree\n \nwas \ndemarcated\n \nonly through \nbacterial \nvariables;\n \nhere \nHespellia\n, \nClostridium bolteae\n, and \nBa\ncillus \nare \npresented\n.\n \nChildren with ASD \nhad \na component \ntwo\n \nwith \nEnterococcus\n \nand \nBacillus\n \nthat\n \ncorrelated \ninversely with \nClostridium difficile\n, \nfood \nvariables were cereal, eggs and white meat, and milk \nproducts. Component three in children with ASD \nhad \na \nmix between bacterial variables and snack \nand soft drink consumption, here \nBifidobacterium\n, \nClostridium bolteae\n, and snack and soft drink \nconsumption \nwere \ncorrelated negatively with \nButyrivibrio\n \nand \nPrevotella. \n \nComponent two in children with ANMR \nwas \ndefi\nned by \nClostridium difficile\n, \nHespellia \nand fish \nconsumption correlated \nnegatively \nwith vegetables and milk products consumption\n, and\n, \ncomponent\n \nthree\n \nwas \nexclusively determined by bacterial variables, here \nBifidobacterium \nand\n \nClostridium bolteae\n \nwere rela\nted\n \nnegatively \nwith \nPrevotella. \n \nFinally, c\nomponent two in children with AMR \nwas defined \nthrough bacterial variables; \nClostridium bolteae\n, \nBacillus\n, \nBifidobacterium\n \nand \nEnterococcus \ncorrelated positively with cereal and \nsnacks and soft drinks consumption\n \n(\nFigure 3)\n.\n \n \nFigure 3. \nPrincipal component analysis between intestinal microbiota and food consumption in \nchildren with ASD and healthy children. \nExtraction of the initial set of uncorrelated components was \naccomplished with the principal factor method and\n \nthen the orthogonal rotation of components was \nused to facilitate interpretation.\n \nFactor loading was used to interpret the factor structure. Loadings \nare equivalent to Pearson correlation coefficients, and a higher loading indicates a stronger relation \nbe\ntween a factor and an observed variable. Strong loading was defined as a value \n\u2265 0.6\n; moderate as \n0.4\n\u2013\n0.59 and low as <0.4\n.\n \n(\nA\n)\n \nControl group\n,\n \n(\nB\n)\n \nChildren with ASD,\n \n(\nC\n)\n \nChildren with ANMR\n,\n \n(\nD\n)\n \nChildren with AMR. ASD, children with autism spectrum disorder\ns; AMR, children with autism \nmental regression; ANMR, children with autism non\n-\nmental regression.\n Nutrients\n \n2019\n,\n \n11\n, 337\n \n11\n \nof \n17\n \n \n4. \nDiscussion\n \nThe present study analyzes the\n \nfecal microbiota in \nchildren with ASD\n,\n \nclassified \naccording to\n \nmental regression phenotype\ns\n \nusing \na \nmetagenomic a\npproach. \nThe major findings were that f\necal \nsamples from c\nhildren with\n \nASD \nexhibit\ned\n \nseveral differences \ncompared \nto \na \nhealthy group, \nespecially in \nActinobacteria\n \nand \nProteobacteria\n, \nas \nthese two phyla were significantly higher in \nchildren with ASD. In add\nition,\n \nActinobacteria\n \nclass\n, \nBacilli\n, \nErysipelotrichi\n, and \nGammaproteobacteria\n \nlevels were increased in children with ASD\n.\n \nMoreover, \nBacillaceae, Bifidobacteriaceae, \nCorynebacteriaceae, Desulfohalobiaceae, Enterobacteriaceae, Enterococcaceae, Erysipelotric\nhaceae, \nFusobacteriaceae, Microbacteriaceae, and Thermoactinomycetaceae, and \nBacillus\n, \nBifidobacterium\n, \nButyrivibrio\n, \nEnterococcus\n, \nHespellia\n, \nPrevotella\n, \nClostridium bolteae\n, and \nClostridium difficile\n \nwere \nsignificantly \naugmented in\n \nchildren with ASD\n. Whe\nn children with ASD were divided according \nMR, \nCorynebacteriaceae\n \nand \nClostridiales \nFamily XVII\n \nwere solely higher in children with ANMR\n, \nwhereas \nProteobacteria\n, \nThermoactinomycetaceae\n \nand \nEnterococcus\n \nabundances were exclusively higher \nin children with AM\nR. These findings support previous studies \nreporting\n \nchanges in intestinal \nmicrobiota from children with ASD, and add new information regarding \nmental regression\n, a new \nvariable in ASD that could influence the intestinal microbiota profile\n.\n \n \nPatients with \nASD who present gastrointestinal symptoms might display significant behavioral \nmanifestations, such as anxiety, self\n-\ninjury and aggression \n[\n11\n]\n. \nWe mentioned earlier that gut \nmicroorganisms can affect brain functions through the vagus nerve\n \n[\n31\n], \nand accum\nulating evidence \ndemonstrates that this gut microbiota is directly or indirectly associated with ASD symptoms, in \npart by influencing the immune system and metabolism\n \n[\n51\n,\n52\n]\n.\n \nChanges in the composition of gut \nmicroorganisms can affect both the enteric ner\nvous system and the central nervous system (CNS), \nthereby indicating the existence of a microbiota\n\u2014\ngut\n\u2014\nbrain axis\n \n[31].\n \nActinobacteria \nis an important phylum \nexhibiting \ndiff\nerences between children with A\nS\nD\n \ncompared with healthy \nones\n.\n \nFour \nspecific \nstudies\n \n[\n18\n,\n21\n,\n27\n,\n53\n]\n \nhave reported decreased \nActinobacteria\n \nin children with ASD, whereas a study in 2005 showed no differences\n \n[\n54\n]\n.\n \nOpposite to \nthat reported in previous work\n, our study \nshowed\n \nan increase in \nthat \nphylum\n. According to mental \nregression, \nchildre\nn with ANMR \nhad \nsignificantly higher \nActinobacteria\n \nin comparison \nwith \nthe \nhealthy group\n.\n \nBifidobacterium \nrepresents a genus within the \nActinobacteria\n \nphylum\n \nspecially found\n \nin \ninfants during lactation. Bifidobacteria are \nearly \ncolonizers of gut microbiota\n, and ha\nve\n \nreported \nproperties in \nthe \nmetabolism\n \nof dietary components\n, and even effects over maturation of the \nimmune system \n[\n55\n,\n56\n]\n. \nIn addition, consumption of yogurt and other fermented dairy products is \nassociated with an increase of fecal bifidobacte\nria\n \n[57\n\u2013\n59\n]\n. \nChildren with ASD, ANMR and AMR \nhad \nsignificantly higher \namounts of\n \nBifidobacterium \nin comparison \nto the \nhealthy group\n, which may be \nrelated to a high\n \nconsumption of dairy products\n.\n \nIn \nAkkermansia\n \ngenus, we found \nA. muciniphila\n \nan important ba\ncterium able to prevent the \ndevelopment of obesity in animal models. A pasteurized version of \nA. muciniphila\n \nwas capable to \nreduce fat mass development, insulin resistance, and dyslipidemia in mice; moreover, the \npasteurized bacterium modulated both the ho\nst urinary metabolome and intestinal energy \nabsorption \n[\n60\n]\n. \nAkkermansia \ngenus was not different in none comparison in our studied children. \nIn \nfact, \nAkkermansia \ngenus was similar in all groups, \nshowing a wide variation between the evaluated \nsamples. \nThe r\nesults in this genus are contradictory; Kang et al. \n[\n61\n]\n \nfound\n \nsimilar results\n \nwith our \nstudy\n, unchanged genus in the comparison with children with ASD. De Angelis et al. \n[\n53\n]\n \nreported \nincreased amount in \nAkkermansia\n, \nand \nin contrast, Wang et al.\n \n[\n18\n]\n \nfoun\nd\n \nthe \nopposite. \n \nPrevotella\n \nis a large genus that includes almost 40 different species with a vast genomic \ndiversity. It has been suggested that \nPrevotella\n \nis a beneficial bacteria as it is associated with a \nplant\n-\nrich diet, however it is also linked to ch\nronic inflammatory conditions, such as arthritis and \nmucosal and systemic T\n-\ncell activation in untreated human immunodeficiency virus type 1 (HIV\n-\n1) \ninfection \n[\n62\n,\n63\n]\n. \nThe case of \nPrevotella \nis s\nimilar to \nthe \nprevious genus\n \nAkkermansia\n, unchanged \nrelative \nabundance in Wang study \n[\n18\n]\n, decreased levels in Kang et al. \n[\n61\n]\n \nstudy and finally, \naugmented levels in De Angelis et al. \n[\n53\n]\n \nstudy. For \nPrevotella\n,\n \nwe report\n \na significant increase in \nchildren with ASD.\n \n Nutrients\n \n2019\n,\n \n11\n, 337\n \n12\n \nof \n17\n \n \nChanges in the gut microbiota associated with AS\nD might be related to an increased \npermeability of the intestinal tract of individuals, referred to as a \u201cleaky gut\n\u201d\n \n[\n64\n]\n, but this factor is \nrelated \ndirectly \nwith \nother factors, such as, \nimmune response\n. Previous studies have demonstrated \nthat ASD animal\n \nmodel\ns present defects in the gastrointe\ns\ntinal barrier, resulting in the entry of the \ntoxins and bacterial products into the bloodstream, which influence brain function\n \n[\n14\n,\n65\n]\n. \nThese \narguments \nwere\n \nsupported \nwith\n \nthe idea \nof\n \nlevel changes in some immune c\nells and cytokines, such \nas, interleukin (IL)\n-\n6, IL\n-\n1\u03b2, IFN\n-\n\u03b3, and TNF\n-\n\u03b1, among others. \nHowever, p\nlasma cytokine levels in \nour \nchildren with ASD compared \nto \nthe levels in the healthy control group, only \nshowed \ndifferences \nin the nerve growth factor, \nbut \nth\ne aforementioned cytokines were not significantly different\n \n[\n22\n]\n.\n \nAlthough \nmicrobiota changes are related with \nimmunological \nresponses, profound differences \nrequire more variables to explain the present variance.\n \nAccordingly, Lovene et al. found that in fe\nw \nASD\n-\npositive samples, with low\n-\nmild augmented calprotectin values, no correlation was found with \neither increase or decrease of bacterial/yeast species. A correlation was, however, present with \ndisease degree (CARS score), thus possibly confirming that g\nut inflammation also could participate \nto gut discomfort ending in influence on behavior \n[\n24\n]\n. \n \nA\nn association between high levels of \nSutterella\n \nspecies and \ngastrointestinal\n \ndisturbances in \nchildren with \nASD\n \nwas reported\n. These findings \nin ileal and cecal \nbiopsy samples have \ndemonstrat\ned \nthat \nSutterella\n, a bacterium with a low abundance in the microbiota, \nis a major \ncomponent of the microbiota in over half of children with \nASD\n \nand gastrointestinal\n \ndysfunction and \nis absent in \nhealthy \nchildren with only gast\nrointestinal dysfunction\n \n[\n66\n]\n. Microbes are different from \nthe place\ns\n \nwhere they are extracted \n[\n67\n]\n, in our study \nSutterella \nwas not \ndetected\n \nin none \nanalyzed \ngroup.\n \nThis might be related to the usual \nMediterra\nnean diet consumed in Spain compared to other \ncountries.\n \nMaternal obesity during pregnancy and gestational diabetes alter the gut microbiota and might \nbe associated with ASD in humans \n[\n68\n]\n. As shown by Buffington et al., a maternal high\n-\nfat diet \ninduces dysbiosis and autism\n-\nlike phenotypes in mice, an\nd \nLactobacillus reuteri\n \nrestores these \nalternations \n[\n69\n]\n. Diet might ha\nve\n \na tremendous influence in the development of ASD. \nHowever, a\n \nsystematic review concluded that the evidence to support a gluten\n-\nfree, casein\n-\nfree diet is limited \nand weak, considering\n \nthat dietary restrictions might be responsible for further social withdrawal \nand integration, in addition to potential adverse clinical effects \n[\n70\n]\n. Elimination diets for ASD \npatients should only be initiated after reaching a diagnosis of an adverse food\n \nreaction.\n \nOn the other \nhand, the administration of pr\nobiotics can be useful for restoring the microbial balance in the \nintestine and ameliorating gastrointestinal symptoms. Some evidence has accumulated regarding \nthe possible role of probiotics in modulat\ning some neurological symptoms\n \n[\n71\n]\n. Because ASD \npatients presented GI dysbiosis \n[\n20\n,\n21\n]\n, which may exacerbate the disease \n[\n19\n]\n. \nHowever, i\nn our \nstudy, alpha \ndiversity was \nnot significantly different \nin all tested groups.\n \nWe have included in our study, a d\nietary dimension, transforming the consumed portions with \nthe recommendations of\n \nSpanish Society of Community Nutrition (\nSENC\n) Food Guide\n \nPyramid in \nscholar age to determine or assess \npotential \nrelationship\ns\n \nbetween microbiota and diet \n[\n45\n]\n.\n \nThe \nprofile in\n \nhealthy children was determ\nined by consumption of fish, re\nd meat and processed cold \nmeat, cereal and milk products, whereas children with ASD have cakes and pastry with red meat \nand processed cold meat\n,\n \nand fish consumption, which related negatively with \nvegetables \nconsumption\n. \nMoreover, b\nacterial variables in component one\n,\n \nwere \nClostridium difficile\n \nand \nButiryvibrio\n, \nwhich\n \ncorrelated inversely with \nPrevotella\n \nin healthy children.\n \nIn contrast, \nin \nchildren \nwith ASD \nHespellia \nwas the only bacterial variable\n \nreported in component one. According \nto \nmental \nregression, children with ANMR seem \nto exhibit a microbiota profile typical of \nchildren with ASD \nthan AMR group\n;\n \nhowever\n \nfurther analyses are needed to confirm these results\n. \n \nA limitation of \nthe present \nstud\ny \naccording to microbiota \nwas the biological material analyzed\n;\n \nwe just \nwere \nable\n \nto\n \nevaluate fecal samples, and others, such as, buccal samples, urine samples or \nsaliva will be required to connect these findings with an overall \n\u201c\nmicrobiome\n\u201d\n \nview. \nTo bette\nr \nunderstand the role of the microbiota and the interplay between nutrition and the microbiota in \nASD, future studies should systematically investigate the role of \nfood and \nnutrition in the microbial Nutrients\n \n2019\n,\n \n11\n, 337\n \n13\n \nof \n17\n \n \ncomposition of children with ASD and stress the importan\nce of analyzing the microbiota in the \ncontext of diet and medication \n[\n72\n]\n. In addition,\n \nm\nulticomponent analyses \nincluding \nmicrobiota \npatterns\n, \ngenetic and \nmetabolomics approaches, and nutrition assessment are required to \nunderstand \nhow children with \nASD\n \nca\nn exhibit different phenotypes and behaviors\n.\n \n \n5. Conclusions\n \nIn conclusion\n, \nseveral differences between children with ASD compared with healthy group \nwere detected\n;\n \nActinobacteria\n \nand \nProteobacteria \nat phylum level, and \nActinobacteria,\n \nBacilli\n, \nErysipelot\nrichi\n, and \nGammaproteobacteria\n \nat class level were \nhigher\n \nin children \nwith \nASD. \nAdditionally, \nProteobacteria \nlevels were augmented exclusively in children with AMR\n. Mixed \nbacterial and nutritional variables showed differential patterns in children with ASD\n, ANMR and \nAMR. Furthermore, \nCorynebacteriaceae\n \nand \nClostridiales Family\n \nXVII were solely higher in children \nwith ANMR, whereas \nProteobacteria\n, Thermoactinomycetaceae and \nEnterococcus\n \nabundances were \nexclusively higher in children with AMR.\n \nFurther analyse\ns mixing omics technologies\n, diet \nquestionnaires and inflammation pathways \nare needed in larger \nASD \ncohort\ns\n \nto confirm the results\n \nof the present study\n \nin\n \nterms of the population of children in Spain\n.\n \nAuthor Contributions: \nA\n.\nG\n.\n-\nF\n.\n, M\n.\nG\n.\n-\nC\n.\n, and J\n.\nP\n.\n-\nN\n.\n \ncon\ntributed to the study conception and study design. \nA.G.\n-\nF.\n, K\n.\nF\n.\n-\nR\n.\n, and \nM\n.\nJ\n.\n-\nT\n.\n \ncollected all the data, acquired the behavioral data, and assisted with regulatory \nresponsibilities. \nN\n.\nC\n.\n, F\n.\nG\n.\n \nand P\n.\nS\n.\nU\n.\n \ncarried out the analysis. \nJ\n.\nP\n.\n-\nD\n.\n \nand F\n.\nJ\n.\nR\n.\nO\n.\n \nreali\nzed statistical analysis. \nJ\n.\nP\n.\nD\n.\n, A\n.\nG\n.\n \nand M\n.\nG\n.\n-\nC\n.\n \nwere responsible for the interpretation of the data, as well as drafting the manuscript. \nAll authors read and approved the final \nmanuscript.\n \nFunding: \nThis study was supported by the FUNDACI\u00d3 AGRUPACI\u00d3 \u00c0mbi\nt de la Inf\u00e0ncia, 404 Research \nGrant INVEST from the Spanish Society of Pediatrics and Red de Salud Materno Infantil (RED SAMID). The \nfunding bodies did not have any role in the design, collection, analyses, or interpretation of data or in writing \nthe manu\nscript.\n \nAcknowledgments: \nJulio Plaza\n-\nDiaz is \nis part of\n \nUniversity of Granada, Plan Propio de Investigaci\u00f3n 2016, \nExcellence actions: Units of Excellence; Unit of Excellence on Exercise and Health (UCEES). Patricio Solis\n-\nUrra \nwas supported by a grant from \nCONICYT/BECAS Chile/72180543.\n \nConflicts of Interest: \nThe authors declare no conflict\ns\n \nof interest. \n \nReferences\n \n1.\n \nGilbert, J.A.; Krajmalnik\n-\nBrown, R.; Porazinska, D.L.; Weiss, S.J.; Knight, R. Toward effective probiotics for \nautism and other neurodevelopmenta\nl disorders. \nCell \n2013\n, \n155\n, 1446\n\u2013\n1448, doi:10.1016/j.cell.2013.11.035.\n \n2.\n \nPlaza\n-\nDiaz, J.; Ruiz\n-\nOjeda, F.J.; Vilchez\n-\nPadial, L.M.; Gil, A. Evidence of the Anti\n-\nInflammatory Effects of \nProbiotics and Synbiotics in Intestinal Chronic Diseases. \nNutrients \n2017\n, \n9\n, 555, doi:10.3390/nu9060555.\n \n3.\n \nPlaza\n-\nDiaz, J.; Ruiz\n-\nOjeda, F.J.; Gil\n-\nCampos, M.; Gil, A. Immune\n-\nMediated Mechanisms of Action of \nProbiotics and Synbiotics in Treating Pediatric Intestinal Diseases. \nNutrients \n2018\n, \n10\n, \ndoi:10.3390/nu10010042.\n \n4.\n \nde la Fuente\n-\nNu\nnez, C.; Meneguetti, B.T.; Franco, O.L.; Lu, T.K. Neuromicrobiology: How Microbes \nInfluence the Brain. \nACS Chem. Neurosci. \n2018\n, \n9\n, 141\n\u2013\n150, doi:10.1021/acschemneuro.7b00373.\n \n5.\n \nYang, Y.; Tian, J.; Yang, B. Targeting gut microbiome: A novel and potential ther\napy for autism. \nLife Sci. \n2018\n, \n194\n, 111\n\u2013\n119, doi:10.1016/j.lfs.2017.12.027.\n \n6.\n \nBaio, J.; Wiggins, L.; Christensen, D.L.; Maenner, M.J.; Daniels, J.; Warren, Z.; Kurzius\n-\nSpencer, M.; \nZahorodny, W.; Robinson Rosenberg, C.; White, T.; et al. Prevalence of Autis\nm Spectrum Disorder Among \nChildren Aged 8 Years\n\u2014\nAutism and Developmental Disabilities Monitoring Network, 11 Sites, United \nStates, 2014. \nMorb. Mortal. Wkly Rep. Surveill. Summ. \n2018\n, \n67\n, 1\n\u2013\n23, doi:10.15585/mmwr.ss6706a1.\n \n7.\n \nMorales\n-\nHidalgo, P.; Roige\n-\nCastellv\ni, J.; Hernandez\n-\nMartinez, C.; Voltas, N.; Canals, J. Prevalence and \nCharacteristics of Autism Spectrum Disorder Among Spanish School\n-\nAge Children. \nJ. Autism Dev. Disord. \n2018\n, \n48\n, 3176\n\u2013\n3190, doi:10.1007/s10803\n-\n018\n-\n3581\n-\n2.\n \n8.\n \nLi, Q.; Zhou, J.M. The microbiota\n-\ngut\n-\nbrain axis and its potential therapeutic role in autism spectrum \ndisorder. \nNeuroscience \n2016\n, \n324\n, 131\n\u2013\n139, doi:10.1016/j.neuroscience.2016.03.013.\n Nutrients\n \n2019\n,\n \n11\n, 337\n \n14\n \nof \n17\n \n \n9.\n \nSchieve, L.A.; Gonzalez, V.; Boulet, S.L.; Visser, S.N.; Rice, C.E.; Van Naarden Braun, K.; Boyle, C.A.\n \nConcurrent medical conditions and health care use and needs among children with learning and \nbehavioral developmental disabilities, National Health Interview Survey, 2006\n-\n2010. \nRes. Dev. Disabil. \n2012\n, \n33\n, 467\n\u2013\n476, doi:10.1016/j.ridd.2011.10.008.\n \n10.\n \nKohane, \nI.S.; McMurry, A.; Weber, G.; MacFadden, D.; Rappaport, L.; Kunkel, L.; Bickel, J.; Wattanasin, N.; \nSpence, S.; Murphy, S.; et al. The co\n-\nmorbidity burden of children and young adults with autism spectrum \ndisorders. \nPLoS ONE \n2012\n, \n7\n, e33224, doi:10.1371/jo\nurnal.pone.0033224.\n \n11.\n \nBuie, T.; Fuchs, G.J., 3rd; Furuta, G.T.; Kooros, K.; Levy, J.; Lewis, J.D.; Wershil, B.K.; Winter, H. \nRecommendations for evaluation and treatment of common gastrointestinal problems in children with \nASDs. \nPediatrics \n2010\n, \n125 \n(Suppl. \n1), S19\n\u2013\nS29, doi:10.1542/peds.2009\n-\n1878D.\n \n12.\n \nEmanuele, E.; Orsi, P.; Boso, M.; Broglia, D.; Brondino, N.; Barale, F.; di Nemi, S.U.; Politi, P. Low\n-\ngrade \nendotoxemia in patients with severe autism. \nNeurosci. Lett. \n2010\n, \n471\n, 162\n\u2013\n165, \ndoi:10.1016/j.neulet.2010\n.01.033.\n \n13.\n \nDing, H.T.; Taur, Y.; Walkup, J.T. Gut Microbiota and Autism: Key Concepts and Findings. \nJ. Autism Dev. \nDisord. \n2017\n, \n47\n, 480\n\u2013\n489, doi:10.1007/s10803\n-\n016\n-\n2960\n-\n9.\n \n14.\n \nHsiao, E.Y.; McBride, S.W.; Hsien, S.; Sharon, G.; Hyde, E.R.; McCue, T.; Codelli, J.\nA.; Chow, J.; Reisman, \nS.E.; Petrosino, J.F.; et al. Microbiota modulate behavioral and physiological abnormalities associated with \nneurodevelopmental disorders. \nCell \n2013\n, \n155\n, 1451\n\u2013\n1463, doi:10.1016/j.cell.2013.11.024.\n \n15.\n \nFoley, K.A.; MacFabe, D.F.; Kavalie\nrs, M.; Ossenkopp, K.P. Sexually dimorphic effects of prenatal \nexposure to lipopolysaccharide, and prenatal and postnatal exposure to propionic acid, on acoustic startle \nresponse and prepulse inhibition in adolescent rats: Relevance to autism spectrum diso\nrders. \nBehav. Brain \nRes. \n2015\n, \n278\n, 244\n\u2013\n256, doi:10.1016/j.bbr.2014.09.032.\n \n16.\n \nO'Mahony, S.M.; Clarke, G.; Borre, Y.E.; Dinan, T.G.; Cryan, J.F. Serotonin, tryptophan metabolism and the \nbrain\n-\ngut\n-\nmicrobiome axis. \nBehav. Brain Res. \n2015\n, \n277\n, 32\n\u2013\n48, doi:10.101\n6/j.bbr.2014.07.027.\n \n17.\n \nHornig, M. The role of microbes and autoimmunity in the pathogenesis of neuropsychiatric illness. \nCurr. \nOpin. Rheumatol. \n2013\n, \n25\n, 488\n\u2013\n795, doi:10.1097/BOR.0b013e32836208de.\n \n18.\n \nWang, L.; Christophersen, C.T.; Sorich, M.J.; Gerber, J.P.; A\nngley, M.T.; Conlon, M.A. Low relative \nabundances of the mucolytic bacterium Akkermansia muciniphila and Bifidobacterium spp. in feces of \nchildren with autism. \nAppl. Environ. Microbiol. \n2011\n, \n77\n, 6718\n\u2013\n6721, doi:10.1128/AEM.05212\n-\n11.\n \n19.\n \nSandler, R.H.; Finegold\n, S.M.; Bolte, E.R.; Buchanan, C.P.; Maxwell, A.P.; Vaisanen, M.L.; Nelson, M.N.; \nWexler, H.M. Short\n-\nterm benefit from oral vancomycin treatment of regressive\n-\nonset autism. \nJ. Child \nNeurol. \n2000\n, \n15\n, 429\n\u2013\n435, doi:10.1177/088307380001500701.\n \n20.\n \nFinegold, S.M. \nTherapy and epidemiology of autism\n--\nclostridial spores as key elements. \nMed. Hypotheses \n2008\n, \n70\n, 508\n\u2013\n511, doi:10.1016/j.mehy.2007.07.019.\n \n21.\n \nFinegold, S.M.; Dowd, S.E.; Gontcharova, V.; Liu, C.; Henley, K.E.; Wolcott, R.D.; Youn, E.; Summanen, \nP.H.; Granpees\nheh, D.; Dixon, D.; et al. Pyrosequencing study of fecal microflora of autistic and control \nchildren. \nAnaerobe \n2010\n, \n16\n, 444\n\u2013\n453, doi:10.1016/j.anaerobe.2010.06.008.\n \n22.\n \nGomez\n-\nFernandez, A.; de la Torre\n-\nAguilar, M.J.; Gil\n-\nCampos, M.; Flores\n-\nRojas, K.; Cruz\n-\nRic\no, M.D.; \nMartin\n-\nBorreguero, P.; Perez\n-\nNavero, J.L. Children With Autism Spectrum Disorder With Regression \nExhibit a Different Profile in Plasma Cytokines and Adhesion Molecules Compared to Children Without \nSuch Regression. \nFront. Pediatr. \n2018\n, \n6\n, 264, doi\n:10.3389/fped.2018.00264.\n \n23.\n \nKern, J.K.; Geier, D.A.; Geier, M.R. Evaluation of regression in autism spectrum disorder based on parental \nreports. \nN. Am. J. Med. Sci. \n2014\n, \n6\n, 41\n\u2013\n47, doi:10.4103/1947\n-\n2714.125867.\n \n24.\n \nIovene, M.R.; Bombace, F.; Maresca, R.; Sapone,\n \nA.; Iardino, P.; Picardi, A.; Marotta, R.; Schiraldi, C.; \nSiniscalco, D.; Serra, N.; et al. Intestinal Dysbiosis and Yeast Isolation in Stool of Subjects with Autism \nSpectrum Disorders. \nMycopathologia \n2017\n, \n182\n, 349\n\u2013\n363, doi:10.1007/s11046\n-\n016\n-\n0068\n-\n6.\n \n25.\n \nCar\nding, S.; Verbeke, K.; Vipond, D.T.; Corfe, B.M.; Owen, L.J. Dysbiosis of the gut microbiota in disease. \nMicrob. Ecol. Health Dis. \n2015\n, \n26\n, 26191, doi:10.3402/mehd.v26.26191.\n \n26.\n \nBuie, T. Potential Etiologic Factors of Microbiome Disruption in Autism. \nClin. T\nher. \n2015\n, \n37\n, 976\n\u2013\n983, \ndoi:10.1016/j.clinthera.2015.04.001.\n \n27.\n \nAdams, J.B.; Johansen, L.J.; Powell, L.D.; Quig, D.; Rubin, R.A. Gastrointestinal flora and gastrointestinal \nstatus in children with autism\n--\ncomparisons to typical children and correlation with a\nutism severity. \nBMC \nGastroenterol. \n2011\n, \n11\n, 22, doi:10.1186/1471\n-\n230X\n-\n11\n-\n22.\n Nutrients\n \n2019\n,\n \n11\n, 337\n \n15\n \nof \n17\n \n \n28.\n \nMulak, A.; Bonaz, B. Irritable bowel syndrome: A model of the brain\n-\ngut interactions. \nMed. Sci. Monit. \n2004\n, \n10\n, RA55\n-\n62.\n \n29.\n \nForsythe, P.; Bienenstock, J.; Kunze, W.A. Vagal pathway\ns for microbiome\n-\nbrain\n-\ngut axis communication. \nAdv. Exp. Med. Biol. \n2014\n, \n817\n, 115\n\u2013\n133, doi:10.1007/978\n-\n1\n-\n4939\n-\n0897\n-\n4_5.\n \n30.\n \nBravo, J.A.; Forsythe, P.; Chew, M.V.; Escaravage, E.; Savignac, H.M.; Dinan, T.G.; Bienenstock, J.; Cryan, \nJ.F. Ingestion of Lactobaci\nllus strain regulates emotional behavior and central GABA receptor expression \nin a mouse via the vagus nerve. \nProc. Natl. Acad. Sci. USA \n2011\n, \n108\n, 16050\n\u2013\n16055, \ndoi:10.1073/pnas.1102999108.\n \n31.\n \nZhu, X.; Han, Y.; Du, J.; Liu, R.; Jin, K.; Yi, W. Microbiota\n-\ngut\n-\nbrain axis and the central nervous system. \nOncotarget \n2017\n, \n8\n, 53829\n\u2013\n53838, doi:10.18632/oncotarget.17754.\n \n32.\n \nAraque, A.; Carmignoto, G.; Haydon, P.G.; Oliet, S.H.; Robitaille, R.; Volterra, A. Gliotransmitters travel in \ntime and space. \nNeuron \n2014\n, \n81\n, 728\n\u2013\n7\n39, doi:10.1016/j.neuron.2014.02.007.\n \n33.\n \nChung, W.; Choi, S.Y.; Lee, E.; Park, H.; Kang, J.; Park, H.; Choi, Y.; Lee, D.; Park, S.G.; Kim, R.; et al. Social \ndeficits in IRSp53 mutant mice improved by NMDAR and mGluR5 suppression. \nNat. Neurosci. \n2015\n, \n18\n, \n435\n\u2013\n443, doi:10.1038/nn.3927.\n \n34.\n \nErny, D.; Hrabe de Angelis, A.L.; Jaitin, D.; Wieghofer, P.; Staszewski, O.; David, E.; Keren\n-\nShaul, H.; \nMahlakoiv, T.; Jakobshagen, K.; Buch, T.; et al. Host microbiota constantly control maturation and function \nof microglia in t\nhe CNS. \nNat. Neurosci. \n2015\n, \n18\n, 965\n\u2013\n977, doi:10.1038/nn.4030.\n \n35.\n \nMorgan, J.T.; Chana, G.; Abramson, I.; Semendeferi, K.; Courchesne, E.; Everall, I.P. Abnormal \nmicroglial\n-\nneuronal spatial organization in the dorsolateral prefrontal cortex in autism. \nBrain Re\ns. \n2012\n, \n1456\n, 72\n\u2013\n81, doi:10.1016/j.brainres.2012.03.036.\n \n36.\n \nEdmonson, C.; Ziats, M.N.; Rennert, O.M. Altered glial marker expression in autistic post\n-\nmortem \nprefrontal cortex and cerebellum. \nMol. Autism \n2014\n, \n5\n, 3, doi:10.1186/2040\n-\n2392\n-\n5\n-\n3.\n \n37.\n \nSuzuki, K.; Sugi\nhara, G.; Ouchi, Y.; Nakamura, K.; Futatsubashi, M.; Takebayashi, K.; Yoshihara, Y.; \nOmata, K.; Matsumoto, K.; Tsuchiya, K.J.; et al. Microglial activation in young adults with autism \nspectrum disorder. \nJAMA Psychiatry \n2013\n, \n70\n, 49\n\u2013\n58, doi:10.1001/jamapsyc\nhiatry.2013.272.\n \n38.\n \nSharon, G.; Sampson, T.R.; Geschwind, D.H.; Mazmanian, S.K. The Central Nervous System and the Gut \nMicrobiome. \nCell \n2016\n, \n167\n, 915\n\u2013\n932, doi:10.1016/j.cell.2016.10.027.\n \n39.\n \nLu, J.; Lu, L.; Yu, Y.; Cluette\n-\nBrown, J.; Martin, C.R.; Claud, E.C. Ef\nfects of Intestinal Microbiota on Brain \nDevelopment in Humanized Gnotobiotic Mice. \nSci. Rep. \n2018\n, \n8\n, 5443, doi:10.1038/s41598\n-\n018\n-\n23692\n-\nw.\n \n40.\n \nBjorklund, G. The role of zinc and copper in autism spectrum disorders. \nActa Neurobiol. Exp. \n2013\n, \n73\n, \n225\n\u2013\n236.\n \n41.\n \nOng,\n \nI.M.; Gonzalez, J.G.; McIlwain, S.J.; Sawin, E.A.; Schoen, A.J.; Adluru, N.; Alexander, A.L.; Yu, J.J. Gut \nmicrobiome populations are associated with structure\n-\nspecific changes in white matter architecture. \nTransl. Psychiatry \n2018\n, \n8\n, 6, doi:10.1038/s4139\n8\n-\n017\n-\n0022\n-\n5.\n \n42.\n \nWorld Health Organization. The ICD\n-\n10 Classification of Mental and Behavioural Disorders: Clinical \nDescriptions and Diagnostic Guidelines; World Health Organization: \nGeneva, Switzerland, \n1992; Volume \n1.\n \n43.\n \nAmerican Psychiatric Pub. \nDiagnostic an\nd Statistical Manual of Mental Disorders (DSM\n-\n5\u00ae)\n; American \nPsychiatric Pub: \nWashington, DC\n, USA, 2013.\n \n44.\n \nKim, S.H.; Lord, C. New autism diagnostic interview\n-\nrevised algorithms for toddlers and young \npreschoolers from 12 to 47 months of age. \nJ. Autism Dev. D\nisord. \n2012\n, \n42\n, 82\n\u2013\n93, \ndoi:10.1007/s10803\n-\n011\n-\n1213\n-\n1.\n \n45.\n \nAranceta Bartrina, J. Role of gastronomy and new technologies in shaping a healthy diet. \nNutricion \nHospitalaria \n2018\n, \n35\n, 3\n\u2013\n9, doi:10.20960/nh.2118.\n \n46.\n \nHerlemann, D.P.; Labrenz, M.; Jurgens, K.; Bertilsso\nn, S.; Waniek, J.J.; Andersson, A.F. Transitions in \nbacterial communities along the 2000 km salinity gradient of the Baltic Sea. \nISME J. \n2011\n, \n5\n, 1571\n\u2013\n1579, \ndoi:10.1038/ismej.2011.41.\n \n47.\n \nSchloss, P.D.; Westcott, S.L.; Ryabin, T.; Hall, J.R.; Hartmann, M.; Hol\nlister, E.B.; Lesniewski, R.A.; Oakley, \nB.B.; Parks, D.H.; Robinson, C.J.; et al. Introducing mothur: Open\n-\nsource, platform\n-\nindependent, \ncommunity\n-\nsupported software for describing and comparing microbial communities. \nAppl. Environ. \nMicrobiol. \n2009\n, \n75\n, 75\n37\n\u2013\n7541, doi:10.1128/AEM.01541\n-\n09.\n \n48.\n \nMeyer, F.; Paarmann, D.; D'Souza, M.; Olson, R.; Glass, E.M.; Kubal, M.; Paczian, T.; Rodriguez, A.; \nStevens, R.; Wilke, A.; et al. The metagenomics RAST server\n\u2014\nA public resource for the automatic Nutrients\n \n2019\n,\n \n11\n, 337\n \n16\n \nof \n17\n \n \nphylogenetic and functio\nnal analysis of metagenomes. \nBMC Bioinform. \n2008\n, \n9\n, 386, \ndoi:10.1186/1471\n-\n2105\n-\n9\n-\n386.\n \n49.\n \nMarques, R.C.; Bernardi, J.V.; Dorea, J.G.; Bastos, W.R.; Malm, O. Principal component analysis and \ndiscrimination of variables associated with pre\n-\n \nand post\n-\nnatal expos\nure to mercury. \nInt. J. Hyg. Environ. \nHealth \n2008\n, \n211\n, 606\n\u2013\n614, doi:10.1016/j.ijheh.2007.09.008.\n \n50.\n \nWeiss, R.; Dziura, J.; Burgert, T.S.; Tamborlane, W.V.; Taksali, S.E.; Yeckel, C.W.; Allen, K.; Lopes, M.; \nSavoye, M.; Morrison, J.; et al. Obesity and the me\ntabolic syndrome in children and adolescents. \nN. Engl. J. \nMed. \n2004\n, \n350\n, 2362\n\u2013\n2374, doi:10.1056/NEJMoa031049.\n \n51.\n \nDe Angelis, M.; Francavilla, R.; Piccolo, M.; De Giacomo, A.; Gobbetti, M. Autism spectrum disorders and \nintestinal microbiota. \nGut Microbes \n2015\n, \n6\n, 207\n\u2013\n213, doi:10.1080/19490976.2015.1035855.\n \n52.\n \nMead, J.; Ashwood, P. Evidence supporting an altered immune response in ASD. \nImmunol. Lett. \n2015\n, \n163\n, \n49\n\u2013\n55, doi:10.1016/j.imlet.2014.11.006.\n \n53.\n \nDe Angelis, M.; Piccolo, M.; Vannini, L.; Siragusa, S.; De Giaco\nmo, A.; Serrazzanetti, D.I.; Cristofori, F.; \nGuerzoni, M.E.; Gobbetti, M.; Francavilla, R. Fecal microbiota and metabolome of children with autism \nand pervasive developmental disorder not otherwise specified. \nPLoS ONE \n2013\n, \n8\n, e76993, \ndoi:10.1371/journal.p\none.0076993.\n \n54.\n \nParracho, H.M.; Bingham, M.O.; Gibson, G.R.; McCartney, A.L. Differences between the gut microflora of \nchildren with autistic spectrum disorders and that of healthy children. \nJ. Med. Microbiol. \n2005\n, \n54\n, 987\n\u2013\n991, \ndoi:10.1099/jmm.0.46101\n-\n0.\n \n55.\n \nRui\nz, L.; Delgado, S.; Ruas\n-\nMadiedo, P.; Sanchez, B.; Margolles, A. Bifidobacteria and Their Molecular \nCommunication with the Immune System. \nFront. Microbiol. \n2017\n, \n8\n, 2345, doi:10.3389/fmicb.2017.02345.\n \n56.\n \nBermudez\n-\nBrito, M.; Plaza\n-\nDiaz, J.; Munoz\n-\nQuezada, S.; \nGomez\n-\nLlorente, C.; Gil, A. Probiotic mechanisms \nof action. \nAnn. Nutr. Metab. \n2012\n, \n61\n, 160\n\u2013\n174, doi:10.1159/000342079.\n \n57.\n \nShiby, V.K.; Mishra, H.N. Fermented milks and milk products as functional foods\n\u2014\nA review. \nCrit. Rev. \nFood Sci. Nutr. \n2013\n, \n53\n, 482\n\u2013\n496, \ndoi:10.1080/10408398.2010.547398.\n \n58.\n \nPalaria, A.; Johnson\n-\nKanda, I.; O'Sullivan, D.J. Effect of a synbiotic yogurt on levels of fecal bifidobacteria, \nclostridia, and enterobacteria. \nAppl. Environ. Microbiol. \n2012\n, \n78\n, 933\n\u2013\n940, doi:10.1128/AEM.05848\n-\n11.\n \n59.\n \nTanaka\n, Y.; Takami, K.; Nishijima, T.; Aoki, R.; Mawatari, T.; Ikeda, T. Short\n-\n \nand long\n-\nterm dynamics in \nthe intestinal microbiota following ingestion of Bifidobacterium animalis subsp. lactis GCL2505. \nBiosci. \nMicrobiota Food Health \n2015\n, \n34\n, 77\n\u2013\n85, doi:10.1293\n8/bmfh.2015\n-\n001.\n \n60.\n \nPlovier, H.; Everard, A.; Druart, C.; Depommier, C.; Van Hul, M.; Geurts, L.; Chilloux, J.; Ottman, N.; \nDuparc, T.; Lichtenstein, L.; et al. A purified membrane protein from Akkermansia muciniphila or the \npasteurized bacterium improves met\nabolism in obese and diabetic mice. \nNat. Med. \n2017\n, \n23\n, 107\n\u2013\n113, \ndoi:10.1038/nm.4236.\n \n61.\n \nKang, D.W.; Park, J.G.; Ilhan, Z.E.; Wallstrom, G.; Labaer, J.; Adams, J.B.; Krajmalnik\n-\nBrown, R. Reduced \nincidence of Prevotella and other fermenters in intestinal micro\nflora of autistic children. \nPLoS ONE \n2013\n, \n8\n, \ne68322, doi:10.1371/journal.pone.0068322.\n \n62.\n \nLey, R.E. Gut microbiota in 2015: Prevotella in the gut: Choose carefully. \nNat. Rev. Gastroenterol. Hepatol. \n2016\n, \n13\n, 69\n\u2013\n70, doi:10.1038/nrgastro.2016.4.\n \n63.\n \nKovatcheva\n-\nDa\ntchary, P.; Nilsson, A.; Akrami, R.; Lee, Y.S.; De Vadder, F.; Arora, T.; Hallen, A.; Martens, \nE.; Bjorck, I.; Backhed, F. Dietary Fiber\n-\nInduced Improvement in Glucose Metabolism Is Associated with \nIncreased Abundance of Prevotella. \nCell Metab. \n2015\n, \n22\n, 9\n71\n\u2013\n982, doi:10.1016/j.cmet.2015.10.001.\n \n64.\n \nQuigley, E.M. Leaky gut\n\u2014\nConcept or clinical entity? \nCurr. Opin. Gastroenterol. \n2016\n, \n32\n, 74\n\u2013\n79, \ndoi:10.1097/MOG.0000000000000243.\n \n65.\n \nOnore, C.; Careaga, M.; Ashwood, P. The role of immune dysfunction in the pathophysiol\nogy of autism. \nBrain Behav. Immunity \n2012\n, \n26\n, 383\n\u2013\n392, doi:10.1016/j.bbi.2011.08.007.\n \n66.\n \nWilliams, B.L.; Hornig, M.; Parekh, T.; Lipkin, W.I. Application of novel PCR\n-\nbased methods for detection, \nquantitation, and phylogenetic characterization of Sutterella \nspecies in intestinal biopsy samples from \nchildren with autism and gastrointestinal disturbances. \nmBio \n2012\n, \n3\n, doi:10.1128/mBio.00261\n-\n11.\n \n67.\n \nDethlefsen, L.; McFall\n-\nNgai, M.; Relman, D.A. An ecological and evolutionary\n \nperspective on \nhuman\n-\nmicrobe mutualism and disease. \nNature \n2007\n, \n449\n, 811\n\u2013\n818, doi:10.1038/nature06245.\n \n68.\n \nConnolly, N.; Anixt, J.; Manning, P.; Ping, I.L.D.; Marsolo, K.A.; Bowers, K. Maternal metabolic risk factors \nfor autism spectrum disorder\n-\nAn analysis \nof electronic medical records and linked birth data. \nAutism Res. \n2016\n, \n9\n, 829\n\u2013\n837, doi:10.1002/aur.1586.\n Nutrients\n \n2019\n,\n \n11\n, 337\n \n17\n \nof \n17\n \n \n69.\n \nBuffington, S.A.; Di Prisco, G.V.; Auchtung, T.A.; Ajami, N.J.; Petrosino, J.F.; Costa\n-\nMattioli, M. Microbial \nReconstitution Reverses Maternal Diet\n-\nInd\nuced Social and Synaptic Deficits in Offspring. \nCell \n2016\n, \n165\n, \n1762\n\u2013\n1775, doi:10.1016/j.cell.2016.06.001.\n \n70.\n \nMari\n-\nBauset, S.; Zazpe, I.; Mari\n-\nSanchis, A.; Llopis\n-\nGonzalez, A.; Morales\n-\nSuarez\n-\nVarela, M. Evidence of \nthe gluten\n-\nfree and casein\n-\nfree diet in auti\nsm spectrum disorders: A systematic review. \nJ. Child Neurol. \n2014\n, \n29\n, 1718\n\u2013\n1727, doi:10.1177/0883073814531330.\n \n71.\n \nPatusco, R.; Ziegler, J. Role of Probiotics in Managing Gastrointestinal Dysfunction in Children with \nAutism Spectrum Disorder: An Update for Pr\nactitioners. \nAdv. Nutr. \n2018\n, \n9\n, 637\n\u2013\n650, \ndoi:10.1093/advances/nmy031.\n \n72.\n \nBerding, K.; Donovan, S.M. Microbiome and nutrition in autism spectrum disorder: Current knowledge \nand research needs. \nNutr. Rev. \n2016\n, \n74\n, 723\n\u2013\n736, doi:10.1093/nutrit/nuw048.\n \n\u00a9 \n2019 \nby\n \nthe authors. Licensee MDPI, Basel, Switzerland. This article is an open access \narticle distributed under the terms and conditions of the Creative Commons Attribution \n(CC BY) license (http://creativecommons.org/licenses/by/4.0/).\n \n Vol.:(0123456789)1 3Metabolomics           (2019) 15:99  \nhttps://doi.org/10.1007/s11306-019-1562-x\nORIGINAL ARTICLE\nMetabolic profiling in\u00a0children with\u00a0autism spectrum disorder \nwith\u00a0and\u00a0without\u00a0mental regression: preliminary results from\u00a0a\u00a0cross\u2011sectional case\u2013control study\nO.\u00a0D.\u00a0Rangel\u2011Huerta1,2\u00a0\u00b7 A.\u00a0Gomez\u2011Fern\u00e1ndez3\u00a0\u00b7 M.\u00a0J.\u00a0de\u00a0la\u00a0Torre\u2011Aguilar3\u00a0\u00b7 A.\u00a0Gil4,5\u00a0\u00b7 J.\u00a0L.\u00a0Perez\u2011Navero3\u00a0\u00b7 \nK.\u00a0Flores\u2011Rojas3,6\u00a0\u00b7 P .\u00a0Mart\u00edn\u2011Borreguero7\u00a0\u00b7 M.\u00a0Gil\u2011Campos3,6\nReceived: 22 January 2019 / Accepted: 20 June 2019 \n\u00a9 Springer Science+Business Media, LLC, part of Springer Nature 2019\nAbstract\nIntroduction It is challenging to establish the mechanisms involved in the variety of well-defined clinical phenotypes in \nautism spectrum disorder (ASD) and the pathways involved in their pathogeneses.Objectives The aim of the present study was to evaluate the metabolomic profiles of children with ASD subclassified by \nmental regression (AR) phenotype and with no regression (ANR).Methods The present study was a cross-sectional case\u2013control study. Thirty children aged 2\u20136\u00a0years with ASD were included: \n15 with ANR and 15 with AR. In addition, a control group of 30 normally developing children was selected and matched to the ASD group by sex and age. Plasma samples were analyzed with a metabolomics single platform methodology based on liquid chromatography-mass spectrometry. Univariate and multivariate analysis, including orthogonal partial least squares-discrimi-nant analysis modeling and Shared-and-Unique-Structures plots, were performed using MetaboAnalyst 4.0 and SIMCA-P 15. The primary endpoint was the metabolic signature profiling among healthy children and autistic children and their subgroups.Results Metabolomic profiles of 30 healthy children, 15 ANR and 15 AR were compared. Several differences between \nhealthy children and children with ASD were detected, involving mainly amino acid, lipid and nicotinamide metabolism. Furthermore, we report subtle differences between the ANR and AR groups.Conclusions In this study, we report, for the first time, the plasmatic metabolomic profiles of children with ASD, including \ntwo different phenotypes based on mental regression status. The use of a liquid chromatography-mass spectrometry platform approach for metabolomics in ASD children using plasma appears to be very efficient and adds further support to previous findings in urine. Furthermore, the present study documents several changes related to amino acid,  NAD\n+ and lipid metabo-\nlism that, in some cases, such as arginine and glutamate pathway alterations, seem to be associated with the AR phenotype. Further targeted analyses are needed in a larger cohort to validate the results presented herein.\nKeywords Autism spectrum disorders\u00a0\u00b7 Metabolomics\u00a0\u00b7 Metabolic profiling\u00a0\u00b7 Mental regression\nElectronic supplementary material The online version of this \narticle (https ://doi.org/10.1007/s1130 6-019-1562-x) contains \nsupplementary material, which is available to authorized users.\n * M. Gil-Campos \n mercedes_gil_campos@yahoo.es\n1 Department of\u00a0Nutrition, University of\u00a0Oslo, Oslo, Norway\n2 Norwegian Veterinary Institute, Oslo, Norway\n3 Department of\u00a0Pediatrics, Reina Sofia University Hospital, \nUniversity of\u00a0C\u00f3rdoba, IMIBIC, C\u00f3rdoba, Spain\n4 Department of\u00a0Biochemistry and\u00a0Molecular Biology II, Institute of\u00a0Nutrition and\u00a0Food Technology \u201cJos\u00e9 Mataix\u201d, Centre for\u00a0Biomedical Research, University of\u00a0Granada, Granada, Spain5 CIBEROBN, Madrid, Spain\n6 Paediatric Metabolism Unit, CIBEROBN, Madrid, Spain\n7 Paediatric Mental Unit, Reina Sofia University Hospital, \nC\u00f3rdoba, Spain O.\u00a0D.\u00a0Rangel-Huerta et al.\n1 3    99  Page 2 of 11\n1  Background\nAutism spectrum disorder (ASD) is a neurodevelopmental \ndisorder characterized by persistent deficits in social com-munication and social interaction across multiple contexts with repetitive and restricted patterns of behaviors, activi-ties, and interests (American Psychiatric Publishing 2013). There is a large heterogeneous spectrum of features and a wide range of medical comorbidities. The American Psychi-atric Association\u2019s Diagnostic and Statistical Manual, Fifth Edition (DSM-5), established the criteria for ASD cover -\ning two domains, i.e., social communication difficulties and repetitive and restricted behaviors, and includes abnormal sensory responses as a cardinal symptom (Howes et\u00a0al. 2018). Symptoms must be present in early development of ASD, but the age of onset and its evolution, i.e., with or without mental regression, varies considerably. There are phenotypes in which some children undergo normal neu-rodevelopment and then regress in their developmental mile-stones. Metabolic alterations can underlie several comor -\nbidities associated with ASD, such as seizures and sleep disorders and could contribute to autism severity (Altieri et\u00a0al. 2011; Gabriele et\u00a0al. 2014; Gevi et\u00a0al. 2016).\nThe diagnosis of ASD is based on reported and observed \nbehavior in keeping with diagnostic classification systems supported by test to exclude other explanations of the behav -\niors. Therefore, it is difficult to establish the variety of well-defined phenotypes in autism disorders and the pathways involved in their pathogeneses. Therefore, novel techniques, such as metabolomic profiling, can contribute to this objec-tive because of their potential to enable the global analysis of low-molecular-weight metabolites, thus aiding in elucidat-ing systemic perturbations. For instance, in 2010, Yap et\u00a0al. (2010) reported a perturbation in the tryptophan-nicotinic \nacid metabolic pathway using an nuclear magnetic reso-nance-based platform in urine from autistic children. Meta-bolic alterations related to amino acids, carbohydrates and oxidative stress pathways were then described after urinary analysis using liquid chromatography-mass spectrometry (LC\u2013MS) (Bitar et\u00a0al. 2018; Mavel et\u00a0al. 2013; Ming et\u00a0al. 2012) and nuclear magnetic resonance (Noto et\u00a0al. 2014). Overall, the plasma and urine metabolomes associate ASD with perturbed metabolic pathways related to tryptophan, nicotinic acid, purines, vitamin B6, and the enhancement of oxidative stress, as well as gut microbiota alterations. (Gevi et\u00a0al. 2016; Lussu et\u00a0al. 2017; Mavel et\u00a0al. 2013; Mussap \net\u00a0al. 2016; Nadal-Desbarats et\u00a0al. 2014).\nNovel changes in several plasma metabolites in ASD \nwere recently reported (West et\u00a0al. 2014). Interestingly, such findings, including alterations in the aspartate, cit-rate, creatinine, DHEA-S, isoleucine, glutamate and glutar -\nate metabolic pathways, had not been previously reported in the metabolomic profiling of urine (West et\u00a0al. 2014). Hence, metabolomic analysis in plasma appears to be a suit-able tool for further investigation of the disease mechanisms and has the potential to identify metabolic profiles within ASD. Thus, the aim of the present study was to evaluate the metabolomic profile of children with ASD subclassified by mental regression phenotype (AR) and non-mental regres-sion (ANR) in plasma samples with an analytical platform methodology based on LC\u2013MS.\n2  Subjects and\u00a0methods\nThe present study was a cross-sectional case\u2013control study and was approved by the Clinical Research and Bioethics Committee at Reina Sofia University Hospital respecting the fundamental principles established in the Declaration of Hel-sinki. The selected subjects were incorporated into the study after all inclusion criteria were fulfilled and informed written consent from the children\u2019s legal guardians was obtained.\n2.1  Participants\nFifty-seven ASD children were initially selected for this study (the recruitment started during 2015 in the Depart-ment of Psychology, Reina Sofia University Hospital, Cor -\ndoba, Spain). Of those, three children were excluded for not meeting the diagnostic criteria for ASD during the sub-sequent follow-up interviews at 18\u00a0months. Such interview is a follow-up to verify if the individuals continue meeting the DSM-5 Criteria.\nAll ASD children selected were between 2 and 6\u00a0years \nold with an agreed clinical diagnosis using the criteria of the International Classification Disease 10th Edition for ASD (World Health Organization 1992) and DSM-5 \n(American Psychiatric Publishing 2013). The diagnosis was confirmed by scores above the cut-off points of two tests, the Autism Diagnostic Observation Schedule test, with revised algorithms, and the Pervasive Developmen-tal Disorders (Behavior Inventory) (PDDBI), the latter as a means of obtaining a measure of the severity of ASD. The ASD group was also classified according to whether the children presented developmental delay (a score lower than 70 in the cognitive quotient of the Battelle develop-mental test) or not. Within the ASD group, there were 20 children classified as AR and 32 classified as ANR: two children could not be clearly classified into either of these subgroups. The subdivision (ANR and AR) was based on the presence or absence of developmental regression dur -\ning the first 2 years of life, which was assessed by a five-item questionnaire following the guide used by the ADI-R clinical interview for the evaluation of this process (Kim Metabolic profiling in\u00a0children with\u00a0autism spectrum disorder with\u00a0and\u00a0without\u00a0mental\u2026\n1 3Page 3 of 11    99 \nand Lord 2012). ASD children who obtained a score equal \nto or greater than three were included in the mental regres-\nsion group and those with a score of less than three were included in the non-mental regression group.\nASD children presenting with other known neurologi-\ncal, metabolic or genetic diagnoses were excluded, as were children with medical treatment for autism-related behav -\nioral comorbidities that may interfere with the results, such as sedatives, muscle relaxants or similar.\nFor the present study, we selected a subsample of 30 \nASD subjects (15 ANR and 15 AR) choosing those with higher scores towards one group or another in the tests thus eliminating those with more doubtful data.\nAdditionally, a control group of 30 normally developing \nchildren was selected and matched to the ASD group by sex and age. Children in the control group were chosen from those who came to the hospital for pre-anesthesia for minor surgery (mainly hernias). The clinical and analytical absence of illness was confirmed in this group of healthy children after normal results. Table\u00a0 1 shows the general characteristics of the selected \nASD subgroups and healthy children (HC) participants.\n2.2  Blood sampling\nBlood samples (6\u00a0ml) were drawn following a 12-h fast. In all the children with ASD, the blood test was carried out after confirming the diagnosis, at the recruitment. In HC, all the analysis were realized before the anesthesia and sur -\ngery intervention. Blood and general biochemical analyses were performed to confirm the absence of other diseases, and other plasma aliquots were stored at \u2212\u00a080\u00a0\u00b0C.\n2.3  Metabolomics analysis\nThe major outcome of the study was to investigate differ -\nential metabolomic signatures among groups, therefore, we considered a broad analytical platform for such aim. Metabo-lon Inc. (Durham, NC, USA) platform have proven reliable and fit our needs due to its broad coverage. All metabolomics analyses were developed by Metabolon, Inc. (Durham, NC, USA) following methods previously described (Evans et\u00a0al. 2009, 2014). Details of the analytical methods, data extrac-\ntion, preprocessing and compound identification are listed in eMethods 1 in Additional File 1.\n2.4  Statistical analysis\n2.4.1  Univariate analysis\nWe used ANOVA tests to identify biochemical compounds \nthat differed significantly between experimental groups. We performed a log transformation (to reduce the heteroscedas-ticity) and due to the difficulty of this method to handle zero or missing values we imputed missing values, if any, using a value corresponding to half of the minimum positive of each variable. Furthermore, to correct for multiple testing and false positives we used a false discovery rate cut-off of q < 0.1 (more in eMethods 1 in Additional File 1).\n2.4.2  Multivariate analysis\n2.4.2.1 Data processing The metabolomics dataset was \npreprocessed using MetaboAnalyst v4.0 (Xia et\u00a0 al. 2015) \n(Quebec, Canada). All missing values were replaced using a value corresponding to half of the minimum positive of each variable. Next, the variables were log-transformed and unit variance-scaled. Data were introduced into SIMCA-P (SIMCA-P 15.0, Umetrics, Ume\u00e5, Sweden) for multivariate analysis using unsupervised and supervised models.\n2.4.2.2 PCA and\u00a0 OPLS\u2011DA Principal component analysis \n(PCA) and orthogonal partial least-squares-discriminant \nanalysis (OPLS-DA) were carried out to visualize the met-\nTable 1  Demographic, \nanthropometric data and \npsychological tests results in children with ASD compared with healthy children\np values were obtained from an ANOVA test or Student\u2019s t test. p < 0.05 was considered statistically signifi-\ncant\nANR autistic without regression, AR autistic with regression, BMI body mass index, CARS Childhood \nAutism Rating Scale Test, HC healthy children, PDDBI Pervasive Developmental Disorders (Behavior \nInventory)HC (mean \u00b1 SD) ANR (mean \u00b1 SD) AR (mean \u00b1 SD) p\nSex (male) 4/30 2/15 3/15 NS\nAge (months) 48.67 \u00b1 15.03 44.8 \u00b1 9.37 45.0 \u00b1 12.65 NS\nWeight (kg) 16.74 \u00b1 3.6 16.23 \u00b1 3.4 16.91 \u00b1 3.6 NS\nHeight (cm) 101.74 \u00b1 8.25 103.9 \u00b1 8.7 104.1 \u00b1 12.39 NS\nBMI (kg/m2) 16.0 \u00b1 1.6 14.9 \u00b1 1.5 16.4 \u00b1 1.7 0.033\nBattelle test \u2013 60.96 \u00b1 13.29 47.05 \u00b1 10.33 0.002\nCARS test \u2013 30.6 \u00b1 6.11 35.9 \u00b1 8.12 0.009\nPDDBI test \u2013 46.13 \u00b1 10.47 53.93 \u00b1 10.39 0.023 O.\u00a0D.\u00a0Rangel-Huerta et al.\n1 3    99  Page 4 of 11\nabolic alterations in HC and ASD children and between \nthe AR and ANR groups. PCA modeling was used for an initial exploration of the data with the main purpose of detecting potential outliers and patterns. OPLS-DA mod-els were built to identify patterns and the features that discriminate between the different groups, e.g., ASD vs HC and ANR vs AR. In these discriminant analyses, the default seven-round cross-validation in the SIMCA-P soft-ware package was applied. Furthermore, the cross-valida-tion ANOVA (CV-ANOVA) was calculated to assess the reliability of the models (further details in eMethods1). Also 100-fold permutation tests were calculated and its plots and together with the observed vs. predicted plots are included in the supplemental material (eFigure\u00a03). We also obtained the so-called variable importance in the projec-tion (VIP) values that were relevant for group discrimi-nation. We selected features with a VIP > 1.5 to integrate \nthe pathway analysis. Furthermore, the advantage of using OPLS-DA is the capability of this model to decompose the data into \u201cpredictive\u201d information related to the response of Y (in our study, HC vs ASD, ANR or AR) and \u201corthog-onal\u201d structured information not related to the response (and that could be related to other factors such as technical or biological variation).\nTo improve the interpretation, shared-and-unique \n(SUS)-plots were built using the p(corr) of two different models. Thus, it is possible to extract metabolites related to a specific model and to identify shared features between both models either in a similar trend or in the inverse direc-tion (more details are provided in eFigure\u00a01 in Additional File 1).\n3  Results\n3.1  General characteristics\nTable\u00a0 1 also shows the results of the Battelle, CARS and \nPDDBI psychological tests for both AR and ANR children, which were significantly different among groups.\n3.2  Metabolite identification using an\u00a0untargeted \napproach in\u00a0a\u00a0UPLC\u2013MS/MS platform\nPlasma metabolic profiling was established to explore meta-\nbolic patterns associated with ASD and the mental regres-sion status. Seven-hundred fifty metabolites were detected: 295 in C18-negative mode, 75 in negative HILIC mode, 189 in early positive mode and 191 in late positive mode. A sum-mary of the compounds that achieved statistical significance (p \u2264 0.05) between the ASD and HC groups is shown in eTa-\nble\u00a01 in Additional File 2.3.2.1  Univariate analysis: single differences between\u00a0classes\n3.2.1.1 HC versus\u00a0ASD ANOVA of the HC and ASD groups \nshowed several metabolites whose concentrations differed significantly (eTable\u00a01 in Additional File 2; p < 0.001 and \nFDR < 0.1). Such metabolites corresponded mainly to the \nmalate-aspartate shuttle, the urea cycle, ammonia recycling, the glucose-alanine cycle, beta-alanine metabolism, and the aspartate and tryptophan metabolic pathways (according to KEGG pathway analysis). A heatmap (including the top 25 significant metabolites) in which it was possible to highlight the differences between the two groups can be seen in Fig.\u00a0 1.\n3.2.1.2 ANR versus\u00a0AR When comparing the ANR and AR \nsubgroups, seven compounds (decanoylcarnitine C10, ara-chidate, laurate, octanoylcarnitine, quinate, 7-methylurate and myristate) were significantly different (all p < 0.001 and \nFDR < 0.1). These metabolites were related mainly to fatty \nacid metabolism, except for quinate and 7-methylurate.\n3.2.2  Multivariate analysis3.2.2.1 PCA It was not possible to identify a valid separa-\ntion between the HC and ASD groups using this approach \n(Fig.\u00a0 2a). When labelling the samples as HCs, ANR and \nAR we did not detect any clustering (Fig.\u00a0 2b (PCA model: \nR = 0.66; Q = 0.0708)).\n3.2.2.2 OPLS\u2011DA modeling Four different models were \nbuilt. The first compared the HC vs ASD groups (Fig.\u00a0 2c). \nThe other models built were as follows: HC vs ANR, HC vs \nAR and ANR vs AR (non-significant). Table\u00a0 2 summarizes \nthe predictive abilities of each constructed model, and sev -\neral lists of VIP (total, predictive and orthogonal) features are included in eTables\u00a02\u20134 in Additional File 2.\nThe SUS-plot (eFigure\u00a01 in Additional File 1), which com-\nbines the HC vs ANR and HC vs AR models (built in binary mode using the HC group as a reference), helps identify two metabolites shared by both models in a decreasing trend in both subgroups (glutamate and aspartate). 4-Methyl-oxopen-tanoate was found in both models but in an increasing trend. Furthermore, three metabolites were identified in relation to ANR in an increasing trend: 3-methylxanthine, 7-methylurate and 3-methylhistidine. Finally, we identified a decrease in laurate as the only marker specific to the AR group.\n3.3  Pathway enrichment analysis constructed \nusing OPLS\u2011DA predictive and\u00a0orthogonal \ncomponents\nTwo lists of VIP features were used for the pathway enrich-\nment analysis using MetaboAnalyst 4.0: one was built from Metabolic profiling in\u00a0children with\u00a0autism spectrum disorder with\u00a0and\u00a0without\u00a0mental\u2026\n1 3Page 5 of 11    99 \nthe predictive component (related to the class) and the other \nwas built from the orthogonal components (not related to the class but to orthogonal variation). Due to limitations of the database (KEGG pathways) within the MetaboAnalyst platform, not all the metabolites were recognized. Addition-ally, an over-representation analysis was performed with-out significant results after FDR cutoff (Figure included as eFigure\u00a03).\n3.3.1  HC versus\u00a0ASDNinety-one metabolites were selected from the predictive \ncomponent (eTable\u00a02); however, only 77 were recognized. The integration of these metabolites showed that five canoni-cal pathways were significantly modified in the ASD group compared with HCs, namely, aminoacyl-tRNA biosynthesis, alanine, aspartate and glutamate metabolism, galactose and nicotinate and nicotinamide metabolism and panthothen-ate and CoA (all with raw p values \u2264 0.01 and FDR < 0.1). \nThe inclusion of compounds into the orthogonal compo-nent revealed only a change in aminoacyl-tRNA biosyn-thesis, which did not correlate with the ASD condition (p value \u2264 0.01 and FDR < 0.1).\n3.3.2  HC versus\u00a0ANRThe pathway enrichment analysis included 88 metabolites \nfrom the predictive component and 80 from the orthogo -\nnal component (eTable\u00a03). Only caffeine metabolism in the first and nitrogen metabolism in the latter were significantly affected (raw p values \u2264 0.01 and FDR < 0.1).\n3.3.3  HC versus\u00a0AR\nNinety-four compounds from the predictive component \nand 58 from the orthogonal components were analyzed (eTable\u00a04); Four canonical pathways reflected a significant change related to the predictive component, namely, ami-noacyl-tRNA biosynthesis; alanine, aspartate and glutamate metabolism; panthothenate; and CoA and fatty acid biosyn -\nthesis (raw p values \u2264 0.01 and FDR  < 0.1). No pathway was \nassociated with the orthogonal component.\n4  Discussion\nIn this study, we report, for the first time, the plasmatic metabolomic profiling of ASD children subclassified by mental regression (AR) phenotype and with no regression (ANR). With the use of an LC\u2013MS platform including C18 and HILIC columns, we covered a broad range of metabo-lites, which was complemented with comprehensive statis-tical and pathway enrichment analyses. We present several alterations observed in ASD compared with HCs involv -\ning mainly amino acid, lipid and nicotinamide metabolism. However, we were able to distinguish only subtle significant differences when isolating the ASD subgroups.\nFig. 1  Heatmap built using the top 25 significant metabolites between the HC and ASD groups. The significant metabolites were selected using \na t test. The color bar corresponds to the fold change from HC vs ASD O.\u00a0D.\u00a0Rangel-Huerta et al.\n1 3    99  Page 6 of 11\nFig. 2  a PCA scores plot \nincluding samples from HC and \nASD. HC healthy children, ASD autistic children. b PCA scores plot including samples from HC and autistic children (labelled as ANR and AR). HC healthy children, AR autistic mental-regression children, ANR autistic non-mental regression children. c OPLS-DA model score plot showing separation by condition, including ASD children and HCs. HC healthy \nchildren, ASD autistic children\nMetabolic profiling in\u00a0children with\u00a0autism spectrum disorder with\u00a0and\u00a0without\u00a0mental\u2026\n1 3Page 7 of 11    99 \nDue to the complexity of ASD, rather than focusing on \nsingle biomarkers, which might result in inaccurate results, \nthe strength of our research lies in the integration of the most discriminant metabolites (and the exclusion of the orthogo-nal metabolites) in their respective pathways, which was pro-vided by the OPLS-DA modelling. Nevertheless, the use of univariate and multivariate analysis should be considered as complementary and confirmatory; i.e. laurate that was significantly different between ANR and AR as shown in the univariate analysis, also appeared to be as a significant discriminator in the SUS-plot (built from the multivariate modeling).\n4.1  Endogenous metabolites\nGlutamate functions as a major excitatory molecule in the brain, and alterations in its metabolism can lead to imbal-ances in the excitation/inhibition equilibrium of neural net-works, which may lead to autistic-like symptoms. Herein, we report similar decrease in glutamate in both the ANR and AR groups compared with the HC group (in both univariate and multivariate analysis). Although the relative concen -\ntrations of aspartate and glutamate were modified in both groups, other metabolites were specific within each group, as shown by both statistical analyses, such as gamma carboxy -\nglutamate, N-Carboxyethyl-gamma-aminobutyric acid and 4-hydroxyglutamate in the ANR group and N-acetyl-aspar -\ntyl-glutamate (NAAG) in the AR group. Alterations of these metabolic pathways in ASD have been previously reported in urine but in an inverse manner (Ka\u0142u\u017cna-Czapli\u0144ska et\u00a0al. 2017; Rolf et\u00a0al. 1993; Rossignol and Frye 2012; Yap et\u00a0al. 2010) and may be related with the pathogenesis of the dis-order and disease severity (Alabdali et\u00a0al. 2014). However, they may also be associated with food restrictions, such as diets low in protein or lacking certain types of food or impaired digestion. Also, the restriction might lead to the substitution with other types of foods thus this should be analyzed thoroughly (Ka\u0142u\u017cna-Czapli\u0144ska et\u00a0al. 2017). Interestingly, using the SUS-plot, we identified metabolites specific to each group that although have been proposed as biomarkers of intake of dietary products, such as meat (Sch -\nmedes et\u00a0al. 2016) or cocoa (Garcia-Aloy et\u00a0al. 2015) could be related also to some metabolic alterations and need to be studied in detail in further studies.\nSome biochemicals comprising the malate-aspartate shut-\ntle were decreased in the entire ASD cohort (as shown in both analyses), suggesting deregulation in this mitochondrial process. The malate-aspartate shuttle is a crucial system that supports oxidative phosphorylation and ATP production (Napolioni et\u00a0al. 2011). We should note that changes in the activity of aspartate-glutamate carriers have been detected in gray matter obtained from autistic individuals (Palmieri et\u00a0al. 2010). Taken together, the imbalance in glutamate \nmetabolism may also originate from changes in malate-aspartate shuttle activity.\nArginine, N-acetylarginine, homoarginine and n-alpha-\nacetylornithine discriminated the ASD cohort, and particu-larly the AR group, from the control group (multivariate analysis, univariate analysis only shows arginine as signifi-cant). In this regard, urinary (Di\u00e9m\u00e9 et\u00a0al. 2015) and plas-matic (Delwing et\u00a0al. 2008) arginine have been reported to \nbe increased in ASD children. An excessive amount of argi-nine and its compounds might increase oxidative stress by increasing nitric oxide (NO). As reviewed by Rossignol et\u00a0al. it seems that ASD patients might be both, more vulnerable to NO and present higher concentrations of NO at baseline, factors that could act synergistically to cause significant mitochondrial impairment (Rossignol and Frye 2012). Our findings suggest that AR subjects have a more dysregulated NO pathway, and such alterations may be related with the regression.\nThe branched-chain amino acids (BCAAs), valine, iso-\nleucine, and leucine, are important constituents of proteins but are also readily degraded into carbon skeletons that may enter anabolic pathways (i.e., gluconeogenesis or fatty acid synthesis) or pathways associated with energy generation (i.e., the TCA cycle). In the present study, we found a pos-sible alteration in the BCAA metabolism in ASD, which was supported by an accumulation of several alpha-keto derivates, such as 3-methyl-2-oxobutyrate, 3-methyl-2-ox-ovalerate, and 4-methyl-2-oxopentanoate. These accumula-tions indicate that these compounds exhibit reduced incorpo-ration into the TCA cycle, thus contributing to alterations in anabolic processes and/or energy generation. These changes Table 2  Summary of the \npredictive abilities of the \nOPLS-DA models constructed\nANR ASD without mental regression, AR ASD with mental regression, ASD autism spectrum disorder, NS non-significantComparison Predictive componentOrthogonal componentsR\n2X (cum) R2Y (cum) Q2 (cum) CV-ANOVA\nHC vs. ASD 1 2 0.2 0.939 0.625 1.33E\u221209\nHC vs. ANR 1 2 0.206 0.950 0.539 2.696E\u221205\nHC vs. AR 1 3 0.261 0.977 0.401 0.0130924\nANR vs. AR NS NS NS NS NS NS O.\u00a0D.\u00a0Rangel-Huerta et al.\n1 3    99  Page 8 of 11\npoint towards a dysregulation in glutamate homeostasis, as \nthe BCAA aminotransferase utilizes alpha-ketoglutarate to transfer the amino group and forms glutamate, both of which were decreased in the ASD cohort (univariate and multivariate analyses). Moreover, in connection with these alterations, we detected an increase in carnitine-conjugated intermediates (i.e., isovalerylcarnitine and isobutyrylcarni-tine) in the ASD cohort, and acylcarnitines decanoylcarni-tine and octanoylcarnitine were significantly higher in the ANR group than the AR group as shown in the univariate and multivariate analyses. It is known that the inhibition of the TCA cycle may result in an elevation of TCA cycle inter -\nmediates but also impairs fatty acid \u03b2-oxidation. Therefore, these abnormalities may be associated with mitochondrial dysfunction in children with ASD (Frye et\u00a0al. 2013; Ros-signol and Frye 2012).\nIn addition, the association between alterations in uri-\nnary tryptophan metabolism in autistic children (Ka\u0142u\u017cna-Czapli\u0144ska et\u00a0al. 2017) entails numerous irregularities, \nincluding the serotonin pathways. In this regard, we found that tryptophan was significantly higher in both subgroups (ANR and AR, both statistical analyses) than in HCs. Fur -\nthermore, other tryptophan-associated metabolites, such as kynurenine, 5-bromotryptophan, 3-indoxyl sulfate, indolelactate and 6-hydroxyindole sulfate, were elevated in the ANR group. Kynurenine is produced by indoleamine 2,3-dioxygenase in response to inflammatory stimuli. Thus, an increase in the kynurenine level may reflect increased inflammation in the ASD group. Changes in  NAD\n+ metab-\nolism were noted, with a significant decline in the nicoti-namide levels and increases in 1-methyl-nicotinamide and N-methyl-2-pyridone-5-carboxamide (with a VIP = 1.46) in \nthe ASD cohort. Remarkably, similar changes, but in urine, have been reported (Adams et\u00a0al. 2011; Yap et\u00a0al. 2010). Nic-otinamide is a key intermediate in the synthesis of  NAD\n+, a \ncoenzyme that plays a vital role in redox reactions by accept-ing electrons and forming NADH as part of \u03b2-oxidation, glycolysis, and the TCA cycle. In ASD patients, a decrease in the conversion of tryptophan to melatonin could lead to an increase in nicotinic synthesis, thus increasing the demand for methylation and increasing the susceptibility to oxidative stress (Mussap et\u00a0al. 2016). In fact, n-methyl nicotinamide and N-methyl-2-pyridone-5-carboxamide have been impli-cated in the pathogenesis of Parkinson\u2019s disease (Fukushima et\u00a0al. 1995; Willets et\u00a0al. 1993).\n4.2  Lipid metabolism\nEvidence has shown that abnormalities in lipid metabo-lism may play a role in the pathogenesis of ASD and can be connected with metabolic and dietary altera-tions in the regressive form of autism (El-Ansary et\u00a0 al. 2011; Goldani et\u00a0 al. 2014). The lysolipids 1-palmitoyl-glycerol-phosphatidyl-etholamine (GPE) and 1-stearoyl-GPE were decreased in plasma obtained from autistic individuals (univariate and multivariate analysis, eTables1, 2). These are degradation products derived from phospholipids and are formed when phospholipases remove fatty acid moieties from the Sn- 1 and Sn- 2 positions of phos-\npholipids (Khaselev and Murphy 2000). Changes in tria-cylglycerol metabolism were also noted based on mental regression status, with an accumulation of several species of mono- and diacylglycerols in the AR group compared to the ANR group (univariate analysis, eTable\u00a01). Mono- and diacylglycerols are intermediates in triacylglycerol metabo-lism; they are formed when lipases remove fatty acids from the glycerol backbone of triacylglycerols. Moreover, the uni-variate analysis (eTable\u00a01) revealed that there was a marked decrease in both long- and medium-chain fatty acids in samples from the AR group. These alterations may indicate differences in triacylglycerol and phospholipid metabolism, fatty acid utilization, and beta-oxidation. We should note that the changes in free fatty acids were more pronounced in the AR subgroup and, in some cases, showed significant changes between the AR and ANR groups (i.e.,myristate and palmitate) in the univariate analysis, and the change in laurate appears to be specific to the AR group, as reflected in the univariate and the SUS-plot (the OPLS-DA model comparing AR and ANR was not analyzed due to the lack of significance and thus, invalid). These results agree with the report by El-Ansary (El-Ansary et\u00a0al. 2011) in which they concluded that impaired fatty acid profiles could be used as highly reliable diagnostic biomarkers in a Saudi autistic cohort and may reflect mitochondrial dysfunction as a puta-tive causative mechanism (Pastural et\u00a0al. 2009).\nSeveral sphingomyelins discriminated the ASD cohort \n(eTable\u00a02) from the HCs in the predictive component. How -\never, due to limitations in the MetaboAnalyst module, it was not possible to integrate them into their respective pathways. Nevertheless, an alteration in sphingolipid metabolism, in particular sphingomyelins, has been associated with autism and is due to an abnormal developmental trajectory of white matter (Barnea-Goraly et\u00a0al. 2004; Mak-Fan et\u00a0al. 2013; Wang et\u00a0al. 2016). Nonetheless, we did not observe differ -\nences among the subgroups.\nOverall, the pathway enrichment analysis showed sev -\neral routes modified in the ASD cohort compared with HCs. Nonetheless, when analyzing the subgroups, these routes were not maintained; the ANR group showed fewer changes. We speculate that differences in the AR group were strong enough to make significant differences in the ASD cohort and therefore these differences may be associated with the regression in the disease. However, we could not discard that some changes may be related to lifestyle (i.e., diet, physical activity, etc.) although we used a multivariate model which Metabolic profiling in\u00a0children with\u00a0autism spectrum disorder with\u00a0and\u00a0without\u00a0mental\u2026\n1 3Page 9 of 11    99 \nhelps to isolate the effect of features that are not related to \nthe class studied (in this case, ASD or its subgroups).\nThe global approach that we developed in the present study \nseems to be very effective and provides broad coverage; how -\never, it is important to address several limitations. Although it was possible to detect significant differences between the groups and using cross-validation methods in the multivari-ate analysis, the sample size was small, and a larger number of subjects should be included in further studies to detect more subtle changes, particularly when comparing the AR and ANR subgroups. Differences between the univariate and multivariate analysis show slightly differences that might be due to the restrictive cutoffs utilized on each type of analysis, however, the use of both approaches help us to confirm some changes with confidence when they appear in both analyses.\nMoreover, it is necessary to perform targeted analyses \nto make a proper quantification of the metabolites and their impact through the different metabolic pathways and to vali-date these findings reported in an external cohort.\nOur main interest is to continue this investigation includ-\ning data from the microbiome and additional food intake and lifestyle questionnaires to identify the changes relates to the latter or those linked to the disease or a specific phenotype. In the future, if a genetic or molecular profile in patients could be identified, patients could be stratified according to it and subsequently compared regarding cognitive, neuro-imaging and biochemical measures to treat individuals with ASD more efficiently and with a more personalized approach (Howes et\u00a0al. 2018).\n5  Conclusion\nIn summary, the use of an LC-MS platform approach, including C18 and HILIC columns, for metabolomics in ASD children using plasma appears to have a broad cover -\nage of the metabolome and adds further support to previ-ous findings in urine, such as changes in tryptophan and nicotinic acid metabolic pathway. Furthermore, the present study documents several changes related to amino acid,  NAD\n+ and lipid metabolism in plasma. In some cases, such \nas in the arginine and the glutamate pathways and free fatty acids, alterations may be associated with mental regression in ASD. Further targeted analyses, including a systems biol-ogy approach with the study of genome, transcriptome and the study of the microbiome, including a larger cohort are needed to validate the results presented herein. Research regarding potential mitochondrial dysfunction in a subset of ASD subjects is guarantee.\nAcknowledgements We gratefully acknowledge the patients, controls \nand family members who participated in this study.Author contributions ODRH conducted the metabolomics data analy -\nses, analyzed and interpreted the biochemical data and wrote the manu-\nscript. AGF, MJTA, collected the plasma samples, interpreted the data. \nMGC and AG designed the study. JLPN, KFR, PMB were responsible \nof the clinical assessments and interpreted the data. All authors read and approved the manuscript.\nFunding ODRH has received funding from the European Union Sev -\nenth Framework Programme (FP7-PEOPLE-2013-COFUND) under \ngrant agreement n\u00b0 609020 - Scientia Fellows.\nData availability  The metabolomics datasets used and/or analyzed dur -\ning the current study are included as Supplemental Material and any \nadditional data is available from the corresponding author on reason-able request.\nCompliance with ethical standards  \nConflict of interest The authors declare that they have no competing \ninterests.\nEthical approval The present study was a cross-sectional case\u2013control \nstudy case\u2013control study and was approved by the Clinical Research \nand Bioethics Committee at Reina Sofia University Hospital respecting the fundamental principles established in the Declaration of Helsinki \nof 1964.\nInformed consent Informed consent from the children\u2019s legal guard-\nians was obtained.\nReferences\nAdams, J. B., Audhya, T., McDonough-Means, S., Rubin, R. A., Quig, \nD., Geis, E., et\u00a0al. (2011). Nutritional and metabolic status of \nchildren with autism vs. neurotypical children, and the association with autism severity. Nutrition & Metabolism, 8(1), 34. https ://doi.\norg/10.1186/1743-7075-8-34.\nAlabdali, A., Al-Ayadhi, L., & El-Ansary, A. (2014). Association of \nsocial and cognitive impairment and biomarkers in autism spec-trum disorders. Journal of Neuroinflammation, 11(1), 4. https ://\ndoi.org/10.1186/1742-2094-11-4.\nAltieri, L., Neri, C., Sacco, R., Curatolo, P., Benvenuto, A., Muratori, \nF., et\u00a0al. (2011). Urinary p-cresol is elevated in small children with severe autism spectrum disorder. Biomarkers. https ://doi.\norg/10.3109/13547 50x.2010.54801 0.\nAmerican Psychiatric Publishing, I. (2013). Diagnostic and statisti-\ncal manual of mental disorders: DSM-5\u2122 (5th ed.). Arlington: American Psychiatric Publishing Inc.\nBarnea-Goraly, N., Kwon, H., Menon, V., Eliez, S., Lotspeich, L., & \nReiss, A. L. (2004). White matter structure in autism: Preliminary evidence from diffusion tensor imaging. Biological Psychiatry,  \n55(3), 323\u2013326. https ://doi.org/10.1016/j.biops ych.2003.10.022.\nBitar, T., Mavel, S., Emond, P., Nadal-Desbarats, L., Lef\u00e8vre, A., \nMattar, H., et\u00a0al. (2018). Identification of metabolic pathway disturbances using multimodal metabolomics in autistic disor -\nders in a Middle Eastern population. Journal of Pharmaceutical \nand Biomedical Analysis, 152, 57\u201365. https ://doi.org/10.1016/j.\njpba.2018.01.007.\nDelwing, D., Delwing, D., Bavaresco, C. S., & Wyse, A. T. S. (2008). \nProtective effect of nitric oxide synthase inhibition or antioxi-dants on brain oxidative damage caused by intracerebroventricular  O.\u00a0D.\u00a0Rangel-Huerta et al.\n1 3    99  Page 10 of 11\narginine administration. Brain Research, 1193, 120\u2013127. https ://\ndoi.org/10.1016/j.brain res.2007.11.052.\nDi\u00e9m\u00e9, B., Mavel, S., Blasco, H., Tripi, G., Bonnet-Brilhault, F., \nMalvy, J., et\u00a0al. (2015). Metabolomics study of urine in autism \nspectrum disorders using a multiplatform analytical methodology. Journal of Proteome Research, 14(12), 5273\u20135282. https ://doi.\norg/10.1021/acs.jprot eome.5b006 99.\nEl-Ansary, A. K., Ben Bacha, A. G., & Al- Ayahdi, L. Y. (2011). \nPlasma fatty acids as diagnostic markers in autistic patients from Saudi Arabia. Lipids in Health and Disease, 10(1), 62. https ://doi.\norg/10.1186/1476-511X-10-62.\nEvans, A. M., Bridgewater, B. R., Liu, Q., Mitchell, M. W., Robinson, \nR. J., Dai, H., et\u00a0al. (2014). High resolution mass spectrometry improves data quantity and quality as compared to unit mass reso-lution mass spectrometry in high-throughput profiling metabo-lomics. Journal of Postgenomics Drug & Biomarker Develop-\nment. https ://doi.org/10.4172/2153-0769.10001 32.\nEvans, A. M., DeHaven, C. D., Barrett, T., Mitchell, M., & Milgram, \nE. (2009). Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrom-etry platform for the identification and relative quantification of the small-molecule complement of biological systems. Ana-\nlytical Chemistry, 81(16), 6656\u20136667. https ://doi.org/10.1021/\nac901 536h.\nFrye, R. E., Melnyk, S., & MacFabe, D. F. (2013). Unique acyl-\ncarnitine profiles are potential biomarkers for acquired mito-chondrial disease in autism spectrum disorder. Translational \nPsychiatry, 3(1), e220. https ://doi.org/10.1038/tp.2012.143.\nFukushima, T., Tawara, T., Isobe, A., Hojo, N., Shiwaku, K., & \nYamane, Y. (1995). Radical formation site of cerebral complex I and Parkinson\u2019s disease. Journal of Neuroscience Research,  \n42, 385\u2013390.\nGabriele, S., Sacco, R., Cerullo, S., Neri, C., Urbani, A., Tripi, G., \net\u00a0al. (2014). Urinary p-cresol is elevated in young French chil-dren with autism spectrum disorder: A replication study. Bio-\nmarkers. https ://doi.org/10.3109/13547 50x.2014.93691 1.\nGarcia-Aloy, M., Llorach, R., Urpi-Sarda, M., J\u00e1uregui, O., Corella, \nD., Ruiz-Canela, M., et\u00a0al. (2015). A metabolomics-driven approach to predict cocoa product consumption by designing a multimetabolite biomarker model in free-living subjects from the PREDIMED study. Molecular Nutrition & Food Research,  \n59(2), 212\u2013220. https ://doi.org/10.1002/mnfr.20140 0434.\nGevi, F., Zolla, L., Gabriele, S., & Persico, A. M. (2016). Urinary \nmetabolomics of young Italian autistic children supports abnor -\nmal tryptophan and purine metabolism. Molecular Autism, 7(1), \n47. https ://doi.org/10.1186/s1322 9-016-0109-5.\nGoldani, A. A. S., Downs, S. R., Widjaja, F., Lawton, B., & Hendren, \nR. L. (2014). Biomarkers in autism. Frontiers in Psychiatry, 5, \n100. https ://doi.org/10.3389/fpsyt .2014.00100 .\nHowes, O. D., Rogdaki, M., Findon, J. L., Wichers, R. H., Char -\nman, T., King, B. H., et\u00a0al. (2018). Autism spectrum disorder: Consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology. Journal of Psychopharmacology. https ://doi.org/10.1177/02698 81117  \n74176 6.\nKa\u0142u\u017cna-Czapli\u0144ska, J., J\u00f3\u017awik-Pruska, J., Chirumbolo, S., & \nBj\u00f8rklund, G. (2017). Tryptophan status in autism spectrum disorder and the influence of supplementation on its level. Meta -\nbolic Brain Disease, 32(5), 1585\u20131593. https ://doi.org/10.1007/\ns1101 1-017-0045-x.\nKhaselev, N., & Murphy, R. C. (2000). Structural characterization \nof oxidized phospholipid products derived from arachidonate-containing plasmenyl glycerophosphocholine. Journal of Lipid \nResearch, 41(4), 564\u2013572.\nKim, S. H., & Lord, C. (2012). New autism diagnostic interview-\nrevised algorithms for toddlers and young preschoolers from 12 to 47\u00a0months of age. Journal of Autism and Developmen -\ntal Disorders, 42(1), 82\u201393. https ://doi.org/10.1007/s1080  \n3-011-1213-1.\nLussu, M., Noto, A., Masili, A., Rinaldi, A. C., Dess\u00ec, A., De Ange-\nlis, M., et\u00a0al. (2017). The urinary 1H-NMR metabolomics pro-\nfile of an italian autistic children population and their unaf-fected siblings. Autism Research, 10(6), 1058\u20131066. https ://doi.\norg/10.1002/aur.1748.\nMak-Fan, K. M., Morris, D., Vidal, J., Anagnostou, E., Roberts, W., \n& Taylor, M. J. (2013). White matter and development in chil-dren with an autism spectrum disorder. Autism, 17(5), 541\u2013557. \nhttps ://doi.org/10.1177/13623 61312 44259 6.\nMavel, S., Nadal-Desbarats, L., Blasco, H., Bonnet-Brilhault, F., \nBarth\u00e9l\u00e9my, C., Montigny, F., et\u00a0al. (2013). 1H-13C NMR-based urine metabolic profiling in autism spectrum disorders. Talanta,  \n114, 95\u2013102. https ://doi.org/10.1016/j.talan ta.2013.03.064.\nMing, X., Stein, T. P., Barnes, V., Rhodes, N., & Guo, L. (2012). \nMetabolic perturbance in autism spectrum disorders: A metab-olomics study. Journal of Proteome Research,  11(12), 5856\u2013\n5862. https ://doi.org/10.1021/pr300 910n.\nMussap, M., Noto, A., & Fanos, V. (2016). Metabolomics of autism \nspectrum disorders: Early insights regarding mammalian-micro-bial cometabolites. Expert Review of Molecular Diagnostics,  \n16(8), 869\u2013881. https ://doi.org/10.1080/14737 159.2016.12027  \n65.\nNadal-Desbarats, L., A\u00efdoud, N., Emond, P., Blasco, H., Filipiak, \nI., Sarda, P., et\u00a0al. (2014). Combined 1H-NMR and 1H-13C HSQC-NMR to improve urinary screening in autism spec-trum disorders. Analyst, 139(13), 3460\u20133468. https ://doi.\norg/10.1039/c4an0 0552j .\nNapolioni, V., Persico, A. M., Porcelli, V., & Palmieri, L. (2011). \nThe mitochondrial aspartate/glutamate carrier AGC1 and cal-cium homeostasis: Physiological links and abnormalities in autism. Molecular Neurobiology, 44(1), 83\u201392. https ://doi.\norg/10.1007/s1203 5-011-8192-2.\nNoto, A., Fanos, V., Barberini, L., Grapov, D., Fattuoni, C., Zaf -\nfanello, M., et\u00a0al. (2014). The urinary metabolomics profile of an Italian autistic children population and their unaffected siblings. The Journal of Maternal-Fetal & Neonatal Medicine,  \n27(sup2), 46\u201352. https ://doi.org/10.3109/14767 058.2014.95478  \n4.\nPalmieri, L., Papaleo, V., Porcelli, V., Scarcia, P., Gaita, L., Sacco, \nR., et\u00a0al. (2010). Altered calcium homeostasis in autism-spec-trum disorders: Evidence from biochemical and genetic stud-ies of the mitochondrial aspartate/glutamate carrier AGC1. Molecular Psychiatry, 15(1), 38\u201352. https ://doi.org/10.1038/\nmp.2008.63.\nPastural, \u00c9., Ritchie, S., Lu, Y., Jin, W., Kavianpour, A., Khine Su-\nMyat, K., et\u00a0al. (2009). Novel plasma phospholipid biomark -\ners of autism: Mitochondrial dysfunction as a putative causa-tive mechanism. Prostaglandins Leukotrienes and Essential Fatty Acids, 81(4), 253\u2013264. https ://doi.org/10.1016/j.plefa  \n.2009.06.003.\nRolf, L. H., Haarmann, F. Y., Grotemeyer, K. H., & Kehrer, H. \n(1993). Serotonin and amino acid content in platelets of autis-tic children. Acta Psychiatrica Scandinavica, 87(5), 312\u2013316.\nRossignol, D. A., & Frye, R. E. (2012). Mitochondrial dysfunction \nin autism spectrum disorders: A systematic review and meta-analysis. Molecular Psychiatry, 17(3), 290\u2013314. https ://doi.\norg/10.1038/mp.2010.136.\nSchmedes, M., Aadland, E. K., Sundekilde, U. K., Jacques, H., \nLavigne, C., Graff, I. E., et\u00a0al. (2016). Lean-seafood intake decreases urinary markers of mitochondrial lipid and energy \nmetabolism in healthy subjects: Metabolomics results from a \nrandomized crossover intervention study. Molecular Nutrition Metabolic profiling in\u00a0children with\u00a0autism spectrum disorder with\u00a0and\u00a0without\u00a0mental\u2026\n1 3Page 11 of 11    99 \n& Food Research,  60(7), 1661\u20131672. https  ://doi.org/10.1002/\nmnfr.20150 0785.\nWang, H., Liang, S., Wang, M., Gao, J., Sun, C., Wang, J., et\u00a0al. \n(2016). Potential serum biomarkers from a metabolomics study \nof autism. Journal of Psychiatry and Neuroscience, 41(1), \n27\u201337. https ://doi.org/10.1503/jpn.14000 9.\nWest, P. R., Amaral, D. G., Bais, P., Smith, A. M., Egnash, L. A., \nRoss, M. E., et\u00a0al. (2014). Metabolomics as a tool for discov -\nery of biomarkers of autism spectrum disorder in the blood plasma of children. PLoS ONE,  9(11), e112445. https  ://doi.\norg/10.1371/journ al.pone.01124 45.\nWillets, J. M., Lunec, J., Williams, A. C., & Griffiths, H. R. (1993). \nNeurotoxicity of nicotinamide derivatives: Their role in the aeti-ology of Parkinson\u2019s disease. Biochemical Society Transactions,  \n21(Pt 3), 299S.World Health Organization. (1992). The ICD-10 classification of \nmental and behavioural disorders. International Classification,  \n10, 1\u2013267. https ://doi.org/10.1002/1520-6505(2000)9:5%3c201  \n:AID-EVAN2 %3e3.3.CO;2-P .\nXia, J., Sinelnikov, I. V., Han, B., & Wishart, D. S. (2015). Metabo -\nAnalyst 3.0\u2014Making metabolomics more meaningful. Nucleic Acids Research. https ://doi.org/10.1093/nar/gkv38 0.\nYap, I. K. S., Angley, M., Veselkov, K. A., Holmes, E., Lindon, J. \nC., & Nicholson, J. K. (2010). Urinary metabolic phenotyping differentiates children with autism from their unaffected siblings and age-matched controls. Journal of Proteome Research, 9(6), \n2996\u20133004. https ://doi.org/10.1021/pr901 188e.\nPublisher\u2019s Note Springer Nature remains neutral with regard to \njurisdictional claims in published maps and institutional affiliations.7 OTRA PRODUCCI\u00d3N CIENT\u00cdFICA Y RECONOCIMIENTOS \n7.1 Premios y  reconocimientos\n1-Beca  de  investigaci\u00f3n  Invest-AEP  de  la  Asociaci\u00f3n  Espa\u00f1ola  de\nPediatr\u00eda, al proyecto \u201cDetecci\u00f3n de alteraciones epigen\u00e9ticas en pacientes\ninfantiles con Trastorno del Espectro Autista\u201d ( 2018).\n2-Beca Ballabriga concedida por la Sociedad Espa\u00f1ola de Investigaci\u00f3n\nen Nutrici\u00f3n Pedi\u00e1trica (SEINAP)  por el trabajo \u201cEficacia y seguridad del\n\u00e1cido docosahexaenoico en el tratamiento coadyuvante de ni\u00f1os con Trastorno\ndel espectro Autista\u201d (2019).\n7.2 Comunicaciones en Reuniones Cient\u00edficas  y Congresos nacionales\n1-Antonio G\u00f3mez Fern\u00e1ndez AR, Flores Rojas K, Dominguez Osorio I, De la\nTorre  Aguilar  MJ,  P\u00e9rez  Navero  JL,  Gil  Campos  M.  EVALUACI\u00d3N\nNUTRICIONAL  EN  NI\u00d1OS  PREESCOLARES  CON  TRASTORNO  DEL\nESPECTRO  AUTISTA.  XVI  Congreso  de  la  Sociedad  Espa\u00f1ola  de\nInvestigaci\u00f3n en Nutrici\u00f3n Pedi\u00e1trica. 30 de septiembre y 1 de octubre de 2016.\n2-Cristina P\u00e9rez-Garc\u00eda, Antonio R. G\u00f3mez-Fern\u00e1ndez, Maria Jos\u00e9 de la Torre\nAguilar,  Katherine  Flores-Rojas,  Juan  Luis  P\u00e9rez-Navero,  Mercedes  Gil-\nCampos.PLASMA PROFILE OF CYTOKINES AND ADHESION MOLECULES\nIN CHILDREN WITH AUTISM SPECTRUM DISORDER .  8 th Imibic Young\nInvestigators Meeting. C\u00f3rdoba. 30 y 31 de mayo de 2017.\n3-Cristina  P\u00e9rez-Garc\u00eda,  Antonio  R.  G\u00f3mez-Fern\u00e1ndez,  Fernando  Gil\nHern\u00e1ndez, Katherine Flores-Rojas, Concepci\u00f3n Mart\u00edn-Domingo, Maria Jos\u00e9\nde la Torre Aguilar, Juan Luis P\u00e9rez-Navero, Mercedes Gil-Campos.  AUTISM\nSPECTRUM DISORDERS IS NOT ASSOCIATED WITH NEUROTOXICITY BY\nMERCURY.8 th Imibic Young Investigators Meeting. C\u00f3rdoba. 30 y 31 de mayo\nde 2017.4-Antonio  R.  G\u00f3mez-Fern\u00e1ndez,  Katherine  Flores-Rojas,  Mar\u00eda  Jos\u00e9  de  la\nTorre Aguilar, Pilar Mart\u00edn Borreguero, Mercedes Gil Campos, Juan Luis P\u00e9rez-\nNavero.PERFIL  DE  CITOQUINAS  Y  MOL\u00c9CULAS  DE  ADHESI\u00d3N\nPLASM\u00c1TICAS EN NI\u00d1OS CON TRASTORNO DEL ESPECTRO AUTISTA .\n65 Congreso de la Asociaci\u00f3n Espa\u00f1ola de Pediatr\u00eda, 1, 2 y 3 de junio de 2017.\n5-Fernando Gil Hern\u00e1ndez, Antonio R. G\u00f3mez-Fern\u00e1ndez, Juan Luis P\u00e9rez-\nNavero, Katherine Flores-Rojas, Maria Jos\u00e9 de la Torre Aguilar, Concepci\u00f3n\nMart\u00edn-Domingo, J, Mercedes Gil-Campos. EL TRASTORNO DEL ESPECTRO\nAUTISTA  NO  EST\u00c1  ASOCIADO  A  TOXICIDAD  POR  MERCURIO .  65\nCongreso de la Asociaci\u00f3n Espa\u00f1ola de Pediatr\u00eda, 1, 2 y 3 de junio de 2017.\n6-Cristina P\u00e9rez Garc\u00eda, Antonio R. G\u00f3mez-Fern\u00e1ndez, Katherine Flores-Rojas,\nG Gil Hern\u00e1ndez, Mar\u00eda Jos\u00e9 de la Torre Aguilar, Juan Lu\u00eds P\u00e9rez Navero,\nMercedes Gil Campos. \u00bfNEUROTOXICIDAD INDUCIDA POR MERCURIO EN\nEL TRASTORNO DEL ESPECTRO AUTISTA?  XVII Congreso de la Sociedad\nEspa\u00f1ola  de  Investigaci\u00f3n en Nutrici\u00f3n y Alimentaci\u00f3n en Pediatr\u00eda.  6 y  7\noctubre de 2017\n7-Antonio R. G\u00f3mez-Fern\u00e1ndez, Mercedes Gil Campos, Maria Jos\u00e9 de la Torre\nAguilar, Katherine Flores-Rojas, M. Cruz Rico, Pilar Mat\u00edn Borreguero, Juan\nLuis P\u00e9rez-Navero. PERFIL DE CITOQUINAS Y MOL\u00c9CULAS DE ADHESI\u00d3N\nPLASM\u00c1TICAS EN NI\u00d1OS CON TRASTORNO DEL ESPECTRO AUTISTA .\nCVII  Reuni\u00f3n  de  la  Sociedad  de  Pediatr\u00eda  de  Andaluc\u00eda  Occidental  y\nExtremadura. 25 de Noviembre de 2017.\n8-Antonio  R.  G\u00f3mez-Fern\u00e1ndez,  Cristina  P\u00e9rez  Garc\u00eda,  F.  Gil  Hern\u00e1ndez,\nKatherine Flores-Rojas, Concepci\u00f3n Mart\u00edn-Domingo,  Mar\u00eda Jos\u00e9 de la Torre\nAguilar, Juan Lu\u00eds P\u00e9rez Navero. EL TRASTORNO DEL ESPECTRO AUTISTA\nNO EST\u00c1 ASOCIADO A TOXICIDAD POR MERCURIO . CVII Reuni\u00f3n de la\nSociedad  de  Pediatr\u00eda  de  Andaluc\u00eda  Occidental  y  Extremadura.  25  de\nNoviembre de 2017.\n9-Oscar Daniel Rangel-Huerta, Antonio Gomez-Fern\u00e1ndez, Katherine Flores-Rojas, Angel Gil, Mar\u00eda Jos\u00e9 de la Torre-Aguilar, Juan Perez-Navero, Mercedes\nGil-Campos.PLASMA  METABOLIC  PROFILING  IN  AUTISTIC  CHILDREN\nWITH  OR  WITHOUT  MENTAL  REGRESSION:  A  CONTROLLED\nPROSPECTIVE  OBSERVATIONAL  CASE-CONTROL  STUDY .  IV  World\nCongress of Public Health Nutrition y el XII Congreso de la Sociedad Espa\u00f1ola\nde Nutrici\u00f3n Comunitaria (SENC) \u2013 NUTRIMAD 2018. Madrid, del 24 al 27 de\noctubre de 2018.\n10-Gomez-Fern\u00e1ndez AR, de la Torre-Aguilar MJ, Perez-Navero JL, Flores-\nRojas  K,  Mat\u00edn-Borreguero  P,  Olivares  M,  Gil-Campos  M. EFICACIA  Y\nSEGURIDAD  DEL  \u00c1CIDO  DOCOXAHENOICO  EN  EL  TRATAMIENTO\nCOADYUVANTE DE NI\u00d1OS CON TRASTORNO DEL ESPECTRO AUTISTA .\nXIX  Congreso  de  la  Sociedad  Espa\u00f1ola  de  Investigaci\u00f3n  en  Nutrici\u00f3n  y\nAlimentaci\u00f3n en Pediatr\u00eda. 4 y 5 de octubre de 2019.", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}